10TH INTERNATIONAL CONGRESS ON AUTOIMMUNITY
APRIL 6-10, 2016, LEIPZIG, GERMANY

PROGRAM BOOK
Join Us in Lisbon

11th International Congress on Autoimmunity

Lisbon, Portugal, 16-20 May 2018

autoimmunity.kenes.com
10TH INTERNATIONAL CONGRESS ON AUTOIMMUNITY
APRIL 6-10, 2016, LEIPZIG, GERMANY

PROGRAM BOOK

CONGRESS ORGANIZERS

Rue François-Versonnex 7, CH-1207 Geneva, SWITZERLAND
Tel: +41 22 908 0488
Fax: +41 22 906 9140
Email: autoimmunity@kenes.com
Website: autoimmunity.kenes.com

LEIPZIG 2016
10th INTERNATIONAL CONGRESS ON AUTOIMMUNITY
# TABLE OF CONTENTS

Welcome Message ................................................. 3
Committees ......................................................... 4
Timetable .......................................................... 6
General Information ........................................... 10
CME/CPD Accreditation ........................................ 12
Information for Presenters ..................................... 15
E-Poster Discussion Sessions ............................. 16
Venue Maps ......................................................... 18
About Leipzig ...................................................... 20
Awards ............................................................... 21
Networking Events .............................................. 26
Congress App ....................................................... 27
4th International Symposium on Vaccines ............ 28
Basic Immunology Course ................................. 29
Patient Forum ...................................................... 30

# SCIENTIFIC PROGRAM & E-POSTER DISCUSSIONS

Wednesday, April 6 ............................................. 33
Thursday, April 7 ................................................ 39
Friday, April 8 ..................................................... 81
Saturday, April 9 .................................................. 129
Sunday, April 10 .................................................. 177
Index ................................................................ 187

# ACKNOWLEDGEMENTS & INDUSTRY SUPPORT

Acknowledgements .............................................. 211
Industry Symposia .............................................. 214
Exhibition Map ................................................... 218
List of Exhibitors ............................................... 219
Supporter & Exhibitor Profiles ............................ 223
WELCOME MESSAGE

Dear Friends,

The International Congress on Autoimmunity has reached a historical moment: in April 2016 more than 2000 of the world’s autoimmunologists have gathered for the 10th time to exchange knowledge about the more than 80 autoimmune diseases.

The meeting point this time is the artistic city of Leipzig, Germany, known for its long tradition in trade fairs and its compelling selection of museums, musical events and other cultural offerings.

Our loyal participants are already familiar with the high level of medical science that awaits them at the International Congresses on Autoimmunity and our newcomers will be impressed by the diversity of excellent sessions offered on a variety of topics, ranging from basic research to novel diagnostic and treatment methods of autoimmune diseases. This year’s Congress introduces a variety of hot subjects for the first time: from spicy food and cannabis to obesity, smoking, the microbiome, novel peptides and revolutionary therapies.

The International Congress on Autoimmunity is the biggest multidisciplinary congress that discusses all aspects of the related diseases under one roof, offering courses and lectures by some of the world’s most distinguished experts. At the same time, the Congress prides itself on providing a stage for young upcoming talents to present their research to a first-rate audience.

Join us and enjoy the inspiring atmosphere of medical science among old and new colleagues; share, learn and network to build the future of autoimmunology at the 10th International Congress on Autoimmunity!

Sincerely,

Yehuda Shoenfeld, MD, FRCP, MaACR
Congress President
COMMITTEES

CONGRESS PRESIDENT & SCIENTIFIC PROGRAM CHAIRMAN
Yehuda Shoenfeld, Israel

CONGRESS CO-CHAIRPERSONS & LOCAL SCIENTIFIC COMMITTEE
Karsten Conrad, Dresden, Germany
Arno Kromminga, Hamburg, Germany
Annegret Kuhn, Mainz, Germany
Enno Schmidt, Lübeck, Germany
Torsten Witte, Hannover, Germany

LOCAL CONGRESS SUPPORT GROUP
Thomas Dörner, Berlin, Germany
Rüdiger Eming, Marburg, Germany
Falk Hiepe, Berlin, Germany
Yoachim Kalden, Erlangen, Germany
Jürgen Kratzsch, Leipzig, Germany
Min Ae Lee-Kirsch, Dresden, Germany
Ulrich Sack, Leipzig, Germany
Reinhold Ernst Schmidt, Hannover, Germany
Günter Steiner, Vienna, Austria
Michael Sticherling, Erlangen, Germany
Georg Wick, Innsbruck, Austria
INTERNATIONAL CONGRESS SUPPORT GROUP

Abul K. Abbas, USA
Steven B. Abramson, USA
Razzaque Ahmed, USA
Juan Manuel Anaya, Colombia
Luis E. Coelho Andrade, Brazil
Tatsuya Atsumi, Japan
Tadej Avcin, Slovenia
Cristina Belizna, France
Sonia Berrih-Aknin, France
Nicola Bizzaro, Italy
Miri Blank, Israel
Dimitrios Bogdanos, Greece
Dimitrios Boumpas, Greece
Ricard Cervera, Spain
Edward Chan, USA
Christopher Chang, USA
Joab Chapman, Israel
Shunle Chen, China
Douglas Cines, USA
Jan Willem Cohen Tervaert, The Netherlands
Maurizio Cutolo, Italy
Terry Davies, USA
David D’Cruz, UK
Caterina De Carolis, Italy
Carlos Dias, Portugal
Andrea Doria, Italy
Christopher Edwards, UK
Kok-Yong Fong, Singapore
João Eurico Fonseca, Portugal
Johan Frostegard, Sweden
Mauro Galeazzi, Italy
Roberto Gerli, Italy
M. Eric Gershwin, USA
Ahmet Gul, Turkey
Michael Hayden, Canada
Chunyu Huang, China
Graham Hughes, UK
Luis Javier Jara, Mexico
Cees Kallenberg, The Netherlands
Munther Khamashta, UK
Takao Koike, Japan
Ivica Lazurova, Slovak Republic
Roger Levy, Brazil
ZhanGuo Li, China
Claudio Lunardi, Italy
Trevor Marshall, USA
Eiji Matsuura, Japan
Marco Matucci-Cerinic, Italy
David McLain, USA
Pier Luigi Meroni, Italy
Tsuneyo Mimori, Japan
Pierre Miossec, France
Eric Morand, Australia
Marta Mosca, Italy
Luc Mouthon, France
David Naor, Israel
Yaakov Naparstek, Israel
Sandra Navarra, Philippines
Ferdinando Nicoletti, Italy
David Norris, USA
Roberto Perricone, Italy
Alexander B. Poletaev, Russia
Bernardo Pons-Estel, Argentina
Chaim Putterman, USA
Noel R. Rose, USA
Eric Rosenthal, France
Piercarlo Sarzi-Puttini, Italy
Guy Serre, France
Veerle Somers, Belgium
Zoltán Szekanecz, Hungary
Zera Tellier, France
Angela Tincani, Italy
Yaron Tomer, USA
Elias Toubi, Israel
George C. Tsokos, USA
Athanasios Tzioufas, Greece
Guido Valesini, Italy
Carlos Vasconcelos, Portugal
Matthias G. von Herrath, USA
Allan Wiik, Denmark
Kazuhiko Yamamoto, Japan
Pierre Youinou, France
Gisele Zandman-Goddard, Israel
Xiaofeng Zeng, China
## WEDNESDAY, APRIL 6

<table>
<thead>
<tr>
<th>Hall 1</th>
<th>Hall MP3&amp;4</th>
<th>Hall 2</th>
<th>Hall 3</th>
<th>Hall 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:00 – 12:30</td>
<td></td>
<td>4th INT’L SYMPOSIUM ON VACCINES in collaboration with CMSRI</td>
<td>BASIC IMMUNOLOGY COURSE Abul K. Abbas, USA</td>
<td>Industry Session not included in main event CME/CPD credit</td>
</tr>
<tr>
<td>12:30 – 13:00</td>
<td></td>
<td></td>
<td>Coffee Break</td>
<td></td>
</tr>
<tr>
<td>13:00 – 13:30</td>
<td></td>
<td>Industry Session not included in main event CME/CPD credit</td>
<td>4th INT’L SYMPOSIUM ON VACCINES in collaboration with CMSRI</td>
<td></td>
</tr>
<tr>
<td>13:30 – 14:00</td>
<td></td>
<td></td>
<td>Coffee Break</td>
<td></td>
</tr>
<tr>
<td>14:00 – 14:30</td>
<td></td>
<td>Coffee Break</td>
<td>BASIC IMMUNOLOGY COURSE Abul K. Abbas, USA</td>
<td></td>
</tr>
<tr>
<td>14:30 – 14:50</td>
<td></td>
<td>15:00 – 15:30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:50 – 15:00</td>
<td></td>
<td>15:30 – 16:10</td>
<td>Industry Session not included in main event CME/CPD credit</td>
<td></td>
</tr>
<tr>
<td>15:00 – 15:30</td>
<td></td>
<td>16:10 – 16:30</td>
<td>4th INT’L SYMPOSIUM ON VACCINES in collaboration with CMSRI</td>
<td></td>
</tr>
<tr>
<td>15:30 – 16:10</td>
<td></td>
<td>16:00 – 17:00</td>
<td>Coffee Break</td>
<td></td>
</tr>
<tr>
<td>16:10 – 16:30</td>
<td></td>
<td>17:00 – 17:30</td>
<td>4th INT’L SYMPOSIUM ON VACCINES in collaboration with CMSRI</td>
<td></td>
</tr>
<tr>
<td>16:30 – 17:00</td>
<td></td>
<td>17:30 – 18:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:00 – 17:30</td>
<td></td>
<td>18:00 – 19:45</td>
<td></td>
<td>Opening Ceremony followed by Welcome Reception (in the Exhibition Area)</td>
</tr>
<tr>
<td>18:00 – 19:45</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Hall 1</td>
<td>Hall MP3&amp;4</td>
<td>Hall 2</td>
<td>Hall 3</td>
</tr>
<tr>
<td>--------------</td>
<td>--------------------------------------------</td>
<td>-------------------------------------</td>
<td>--------------------------------------------</td>
<td>--------------------------------------------</td>
</tr>
<tr>
<td>08:00 – 10:00</td>
<td><strong>PL01 PLenary Session</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00 – 10:30</td>
<td>Coffee break, Exhibition and E-Poster sessions</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30 – 12:30</td>
<td><strong>PS01 Etiology and pathogenesis of autoimmunity</strong></td>
<td><strong>PS02 Celiac disease: novelties in 2016</strong></td>
<td><strong>PS03 IVlg: the best biologic?</strong></td>
<td><strong>PS04 Standardization and harmonization in autoantibody testing</strong></td>
</tr>
<tr>
<td>12:30 – 14:00</td>
<td>Industry Session not included in main event CME/CPD credit</td>
<td>Lunch break, Exhibition and E-Poster viewing</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:00 – 16:00</td>
<td><strong>PS07 Hygiene theory, microbiome, probiotics</strong></td>
<td><strong>PS08 Novel biologics and biosimilars</strong></td>
<td><strong>PS09 B cells: pathogenesis and suppression</strong></td>
<td><strong>PS10 Immuno-modulation by vitamin D and IVlg</strong></td>
</tr>
<tr>
<td>16:00 – 16:30</td>
<td>Coffee break, Exhibition and E-Poster sessions</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:30 – 18:30</td>
<td><strong>PS13 Vasculitides</strong></td>
<td><strong>PS14 Vaccines and autoimmunity</strong></td>
<td><strong>PS15 Autoimmune pathways in multiple sclerosis, myasthenia gravis and the central nervous system</strong></td>
<td><strong>PS16 Induction, determination and the pathogenic role of autoantibodies</strong></td>
</tr>
</tbody>
</table>
## FRIDAY, APRIL 8

<table>
<thead>
<tr>
<th>Time</th>
<th>Hall 1</th>
<th>Hall MP3&amp;4</th>
<th>Hall 2</th>
<th>Hall 3</th>
<th>Hall 4</th>
<th>Hall 5</th>
<th>Hall MP1</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00 – 10:00</td>
<td><strong>PL02</strong> PLENARY SESSION</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00 – 10:30</td>
<td>Coffee break, Exhibition and E-Poster sessions</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30 – 12:30</td>
<td><strong>PS19</strong> T cells in autoimmunity</td>
<td><strong>PS20</strong> Diagnostics: pathogenesis and autoantibody standardization</td>
<td><strong>PS21</strong> SLE: is it the classical autoimmune disease?</td>
<td><strong>PS22</strong> Kidney involvement in autoimmunity</td>
<td><strong>PS23</strong> Autoimmunity in dermatology</td>
<td><strong>PS24</strong> Experimental animal models of autoimmune diseases</td>
<td></td>
</tr>
<tr>
<td>12:30 – 14:00</td>
<td>Industry Session not included in main event CME/CPD credit</td>
<td>Lunch break, Exhibition and E-Poster viewing</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:00 – 16:00</td>
<td><strong>PS25</strong> Prediction, monitoring and personalized medicine</td>
<td><strong>PS26</strong> EASI session: ANCA and ANCA-associated vasculitis</td>
<td><strong>PS27</strong> Autoimmune aspects of neurological diseases</td>
<td><strong>PS28</strong> Peptidomics and new molecules in therapeutics</td>
<td><strong>PS29</strong> Autoimmune liver diseases</td>
<td><strong>PS30</strong> Type 1 diabetes mellitus</td>
<td><strong>PS30B</strong> New horizons in autoimmune therapy</td>
</tr>
<tr>
<td>16:00 – 16:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:30 – 18:30</td>
<td><strong>PS31</strong> Environmental factors and sex hormones in autoimmunity</td>
<td><strong>PS32</strong> Rheumatoid arthritis: challenges in the new era</td>
<td><strong>PS33</strong> Genetics and epigenetics of autoimmune diseases</td>
<td><strong>PS34</strong> European Forum on antiphospholipid antibodies</td>
<td><strong>PS35</strong> Big data analysis, registries and epidemiological studies in autoimmunity</td>
<td><strong>PS36</strong> Systemic onset juvenile idiopathic arthritis and hereditary periodic fever syndromes</td>
<td></td>
</tr>
</tbody>
</table>
### SATURDAY, APRIL 9

<table>
<thead>
<tr>
<th>Time</th>
<th>Hall 1</th>
<th>Hall MP3&amp;4</th>
<th>Hall 2</th>
<th>Hall 3</th>
<th>Hall 4</th>
<th>Hall 5</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00 – 10:00</td>
<td><strong>PL03</strong> PLENARY SESSION</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00 – 10:30</td>
<td>Coffee break, Exhibition and E-Poster sessions</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30 – 12:30</td>
<td><strong>PS37</strong> Systemic lupus erythematosus: the challenge</td>
<td><strong>PS38</strong> Infection and autoimmunity: two edges of the sword</td>
<td><strong>PS39</strong> Highlights in diagnostics</td>
<td><strong>PS40</strong> Innate immunity and natural autoantibodies (IVIg)</td>
<td><strong>PS41</strong> UCTD, MCTD and other connective tissue diseases</td>
<td><strong>PS42</strong> Pregnancy and autoimmunity</td>
</tr>
<tr>
<td>12:30 – 14:00</td>
<td>Lunch break, Exhibition and E-Poster viewing</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:00 – 16:00</td>
<td><strong>PS43</strong> ANA diagnostics and immunofluorescence</td>
<td><strong>PS44</strong> T-reg, B-reg, tolerance and autoimmunity</td>
<td><strong>PS45</strong> Autoimmunity and endocrinology</td>
<td><strong>PS46</strong> Novel studies in autoimmune diseases</td>
<td><strong>PS47</strong> Epstein-Barr virus driven inflammatory diseases: from primary immunodeficiencies to autoimmune diseases (NEDAI session)</td>
<td><strong>PS48</strong> Pearls in autoimmunity: top candidates for the MAI Award 2016</td>
</tr>
<tr>
<td>16:00 – 16:30</td>
<td>Coffee break, Exhibition and E-Poster sessions</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:30 – 18:30</td>
<td><strong>PS49</strong> New therapeutic avenues in autoimmune diseases</td>
<td><strong>PS50</strong> APS: Diagnostics and challenges for the future</td>
<td><strong>PS51</strong> Autoimmune syndrome induced by adjuvants (ASIA syndrome)</td>
<td><strong>PS52</strong> The autoimmune aspects of psoriasis, myositis and atherosclerosis</td>
<td><strong>PS53</strong> The autoimmune side of inflammatory arthritis and autoinflammation</td>
<td><strong>PS54</strong> Cytokines and autoimmunity</td>
</tr>
</tbody>
</table>

### SUNDAY, APRIL 10

<table>
<thead>
<tr>
<th>Time</th>
<th>Hall MP3&amp;4</th>
<th>Hall 2</th>
<th>Hall 3</th>
<th>Hall 4</th>
<th>Hall 5</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00 – 10:00</td>
<td><strong>PL04</strong> PLENARY SESSION</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00 – 10:30</td>
<td>Coffee Break</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30 – 12:30</td>
<td><strong>PS55</strong> Sjogren’s syndrome</td>
<td><strong>PS56</strong> Immunomannipulation</td>
<td><strong>PS57</strong> The autoimmune origin of celiac and gastrointestinal diseases</td>
<td><strong>PS58</strong> New autoimmune diseases, cancer and autoimmunity</td>
<td><strong>PS59</strong> IL-6 and JAK inhibition: new achievements</td>
</tr>
</tbody>
</table>
GENERAL INFORMATION

CONGRESS VENUE
Congress Center Leipzig
Messe-Allee 1, 04356 Leipzig, Germany
Tel.: +49 (0) 341 / 6 78 84 40  Fax: +49 (0) 341 / 6 78 84 42

OPENING HOURS

<table>
<thead>
<tr>
<th></th>
<th>Registration</th>
<th>Exhibition</th>
<th>Tourist Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wednesday, April 6</td>
<td>10:30 – 20:00</td>
<td>18:00 – 20:00</td>
<td>16:00 – 18:00</td>
</tr>
<tr>
<td>Thursday, April 7</td>
<td>07:00 – 18:30</td>
<td>09:30 – 17:00</td>
<td>09:00 – 17:00</td>
</tr>
<tr>
<td>Friday, April 8</td>
<td>07:30 – 18:30</td>
<td>09:30 – 17:00</td>
<td>09:00 – 17:00</td>
</tr>
<tr>
<td>Saturday, April 9</td>
<td>07:30 – 18:30</td>
<td>09:30 – 16:30</td>
<td>09:00 – 17:00</td>
</tr>
<tr>
<td>Sunday, April 10</td>
<td>07:30 – 12:30</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

LANGUAGE
The official language of the Congress is English.

CONGRESS ABSTRACTS
The Congress abstracts are available on USB cards, in the Congress app, on the Congress website, as well as on the Autoimmunity Network. Please collect your abstract USB card from booth No. 4.

INTERNET STATIONS
Internet stations are available for participants’ use in the Exhibition area. Please be considerate of fellow participants when using these facilities.

WI-FI
Free Wi-Fi is available to all participants in the public areas and in the Exhibition area.

AUTOIMMUNITY 2016 APP
Install the Autoimmunity 2016 interactive mobile App to your smartphone and portable devices to access all the Congress information you could need during the Congress:
• See the overview of sessions, speakers and exhibitors.
• Create your personal schedule for the event, including bookmarking the sessions you wish to attend.
• Receive real-time updates.

Download the Autoimmunity 2016 App now to enhance your congress experience! [available on the App Store or Google Play]
BADGE
You are kindly requested to wear your name badge during all Congress sessions and events.

LUNCH AND COFFEE BREAKS
Lunch and coffee will be offered as per the lunch and coffee breaks indicated in the timetable. Catering areas are located in the Exhibition area.

CLOAK ROOM
Cloak room facilities are available on level -1 at a price of €1/item.

PHOTOGRAPHY & RECORDING PRIVILEGES
No photographs, video recording or audio recording will be permitted in the scientific sessions at the Congress, unless authorized by the organizers.

MOBILE PHONES
Participants are kindly requested to keep their mobile phones on silent in the session halls.

SMOKING POLICY
Smoking is prohibited at all times in the session halls, Exhibition and restrooms. Your compliance is appreciated.

LIABILITY AND INSURANCE
The Congress Secretariat and organizers cannot accept liability for personal accidents or loss of or damage to private property of participants, either during or indirectly arising from the Autoimmunity Congress. We recommend that all participants take out personal travel and health insurance for the trip.

ACKNOWLEDGMENTS AND INDUSTRY SUPPORT
In accordance with compliance and regulations, acknowledgment of industry supporting the Congress appears separately from the scientific program. Industry information is available from page 209 onwards, under the section ACKNOWLEDGMENTS AND INDUSTRY SUPPORT. Industry symposia details are available on pages 214–217.

CONGRESS SECRETARIAT

Rue François-Versonnex 7, CH-1207 Geneva, Switzerland
Tel: +41 22 908 0488 | Fax: +41 22 906 9140
Email: autoimmunity@kenes.com | Website: autoimmunity.kenes.com
EDUCATIONAL OBJECTIVES
After attending this event, participants should be able to:
• Address individual needs in compliance with their Continuous Professional Development (CPD) plan.
• Evaluate best practices in Autoimmune Diseases - Discuss new scientific knowledge and recent research findings about Autoimmune Diseases.
• Recognize opportunities for scientific collaborations around the world.
• Integrate the most up to date information in their clinical and research activities.
• Employ novel multidisciplinary treatment strategies for patients with rheumatologic and Autoimmune Diseases.
• Evaluate the most important aspects of diagnosis and treatment of autoimmune diseases.

TARGET AUDIENCE
The 10th International Congress on Autoimmunity is the global meeting place for experts in immunology, rheumatology and related fields to discuss under one roof the genetic, etiology, diagnostic, clinical aspects and novel therapies of 80 autoimmune diseases. Because of the diverse, clinically focused educational offering, participants are able to tailor the curriculum to meet the needs of international clinicians of all levels of experience.

ACCREDITATION STATEMENT AND CREDIT DESIGNATION
EUROPEAN ACCREDITATION COUNCIL FOR CONTINUING MEDICAL EDUCATION (UEMS/EACCME)
The 10th International Congress on Autoimmunity [Autoimmunity 2016] is accredited by European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS): www.uems.net
The 10th International Congress on Autoimmunity is designated for a maximum of, or up to, 24 European external CME credits. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

AMERICAN MEDICAL ASSOCIATION (AMA)
Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME credit to AMA credit can be found at www.ama-assn.org/go/internationalcme.

ROYAL COLLEGE OF PHYSICIANS AND SURGEONS OF CANADA
Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME for ECMEC credits are deemed to be Accredited Group Learning Activities [Section 1] as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada. For more information, visit: www.royalcollege.ca.
SÄCHSISCHE LANDESÄRZTEKAMMER
The 10th International Congress on Autoimmunity (Autoimmunity 2016) is accredited by the Sächsischen Landesärztekammer to provide the following CPD activity for medical specialists. The Sächsischen Landesärztekammer is the professional representation of all doctors in the Free State of Saxony (Freistaat Sachsen). For more information please visit http://www.slaek.de/de/01/fortbildung.php
The 10th International Congress on Autoimmunity (Autoimmunity 2016) is designated for a maximum of, or up to 27 Category B CME credits. Each physician should claim only those hours of credit that he/she actually spent in the educational activity:

06/04/2016 (12:00- 14:30), VNR 276160 201602510 0002, Passwort 8914, Vormittags, 3 credits Category B
06/04/2016 (12:00- 14:30), VNR 276160 201602510 0010, Passwort 8914, Nachmittags, 3 credits Category B
07/04/2016 (08:00- 12:30), VNR 276160 201602510 0028, Passwort 8914, Vormittags, 3 credits Category B
07/04/2016 (14:00- 18:30), VNR 276160 201602510 0036, Passwort 8914, Nachmittags, 3 credits Category B
08/04/2016 (08:00- 12:30), VNR 276160 201602510 0044, Passwort 8914, Vormittags, 3 credits Category B
08/04/2016 (14:00- 18:30), VNR 276160 201602510 0051, Passwort 8914, Nachmittags, 3 credits Category B
09/04/2016 (08:00- 12:30), VNR 276160 201602510 0069, Passwort 8914, Vormittags, 3 credits Category B
09/04/2016 (14:00- 18:30), VNR 276160 201602510 0077, Passwort 8914, Nachmittags, 3 credits Category B
10/04/2016 (08:00- 12:30), VNR 276160 201602510 0085, Passwort 8914, Vormittags, 3 credits Category B

**CREDIT BREAKDOWN**
Each participant should claim only those hours of credit that he/she actually spent in the educational activity.

<table>
<thead>
<tr>
<th>DAY</th>
<th>MAXIMUM CREDITS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wednesday, April 6</td>
<td>3</td>
</tr>
<tr>
<td>Thursday, April 7</td>
<td>6</td>
</tr>
<tr>
<td>Friday, April 8</td>
<td>6</td>
</tr>
<tr>
<td>Saturday, April 9</td>
<td>6</td>
</tr>
<tr>
<td>Sunday, April 10</td>
<td>3</td>
</tr>
<tr>
<td><strong>Total Credits:</strong></td>
<td><strong>24</strong></td>
</tr>
</tbody>
</table>
TO RECEIVE YOUR CME/CPD CERTIFICATE

The CME/CPD certificate will be available after completing the online evaluation and credit claiming procedure. The process takes about 5 minutes. We thank you for your feedback as it is an important part of CME/CPD accreditation and helps improve future educational offerings.

**Before May 8, 2016:**

1. Access the online system via any of the following:
   - Visit the CME-CPD Accreditation page on the Congress website.
   - Follow the link in the email sent at the end of the Congress.
2. Complete the anonymous online evaluation.
3. Complete the credit claim form and submit.
4. The CME/CPD certificate will be available for download; fill-in and retain for your personal records.

**DISCLOSURE AND RESOLUTION OF PERSONAL CONFLICTS OF INTEREST**

In accordance with CME/CPD accreditation criteria and standards for commercial support to ensure balance, independence, objectivity, and scientific rigor, those in control of the educational content must disclose potential or actual conflicts of interest. Disclosure information is evaluated and conflicts of interest resolved. Disclosure is made to participants prior to the activity. Participants will be asked on the evaluation to assess the objectivity and independence of the event.

- Disclosure information is available on the event website and also posted on the notice board in the registration area.

**INDUSTRY SUPPORT DISCLOSURE**

This event is supported, in part, by funding from industry. All support is managed in strict accordance with CME/CPD accreditation criteria and standards for commercial support. Appropriate acknowledgement of all supporting organizations is made in the program guide, on the event website, and with signage during the event.

- A list of all industry supporters is available in the Acknowledgements & Industry Support section at the back of the program book.
- Detailed program for all Industry Sessions are available on page 214–217.
INFORMATION FOR PRESENTERS

ORAL PRESENTATIONS

Please check the program book and the app to stay updated with any last minute scheduling changes.

Speakers presenting in oral sessions are requested to submit their presentations to the speakers’ ready room at least 1 hour before the start of their session. The Speakers’ Ready Room can be found on level 2 and will be open at the following times:

- Wednesday, April 6: 10:30 - 20:00
- Thursday, April 7: 07:00 - 18:30
- Friday, April 8: 07:30 - 18:30
- Saturday, April 9: 07:30 - 18:30
- Sunday, April 10: 07:30 - 12:30

UPLOADING YOUR PRESENTATION:

If using a PowerPoint (or any other) presentation, please note you need to bring it on a CD, a DVD or on a memory stick and load it on one of the conference’ computers in the Speakers’ Ready Room, at least 1 hour before the start of the session.

Please note that the conference computers in the session halls are being supplied with Office 2013.

If combining video films with PowerPoint, please make sure to check it in the session hall where your lecture is taking place during a coffee or lunch break, at least 30 minutes before the start of the session - even after checking it in the Speakers’ Ready Room.

Speakers are requested not to use own computers for presentation. Please note that the time used for connecting own computer will be deducted from the total presentation time.

PRESENTATION DURATION:

The duration of your presentation is indicated in the program book and in the congress app. Please note that your presentation time includes time for questions and answers. Therefore, you are asked to plan your presentation accordingly and leave 1-2 minutes for questions at the end of your presentation. It is possible that there will not be sufficient time for questions after your presentation. Please follow the instructions of the session Chairpersons.
CME COMPLIANCE:
Oral presenters are required to use a Disclosure Slide as the second slide of their presentation. The template can be downloaded from the congress website or obtained at the Speakers’ Ready Room.

IMPORTANT NOTE FOR MACINTOSH USERS:
In order to use MAC presentations on a PC compatible computer, please note that you need to prepare it according to the instructions below, before bringing it to the Speakers’ Ready Room:

1. Use a common font, such as Arial, Times New Roman, Verdana etc. (special fonts might be changed to a default font on a PowerPoint based PC).
2. Insert pictures as JPG files (and not TIF, PNG or PICT - these images will not be visible on a PowerPoint based PC).

Alternatively, you may use your own Macintosh laptop computer. In such a case please ensure you provide a VGA adaptor for external signal and come to check it first in the Speakers’ Ready Room as soon as you arrive and later on in the session hall where your lecture is taking place during the coffee or lunch break, at least 30 minutes before the start of the session.

E-POSTER PRESENTATIONS
Electronic or E-Posters are similar to traditional paper posters but displayed on-site on large LCD screens. E-Posters will be available at the E-Poster stations in the Exhibition area, during the Exhibition opening hours.

Using a simple search engine, you can easily and quickly access the E-Posters you want, searching by author, topic, poster title or keywords. High resolution touch screens provide excellent quality viewing experience of the posters and allow seamless switching from full view to section view.

E-POSTER DISCUSSION SESSIONS (SHORT ORAL PRESENTATIONS)
Discussion sessions will take place at the E-Poster stations during the morning and afternoon coffee breaks on Thursday, Friday and Saturday (April 7-8-9). During the sessions an E-Poster chairperson will be present to discuss E-Posters selected by the Scientific Committee.

Please be sure to arrive 5 minutes prior to the start of your E-Poster discussion session.
### E-POSTER DISCUSSION SESSIONS (SHORT ORAL PRESENTATIONS)

**THURSDAY, APRIL 7, 2016**

<table>
<thead>
<tr>
<th>10:00-10:30</th>
<th>EPD01 APS: revelations</th>
<th>EPD02 New cytokines: the flame and the inflamed</th>
<th>EPD03 SLE: the disease of a thousand faces</th>
<th>EPD04 Modern avenues in autoimmune diagnostics</th>
<th>EPD05 Atherosclerosis and autoimmunity</th>
<th>EPD06 Multiplex diagnostic and chip technique</th>
<th>EPD07 Autoimmunity and hematology</th>
<th>EPD08 How can we immunomodulate autoimmune conditions?</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:00-16:30</td>
<td>EPD09 The mother and the child: autoimmune relationship</td>
<td>EPD10 Etiology and mechanism of autoimmunity</td>
<td>EPD11 SLE: more systemic than systemic</td>
<td>EPD12 Steps in autoimmune diagnostics</td>
<td>EPD13 Cancer and autoimmunity</td>
<td>EPD14 Vasculitis: the autoimmune inflammation of the vessels</td>
<td>EPD15 Novel therapies in autoimmunity</td>
<td>EPD16 The bugs and us: inter-relationship of autoimmunity</td>
</tr>
</tbody>
</table>

**FRIDAY, APRIL 8, 2016**

<table>
<thead>
<tr>
<th>10:00-10:30</th>
<th>EPD17 APS diagnostics</th>
<th>EPD18 Pathogenetic avenues in autoimmune diseases</th>
<th>EPD19 SLE: what can we learn about autoimmunity?</th>
<th>EPD20 What’s new in autoimmune diagnostics?</th>
<th>EPD21 CNS involvement in autoimmunity</th>
<th>EPD22 Systemic sclerosis: how can we overcome an unknown etiology?</th>
<th>EPD23 Are there breakthroughs in the therapy of autoimmune diseases?</th>
<th>EPD24 Immunomodulation: better than immunosuppression</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:00-16:30</td>
<td>EPD25 Type 1 diabetes mellitus: the sweet and the autoimmune</td>
<td>EPD26 Experimental models: from mice to men</td>
<td>EPD27 SLE: novel aspects</td>
<td>EPD28 Methods in autoimmune diagnostics</td>
<td>EPD29 Celiac: don’t miss the diagnosis</td>
<td>EPD30 Sjogren’s syndrome: the ultimate B cell stimulation</td>
<td>EPD31 Myasthenia gravis &amp; multiple sclerosis</td>
<td>EPD32 IVlg, innate immunity: how to restore the immune system to normal</td>
</tr>
</tbody>
</table>

**SATURDAY, APRIL 9, 2016**

<table>
<thead>
<tr>
<th>10:00-10:30</th>
<th>EPD33 APS: novelties</th>
<th>EPD34 Gene, families, RNA</th>
<th>EPD35 SLE: the leading autoimmune condition</th>
<th>EPD36 Diagnostics: from the lab to the clinic</th>
<th>EPD37 CNS: brain, autoimmunity and beyond</th>
<th>EPD38 Vasculitis: a systemic autoimmune condition</th>
<th>EPD39 IL17: why Miossec is right?</th>
<th>EPD40 IVlg: the biologic of preference</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:00-16:30</td>
<td>EPD41 Thyroid: avenues in disease diagnostics</td>
<td>EPD42 Citrullination: an important factor in autoimmune conditions</td>
<td>EPD43 Liver: a piece of the mosaic of autoimmunity</td>
<td>EPD44 ANA diagnostics: the ultimate procedure</td>
<td>EPD45 Additional aspects of gastrointestinal autoimmunity</td>
<td>EPD46 Vasculitis: the great imitator</td>
<td>EPD47 Personalized and precision trends in autoimmunity</td>
<td>EPD48 The skin as the mirror of autoimmunity</td>
</tr>
</tbody>
</table>
VENUE MAPS

LEVEL -1

MAIN ENTRANCE

LEVEL 0

HALL MP 1

HALL MP 3 & 4

To Exhibition & Poster Area
ABOUT LEIPZIG

LEIPZIG IS A COSMOPOLITAN CITY THAT IS ALIVE AND WAITING TO BE EXPLORED

Constantly reinventing itself, Leipzig still preserves the city’s influential and historical aspects. The soul of this city has always been characterized by its energy, creative will and the pride of its citizens. Hospitality and openness to new ideas are centuries-old traditions in the city of Leipzig.

Leipzig is not only famous because of its long trade fair tradition but also because of its multifaceted music and cultural scene. Owing to its unique system of passageways, the historic city centre exudes a distinctive flair. Stylish boutiques and top department stores invite visitors to shop and stroll.

Most of the city’s sights are located within walking distance, e.g. the Old Town Hall, St. Thomas Church, St. Nicholas Church, diverse museums and galleries. Cultural enjoyment is among others provided by the Gewandhaus, the Leipzig Opera or the world-famous St. Thomas Boys Choir.
We are pleased to announce that following the tradition, three distinguished personalities have been chosen to receive the "Lifetime Contribution to Autoimmunity Award" in 2016. This award is presented every two years at the Autoimmunity Congress as a recognition to individuals who have contributed in a significant way to the field of autoimmunology.

The prize will be presented during the Opening Ceremony of the Congress. This award is sponsored by industry. Please see page 211 for the details.

THIS YEAR’S RECIPIENTS

DR. ROBERT MORRIS, USA

Dr. Robert Morris was born in 1940 in New Jersey. After graduating at Rutgers University, he attended Hahneman Medical School and he was accepted to the renowned UCLA Rheumatology Fellowship. Dr. Morris has taught through the UCLA medical school and other institutions for over 25 years.

In 1974 he began private practice, and was troubled by the paucity of quality autoimmune testing for his patients. After much effort Dr. Morris opened RDL in 1977, with the goal of providing the most reliable and cost effective laboratory testing for Rheumatologists throughout the USA. Since its inception, RDL has been a leader in scientific research, always at the forefront of new assay development, including introducing anti-CCP testing in the USA. In 1999 Dr. Morris retired from private practice in order to devote his full energies to RDL. In late 2003, Dr. Morris was diagnosed with a rare form of hydrocephalus resistant to conventional treatments. After two years of hospitalization and rehabilitation, Dr. Morris returned to work full-time at RDL. From the time of his Fellowship until the present, Dr. Morris’ vision has not been limited to his Practice and RDL. He was the primary investigator in the studies which demonstrated the link between HLA-B27, Ankylosing Spondylitis and Reactive Arthritis. This discovery was published in the New England Journal of Medicine in 1974. Dr. Morris was the first clinician to make a finding of legionella infection in synovial fluid. In addition to many other contributions, Dr. Morris has been instrumental in the development of the helminth compound as a potential treatment and/or vaccine for auto-immune disease. In 2014 Dr. Morris was made Master of the ACR.
Angela Tincani is Professor of Rheumatology, University of Brescia and Head of Rheumatology and Clinical Immunology, Brescia General Hospital, Italy. After receiving her MD from the University of Milan in 1974, Prof. Tincani continued postgraduate studies in Allergology and Clinical Immunology, Hematology and Rheumatology, before taking up several senior positions at the University of Brescia. Since 2010 she is Head of Rheumatology and Clinical Immunology Unit of Spedali Civili, Brescia.

Her main clinical and research areas include: pathogenesis, diagnosis and treatment of systemic autoimmune diseases in particular SLE and APS; management of pregnancy in patients with inflammatory arthritis and systemic autoimmune diseases: biomarkers of outcome and use of anti-rheumatic drugs in pregnant patients; evolution of autoantibodies determinations and reliability and clinical significance of emerging new technology. Professor Tincani has been included in the organization of many national and international congresses including the International Congress on Autoimmunity series since 1999 (Tel Aviv). She has served on many international committees for research and education in lupus, most recently the EULAR committee “Points to consider for use of antirheumatic drugs before pregnancy and during pregnancy and lactation” (2013–14) and, as co-chair, “Recommendations for the management of family planning, assisted reproduction, gestation, delivery and menopause in patients with Systemic Lupus Erythematosus.

Professor Tincani is a widely published author (300 publications indexed by PubMed with nearly 11000 citations and H-index 50 [by WOS]. She is regional Editor (Europe) of the journal Autoimmunity and sits on the Editorial Boards of Clinical and Experimental Rheumatology and Autoimmunity Reviews.
Mr. Poju Zabludowicz, UK

Poju Zabludowicz is a global investor, entrepreneur and philanthropist. Poju is Chairman of Tamares which he has led since 1990. Tamares makes long-term investments in real estate, technology and primary sector and is a long-standing contributor to medical facilities. Over the years Poju has had an increased interest in the field of autoimmunity. He created the Zabludowicz Center for Autoimmune Diseases, one of the world’s most advanced centers for research into autoimmune diseases. Poju has contributed to research on subjects like IVIg applications in autoimmunity, immunomodulating drugs and basic research on the etiology and pathogenesis of autoimmune models.

In 1994, together with his wife, Anita Zabludowicz, Poju established The Zabludowicz Collection, a dynamic collection of contemporary art works. The Zabludowicz Collection has supported hundreds of new artists many of which have achieved significant success.

Poju Zabludowicz was born in Finland and remains a passionate supporter of his home country. Alongside Tamares’ investment in Outotec, a leading Finnish mining technology company, Poju serves on its board of directors as well as on the board of the Kiasma Museum of Contemporary Art in Helsinki. He is also a key supporter in the initiative to establish Guggenheim Finland.
MOSAIC OF AUTOIMMUNITY AWARD (MAI) 2016

This annual award was established to encourage progress in autoimmunity research. This is a prize awarded to a young scientist who has enriched the field of autoimmunity through outstanding, creative and independent research. The MAI Award will be delivered during the morning Plenary Session on April 8th, 2016. This award is sponsored by industry. Please see page 211 for the details.

WINNER IN 2016

DR. CARLO PERRICONE, ITALY

Carlo Perricone is a specialist in Rheumatology, PhD in Immunological, Hematologic and Rheumatological Sciences at Sapienza University of Rome. He received his Master Degree with honors in Medicine and Surgery in July 2007 at the University of Rome Tor Vergata, the title of Specialist in Rheumatology at the Sapienza University of Rome in April 2012 and the PhD in Immunological, Hematologic and Rheumatological Sciences at Sapienza University of Rome on February 2016.

His scientific work has been devoted to the study of autoimmune diseases with particular emphasis of systemic lupus erythematosus and antiphospholipid antibody syndrome. His studies focused on the role of NK cells and the complement system in the pathogenesis of autoimmune diseases and the interactions between genetic and multifactorial diseases. In addition, part of his scientific work has been focused on the study of imaging ultrasound in rheumatic diseases and on the autoimmune phenomena associated with vaccines. Teacher of musculoskeletal ultrasound for the European League Against Rheumatism and the Italian Society of Rheumatology. Founder of ReumaCamp for the Italian Society of Rheumatology.

The research activity is documented by more than 100 publications in extenso in prestigious national and international journals. He has authored and co-authored, as well as chapters in books and treatises. Referee for 50 peer-reviewed journals including Arthritis and Rheumatism and Rheumatology (Oxford). Member of the Editorial Board of the World Journal of Immunology. He has participated as investigator in clinical trials of phase III, randomized, controlled, double-blind, multicenter studies. In addition, he has participated as a speaker/chairman at numerous courses, seminars and conferences at national and international level.

The main topic of his research concerns the detection of novel genetic variants associated with the susceptibility to autoimmune diseases, particularly SLE, and capable of influencing disease phenotype. He has already found a locus (TRAF3IP2) potentially involved in SLE pathogenesis, especially in the development of pericarditis. In a further analysis, he has discovered another genetic variant (in HCP5 gene) associated with the presence of antibodies anti-Ro/SSA. His efforts are now dedicated to the unveiling of the pathogenic mechanisms by which an abnormal function of HCP5 may alter the immune response leading to the development of such antibodies, crucial in determining specific disease phenotypes as cutaneous involvement. This may allow to find a novel potential therapeutic target in SLE.
HONORABLE MENTIONS

DR. JOOST SMOLDERS, NETHERLANDS
As a PhD-student at Maastricht University Medical Center (Maastricht,NL) and post-doctoral researcher at the Netherlands Institute for Neuroscience (Amsterdam,NL), Dr. Smolders investigated the association of vitamin D status with clinical and immunological disease outcomes of MS. This work resulted in intervention-studies on the disease and immune modulating effects of vitamin D supplementation in MS. Currently, he works as a neurologist in training and research fellow at the neurology department of a large general hospital. He is also part of the research group of Prof. Dr. Raymond Hupperts at the Academic MS Center Limburg (Sittard, NL). His current research is mainly focused on the interaction between environmental factors and the pathophysiology of MS. Dr. Smolders co-authored over 40 scientific publications.

Current position and Institute:
CWZ MS Center, Department of Neurology, Canisius Wilhelmina Ziekenhuis, Nijmegen (NL)
Academic MS Center Limburg, Department of Neurology, Zuyderland Medical Center, Sittard (NL)

DR. MAURIZIO FAREZ, ARGENTINA
Mauricio Farez is the Director of the Center For Research on Neuroimmunological Diseases (CIEN) and an Associate Researcher in Neurology at the Institute for Neurological Research Dr. Raúl Carrea (FLENI) in Buenos Aires, Argentina. Mauricio received his M.D. degree with honors in 2006 and continued his training as a Research Fellow in Dr. Howard Weiner’s laboratory at Harvard Medical School followed by a Master of Public Health at Harvard School of Public Health.

He has received several awards including the Bruce S. Schoenberg International Award in Neuroepidemiology of the American Academy of Neurology, the Investigator Award by the Allende Foundation the Young Investigation award of the Argentinean Multiple Sclerosis Society and the Du Pre award from the Multiple Sclerosis International Federation. He is coauthor of 36 papers in international peer reviewed journals and has contributed to several book chapters.
NETWORKING EVENTS

OPENING CEREMONY
WEDNESDAY, APRIL 6 18:00-19:00
HALL 1
This year’s Opening Ceremony will take us on a journey back in history, to relive the foundation and the thriving of the Autoimmunity Congress series. The Family of Autoimmunity will reunite for the 10th time on an evening full of music and surprises.

WELCOME RECEPTION
WEDNESDAY, APRIL 6 19:00-20:00
EXHIBITION AREA
Open the 10th International Congress with refreshments and lively discussion among old colleagues and new faces.

BOOK SIGNING
SATURDAY, APRIL 9 12:30-13:00
AUTOIMMUNITY NETWORK BOOTH
Prof. Shoenfeld will be signing his recent book Vaccines and Autoimmunity, available free of charge to Congress participants on a first-come first-served basis. Please exchange your voucher for a copy at the Autoimmunity Network Booth (Booth No.38) during Exhibition opening hours.

NETWORKING DINNER
SATURDAY, APRIL 9 19:30-23:15
PORSCHE CUSTOMER CENTRE LEIPZIG
Porsche Leipzig GmbH
Porschestraße 1, 04158 Leipzig
Join your colleagues for an exciting evening of networking at the famous Porsche Customer Centre in Leipzig where culinary delight meets innovative technology. The centre houses an exhibition of rare and valuable vehicles and offers a unique setting for an informal conversation with old and new friends. Join us for a celebration and let us send off the 10th International Congress on Autoimmunity together. To purchase tickets, please approach the registration desk.
AUTOIMMUNITY 2016
AT YOUR FINGERTIPS

Search “Autoimmunity 2016” and Download the App for the Full Congress Experience

HTTP://LP.WWW2.KENES.COM/AUTOIMMUNITY2016APP/
New Research Links
Autoimmune Diseases and Vaccines in Prone Individuals

The Children’s Medical Safety Research Institute invites you to the
4th International Symposium on Vaccines
Wednesday, April 6
12:00-17:30  Hall 2

Meet the experts and discuss the findings of recent studies on:

• Aluminum-induced macrophagic myofascitis
• Aluminum and long-term neurotoxicity in mouse studies
• Cellular uptake of aluminum adjuvants
• Ovine ASIA syndrome
• Molecular mechanisms in vaccine-induced autoimmunity
• Primary ovarian failure & chronic fatigue syndrome related to HPV vaccine

Attendees will receive a complimentary copy of “Vaccines & Autoimmunity,” a compilation of studies conducted worldwide, edited by Yehuda Schoenfeld, Lucija Tomljenovic and Nancy Agmon-Levin while supplies last.

The Children’s Medical Safety Research Institute is a sponsor of the Autoimmunity Congress and a nonprofit organization dedicated to funding independent research into the causes of autoimmune diseases and to promoting awareness of scientifically validated and published findings. www.cmsri.org

Follow @CMSRIResearch on Twitter
BASIC IMMUNOLOGY COURSE

WEDNESDAY, APRIL 6  12:30 – 17:30, HALL 3

The purpose of the course is to review major topics in basic immunology, with emphasis on recent advances and issues that are relevant to the pathogenesis and treatment of immune-mediated diseases. The course is designed for practicing clinicians, trainees, and scientists in biotech.

At the conclusion of this course, attendees will be able to:
• Describe the major advances in basic immunology that are relevant to human diseases, and the unresolved issues and future challenges.
• Recognize the fundamental mechanisms underlying immunologic diseases.
• Identify the basic principles underlying therapeutic modulation of the immune system, and the mechanisms of action of some of the major classes of immune modulators.

Course Director: Abul K. Abbas, MD, University of California San Francisco, USA

Abul K. Abbas received his medical degree in India, completed training in Pathology at Harvard and joined the faculty at Harvard Medical School and the Brigham and Women’s Hospital, where he rose to become Professor of Pathology and Head of the Immunology Research Division. In 1999, after twenty years on the Harvard faculty, he moved to the University of California San Francisco as Professor and Chairman of the Department of Pathology. Dr. Abbas has received several honors, including election to the Institute of Medicine of the National Academy of Sciences, election as a Fellow of the American Academy of Arts and Sciences, and the Rous-Whipple Award and Robbins Educator Award of the American Society of Investigative Pathology. He has served as one of the founding Editors and Associate Editor of Immunity, Associate Editor and Section Editor for The Journal of Immunology, Associate Editor of Cell, Consulting Editor of The Journal of Clinical Investigation, and founding Editor of the Annual Review of Pathology: Mechanisms of Disease. From 2011-2013, he was the President of the Federation of Clinical Immunology Societies (FOCIS). Dr. Abbas’ research interests are in Immunology, with a focus on the control of immune responses and the causes of autoimmunity. His laboratory has used experimental models to analyze the generation and maintenance of regulatory T cells. He has published over 190 peer-reviewed papers and invited reviews, and is the author of four widely read textbooks, two in Immunology and two in Pathology. He has taught Immunology at Harvard Medical School and UCSF, and has organized and conducted Immunology courses worldwide.
THE ZABLUDOWICZ & MORRIS PATIENT FORUM ON AUTOIMMUNE DISEASES

SATURDAY, APRIL 9  
8:00 – 15:30, HALL MP1

Chairs: Annegret Kuhn (Germany), Yehuda Shoenfeld (Israel)

SESSION 1: AUTOIMMUNITY, PEMPHIGUS AND SCLERODERMA

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00</td>
<td>Ulrich Sack</td>
<td>Immunodeficiency or autoimmunity?</td>
</tr>
<tr>
<td>8:30</td>
<td>Enno Schmidt</td>
<td>Mucous membrane pemphigoid</td>
</tr>
<tr>
<td>9:00</td>
<td>Gabriela Riemekasten</td>
<td>Systemic sclerosis</td>
</tr>
<tr>
<td>9:30</td>
<td>Q&amp;A</td>
<td></td>
</tr>
<tr>
<td>10:00</td>
<td>Coffee Break</td>
<td></td>
</tr>
</tbody>
</table>

SESSION 2: CELIAC, SJOGREN’S, THYROID DISEASE & PSORIASIS

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:25</td>
<td>A. Kuhn &amp; Y. Shoenfeld</td>
<td>Welcome words</td>
</tr>
<tr>
<td>10:30</td>
<td>Georg Wick</td>
<td>Celiac disease - pathogenic mechanisms, diagnosis and treatment</td>
</tr>
<tr>
<td>10:50</td>
<td>Torsten Witte</td>
<td>Sjogren’s syndrome</td>
</tr>
<tr>
<td>11:10</td>
<td>George Kahaly</td>
<td>Autoimmune thyroid diseases</td>
</tr>
<tr>
<td>11:30</td>
<td>Michael Sticherling</td>
<td>The autoimmune aspects of psoriasis</td>
</tr>
<tr>
<td>11:50</td>
<td>Q&amp;A</td>
<td></td>
</tr>
<tr>
<td>12:20</td>
<td>Lunch Break</td>
<td></td>
</tr>
</tbody>
</table>

SESSION 3: LUPUS AND BULLOUS SKIN DISEASES

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:15</td>
<td>Annegret Kuhn</td>
<td>Cutaneous lupus erythematosus</td>
</tr>
<tr>
<td>13:45</td>
<td>Falk Hiepe</td>
<td>Systemic lupus erythematosus</td>
</tr>
<tr>
<td>14:15</td>
<td>Ralf Ludwig</td>
<td>Epidermolysis bullosa acquisita and bullous pemphigoid</td>
</tr>
<tr>
<td>14:45</td>
<td>Q&amp;A</td>
<td></td>
</tr>
</tbody>
</table>

Lectures will be given in German. Participation is free of charge.
SCIENTIFIC PROGRAM
WEDNESDAY, APRIL 6, 2016
JOIN US IN BOLOGNA

4TH INTERNATIONAL CONGRESS ON
CONTROVERSIES IN RHEUMATOLOGY & AUTOIMMUNITY

BOLOGNA, ITALY, 9-11 MARCH 2017

cora2017.kenes.com
**WEDNESDAY, APRIL 6, 2016**

12:00 - 17:30

**Course: 4th INTERNATIONAL SYMPOSIUM ON VACCINES AND AUTOIMMUNITY in collaboration with CMSRI**

Chair: **C. Dwoskin** (USA)
Chair: **C. Exley** (United Kingdom)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:00</td>
<td>THE TOXICITY OF ALUMINIUM ADJUVANTS</td>
<td><strong>C. Exley</strong> (United Kingdom)</td>
</tr>
<tr>
<td>12:20</td>
<td>PHYSICO-CHEMICAL PROPERTIES OF ALUMINIUM ADJUVANTS</td>
<td><strong>E. Shardlow</strong> (United Kingdom)</td>
</tr>
<tr>
<td>12:40</td>
<td>CELLULAR UPTAKE OF ALUMINIUM ADJUVANTS</td>
<td><strong>M. Mold</strong> (United Kingdom)</td>
</tr>
<tr>
<td>13:00</td>
<td>LOW CONCENTRATIONS OF ALUMINIUM (AL) HYDROXIDE ADJUVANT FORMING LIMITED SIZE AGGREGATES SELECTIVELY INDUCE LONG TERM NEUROTOXICITY AND INCREASE CEREBRAL AL CONTENT IN MOUSE</td>
<td><strong>J. Cadasseau</strong> (France)</td>
</tr>
<tr>
<td>13:20</td>
<td>POSITRON EMISSION TOMOGRAPHY OF THE BRAIN IN PATIENTS WITH ALUM-INDUCED MACROPHAGIC MYOFASCIITIS</td>
<td><strong>J. Authier</strong> (France)</td>
</tr>
<tr>
<td>13:40</td>
<td>PANEL DISCUSSION: WHAT DO YOU THINK THAT THE AUTHORITIES ARE TRYING TO HIDE THE TRUTH? WHAT IS THE OBJECTIVE EVIDENCE THAT HPV VACCINATION IS NOT JUSTIFIED? WHAT DO YOU THINK, ARE THE MECHANISMS BY WHICH VACCINE CAN INDUCE AUTOIMMUNITY?</td>
<td><strong>L. Tomljenovic</strong> (Canada), <strong>C. Exley</strong> (United Kingdom), <strong>J. Cadusseau</strong> (France), <strong>W. Kyle</strong> (USA)</td>
</tr>
</tbody>
</table>

14:30 COFFEE BREAK
### Scientific Programme

#### Wednesday

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:50</td>
<td>NEW INSIGHTS IN OVINE ASIA SYNDROME: CLINICOPATHOLOGICAL CHANGES IN EXPERIMENTALLY INDUCED ANIMALS</td>
<td>L. Luján (Spain)</td>
</tr>
<tr>
<td>15:10</td>
<td>MOLECULAR MECHANISMS IN VACCINE INDUCED AUTOIMMUNITY</td>
<td>D. Kanduc (Italy)</td>
</tr>
<tr>
<td>15:30</td>
<td>QUADRIVALENT HUMAN PAPILLOMAVIRUS VACCINE AND AUTOIMMUNE ADVERSE EVENTS: A CASE-CONTROL ASSESSMENT OF THE VACCINE ADVERSE EVENT REPORTING SYSTEM (VAERS) DATABASE</td>
<td>M. Geier, D. Geier (USA)</td>
</tr>
<tr>
<td>15:50</td>
<td>PRIMARY OVARIAN FAILURE AND HPV VACCINE</td>
<td>O. Hamiel (Israel)</td>
</tr>
</tbody>
</table>

#### 16:10 COFFEE BREAK

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:30</td>
<td>CHRONIC FATIGUE SYNDROME FOLLOWING HUMAN PAPILLOMA VIRUS VACCINATION: IS LATENT EPIPHARYNGITIS TO BLAME?</td>
<td>O. Hotta (Japan)</td>
</tr>
<tr>
<td>16:50</td>
<td>SEVERE CASES OF ASIA SYNDROME</td>
<td>L.J. Jara Quezada (Mexico)</td>
</tr>
<tr>
<td>17:10</td>
<td>VACCINES, ADJUVANTS AND AUTOIMMUNITY</td>
<td>L. Eça Guimarães (Portugal)</td>
</tr>
</tbody>
</table>

### 12:30 - 14:30

**Hall 3**

**Course: BASIC IMMUNOLOGY COURSE Part 1**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:30</td>
<td>INTRODUCTION TO THE IMMUNE SYSTEM</td>
<td>A.K. Abbas (USA)</td>
</tr>
<tr>
<td>13:00</td>
<td>INNATE IMMUNITY</td>
<td>A.K. Abbas (USA)</td>
</tr>
<tr>
<td>13:45</td>
<td>ANTIGEN PRESENTATION AND T CELL ACTIVATION</td>
<td>A.K. Abbas (USA)</td>
</tr>
</tbody>
</table>

#### 14:30 COFFEE BREAK

---

[Page 34]
13:30 - 15:30  MP3 & 4

Industry Supported Session:
NOT INCLUDED IN MAIN EVENT CME/CPD CREDIT

15:00 - 17:00  Hall 3

Course: BASIC IMMUNOLOGY COURSE Part 2

15:00  T CELL SUBSETS, CYTOKINES
A.K. Abbas (USA)

15:40  B CELLS AND ANTIBODIES
A.K. Abbas (USA)

16:20  IMMUNE REGULATION, TOLERANCE AND AUTOIMMUNITY
A.K. Abbas (USA)

15:30 - 17:00  Hall 4

Industry Supported Session:
NOT INCLUDED IN MAIN EVENT CME/CPD CREDIT

18:00 - 19:45  Hall 1

OPENING CEREMONY FOLLOWED BY WELCOME RECEPTION (IN THE EXHIBITION AREA)
SCIENTIFIC PROGRAM

THURSDAY, APRIL 7, 2016
Join Us in Cancun

6th Latin American Congress on Autoimmunity

Cancun, Mexico, 26-29 November 2017

laca2017.kenes.com
# THURSDAY, APRIL 7, 2016

## 8:00 - 10:00

### Hall 1

#### PLENARY SESSION 1

Chair: **G. Hughes** (United Kingdom)  
Chair: **N.R. Rose** (USA)  
Chair: **P. Youinou** (France)  

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00</td>
<td>THE MANY FACES OF TRANSGlutaminase AND CELIAC DISEASE</td>
<td>A. Lerner (Germany)</td>
<td>26 Hall 1</td>
</tr>
<tr>
<td>8:30</td>
<td>SLE AND APS: TWO SYSTEMIC AUTOIMMUNE DISEASES CLOSE BUT STILL DIFFERENT</td>
<td>P.L. Meroni (Italy)</td>
<td>27 Hall 1</td>
</tr>
<tr>
<td>9:00</td>
<td>IL-17: FROM DISCOVERY TO TARGETING</td>
<td>P. Miossec (France)</td>
<td>28 Hall 1</td>
</tr>
<tr>
<td>9:30</td>
<td>RHEUMATOID ARTHRITIS: BEYOND ANTI-TNF - CAN WE DO BETTER?</td>
<td>R. van Vollenhoven (Sweden)</td>
<td>29 Hall 1</td>
</tr>
</tbody>
</table>
### 10:00 - 10:30

#### COFFEE BREAK & EXHIBITION

#### 10:00 - 10:30

**Station 1**

**E-PD01: APS: REVELATIONS**

**Chair:** R. Willis (USA)

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00</td>
<td>THE PLASMATIC PLATELET-ACTIVATING FACTOR ACETYLHYDROLASE ACTIVITY: A POSSIBLE RISK BIOMARKER IN PATIENTS WITH ANTI-PHOSPHOLIPID SYNDROME</td>
<td>A. Cifu’, M. Fabris, R. Giacomello, C. Pistis, E. Tonutti, F. Curcio (Italy)</td>
</tr>
<tr>
<td>10:05</td>
<td>NK CELLS EXPANSION ASSOCIATED WITH ANTI-PHOSPHOLIPID SYNDROME IN PATIENTS WITH RECURRENT REPRODUCTIVE FAILURE</td>
<td>A. Comins-Boo, J. Ochoa-Grullón, M. Núñez-Beltrán, A. García-Segovia, S. Sánchez-Ramón (Spain)</td>
</tr>
<tr>
<td>10:15</td>
<td>A NEW DIAGNOSTIC PROFILE FOR ANTI-PHOSPHOLIPID SYNDROME IN GENDER PERSPECTIVE</td>
<td>P. Sabatini, P. Amato, A.M. D’ursi, A. Vitagliano (Italy)</td>
</tr>
<tr>
<td>10:20</td>
<td>ANTIPHOSPHOLIPID AUTOANTIBODY VARIATION IN A PRIMARY ANTI-PHOSPHOLIPID ANTIBODY PATIENT - CLINICAL INSIGHTS</td>
<td>Z. Shums, R. Willis, C. Gleason, E.B. Gonzalez, M. Mahler, G.L. Norman (USA)</td>
</tr>
</tbody>
</table>
10:00 - 10:30  Station 2

**EPD02: NEW CYTOKINES: THE FLAME AND THE INFLAMED**

Chair: D. Thiyagarajan (Norway)

10:00  IL-33 IS PROCESSED INTO PRO-INFLAMMATORY ISOFORMS BY DYING NEUTROPHILS IN GRANULOMATOSIS WITH POLYANGIITIS  
A. Kerstein, A. Erschig, K. Holl-Ulrich, G. Marschner, S. Pitann, A. Mueller, G. Riemekasten, P. Lamprecht (Germany)

10:05  TOXICITY, TOXICOKINETICS AND IMMUNOGENICITY OF NOVEL IL-1 TRAP HETERODIMERIC FUSION PROTEIN  
A. Krotkova, E. Shipaeva, C.M. Luetjens, F.T. Ludwig, T. Hardwick, Y. Lavrovsky, M. Samsonov (Russia)

10:10  CLINICALLY INACTIVE DISEASE STATUS WITH TOCILIZUMAB EVERY 4 WEEKS IN REFRACTORY SYSTEMIC-ONSET JUVENILE IDIOPATHIC ARTHRITIS  
H. Xiao, H. Song, H. Wang, W. Wang, Y.H. Yanyan He, M. Wei (China)

10:15  ADIPONECTIN-ADIPOR1-STAT3 DEPENDENT PATHWAY IS A CRITICAL REGULATOR OF TH17 CELL DIFFERENTIATION IN COLLAGEN-INDUCED ARTHRITIS  
X. Sun, W. Tan, Y. Wang, M. Zhang (China)

10:20  ENDOGENOUS IL-1BETA PROMOTES NUCLEAR TRANSLOCATION AND A DE NOVO FUNCTION OF DNASEI AS TRANSCRIPTION FACTOR FOR THE FAS RECEPTOR GENE  
D. Thiyagarajan, H.L. Pedersen, K.D. Horvei, N. Seredkina, O.P. Rekvig (Norway)
10:00 - 10:30

Station 3

EPD03: SLE: THE DISEASE OF A THOUSAND FACES

Chair: S. Hirohata (Japan)

10:00 ETHOSUXIMIDE-INDUCED LUPUS-LIKE SYNDROME: A CASE REPORT
G. Zani, D. Vairo, M. Cattalini, S. Giliani, R. Ferraro, L. Giordano (Italy)

10:05 ROLE OF SERUM AUTOANTIBODIES IN BLOOD BRAIN BARRIER DAMAGES IN NEUROPSYCHIATRIC SYSTEMIC LUPUS ERYTHEMATOSUS
S. Hirohata, Y. Sakuma, T. Yanagida, T. Yoshio (Japan)

10:10 DIAGNOSIS AND TREATMENT DIFFICULTIES OF SLE AND LUNG TUBERCULOSIS COINFECTION
N. Indriyaningrum, H. Kalim, B.P.P. Suryana, C.S. Wahono (Indonesia)

10:15 INCIDENCE AND RISK FACTORS FOR FREQUENT HOSPITALIZATIONS IN SYSTEMIC LUPUS ERYTHEMATOSUS
S.S. Lee, J.W. Lee, D.J. Park, Y.R. Yim, J.E. Kim, L. Wen, K.E. Lee (Republic of Korea)

10:20 MUCOSAL-ASSOCIATED IN Variant T CELL DEFICIENCY IN SYSTEMIC LUPUS ERYTHEMATOSUS
Y.W. Park, S.J. Kee, Y.N. Cho, H.M. Jin (Republic of Korea)

10:25 FINDING POSSIBLE SURROGATE MARKERS OF RENAL BIOPSY IN PATIENTS OF LUPUS NEPHRITIS
I. Thakur, A. Karmakar, S.K. Chatterjee (India)
EPD04: MODERN AVENUES IN AUTOIMMUNE DIAGNOSTICS

Chair: F. Struck (Germany)

10:00 A NOVEL, AUTOMATED AND RANDOM-ACCESSED CHEMILUMINESCENCE IMMUNOASSAY ON TESTING TO ANTI-NUCLEAR ANTIBODIES IN HEALTHY INDIVIDUALS
X. Chen, Z. Chen, X. Zhang, Q. Li, Q. Wei, S. Cao, J. Gu, C. Lee, J. Li, L. Liu (China)

10:05 SHOULD DENSE FINE SPECKLED 70 (DFS70) PATTERN BE REPORTED?
BIOGNIS REFERENCE LAB EXPERIENCE ON 12619 ANA SCREENING CONSECUTIVE SERA
L. Guis, A. Ebel, J. Leroy, S.A. Michaud, A. Pomaredes, C. Marcenaro, L. Chalouas (France)

10:10 UTILITY ANTI-SINTHETASE ANTIBODIES FOR EVOLUTION IDIOPATHIC INTERSTITIAL LUNG DISEASE (ILD) TO SYSTEMIC AUTOIMMUNE DISEASE: PRELIMINARY STUDY
F. Marques-Garcia, M.B. Aparicio-Hernandez, I. De Los Santos, J.M. Gonzalez-Ruiz, M.D. Ludeña-Cruz (Spain)

10:15 THE STUDY OF ASTHMA AMONG PATIENTS WITH RHEUMATOID ARTHRITIS (RA) DISEASES
H.A. Khazaei, N.A. Moulaei, A. Khazaei, F. Hejazenia, B. Khazaei (Iran)

10:20 DEVELOPMENT AND EVALUATION OF 4G AUTOIMMUNE ANA PANEL ON THE AUTOMATED IMMUNOASSAY LUMIRAY® 1260 ANALYZER
C. Lee, L. Liu, F. Qin, Z. Ma, Y. Xie, J. Wang, J. Wang, L. Cui, Z. Zhao (China)

10:25 PERFORMANCE OF THE IMPROVED MIKROGEN LINE IMMUNOASSAY DETECTING CIRCULATING AUTOANTIBODIES TO NUCLEAR AND CYTOPLASMIC PROTEINS WITH SPECIAL CONSIDERATION OF SLE AUTOANTIGENS
F. Struck, T. Lütthich, I. Albrecht-Walz, O. Böcher, E. Soutschek (Germany)
10:00 - 10:30

Station 5

EPD05: Atherosclerosis and Autoimmunity

Chair: J. Schofield (USA)

10:00 Correlation between cardiovascular parameters and disease activity in patients with ankylosing spondylitis

L. Gianturco, F. Atzeni, S. Bongiovanni, L. Boccassini, P. Sarzi-Puttini, M. Turiel (Italy)

10:05 Evaluation of glucose metabolism in rheumatic patients: a case control study

M. Bellan, S. Bor, A. Gibbin, G. Guaschino, D. Sola, R. Pedrazzoli, A. Rossini, R. Bonometti, G.P. Carnavale Schianca, M. Pirisi, P.P. Sainaghi (Italy)

10:10 Anti-calreticulin autoantibodies and calreticulin in sera of patients diagnosed with dilated cardiomyopathy and patients with hypertrophic cardiomyopathy


10:15 Autonomic neuropathy – in its many guises – as the initial manifestation of the antiphospholipid syndrome

J. Schofield (USA)
10:00 - 10:30  Station 6

**EPD06: MULTIPLEX DIAGNOSTIC AND CHIP TECHNIQUE**

**Chair:** M.E. Crisostomo (USA)

10:00  THE BIOPLEX® 2200 ANTIPHOSPHOLIPID SYNDROME (APLS) MULTIPLEX IMMUNOASSAYS DEMONSTRATE HIGHER ANALYTICAL SENSITIVITY  
*M. Crisostomo*, S. Zhou, H. Scholz, R. Walker, E. Barrett (USA)

10:05  25-HYDROXY-VITAMIN D ON THE BIO-RAD BIOPLEX 2200 - COMPARISON WITH BECKMAN DXI AND MASS SPECTROMETRY  
D. Spradbery, R. Wilmot, **S. Holding** (United Kingdom)

10:10  NEXT GENERATION MULTIPLEX CHIP-BASED DETECTION OF AUTOANTIBODIES FOR THE DIAGNOSIS OF SYSTEMIC AUTOIMMUNE DISEASES: EXPERIENCE IN A TERTIARY CARE CENTER LABORATORY  

10:15  SCREENING FOR NOVEL AUTOANTIBODIES ON 42K PROTEIN MICROARRAYS  
R. Sjöberg, C. Hellström, E. Andersson, C. Mattsson, P. Nilsson (Sweden)

10:20  APLS AND CELIAC ANALYTICAL SENSITIVITY ON THE BIOPLEX 2200  
W. Vandam, M. Crisostomo, H. Scholz, R. Walker (USA)

10:25  COMPARISON OF FOUR AUTOMATED INDIRECT IMMUNOFLUORESCENCE SYSTEMS IN THE DETECTION OF ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES  
**S. Degandt**, M. Hutsebaut, P. Vogelee, H. Devos (Belgium)
10:00 - 10:30

Station 7

**EPD07: AUTOIMMUNITY AND HEMATOLOGY**

**Chair:** D. Škorić (Serbia)

10:00 CLINICAL MANIFESTATIONS OF IGG4-RELATED DISEASE IN COLOMBIA

10:05 A RARE CASE OF ERDHEIM-CHESTER DISEASE (ECD) MIMICKING IGG4-RELATED DISEASE (IGG4-RD)
E. Sokol, V. Vaslyev, S. Palshina, A. Pavlovskaya, N. Kokosadze (Russia) 71

10:10 PREVALENCE AND CLINICAL SIGNIFICANCE OF ANTITHYROID ANTIBODIES IN CHILDREN WITH IMMUNE THROMBOCYTOPENIC PURPURA-OUR EXPERIENCE
D. Škorić, J. Kovacevic, G. Milosevic (Serbia) 72

10:15 EFFECTS OF RITUXIMAB (RTX) THERAPY IN ADULT PATIENTS WITH HENOCH-SHONLEIN PURPURA (HSP)
F. Roberta, C. Naretto, G. Quattrocchio, M. Ferro, M. Paola, B. Giulietta, D. Roccatello (Italy) 73

10:20 AUTOIMMUNE HEMOLYTIC ANEMIA AND HODGKIN LYMPHOMA: A RARE ASSOCIATION
M. Kechida, N. Lorenzo Villalba, R. Klii, W. Bouteraa, S. Hammami, I. Khochtali (Tunisia) 74
10:00 - 10:30  Station 8

EPD08: HOW CAN WE IMMUNOMODULATE AUTOIMMUNE CONDITIONS?

Chair: J.C. Aguillón [Chile]

10:00 TRANSCRIPTIONAL PROGRAMS OF MONOCYTE-DERIVED TOLERGENIC DENDRITIC CELLS FROM RHEUMATOID ARTHRITIS PATIENTS AND HEALTHY SUBJECTS OBTAINED BY MODULATION WITH DEXAMETHASONE AND MONOPHOSPHORYL LIPID A


10:05 CONTRIBUTION OF CD8+ T CELLS IN THE PATHOPHYSIOLOGY OF AMYOTROPIC LATERAL SCLEROSIS


10:10 EXPLOITING ANNEXIN-INDUCED IMMUNOSUPRESSION TO INDUCE ANTIGEN-SPECIFIC TOLERANCE

C. Eck, H. Weyd, P.H. Krammer [Germany]

10:15 EFFECT OF HYPERLIPIDEMIA ON IL-17, IL-6 AND TGF-β SERUM LEVELS

E.F. Elf, E. Darwin [Indonesia]

10:20 DRUG REPURPOSING FOR AUTOIMMUNE DISEASES- FINDING NEW AGENTS TO TARGET NEUTROPHIL ACTIVATION

S. Ghorbanalipoor, R.J. Ludwig, D. Zillikens, K. Bieber [Germany]

10:25 DRUG RE-PURPOSING IDENTIFIES NOVEL B-CELL INHIBITORY DRUGS WITHIN THE PRESTWICK CHEMICAL LIBRARY®

10:30 - 12:30

PARALLEL SESSION 01: ETOLOGY AND PATHOGENESIS OF AUTOIMMUNITY

Chair: G. Steiner (Austria)  
Chair: E. Rosenthal (France)  
Chair: C. Chang (USA)

10:30 THE ROLE OF NUCLEIC ACIDS AND THEIR RECEPTORS IN THE PATHOGENESIS OF AUTOIMMUNE ARTHRITIS IN RATS AND MEN  
G. Steiner (Austria)

10:50 VASCULAR HYPOTHESIS REVISITED: ROLE OF STIMULATING ANTIBODIES AGAINST ANGIOTENSIN AND ENDOTHELIN RECEPTORS IN THE PATHOGENESIS OF SYSTEMIC SCLEROSIS  
G. Riemekasten (Germany)

11:10 ROLE OF MICROPARTICLES ON ENDOTHELIAL CELL FATE IN RHEUMATOID ARTHRITIS PATIENTS  
C. Barbati, C. Alessandri, T. Colasanti, M. Pendolino, V. Marta, F. Spinelli, F. Miranda, F. Conti, V. Guido (Italy)

11:20 ANTIGEN-DRIVEN SELECTION OF PLASMABLASTS, BUT NOT GENERAL GENETIC RESTRICTION OF NAIVE B CELLS, IS PATHOGNOMONIC FOR PEMPHIGUS VULGARIS PATIENT  

11:30 PANDEMRIX-ASSOCIATED NARCOLEPSY: SPECIFIC (AND UNEXPECTED) ANTIGEN-ASSOCIATED MOLECULAR MIMICRY COUPLED TO NON-SPECIFIC (AND EXPECTED) IMMUNOSTIMULATION  
S.S. Ahmed, W. Volkmuth, L. Steinman (Italy)

11:40 COMPARISON OF THE RELIABILITY OF CELIAC DISEASE SEROLOGY TO REFLECT INTESTINAL DAMAGE  
T. Matthias, P. Jeremias, S. Neidhoefer, A. Lerner (Germany)

11:50 A NOVEL FULLY HUMANIZED AND HIGHLY SENSITIVE ASSAY TO QUANTIFY NEUTROPHIL EXTRACELLULAR TRAPS (NETS) REVEAL ROS-INDEPENDENT NET RELEASE BY IMMUNE COMPLEXES  
12:00  ROLE OF EXTRACELLULAR VESICLES IN AUTOIMMUNE DISEASES
D. Turpin (France)  92

12:10  IMMUNE RESET - LESSONS FROM IMMUNOABLATION: A PATHOGENIC IMMUNOLOGIC MEMORY IS DRIVING CHRONIC INFLAMMATION
T. Alexander (Germany)  93

12:20  RETINOID-RELATED ORPHAN RECEPTOR GAMMA ADULT INDUCED KNOCKOUT MICE DEVELOPS LYMPHOBLASTIC LYMPHOMA

12:30-14:00  Exhibition
LUNCH BREAK, EXHIBITION, E-POSTER VIEWING
TLRSARSDAY

10:30 - 12:30

PARALLEL SESSION 02: CELIAC DISEASE: NOVELTIES IN 2016

Chair: M. Thomas (Germany) 95
Chair: J. Kratzsch (Germany) 96
Chair: T. Matthias (Germany) 97

10:30 PREDICTIVE POWER OF ANTIBODY ASSAYS IN THE DIAGNOSTICS OF COELIAC DISEASE
M. Thomas (Germany) 98

10:50 THE RELEVANCE OF HLA-DQ2/DQ8 DETERMINATION IN THE DIAGNOSIS OF CELIAC DISEASE
E. Tibenska (Slovakia) 99

11:10 NEW THERAPEUTIC STRATEGIES IN CELIAC DISEASE
D. Leffler (USA) 100

11:25 TG2 AND ANTI TG2: THE TWO SIDES OF THE COIN
K. Lindfors (Finland) 101

11:40 ANTI-MICROBIAL TRANSGlutaminase IS A NEW BIO-MARKER AND A POTENTIAL INDUCER OF CELIAC DISEASE
T. Matthias, P. Jeremias, S. Neidhofer, A. Lerner (Germany) 102

12:00 NEO-EPITOPE SEROLOGY A POWERFUL TOOL IN GLUTEN ASSOCIATED CONDITIONS
K. Guzmán-López, P. Jeremias, S. Neidhöfer, M. Torsten, A. Lerner, A. Plaza-López (Spain) 103

12:10 EVALUATION OF BIOPLEX 2200 FOR THE DETECTION OF IGA AND IGG ANTI-TRANSGlutaminase AND DEAMINATED GLIADIN PEPTIDE ANTIBODIES IN CELIAC DISEASE
J. Irure-ventura, E. Asensio, L. Riesco, D. Ramos, M. Toca, M. Lopez-Hoyos (Spain) 104

12:20 ANTIBODY DIAGNOSTICS IN PAEDIATRIC COELIAC DISEASE: REPORT ON AN ONGOING PROSPECTIVE MULTICENTRE TRIAL
J. Wolf, D. Hasenclever, D. Petroff, T. Mothes (Germany) 105

12:30-14:00

Exhibition

LUNCH BREAK, EXHIBITION, E-POSTER VIEWING
10:30 - 12:30

PARALLEL SESSION 03: IVIG: THE BEST BIOLOGIC?

Chair: D.R. Branch (Canada)  
Chair: M.G. Danielli (Italy)  
Chair: F. Käsermann (Switzerland)

10:30 IVIG AND AUTOIMMUNE DISEASE - POTENTIAL NEXT GENERATION BIOLOGICS 109
A. Zuercher, R. Spirig, A. Baz Morelli, F. Käsermann (Switzerland)

10:45 SMALL MOLECULE PHAGOCYTOSIS INHIBITORS FOR IMMUNE CYTOPENIAS 110
D.R. Branch, M.K. Purohit, A. Bello, M.C. Bareau, E. Burke-Murphy, T.N. Tong, A. Neschadim, L.P. Kotra (Canada)

11:00 MONOVALENT FC RECEPTOR BLOCKADE BY AN ANTI-FCY RECEPTOR/ALBUMIN FUSION PROTEIN 111
X. Yu, M. Menard, J. Prechl, V. Bhakta, W. Sheffield, A. Lazarus (Canada)

11:15 SELECTIVE IMMUNO-MODULATORS OF FC RECEPTORS FOR IMPROVED THERAPY OF ORPHAN AUTOIMMUNE DISEASES 112
A. Manning (USA)

11:35 THE ROLE OF SIALYLATION FOR THE ANTI-INFLAMMATORY ACTIVITY OF INTRAVENOUS IMMUNOGLOBULIN 113
I. Schwab, N. Washburn, C.J. Bosques, A. Lux, F. Nimmerjahn (Germany)

11:50 SPECIFIC IVIG AND ANTI-IDIOPTYPIC ANTIBODIES TO ANTI-CCP 114
M. Blank (Israel)

12:00 LONG-TERM BENEFIT AND SAFETY OF FACILITATED SUBCUTANEOUS IMMUNOGLOBULIN IN THE TREATMENT OF AUTOIMMUNE THROMBOCYTOPENIA CVID-LINKED 115
R. Morariu, S. Agolini, V. Pedini, L. Marinangeli, A. Gabrielli, D. Maria Giovanna (Italy)

12:10 RESPONSE TO SUBCUTANEOUS IMMUNOGLOBULIN (SCIG) IN DIFFERENT ORGAN SYSTEMS IN IDIOPATHIC INFLAMMATORY MYOPATHIES 116
V. Pedini, C. Gelardi, F. Lupidi, F. Logullo, A. Gabrielli, M.G. Danielli (Italy)

12:20 THERAPEUTIC MOROCCAN IVIG LOTS CONTAIN IGG ANTIBODIES AGAINST DIFFERENT HLA CLASS I AND II ALLELES 117
F. El Hilali, Vadim Jucaud, A.E.I. H. El Hilali, M. Moumni, Hamid Mazouz (Morocco)

12:30-14:00  
Exhibition

LUNCH BREAK, EXHIBITION, E-POSTER VIEWING
10:30 - 12:30

PARALLEL SESSION 04: STANDARDIZATION AND HARMONIZATION IN AUTOANTIBODY TESTING

Chair: N. Bizzaro (Italy) 118
Chair: J. Sheldon (United Kingdom) 119
Chair: B. Gilburd (Israel) 120

10:30 WHERE ARE WE IN STANDARDIZATION OF AUTOANTIBODY TESTING?
J. Sheldon (United Kingdom) 121

10:50 HARMONIZATION OF AUTOANTIBODY TESTING: CLINICAL AND DIAGNOSTIC ISSUES
N. Bizzaro (Italy) 122

11:10 THE INTERNATIONAL CONSENSUS ON STANDARDIZED NOMENCLATURE OF ANTINUCLEAR ANTIBODY HEP-2 CELL PATTERNS [ICAP] INITIATIVE - CURRENT STATUS AND INITIATIVES

11:30 THE BURDEN OF THE VARIABILITY INTRODUCED BY THE ASSAY KIT AND THE COMPUTER-AIDED DIAGNOSIS SYSTEM IN ANA INDIRECT IMMUNOFLUORESCENCE TEST
M. Infantino, F. Meacci, V. Grossi, F. Atzeni, P. Sarzi-Puttini, M. Benucci, P. Soda, M. Manfredi (Italy) 124

11:50 STANDARDIZATION IN THE DETECTION OF ANCA IN THE DIAGNOSIS AND FOLLOW-UP OF SMALL VESSEL VASCULITIS IS URGENTLY NEEDED
M. Oyaert, K. Vande Keere, L. Van Hoovels (Belgium) 125

12:00 MULTI-CENTER HARMONIZATION OF FLOW CYTOMETERS FOR MULTI-COLOR ANALYSES OF A LARGE COHORT OF PATIENTS IN THE CONTEXT OF THE EUROPEAN IMI PROJECT “PRECISESADS”

12:10 CAN NON-CONSENSUS ANTIPHOSPHOLIPID ANTIBODY ASSAY TECHNIQUES DIFFERENTIATE BETWEEN APS PATIENTS AND ANTIPHOSPHOLIPID ANTIBODY POSITIVE CARRIERS - TIME FOR RECONSIDERATION?
D. Roggenbuck, P. Schierack, M. Mahler, P. Macor, M.O. Borghi, P.L. Meroni (Germany) 127
12:20 ROLE OF GLYCOXIDATED-HISTONES IN SYSTEMIC LUPUS ERYTHEMATOSUS  
K. Alam (India)

12:30-14:00  
Exhibition  
LUNCH BREAK, EXHIBITION, E-POSTER VIEWING

10:30 - 12:30  
Hall 4  
PARALLEL SESSION 05: THE INTEGUMENT AND ORAL MUCOSA

Chair: M.D. Mignogna (Italy)  
Chair: S. Janket (USA)  
Chair: C. Selmi (Italy)

10:30 HCV RELATED IMMUNO-MEDIATED OROFACIAL DISORDERS  
M. Carrozzo (United Kingdom)

10:50 CLINICO-PATHOLOGICAL FEATURES OF ORAL LICHEN PLANUS AND LICHENOID REACTIONS  
S.B. Woo (USA)

11:10 ORO-FACIAL GRANULOMATOSIS: AN UPDATE  
S. Leuci (Italy)

11:30 ORO-PHARYNGEAL BLISTERING DISEASES  
M.D. Mignogna (Italy)

11:50 MODIFIED IMMUNOTHERAPY FOR ALOPECIA AREATA  
T. Yoshimasu, N. Mikita, N. Kanazawa, Y. Yamamoto, F. Furukawa (Japan)

12:00 OVERLAPPING IGG4 RESPONSES TO SELF AND ENVIRONMENTAL ANTIGENS IN ENDEMIC PEMPHIGUS FOLIACEUS  
Y. Qian (USA)

12:10 FAMILIAL CHILBLAIN LUPUS CAUSED BY AN ACTIVATING MUTATION IN STING  
N. König, C. Fiehn, H.M. Lorenz, V. Tüngler, C. Günther, O. Chara, M.A. Lee-Kirsch (Germany)

12:20 VESICULAR BULLOUS PEMPHIGOID AND PSORIASIS: A VERY RARE ASSOCIATION  
A. Lo Schiavo, R.V. Puca, F. Romano (Italy)

12:30-14:00  
Exhibition  
LUNCH BREAK, EXHIBITION, E-POSTER VIEWING
PARALLEL SESSION 06: CITRULLINATION (CCP)

Chair: G. Serre (France)  
Chair: A. Tanay (Israel)  
Chair: X. Bossuyt (Belgium)

10:30 PATHOPHYSIOLOGICAL ROLE(S) OF ACPA  
G. Serre (France)  

10:50 ACPA INDUCES PATHOGENIC CYTOKINE PROFILE IN LYMPHOCYTES AND OXIDATIVE BURST ACTIVITY IN NEUTROPHILS OF RHEUMATOID ARTHRITIS PATIENTS  
S. Gertel, Y. Shoenfeld, H. Amital (Israel)  

11:10 ANTI-CARBAMYLATED PROTEIN ANTIBODIES: FINE-SPECIFICITY AND CROSS-REACTIVITY  
M.K. Verheul, T. Huizinga, R. Toes, L. Trouw (Netherlands)  

11:30 ANTI-ALPHA-ENOLASE CITRULLINATED PEPTIDE 1 (CEP-1) ANTIBODIES AND PREDICTIVE RESPONSE TO TREATMENT IN RHEUMATOID ARTHRITIS: PRELIMINARY DATA  
M. Fredi, F. Gurrieri, I. Cavazzana, A. Tincani, F. Franceschini (Italy)  

11:40 CONFIRMATION OF SEROLOGICAL ANTIBODIES AGAINST NOVEL CITRULLINATED PROTEINS IN EARLY RHEUMATOID ARTHRITIS  
P. Schulz-Knappe, A. Lueking, P. Schriek, M. Von Darl, H. Goehler, H.D. Zucht, J. Richter, S. Vordenbaeumen, J. Detert, G.R. Burmester, M. Schneider (Germany)  

11:50 AMONG HUMAN MACROPHAGES POLARIZED TO DIFFERENT PHENOTYPES, THE M-CSF-ORIENTED CELLS PRESENT THE HIGHEST PRO-INFLAMMATORY RESPONSE TO THE RHEUMATOID ARTHRITIS-SPECIFIC IMMUNE COMPLEXES CONTAINING ACPA  
C. Clavel, L. Ceccato, F. Anquetil, G. Serre, M. Sebbag (France)  

12:00 FIRST IN CLASS THERAPEUTIC ACPAS REDUCE INFLAMMATION BY INHIBITION OF NETOSIS  
R. Chirivi, J. Van Rosmalen, G. Schmets, H. Van Es, J. Raats (Netherlands)
12:10  UNFOLDED PROTEIN RESPONSE GENE GADD34 (GROWTH ARREST AND DNA DAMAGE-INDUCIBLE GENE 34) IS OVEREXPRESSED IN RHEUMATOID ARTHRITIS AND RELATED TO ANTI-CITRULLINATED PROTEIN ANTIBODY CONCENTRATION


12:20  INCREASED RISK OF THROMBOEMBOLISM AMONG PATIENTS WITH VTE ASSOCIATION WITH RHEUMATOID ARTHRITIS

H. Amital (Israel)

12:30-14:00  Exhibition

LUNCH BREAK, EXHIBITION, E-POSTER VIEWING

12:30 - 14:00  MP3 & 4

Industry Supported Session:

NOT INCLUDED IN MAIN EVENT CME/CPD CREDIT
14:00 - 16:00  Hall 1

PARALLEL SESSION 07: HYGIENE THEORY, MICROBIOME, PROBIOTICS

Chair: L. Luján (Spain)  152
Chair: M. Blank (Israel)  153
Chair: D. Bogdanos (Greece)  154

14:00  MICROBIOME AND AUTOIMMUNITY

O. Koren (Israel)  155

14:20  THE MICROBIOME AND SLE: PROOF OF CONCEPT

G. Zandman-Goddard, T. Kolitz, N. Katz-Agranov (Israel)  156

14:40  HELMINTHES DERIVATIVE FOR TREATING EXPERIMENTAL COLLAGEN INDUCED ARTHRITIS

T. Bashi, M. Fridkin, A. Volkov, I. Barshack, M. Blank, Y. Shoenfeld (Israel)  157

14:55  NATURAL ANTIBODIES AGAINST SMALL LIPID EPITOPES AS PROTECTIVE FACTORS IN AUTOIMMUNITY AND ATHEROSCLEROSIS: A NEW DEVELOPMENT OF THE HYGIENE/MISSING OLD FRIENDS HYPOTHESIS

J. Frostegård, W. Tao, L. Råstam, U. Lindblad, S. Lindeberg (Sweden)  158

15:10  FHHDM-1, A PEPTIDE SECRETED BY THE HELMINTH FASCIOLA HEPATICA PREVENTS AUTOIMMUNE DIABETES AND REDUCES DISEASE SEVERITY OF MULTIPLE SCLEROSIS IN MURINE MODELS

M. Lund, J. Greer, B. O’Brien, J. Dalton, S. Donnelly (Australia)  159

15:20  SKIN MICROBIOME AND SYSTEMIC LUPUS ERYTHEMATOSUS: ASSOCIATION BETWEEN STAPHYLOCOCCUS AUREUS NASAL CARRIAGE AND DISEASE PHENOTYPE

F. Ceccarelli, G. Iaiani, C. Perricone, A. Giordano, F. Miranda, F.R. Spinelli, L. Massaro, V.A. Pacucci, S. Truglia, C. Alessandri, G. Valesini, F. Conti (Italy)  160

15:30  ACTIVATION OF TLR4 BY DYSBIOTIC INTESTINAL MICROBIOTA FOLLOWING IL-1 RECEPTOR ANTAGONIST DEFICIENCY TRIGGERS TH17-MEDIATED ARTHRITIS

R. Rogier, T. Ederveen, J. Boekhorst, H. Wopereis, S. Frambach, J. Garsssen, P. Van der Kraan, M. Koenders, W. Van den Berg, S. Van Hijum, S. Abdollahi-Roodsaz (Netherlands)  161
15:40  THE GUT MICROBIOTA EXACERBATE SPONTANEOUS AUTOIMMUNE HEPATITIS DEVELOPMENT IN A MOUSE MODEL THROUGH TOLL-LIKE RECEPTOR-DEPENDENT MECHANISMS
K. Alexandropoulos, E. Weinstein (USA)

15:50  EFFECTS OF SOCIAL STRESS ON THE FUNCTION OF IMMUNE SYSTEM ARE PARTIALLY IMPRINTED ON THE GUT MICROBIOTA COMPOSITION
O. Avni, O. Koren (Israel)

14:00 - 16:00  MP3 & 4
PARALLEL SESSION 08: NOVEL BIOLOGICS AND BIOSIMILARS
Chair: J. Aelion (USA)
Chair: A. Kromminga (Germany)
Chair: C. Edwards (United Kingdom)

14:00  ARE THERE DANGERS IN BIOLOGICAL THERAPY DOSE REDUCTION STRATEGIES?
C. Edwards (United Kingdom)

14:20  THE WANTED AND UNWANTED: IMMUNOGENICITY OF BIOLOGICALS
A. Kromminga (Germany)

14:40  BIOSIMILARS FROM A PRACTICING RHEUMATOLOGIST PERSPECTIVE
G.F. Schimizzi (USA)

15:00  POTENTIAL PITFALLS OF IMMUNOGENICITY AND PK ASSAYS: NEWS FROM THE BENCH
M. Schaab (Germany)

15:20  ANTIBODIES AGAINST CD74 AS BIOMARKERS OF AXIAL SPONDYLOARTHRITIS
T. Witte (Germany)

15:35  PROTEASOME INHIBITION WITH BORTEZOMIB AMELIORATES CLINICAL MANIFESTATIONS OF REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS BY PLASMA CELL DEPLETION AND TARGETING TYPE I INTERFERON ACTIVITY
T. Alexander (Germany)

15:50  BIOLOGICS AND BIOSIMILARS IN CLINICAL RHEUMATOLOGY PRACTICE- EXPERIENCE FROM SOUTH INDIA
S. Nallasivan (India)
14:00 - 16:00  
**Hall 2**  

**PARALLEL SESSION 09: B CELLS - PATHOGENESIS AND SUPPRESSION**

**Chair:** A.K. Abbas (USA)  
Chair: Z. Vadasz (Israel)  
Chair: C. Putterman (USA)

14:00  ARE B CELLS REQUIRED FOR THE DEVELOPMENT OF NEUROPSYCHIATRIC LUPUS?  
**C. Putterman** (USA)

14:20  RITUXIMAB IMMUNOTHERAPY IS ASSOCIATED WITH IMPROVEMENT OF PERIODONTAL IN SUBJECTS WITH RHEUMATOID ARTHRITIS  
**J.O. Pers**, J. Coat, J. Demoersman, D. Cornec, V. Devauchelle-Pensec, A. Saraux (France)

14:40  THERAPEUTIC LONGTERM DEPLETION OF AUTOACTIVE MEMORY NECESSITATES A COMBINED DEPLETION OF MEMORY PLASMA CELLS AND THEIR PROGENITORS  
A. Taddeo, C. Qingyu, L. Khodadadi, T. Alexander, G. Burmester, A. Radbruch, F. Hiepe, **B. Hoyer** (Germany)

15:00  BAFF, BCMA, CD20: HOW THEY ARE EXPRESSED IN LUPUS NEPHRITIS?  
C.A. Jimenez, J.P. Suso, F.E. Ospina, A.Y. Sánchez, C.A. Cañas, **G. Tobón** (Columbia)

15:10  B CELLS REGULATE HUMORAL RESPONSE THROUGH THE CONTROL OF FOLLICULAR HELPER T CELLS IN HEALTHY INDIVIDUALS AND SJOGREN’S PATIENTS BUT ARE DEFECTIVE IN SLE PATIENTS  
A. Achour, **J.O. Pers**, P. Youinou, C. Jamin (France)

15:20  BLOOD AND SALIVARY GLAND BAFF-DRIVEN B-CELL HYPERACTIVITY IN RITUXIMAB NON-RESPONDER PATIENTS WITH PRIMARY SJOGREN’S SYNDROME  

15:30  REGULATORY B CELLS IN SYSTEMIC SCLEROSIS (SSC) ISOLATED OR CONCOMITANT WITH HASHIMOTO THYROIDITIS (HT)  
I. Gatto, G. Mangino, P. Fallahi, A. Antonelli, **M. Centanni** (Italy)

15:40  LOW-DOSE RITUXIMAB RETREATMENT REGIMEN FOR PATIENTS WITH MIXED CRYOGLOBULINEMIA  
**S. Colantuono**, M. Visentini, M. Mitrevski, A. Boni, M. Fiorilli, M. Casato (Italy)
15:50 ALTERNATIVELY ACTIVATED DENDRITIC CELLS DERIVED FROM SYSTEMIC LUPUS ERYTHEMATOSUS HAVE TOLERGENIC PHENOTYPE AND IMMUNOMODULATORY FUNCTION
M.Y. Mok, H. Wu, Y. Lo (Hong Kong)

14:00 - 16:00 Hall 3

PARALLEL SESSION 10: IMMUNOMODULATION BY VITAMIN D AND IVIG

Chair: P. van Paassen (Netherlands)
Chair: T. Marshall (USA)
Chair: J. Damoiseaux (Netherlands)

14:00 VITAMIN D AS AN IMMUNOMODULATOR, PROTECTIVE OR HARMFUL? - AN INTRODUCTION
C. Dias (Portugal)

14:20 WHAT MORE IS THERE TO DISCOVER ABOUT VITAMIN D?
T. Marshall (USA)

14:40 SYSTEMIC LUPUS ERYTHEMATOSUS AND VITAMIN D
L. Andreoli (Italy)

15:00 C-REACTIVE PROTEIN AS AUXILIARY ELEMENT CONTROLLING IGG-ANTIBODY ACTIVITY AND CLINICAL OUTCOME IN (AUTO)IMMUNE THROMBOCYTOPENIAS
G. Vidarsson (Netherlands)

15:20 IMMUNOTHERAPY IN INFLAMMATORY HEART FAILURE: TO WAIT, TO MODULATE OR TO SUPPRESS?
P. van Paassen (Netherlands)

15:40 VITAMIN-D DEFICIENCY AS A RISK FACTOR FOR IMMUNODEFICIENCY AND AUTOIMMUNITY IN PATIENTS WITH ASIA DUE TO SILICONE BREAST IMPLANTS

15:50 THERAPY WITH EPICUTANEOUS APPLICATION OF MOG PLUS VITAMIN D ANALOGUE IS HIGHLY EFFECTIVE IN EXPERIMENTAL ENCEPHALOMYELITIS
S.F.G. Zorzella-Pezavento, L.A.N. Mimura, T.F.C. Fraga-Silva, L.L.W. Ishikawa, T.G.D. França, A. Sartori (Brazil)
14:00 - 16:00

PARALLEL SESSION 11: SYSTEMIC SCLEROSIS: NEW APPROACHES

Chair: M. Matucci Cerinic (Italy)
Chair: G. Riemekasten (Germany)
Chair: L. Mouthon (France)

14:00 NEW CHALLENGES IN THE DIAGNOSIS OF SYSTEMIC SCLEROSIS: DO ANTIBODIES REALLY COUNT?
M. Matucci Cerinic (Italy)

14:20 CHOOSING WISELY: HEALTHCARE ECONOMICS OF AUTOANTIBODY TESTING IN SCLERODERMA
M. Fritzler (Canada)

14:40 IMPLICATION OF B LYMPHOCYTES IN THE PATHOGENESIS OF SYSTEMIC SCLEROSIS
L. Mouthon (France)

15:00 ANTIBODIES AGAINST CHEMOKINE RECEPTORS CXCR3 AND CXCR4 ARE MARKERS FOR LUNG FIBROSIS IN PATIENTS WITH SYSTEMIC SCLEROSIS
G. Riemekasten, F. Weigold, D. Dragun, E. Siegert, H. Heidecke (Germany)

15:20 CHEMERIN SERUM LEVELS IN SYSTEMIC SCLEROSIS: A NOVEL MARKER OF EARLY AND ACTIVE DISEASE?

15:30 HUMAN ADIPOSE DERIVED MESENCHYMAL STEM CELLS: A POTENT THERAPY IN SYSTEMIC SCLEROSIS
A. Maria, K. Toupet, G. Fonteneau, M. Maumus, C. Bony, N. Pirot, A. Le Quellec, C. Jorgensen, D. Noël, P. Guilpain (France)

15:40 LOCALIZED SCLERODERMA: EXTRA-CUTANEOUS MANIFESTATIONS AND ASSOCIATION WITH OTHER AUTOIMMUNE DISEASES IN A SERIES OF 78 CASES
W.A. Sifuentes Giraldo, C. Sobrino Grande, L. Villalobos Sánchez, A. Alia Jiménez, E. De Las Heras Alonso, C. De la Puente Bujidos, M.L. Gámir Gámir (Spain)

15:50 MYSTERY OF T-REGULATORY CELLS IN SYSTEMIC SCLEROSIS
G. Slobodin (Israel)
14:00 - 16:00 Hall 5

PARALLEL SESSION 12: NOVEL AUTOANTIGENS: DFS70, 14-3-3η

Chair: N. Bizzaro (Italy)
Chair: S. Naides (USA)
Chair: C. Casiano (USA)

14:00 THE DFS70/LEDGFP75 ANTIGEN
C. Casiano (USA)

14:20 DIAGNOSTIC ACCURACY OF NEW IMMUNOBLOT METHODS FOR THE DETECTION OF ANTI-DENSE FINE SPECKLES (DFS70) ANTIBODIES

14:40 IMPROVED ANTI-NUCLEAR ANTIBODY (ANA) SCREENING USING A NOVEL HEP2 SUBSTRATE
K. Malyavantham, V. Ramsperger, E. Berleth, R. Paramanathan, M. Herold, W. Klotz, L. Suressh (USA)

14:50 COMPARISON OF FULLY AUTOMATED IIF SYSTEM AND CHEMILUMINESCENT IMMUNOASSAY FOR THE DETECTION OF ANTI-DFS70 ANTIBODIES IN PATIENTS WITH AND WITHOUT SYSTEMIC AUTOIMMUNE RHEUMATIC DISEASES
O. Shovman, B. Gilburd, C. Chayat, H. Amital, A. Watad, A. Guy, C. Bentow, M. Mahler, Y. Shoenfeld (Israel)

15:00 CLINICAL RELEVANCE OF ANTI-DFS70 AUTOANTIBODIES
K. Conrad, N. Röber, U. Höpner, M. Aringer, S. Rudolph, A. Gräßler, K. Lüthke, L. Unger, M. Mahler (Germany)

15:20 THE USE OF ANTI-DFS70 ANTIBODIES IN THE STUDY OF PATIENTS WITH SARD SUSPICION IS COST-EFFECTIVE
S. Gundín, J. Irure-ventura, E. Asensio, D. Ramos, M. Mahler, V. Martínez-Taboada, M. López-Hoyos (Spain)

15:30 SEEKING CLARIFICATION FOR THE POSITION OF ANTI-DFS70 ANTIBODY TESTING IN ANA TEST ALGORITHMS: RESULTS FROM AN ITALIAN STUDY
M. Infantino, C. Bentow, M. Mahler, M. Benucci, F. Li Gobbi, F. Atzeni, P. Sarzi-Puttini, V. Grossi, F. Meacci, M. Manfredi (Italy)

15:40 14-3-3η, A NEW DIAGNOSTIC MARKER- STATE OF THE ART
S. Naides (USA)
16:00 - 16:30

Station 1

EPD09: THE MOTHER AND THE CHILD: AUTOIMMUNE RELATIONSHIP

Chair: B. Böckle (Austria)

16:00  GENDER AND SEX DETERMINE THE CLINICAL COURSE OF LUPUS ERYTHEMATOSUS
B. Böckle, N. Sepp (Austria)

16:05  ANTI-PHOSPHOLIPID ANTIBODIES AD FEMALE INFERTILITY: A REVISION OF THE LITERATURE
C. Chighizola, G. De Jesus, Branch (Italy)

16:10  PREGNANCY IN SECONDARY ITP - IMMUNE TROMBOCYTOPENIC PURPURA, SLE - SYSTEMIC LUPUS ERYTHEMATOSUS AND APS - ANTIPHOSPHOLIPID SYNDROME
M. Dapcevic (Montenegro)

16:15  AUTO-ANTIBODIES PROFILE IN PATIENTS WITH OBSTETRIC COMPLICATIONS
Y. Lounici, R. Djidjik (Algeria)

16:20  REVIEW CAUSES ASSOCIATED TO FOETAL DEATH IN 38 PATIENTS

16:25  CYTOKINES PROFILE IN PATIENTS WITH EXPANDED NATURAL KILLER CELLS AND RECURRENT REPRODUCTIVE FAILURE
E. Rodriguez Frias, R. Ramos Medina, B. Alonso, M. Nuñez Beltran, A. Comins, S. Sánchez Ramón (Spain)
16:00 - 16:30

Station 2

**EPD10: ETIOLOGY AND MECHANISM OF AUTOIMMUNITY**

Chair: G. Murdaca (Italy) 225

16:00  PYODERMA GANGRENOSUM IN A PATIENT WITH JUVENILE DERMATOMYOSITIS: A RARE PRESENTATION 226
T. Castro, P. Bernardi, S. Lotufo (Brazil)

16:05  POTENTIAL IMPLICATIONS OF THE ENDOPLASMIC RETICULUM ASSOCIATED DEGRADATION IN AUTOIMMUNE DISEASES 227
A. Circiumaru, G. Chiritoiu, L. Sima, M. Bojinca (Romania)

16:10  IMMUNE MECHANISMS OF IFN-ALPHA IN RELAPSING AND MONOPHASIC RAT EXPERIMENTAL AUTOIMMUNE UVEITIS 228
X. Liu, M. Diedrichs-Möhring, G. Wildner (Germany)

16:15  EVALUATION OF SOLUBLE HLA-G IN SYSTEMIC SCLEROSIS 229
G. Murdaca, P. Contini, M. Borro, S. Negrini, F. Puppo (Italy)

16:20  FOOD INTOLERANCE DEPENDED AUTO-IMMUNITY. IS IT A NEW SYNDROME? 230
A.G. Sahan, E. Demirpehlivan, A. Yilmaz, H. Sıvgın, M. Sagcan, E. Bastug, K. Tuna (Turkey)

16:25  INVOLVEMENT OF POST-TRANSLATIONAL MODIFICATION BY REACTIVE OXYGEN SPECIES OF NEURONAL PROTEINS IN THE PATHOLOGY OF MULTIPLE SCLEROSIS 231
C. Vinci (United Kingdom)
16:00 - 16:30

**Station 3**

**EPD11: SLE: MORE SYSTEMIC THAN SYSTEMIC**

*Chair: S. Bettio (Italy)*

**16:00**  
BELIMUMAB IS EFFECTIVE AND REDUCE THE FREQUENCY OF FLARE IN PATIENTS WITH REFRACTORY ARTHRITIS IN A CLINICAL PRACTICE SETTING


**16:05**  
INCREASES CD19CD27C38 B-LYMPHOCYTES IN PATIENTS WITH SYSTEMIC RHEUMATIC DISEASES ARE NOT INFLUENCED BY IMMUNOSUPPRESSIVE THERAPY

*A. Budkova*, S. Lapin, I. Kudryavtsev, I. Trishina, A. Maslyansky (Russia)

**16:10**  
CD4+CD25-FOXP3+ T-CELLS AS A MARKER FOR SYSTEMIC LUPUS NEPHRITIS IN SUEZ CANAL UNIVERSITY HOSPITAL

*O. Dessouki*, L. Metwally, N. El-Maraghy, M. Ghaly, S. Younes (Egypt)

**16:15**  
DISTAL RENAL TUBULAR ACIDOSIS AS THE PRESENTING ILLNESS OF SYSTEMIC LUPUS NEPHRITIS : A CASE STUDY V.S SELVAN, ONG. ZY KHOO TECK PUAT HOSPITAL, SINGAPORE

*S. Senthamilveerasamy* (Singapore)

**16:20**  
PROTEIN PROFILING REVEALS MOLECULAR SUBGROUPS IN SYSTEMIC LUPUS ERYTHOMATOSUS

16:00 - 16:30

Station 4

EPD12: STEPS IN AUTOIMMUNE DIAGNOSTICS

Chair: A. Radice (Italy)

16:00 AUTOANTIBODIES BINDING TO MACROPAIN SUBUNIT C2 IN AOSD
H. Marius, W. Torsten, F. Eugen, M. Frank, G. Wolfgang, F. Dirk, H. Dirk,
S. Reinhold E, N. Baerlecken (Germany)

16:05 EFFECT OF STORAGE CONDITIONS ON C3 AND C4 COMPLEMENT
COMPONENTS IN SERUM
R. Galovic, N. Tomić Sremec, A. Kozmar (Croatia)

16:10 EVALUATION OF A RECENTLY DEVELOPPELED ENZYME LINKED
IMMUNOSORBENT ASSAY FOR THE DETERMINATION OF ANTI-
PHOSPHOLIPASE A2 RECEPTOR ANTIBODIES
A.S. Messiaen, M. Speeckaert, W. Uyttenbroeck, J. Penders, L. Van
Hoovels, C. Verfaillie, L. Persijn, C. Bonroy (Belgium)

16:15 THE VALUE OF ELECTROMYOGRAPHY IN THE DIAGNOSTIC OF
INFLAMMATORY MYOPATHIES - A PROSPECTIVE STUDY ON PATIENTS
WITH WEAKNESS AND MUSCLE PAIN
M.M. Negru, A. Doran, F. Berghea, A. Balanescu, V. Bojinca, D. Opris,
L. Groseanu, I. Saulescu, S. Daia, D. Predeteanu, R. Ionescu (Romania)

16:20 DIAGNOSTIC PERFORMANCE OF ANTI-M-TYPE PHOSPHOLIPASE
A2 RECEPTOR (PLA2R) ANTIBODIES IN IDIOPATHIC MEMBRANOUS
NEPHROPATHY (IMN)
A. Radice, B. Trezzi, G. Ghiggeri, P. Napodano, M. D’Amico, T. Stellato,
R. Brugnano, F. Ravera, D. Rolla, G. Pesce, R. Scanziani, F. Londrino,
D. Santoro, G. Ortisi, R.A. Sinico (Italy)

16:25 MUCOUS MEMBRANE PEMPHIGOID: CLINICOPATHOLOGICAL STUDY IN
EIGHTY SEVEN CASES OF ORAL MUCOSA, UNIVERSITY OF CHILE
R. Sáez-Salgado, D. Adorno, I. Espinoza, M. Solar (Chile)
16:00 - 16:30
Station 5

EPD13: CANCER AND AUTOIMMUNITY

Chair: C. Jamin [France] 245

16:00 IN THE SEARCH OF A HIDDEN TUMOUR: UTILITY OF ONCONEURAL ANTIBODIES
J.L. García de Veas Silva, M.V. Fernandez Varela, M.D.S. Lopez Velez, J.V. Garcia Lario, R. Ruiz Requena, T. De Haro Muñoz [Spain] 246

16:05 IDENTIFICATION AND ROLE OF REGULATORY B CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA

16:10 ANGIOEDEMA: A CORRELATE/CONSEQUENCE OF PSA-SECRETING PROSTATE CANCER?
D. Maddox, K. Rossow [USA] 248

16:15 NON-ORGAN SPECIFIC AUTOIMMUNITY IN CANCER PATIENTS IS ASSOCIATED WITH METASTATIC DISEASE AND POORER PROGNOSIS IN A FIVE-YEAR FOLLOW-UP STUDY
S. Mancini, P. Sena, F. Mariani, P. Muratori, L. Muratori, C. Degli Esposti, A. Manenti, M.T. Mascia, L. Roncucci [Italy] 249

16:20 SCREENING THE AUTOIMMUNE RESPONSE OF PROSTATE CANCER IDENTIFIED PROSTEIN REACTIVITY ASSOCIATION TO CANCER STAGE

16:25 THE CLINICAL SIGNIFICANCE OF ANTI-MITOTIC SPINDLE APPARATUS ANTIBODY (MSA) AND ANTI-CENTROMERE ANTIBODY DETECTED IN PATIENTS WITH SMALL CELL LUNG CANCER (SCLC)
L. Tan [China] 251
16:00 - 16:30

Station 6

**EPD14: VASCULITIS: THE AUTOIMMUNE INFLAMMATION OF THE VESSELS**

**Chair: I. Marie** (France)

16:00 _LONG-TERM FOLLOW-UP OF AORTIC INVOLVEMENT IN RELAPSING POLYCHONDritis_
I. Marie (France)

16:05 _VASCULITIS INDUCED BY TNF-ALPHA INHIBITORS- REPORT OF 2 CASES_
R. Olteanu, A. Zota, C. Stoian (Romania)

16:10 _STANDARDIZATION OF ANCA IIF AS SCREENING TOOL FOR THE DIAGNOSIS AND FOLLOW-UP OF SMALL VESSEL VASCULITIS IS URGENTLY NEEDED_
M. Oyaert, K. Vande Keere, L. Van Hoovels (Belgium)

16:15 _FROSTED BRANCH ANGIITIS: A RARE MANIFESTATION OF BEHCET’S DISEASE. THE ROLE OF ANTI-TNF THERAPY_
P. Sierzputowski, C. Silvestre, I. Goncalves, T. Marques, M.J. Gomes (Portugal)
E-POSTERS

16:00 - 16:30

Station 7

EPD15: NOVEL THERAPIES IN AUTOIMMUNITY

Chair: M. Diedrichs-Möhring (Germany)

16:00 TARGETING DIHYDROOROTATE DEHYDROGENASE FOR TREATING INFLAMMATION AND CHORIORETINAL NEOVASCULARIZATION IN RELAPSING-REMITTING AND CHRONIC EXPERIMENTAL AUTOIMMUNE UVEITIS

M. Diedrichs-Möhring, S. Niesik, J. Leban, S. Strobl, F. Obermayr, S. Thurau, G. Wildner (Germany)

16:05 PERIPHERAL BLOOD B-CELL PHENOTYPE IS AFFECTED BY TNF-INHIBITORS AND TOCILIZUMAB TREATMENT IN RHEUMATOID ARTHRITIS


16:10 COMBINATORIAL ANTIBODY PHAGE DISPLAY LIBRARIES CONSTRUCTED FROM B-CELLS INFILTRATING BRAIN TISSUE OF PEOPLE WITH PROGRESSIVE MULTIPLE SCLEROSIS

C. Maggiore, G. Giovannoni, J. Martin, A. Nissim (United Kingdom)

16:15 MILD BLOCKADE OF KV2.1 CHANNEL POTENTIATES GLP-1’S INSULINOTROPIC EFFECTS IN ISLETS AND REDUCES ITS DOSES REQUIRED FOR IMPROVING GLUCOSE TOLERANCE IN DIABETIC MALE MICE

R. Sukma Rita, K. Dezaki, T. Yada (Indonesia)

16:20 TNF, IL-1 BETA AND LPS INDUCES ANNEXIN-A5 SECRETION IN HUMAN ENDOTHELIAL AND OSTEOARTHRITIS-DERIVED CHONDROCYTES

D. Thiyagarajan, A. Frostegård, J. Frostegård (Sweden)
16:00 - 16:30

Station 8

EPD16: THE BUGS AND US: INTERRELATIONSHIP OF AUTOIMMUNITY

Chair: B. Donatini (France)

16:00 METHOTREXATE (MTX) AND ANTI-TNF TREATMENT IMPROVE ENDOTHELIAL FUNCTION (EF) IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA), PSORIATIC ARTHRITIS (PSA) AND ANKYLOSING SPONDYLITIS (AS)

G. Deyab, I. Hokstad, S. Agewall, M.C. Småstuen, I. Hollan (Norway)

16:05 CROHN DISEASE (CD) WITH ORAL LESIONS IS ASSOCIATED WITH A DECREASED ORAL PORTAGE OF HUMAN PAPILLOMAVIRUS 16 OR 18 (HPV 16/18)

B. Donatini, I. Le Blaye (France)

16:10 CHIKUNGUNYA VIRAL ARTHRITIS IN MEXICO: INFLAMMATORY BIOMARKERS MAY BE PREDICTORS OF CHRONIC ARTHRITIS

J. Sepulveda-Delgado, O. Vera-Lastra, O. Gomez-Cruz, K. Trujilo-Murillo, I. Fernandez-Salas, L. Jara (Mexico)

16:15 COMPARASION OF INTERLEUKIN-1 BETA (IL-1 β ) IN SALIVA ON PERIODONTAL DISEASE

N. Kasuma, A. Aida Fitria (Indonesia)

16:20 A DISTINCT CUTANEOUS MICROBIOTA PROFILE IN AUTOIMMUNE BULLOUS DISEASE PATIENTS


16:25 ENHANCED LEVELS OF NATURAL ANTI-IFN-GAMMA AUTOANTIBODIES IN PATIENTS WITH VISCERAL LEISHMANIASIS DETECTED WITH A NOVEL CAPTURE IMMUNOASSAY. IMPLICATIONS FOR DISEASE PATHOGENESIS

W. Van der Meide, E. Pinelli, A. Tarasov, R. Groenestein, E. Don, H. Van Lith, T. Kortbeek, S. Tarasov, O. Epstein, P. Van der Meide (Netherlands)
16:30 - 18:30

PARALLEL SESSION 13: VASCUlITIDES

Chair: F. Fervenza (USA)  
Chair: W.L. Gross (Germany)  
Chair: U. Specks (USA)

16:30 FROM PATHOGENESIS TO TREATMENT OF MEMBRANOUS NEPHROPATHY IN 2016
F. Fervenza (USA)

16:50 FROM UNDERSTANDING PATHOGENESIS TO TARGETED THERAPY IN ANCA-ASSOCIATED VASCUlITIS
U. Specks (USA)

17:10 IGG4 RELATED DISEASE - A VASCUlITIS MIMIC
D. D’Cruz (United Kingdom)

17:25 IDIOPATHIC ANCA ASSOCIATED VASCUlITIDES VERSUS AAV WITH PROBABLE ETIOLOGY: CLINICAL AND IMMUNOLOGICAL ASPECTS
W.L. Gross (Germany)

17:40 CRYOFIBRINOGENEMIAS : AN UPDATE
M. Michaud (France)

17:50 THE ROLE OF HYDROXYCHLOROQUINE IN ANCA POSITIVE AND NEGATIVE VASCUlITIS
A. Casian, S. Sangle, D. D’Cruz (United Kingdom)

18:00 EFFICACY OF BIOLOGICAL-TARGETED TREATMENTS IN TAKAYASU ARTERITIS: MULTICENTER RETROSPECTIVE STUDY OF 49 PATIENTS

18:10 RISK FACTORS FOR VENOUS THROMBOEMBOLISM IN ANCA-ASSOCIATED VASCUlITIDES: PROSPECTIVE DATA FROM THE EUROPEAN VASCUlITIS SOCIETY (EUVAS) TRIALS
A. Kronbichler, J. Leierer, G. Mayer, A. Casian, K. Westman, P. Hoglund, D. Jayne (Austria)
18:20  COGAN SYNDROME: FRENCH NATIONWIDE RETROSPECTIVE STUDY OF 40 PATIENTS

PARALLEL SESSION 14: VACCINES AND AUTOIMMUNITY

Chair: L. Tomljenovic (Canada)  282
Chair: C. Dwoskin (USA)  283
Chair: D. Kanduc (Italy)  284

16:30 FROM HBV TO HPV: DESIGNING VACCINES FOR EXTENSIVE AND INTENSIVE VACCINATION CAMPAIGNS WORLDWIDE  285
D. Kanduc (Italy)

16:50 ANALYSIS OF MOUSE OVARIAN RESERVE UPON ADMINISTRATION OF EITHER HUMAN-PAPILLOMAVIRUS VACCINE OR ALUMINUM  286
N. Gruber, O. Pinhas-Hamiel, M. Blank, L. Kalich-Philosoph, D. Galiani, N. Dekel, Y. Shoenfeld (Israel)

17:10 CHRONIC FATIGUE SYNDROME FOLLOWING HUMAN PAPILLOMA VIRUS VACCINATION; IS LATENT EPIPHARYNGITIS TO BLAME?  287
O. Hotta, A. Tanaka, A. Torigoe, K. Imai, N. Ieiri (Japan)

17:20 QUADRIVALENT HUMAN PAPILLOMAVIRUS VACCINE AND THE YOUNG ADOLESCENT OVARY: REVIEW OF SAFETY RESEARCH FOLLOWING TWO CASE SERIES OF PREMATURE OVARIAN INSUFFICIENCY  288
D. Little (Australia)

17:30 5 CASE SERIES OF PREMATURE OVARIAN FAILURE WITHIN 3 YEARS OF HPV VACCINE INOCULATION: IS THIS ASIA SYNDROME AND WHAT ARE THE IMPLICATIONS?  289
H. Ward (Australia)

17:40 POST-VACCINATION INFLAMMATORY SYNDROME: A NEW SYNDROME?  290
G. Giannotta (Italy)

17:50 VACCINATION AND IMMUNE THROMBOCYTOPENIC PURPURA: A MOLECULAR MIMICRY SPREADING TO AN AUTOIMMUNE DISEASE  291
M. Bizjak (Slovenia)

18:00 AUTOIMMUNE REACTION AFTER ANTI-TETANUS VACCINATION-DESCRIPTION OF 4 CASES AND REVIEW OF THE LITERATURE  292
N. Ruhrman-Shahar, Y. Levy (Israel)

18:10 VACCINES, ADJUVANTS AND AUTOIMMUNITY  293
L. Eça Guimarães, B. Baker, C. Perricone, Y. Shoenfeld (Portugal)

18:20 REVERSE VACCINES TO TREAT DEGENERATIVE DISEASES  294
P. De Haan (Netherlands)
THURSDAY, APRIL 7

16:30 - 18:30

PARALLEL SESSION 15: AUTOIMMUNE PATHWAYS IN MULTIPLE SCLEROSIS, MYASTHENIA GRAVIS AND THE CENTRAL NERVOUS SYSTEM

Chair: R. Milo (Israel)
Chair: S. Berrih-Aknin (France)
Chair: A. Bar Or (Canada)

16:30 B-CELL BIOLOGY IN MULTIPLE SCLEROSIS
A. Bar Or (Canada)

16:50 THERAPEUTIC STRATEGIES TARGETING B-CELLS IN MULTIPLE SCLEROSIS
R. Milo (Israel)

17:10 POLYMERASE 1 INHIBITOR RAM-589.555 - AN INNOVATIVE TARGETED TREATMENT FOR MULTIPLE SCLEROSIS
A. Achiron, R. Falb, M. Roi, M. Gurevich (Israel)

17:25 MYASTHENIA GRAVIS: NEW CONCEPT OF THE PATHOPHYSIOLOGY
S. Berrih-Aknin (France)

17:40 ANOCTAMIN 2 IDENTIFIED AS AN AUTOIMMUNE TARGET IN MULTIPLE SCLEROSIS

17:50 AUTOANTIBODIES AGAINST THE FLOTILLIN COMPLEX IN OPTIC NEURITIS ASSOCIATED WITH MULTIPLE SCLEROSIS

18:00 AUTOIMMUNITY ANNEXIN AND ANXIETY
R. Weiss, A. Bitton, M. Elgart, L. Nahary, I. Benhar, M. Blank, J. Chapman (Israel)

18:10 INTEGRATIVE TREATMENT OF MULTIPLE SCLEROSIS. THE PSYCHO-NEURO-IMMUNO-TOXICOLOGY APPROACH
B. Brunes (Sweden)

18:20 ANXIETY AND DEPRESSION IN INFLAMMATORY RHEUMATIC DISEASES
M. Petric, D. Martinovic Kaliterna, D. Perkovic, M. Nuic, I. Bozic, M. Radic, D. Marasovic Krstulovic, K. Boric (Croatia)
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker Details</th>
<th>Session Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:30</td>
<td>CLINICAL SIGNIFICANCE AND NEW DETECTION SYSTEMS OF MYOSITIS-SPECIFIC AUTOANTIBODIES</td>
<td>T. Mimori, S. Sato, M. Kuwana, M. Fujimoto (Japan)</td>
<td>307</td>
</tr>
<tr>
<td>16:50</td>
<td>A PHAGE DISPLAY SCREEN FOR NOVEL THERANOSTIC AUTOANTIBODIES IN RHEUMATOID ARTHRITIS</td>
<td>P. Vandormael, D. Quaden, P. Verschueren, V. Somers (Belgium)</td>
<td>311</td>
</tr>
<tr>
<td>17:05</td>
<td>ANALYTICAL AND CLINICAL COMPARISON OF TWO FULLY AUTOMATED IMMUNOASSAY SYSTEMS FOR THE DETECTION OF AUTOANTIBODIES TO EXTRACTABLE NUCLEAR ANTIGENS</td>
<td>P. Van der Pol, L.E. Bakker-Jonges, J.H.S.A.M. Kuijpers, H. Hooijkaas, M.W.J. Schreurs (Netherlands)</td>
<td>312</td>
</tr>
<tr>
<td>17:30</td>
<td>RELATIONSHIP BETWEEN AUTOANTIBODIES TO OXIDIZED LIPOPROTEINS AND ANGIOGRAPHIC DATA IN PATIENTS WITH CORONARY STENOSIS</td>
<td>S. Urazgildeeva, L. Vasina, M. Muzalevskaya, A. Titkov, V. Gurevich (Russia)</td>
<td>314</td>
</tr>
<tr>
<td>17:40</td>
<td>AUTOANTIBODIES AGAINST BONE MORPHOGENETIC PROTEIN 7 IN FRACTURE PATIENTS</td>
<td>A. Schuette, A. Moghaddam, P. Seemann, G. Schmidmaier, L. Schomburg (Germany)</td>
<td>315</td>
</tr>
<tr>
<td>17:50</td>
<td>COMPARATIVE SURVEY OF ADVERSE EVENTS RELATED TO HIGH COST IMMUNOBIOLOGICAL MEDICINES OF SPECIALIZED COMPONENTS OF PHARMACEUTICAL ASSISTANCE TO TREAT COMPLEX DISEASES</td>
<td>I.C. Gubert, V.C. Zanetti, J. Santos, E.L. Feller (Brazil)</td>
<td>316</td>
</tr>
</tbody>
</table>
18:00  EVALUATION OF STAT4, TRAF3IP2 AND HCP5 GENES IN SJOGREN’S SYNDROME: ASSOCIATION WITH DISEASE SUSCEPTIBILITY AND CLINICAL ASPECTS  
S. Colafrancesco, C. Perricone, R. Priori, G. Picarelli, C. Ciccacci, P. Borgiani, G. Valesini (Italy)

18:10  AUTOANTIBODIES BINDING TO STATHMIN AS MARKER OF POLYNEUROPATHY IN PRIMARY SJOGREN SYNDROME  
R. Sabrina, W. Torsten, M. Stangel, S. Reinhold E, N. Baerlecken (Germany)

18:20  AUTO ANTIBODY PROFILING OF PATIENTS WITH SCHIZOPHRENIA  
D. Just, A. Häggmark, E. Lindholm Carlström, E. Jönsson, J.L. Cunningham, P. Nilsson (Sweden)
16:30 - 18:30

PARALLEL SESSION 17: THE AUTOIMMUNE BASIS OF REPRODUCTIVE FAILURE

Chair: C. Huang [China]
Chair: J. Kwak-Kim (USA)
Chair: C. De Carolis (Italy)

16:30 THE PREVALENCE OF ANTIPHOSPHOLIPID ANTIBODIES, ANTI-THYROID ANTIBODIES AND ANTI-NUCLEAR ANTIBODIES IN PATIENTS EXPERIENCING INFERTILITY, REPEATED IMPLANTATION FAILURE AND RECURRENT MISCARRIAGE

C. Huang, X. Chen, L. Diao, R. Lian, T. Zhang, J. Xu, Y. Zeng (China)

16:50 CELLULAR AND HUMORAL AUTOIMMUNITY IN RECURRENT PREGNANCY LOSSES AND MULTIPLE IMPLANTATION FAILURES, AND A POSSIBLE ROLE OF VITAMIN D

J. Kwak-Kim (USA)

17:10 RECURRENT SPONTANEOUS ABORTION: THE GOOD, THE BAD AND THE UGLY

C. De Carolis, C. Perricone, R. Perricone (Italy)

17:30 RISK FACTORS FOR REPRODUCTIVE FAILURE IN ANTIPHOSPHOLIPID SYNDROME

S. De Carolis, S. Salvi, A. Botta, G. Del Sordo, S. Tabacco, A. Lanzone (Italy)

17:50 HLA -DQ2/DQ8 HAPLOTYPES IN RECURRENT PREGNANCY LOSS WOMEN: IS THERE A COMMON LINK WITH CELIAC DISEASE?

S. D’Ippolito, A. Gasbarrini, G. Scambia, N. Di Simone (Italy)

18:00 HUMAN IGG ANTINUCLEAR ANTIBODIES INDUCE PREGNANCY LOSS IN MICE BY INCREASING IMMUNE-COMPLEX DEPOSITION IN PLACENTAL TISSUE: POSSIBLE MECHANISM UNDERLYING THE POOR OBSTETRIC OUTCOME


18:10 EFFECT OF TUMOR NECROSIS FACTOR INHIBITOR PLUS INTRAVENOUS IMMUNOGLOBULIN TREATMENT ON PREGNANCY OUTCOMES IN WOMEN WITH RECURRENT IMPLANTATION FAILURE: A RETROSPECTIVE SINGLE CENTER STUDY

L. Diao, C. Huang, X. Chen, J. Saarimaki, P. Liang, R. Lian, Y. Zeng (China)

18:20 INTRALIPIDS THERAPY IN CHRONIC HISTIOCYTIC INTERVILLOSITIS

A. Bilgar, F. Olivier, C. Lionel, N. Pascale, M. Arsene (France)
16:30 - 18:30  
**Hall 5**

**PARALLEL SESSION 18: AUTOIMMUNE HEMATOLOGICAL DISEASES**

Chair: **D. Cines** (USA)  
Chair: **M. Lee-Kirsch** (Germany)  
Chair: **M. Abu Shakra** (Israel)

16:30  STRUCTURAL BASIS OF AUTOANTIGEN FORMATION IN HEPARIN-INDUCED THROMBOCYTOPENIA  
Zheng Cai, Mark I. Greene, **D. Cines** (USA)  

16:50  LEUKOCYTE IMMUNOGLOBULIN-LIKE RECEPTORS IN AUTOIMMUNITY  
**T. Witte** (Germany)

17:10  PATHOPHYSIOLOGY AND LABORATORY DIAGNOSIS OF PERNICIOUS ANAEMIA  
**B.H. Toh** (Australia)

17:20  EPISODIC ANGIOEDEMA WITH EOSINOPHILIA (Gleich Syndrome): A SURVEY OF 29 CASES  

17:30  ASSESSMENT OF ENDOTHELIAL DAMAGE AND CARDIAC INJURY IN A NEW MOUSE MODEL OF ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA  

17:40  INHERITED THROMBOPHILIA IN WOMEN WITH POOR APL-RELATED OBSTETRIC HISTORY: PREVALENCE AND OUTCOMES. SURVEY OF 203 CASES FROM THE EUROAPS* COHORT  

17:50  FACTORS RELATED TO ERYTHROCYTE AUTOANTIBODY PRODUCTION IN TRANSFUSION DEPENDENT THALASSEMIA  
**A. Kurniawan**, D. Atmakusuma, L. Sukrisman (Indonesia)
18:00  ERYTHROCYTE’S CD59 REVERSIBLE DEFICIENCY PARTICIPATES IN COLD AGGLUTININ AUTO-IMMUNE HEMOLYSIC ANEMIA (CA-AIHA) PATHOGENESIS 341

18:10  AN IDIOPATHIC THROMBOCYTOPENIC PURPURA WITH POLINEUROPATHY 342
   P. David, V. Katchan, Y. Shoenfeld (Brazil)

18:20  SPONTANEOUS RUPTURE OF KIDNEY IN A CHRONIC REFRACTORY IDIOPATHIC THROMBOCYTOPENIC PURPURA CASE: A RARE EVENT 343
   A. Bajpayee, N. Bajpai (India)
JOIN US IN MELBOURNE

ABSTRACT SUBMISSION DEADLINE:
13 SEPTEMBER 2016

12TH INTERNATIONAL CONGRESS ON SLE &
7TH ASIAN CONGRESS ON AUTOIMMUNITY

LUPUS 2017

26-29 MARCH 2017
MELBOURNE, AUSTRALIA

www.lupus2017.org
### FRIDAY, APRIL 8, 2016

8:00 - 10:00  
Hall 1

#### PLENARY SESSION 2

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker/Country</th>
<th>Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00</td>
<td>MAI Award Ceremony</td>
<td></td>
<td>344</td>
</tr>
<tr>
<td>8:10</td>
<td>The Genetic Interplay of Autoimmunity</td>
<td>C. Perricone (Italy)</td>
<td>347</td>
</tr>
<tr>
<td>8:30</td>
<td>Narcolepsy as an Autoimmune Disease</td>
<td>M. Arango, S. Kivity, T. Sasaki, M. Blank, M. Matsuura, Y. Shoenfeld (Israel)</td>
<td>348</td>
</tr>
<tr>
<td>9:00</td>
<td>Autoimmunity and Immunodeficiency - Two Sides of the Same Coin?</td>
<td>R.E. Schmidt (Germany)</td>
<td>349</td>
</tr>
</tbody>
</table>

**LIFETIME CONTRIBUTION TO AUTOIMMUNITY AWARD 2016**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker/Country</th>
<th>Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:30</td>
<td>Pregnancy in Patients with Autoimmune Disease: A Reality in 2016</td>
<td>A. Tincani (Italy)</td>
<td>350</td>
</tr>
</tbody>
</table>
10:00-10:30  Exhibition

COFFEE BREAK & EXHIBITION

10:00 - 10:30  Station 1

**EPD17: APS DIAGNOSTICS**

Chair: **K. Devreese** (Belgium)

10:00  POSITIVE ANTI-CARDIOLIPINE ANTIBODIES DURING SEPSIS AND CORRELATION WITH SOFA SCORE


10:05  ROLE OF ANTI-DOMAIN-1-β2GLYCOPROTEIN I ANTIBODIES IN THE DIAGNOSIS AND RISK STRATIFICATION OF ANTIPHOSPHOLIPID SYNDROME

A.S. De Craemer, J. Musial, **K. Devreese** (Belgium)

10:10  EPIDEMIOLOGY OF THE ANTIPHOSPHOLIPID SYNDROME WITH PARTICULAR REFERENCE TO SEX - A RETROSPECTIVE STUDY AT THE UNIVERSITY HOSPITAL GRAZ, AUSTRIA


10:15  EVALUATION OF SERUM PROFILES OF ANTIPHOSPHOLIPID ANTIBODIES IN A LARGE ROUTINE COHORT AND UTILITY OF ANTIPHOSPHOLIPID IGA ANTIBODIES DETECTED BY BIOPLEX IN SERONEGATIVE PATIENTS


10:20  SCREENING FOR APS DIAGNOSIS USING NON-CRITERIA ANTIPHOSPHOLIPID ANTIBODY TESTS WITH A HIGH POSITIVE PREDICTIVE VALUE: ANTI-BETA2-GPI DOMAIN I AND HOSPHATIDYLSEERINE-DEPENDENT ANTIPROTHROMBIN ANTIBODIES


10:25  LATENT CLASS ANALYSIS AS POSSIBLE SOLUTION FOR THE EVALUATION OF ANTIPHOSPHOLIPID ANTIBODY ASSAYS IN VIEW OF THE LACK OF A REFERENCE STANDARD

**M. Thaler**, A. Bietenbeck, U. Steigerwald, E. Lindhoff-Last, P. Luppa (Germany)
10:00 - 10:30
Station 2

**EPD18: PATHOGENETIC AVENUES IN AUTOIMMUNE DISEASES**

**Chair:** R. Leite Dantas (Germany)

10:00 ADVANCED GLYCATION END PRODUCTS (AGES) AND SOLUBLE RECEPTORS FOR AGES (SRAGE) IN ADULT-ONSET STILL’S DISEASE: ASSOCIATION WITH DISEASE ACTIVITY PARAMETERS
A. Abou-Raya, M. Kamel, S. Abou-Rayya (Egypt)

10:05 ALLERGY; ORIGINATION AND THE CAUSE & EFFECT-PROFILE
L. Behroo (Iran)

10:10 SARCOIDOSIS AND AUTOIMMUNITY: FROM GENETIC BACKGROUND TO ENVIRONMENTAL FACTORS
S. Bindoli, J.J. Torres-Ruiz, C. Perricone, M. Bizjak, Y. Shoenfeld (Italy)

10:15 EPITOPES OF HUMAN AND MICROBIAL TRANSGlutaminases ARE SIMILARLY RECOGNIZED BY CELIAC DISEASE SERA
P. Jeremias, K. Prager, S. Neidhoefer, T. Matthias (Germany)

10:20 TREG LYMPHOCYTES SUPPRESS MONOCYTE-MEDIATED PSORIASIS UPON INDUCTION OF TNFα
R. Leite Dantas, B. Brachvogel, S. Ludwig, V. Wirlex (Germany)

10:25 CRITICAL ROLES OF TONEBP SIGNALING IN MIGRATION AND INVASION OF RHEUMATOID SYNOVIOCYTES
Y.J. Park, H. Eun-Jin, L. Naeun, C. Chul-Soo, K. Wan-Uk (Republic of Korea)
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00</td>
<td>AUTOANTIBODIES AND SYSTEMIC LUPUS ERYTHEMATOSUS CLINICAL SUBSETS</td>
<td>M. Rami, I. Brahim, R. Hazime, L. El Moumou, B. Admou (Morocco)</td>
</tr>
<tr>
<td>10:05</td>
<td>ASSOCIATION OF THE UNCOUPLING PROTEINS POLYMORPHISMS WITH SUSCEPTIBILITY TO ATHEROSCLEROSIS IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS</td>
<td>C.M. Gambino, G. Accardi, A. Aiello, B.G. Gioia, M. Midiri, G. Guggino, G. Candore, C. Caruso (Italy)</td>
</tr>
<tr>
<td>10:15</td>
<td>ANTINUCLEAR ANTIBODY (ANA) TITER AND PATTERN VARY ACCORDING TO DISEASE ACTIVITY IN SYSTEMIC LUPUS ERYTHEMATOSUS</td>
<td>M. Prado, A. Dellavance, L.E.C. Andrade (Brazil)</td>
</tr>
<tr>
<td>10:20</td>
<td>CRITICALLY ILL PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) - CASE SERIES FROM A MEDICAL INTENSIVE CARE UNIT IN SOUTHERN INDIA</td>
<td>M. Thabah, B.D. Pandey, N. Balamurugan, V. Chaturvedi (India)</td>
</tr>
<tr>
<td>10:25</td>
<td>THE CHARACTERISTICS OF ANTIGEN PRESENTING CELLS IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)</td>
<td>A. Wardowska, Z. Smolenska, M. Pikula, M. Zielinski, P. Trzonkowski (Poland)</td>
</tr>
</tbody>
</table>
Station 4

10:00 - 10:30

EPD20: WHAT’S NEW IN AUTOIMMUNE DIAGNOSTICS?

Chair: L.M. De Winter (Belgium)

10:00 THE ISOTYPE REPERTOIRE OF ANTIBODIES AGAINST NOVEL UH-RA PEPTIDES IN RHEUMATOID ARTHRITIS

L.M. De Winter, P. Geusens, J. Lenaerts, J. Vanhoof, P. Stinissen, V. Somers (Belgium)

10:05 THE USE OF A CURRENT METHODOLOGY (ALBIA) FOR THE SIMULTANEOUS MEASUREMENT OF ANTI-DSDNA AND ANTI-NUCLEOSOME (ANUA OR ANTI-CHROMATIN) ANTIBODIES: TWO INDEPENDENT MARKERS OF SLE

M. Infantino, M. Benucci, F. Atzeni, P. Sarzi-Puttini, F. Meacci, V. Grossi, H. Scholz, M. Crisostomo, M. Manfredi (Italy)

10:10 IS THE MEASUREMENT OF IMMUNOGLOBULIN A ALWAYS NECESSARY IN THE STUDY OF CELIAC DISEASE?

J. Jimenez, A. Julia, O. Joaquin, F. Pere, H.D.L. Carmen (Spain)

10:15 BIG DATA-DERIVED DEMOGRAPHIC AND LABORATORY PROFILE OF INDIVIDUALS PRESENTING WITH THE ANTINUCLEAR ANTIBODY DENSE FINE SPECKLED PATTERN

A. Mathias, J.D. Sá, A. Dellavance, F.J. Muramoto, L.E. Andrade (Brazil)

10:20 EVALUATION OF ANTI-DFS70 ANTIBODIES PRE-ABSORPTION PROTOCOL FOR ANA-IIF HEP-2 TESTING IN THE DIAGNOSTIC APPROACH OF SYSTEMIC AUTOIMMUNE RHEUMATIC DISEASES

E. Pipi, E. Synodinou, A. Lemoni, K. Soufleros, M. Alexandridou, Barka C., I. Siampani, M. Aggelakos, C. Sfontouris, A. Tsirogianni (Greece)

10:25 ACUTE PHASE PROTEINS AND INTERLEUKIN-6 ARE IMPORTANT IN DISTINGUISHING BETWEEN GIANT CELL ARTERITIS POSITIVE AND NEGATIVE PATIENTS

P. Zigon, K. Lakota, T. Kuret, M. Tomšič, S. Cučnik, S. Sodin-Šemrl, A. Hočevar (Slovenia)
<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker/Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00</td>
<td>Neuromyelitis Optica (Devic’s Disease - NMO) Complicated by Systemic Lupus Erythematosus (SLE): Clinic-Pathological Report and Review of the Literature</td>
<td>M. Adawi (Israel)</td>
</tr>
<tr>
<td>10:20</td>
<td>A Comparison of Three Commercial Tests for Detecting Anti-Ganglioside Antibodies in Patients with Well-Characterized Dysimmune Peripheral Neuropathies</td>
<td>S. Hue, J.P. Lefaucheur, A. Creange, M. Chalah, C. Dehoulle (France)</td>
</tr>
<tr>
<td>10:25</td>
<td>Clinical Manifestations and Immunotherapy Outcome of Non-Retinal Anti-Recoverin Antibody Autoimmune Syndrome</td>
<td>J. Jun (Republic of Korea)</td>
</tr>
</tbody>
</table>
10:00 - 10:30

Station 6

EPD22: **SYSTEMIC SCLEROSIS: HOW CAN WE OVERCOME AN UNKNOWN ETIOLOGY?**

Chair: **N. Fabien** (France)

10:00  PREVALENCE AND SPECIFICITY OF ANTINEUTROPHIL CYTOPLASMIC ANTI-BODIES (ANCA) IN ALGERIAN PATIENTS WITH SYSTEMIC SCLEROSIS
**L. Aissa**, O. Nerdjess, Y.B. Youcef (Algeria)

10:05  EVALUATING CHOROIDAL CHARACTERISTICS IN SYSTEMIC SCLEROSIS USING ENHANCED DEPTH IMAGING OPTICAL COHERENCE TOMOGRAPHY
**D. Arslan Tas**, E. Esen, S. Sizmaz, İ. Turk, İ. Unal, N. Demircan (Turkey)

10:10  PATIENT-REPORTED OUTCOMES REFLECT CHANGES IN DIGITAL ULCERS STATUS IN PATIENTS WITH SYSTEMIC SCLEROSIS
**C. Bruni**, T. Ngcozana, F. Braschi, S. Guiducci, S. Bellando-Randone, L. Tofani, C. Denton, D. Furst, M. Matucci-Cerinic (Italy)

10:15  B CELLS FROM SYSTEMIC SCLEROSIS PATIENTS EXHIBIT DECREASED REGULATORY PROPERTIES
**D. Catalán**, O. Aravena, A. Ferrier, A. Ramírez, J.C. Aguillón, L. Soto (Chile)

10:20  CLINICAL AND IMMUNOLOGICAL FEATURES IN A COHORT OF 228 PATIENTS WITH SYSTEMIC SCLEROSIS
**C. Grange**, C. Mausservay, C. Khouatra, D. Jullien, P. Seve, J.C. Lega, **F. Nicole**, A. Hot (France)

10:25  CREST SYNDROME AND MENETRIER DISEASE, A UNIQUE ASSOCIATION
**A. Watts Soares**, J. Espirito Santo, M. Lobo Antunes, C. Noronha, A.I. Reis (Portugal)
### 10:00 - 10:30

**Station 7**

**EPD23: ARE THERE BREAKTHROUGHS IN THE THERAPY OF AUTOIMMUNE DISEASES?**

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Authors</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00</td>
<td>UTILITY OF TOCILIZUMAB ON CLINICAL MANIFESTATIONS OF EROSI VE OSTEOARTHRITIS, AN IMMUNE DISEASE?</td>
<td>S.H. Juan Manuel, J. GalvezRomero, W. LopezRodriguez, F. IslasJacome (Mexico)</td>
<td>393</td>
</tr>
<tr>
<td>10:05</td>
<td>BONE MARROW DERIVED DENDRITIC CELLS MODIFIED BY LENTIVIRAL-MEDIATED RELB SHRNA POSSESS TOLEROGENIC PHENOTYPE AND FUNCTIONS ON LUPUS SPLenic LYMPHOCyTES</td>
<td>H. Wu, Y. Lo, M.Y. Mok (Hong Kong)</td>
<td>394</td>
</tr>
<tr>
<td>10:10</td>
<td>ZINC ASPARTATE (UNIZINK®) SUPPRESS ES T CELL ACTIVATION IN VITRO AND TREATS EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS</td>
<td>D. Reinhold, D. Straubel, C. Schubert, K. Guttek, K. Grüngreiff, S. Brocke (Germany)</td>
<td>395</td>
</tr>
<tr>
<td>10:15</td>
<td>GENERATION AND CHARACTERIZATION OF “TNF RECEPTOR ONE SILENCER” (TROS) IN TRANSGENIC HTNFR1 MICE</td>
<td>S. Steeland, C. Libert, R. Vandenbroucke (Belgium)</td>
<td>396</td>
</tr>
<tr>
<td>10:20</td>
<td>ARGX-113, A NOVEL FC-BASED THERAPEUTIC APPROACH FOR ANTIBODY-INDUCED PATHOLOGIES</td>
<td>P. Ulrichts, T. Dreier, N. Ongena, T. Van Hauwermeiren, J. Enriquez, H. De Haard (Belgium)</td>
<td>397</td>
</tr>
<tr>
<td>10:25</td>
<td>EFFECTS OF SUBSTANCES WITH ANTIOXIDANT ACTIVITY ON NEUTROPHIL EXTRACELLULAR TRAP FORMATION</td>
<td>N. Vorobjeva, B. Pinegin (Russia)</td>
<td>398</td>
</tr>
</tbody>
</table>
10:00 - 10:30

Station 8

EPD24: IMMUNOMODULATION: BETTER THAN IMMUNOSUPPRESSION
Chair: L. Ishikawa (Brazil) 400

10:00 MYCOPHENOALTE MOFETIL AS A SECOND LINE THERAPY IN AUTOIMMUNE DISEASES
A. Danza, D. Graña, V. Domínguez, A. Vargas, B. Adriana, M. Goñi (Uruguay) 401

10:05 DANGYUJA (CITRUS GRANDIS OSBECK) TOPICAL TREATMENT ATTENUATES SKIN INFLAMMATION IN MOUSE EAR INDUCED WITH 12-O-TETRADECANYLPHORBOL-13-ACETATE (TPA)

10:10 IMMUNOMODULATORY EFFECT OF HYDROXYCHLOROQUINE IN BONE MARROW-DERIVED DENDRITIC CELLS AND COLLAGEN-INDUCED ARTHRITIS: PRELIMINARY RESULTS

10:15 CD4+CD25+ CELLS ARE ESSENTIAL IN THE INDUCTION AND MAINTAINING OF IMMUNOLOGICAL TOLERANCE IN CHICKENS INOCULATED WITH XENOCENEIC ANTIGENS AT A LATE STAGE OF EMBRYONIC DEVELOPMENT
Y. Xiaoxue, Z. Li (China) 404
10:30 - 12:30

PARALLEL SESSION 19: T CELLS IN AUTOIMMUNITY

Chair: R.E. Schmidt (Germany)  
Chair: C. Dias (Portugal)  
Chair: T. Witte (Germany)

10:30 THERAPY WITH RITUXIMAB - EFFECTS ON T CELL RESPONSE  
R.E. Schmidt (Germany)

10:50 IL-17 PRODUCING PATHOGENIC T LYMPHOCYTES CO-EXPRESS CD20  
AND ARE DEPLETED BY RITUXIMAB IN PRIMARY SJOGREN’S SYNDROME  
A. Alunno, F. Carubbi, O. Bistoni, E. Bartoloni, P. Di Benedetto,  
P. Cipriani, R. Giacomelli, R. Gerli (Italy)

11:00 T-CELL ACTIVATION IS ASSOCIATED WITH HYPOCOMPLEMENTEMIA IN  
PRIMARY ANTIPHOSPHOLIPID SYNDROME  
J.A. Carbone Campoverde, E. Sarmiento, G. Antonio, N. Lanio,  
E. Fernandez-Cruz (Spain)

11:10 PURINERGIC CONTROL OF T FOLLICULAR HELPER CELLS IN  
AUTOIMMUNITY  
C.E. Faliti, L. Perruzza, G. Pellegrini, R. Gualtierotti, P.L. Meroni,  
E. Traggiai, F. Grassi (Switzerland)

11:20 IL-17 ANTAGONISTICALLY REGULATES GM-CSF PRODUCTION DURING  
T CELL DEVELOPMENT EX VIVO AND DURING EXPERIMENTAL ARTHRITIS  
D.M. Roeleveld, R. Rogier, P.M. Van der Kraan, W.B. Van den Berg,  
I.P. Wicks, M.I. Koenders (Netherlands)

11:30 CHARACTERIZING THE FUNCTION OF P-GLYCOPROTEIN IN HUMAN T  
CELL SUBSETS DEMONSTRATE DIFFERENT KINETIC PATTERNS  
L. Yrlid, H. Grindebacke, K. Pardali, J. Jirholt, A. Rudin (Sweden)

11:40 MIR-146A SUPPRESSED T CELL APOPTOSIS BY REGULATING FAF1 IN  
PATIENTS OF RHEUMATOID ARTHRITIS  
L. Jingyi, G. Qiuye, W. Ying, W. Yuzhang (China)

11:50 STATIN REPRESSES HUMAN DENDRITIC CELL MATURATION INDUCED  
BY OXLDL AND LIMITS THE CONSEQUENT T CELL PROLIFERATION  
A. Liu, Y. Zhang, J. Sun, J. Frostegard (Sweden)
12:00  REGULATORY T CELL COMPENSATION FAILURE: POSSIBLE MECHANISM FOR THE DYSREGULATION OF IMMUNE RESPONSE IN MURINE MODEL OF SYSTEMIC LUPUS ERYTHEMATOSUS
K. Handono, H. Kalim, E. Mustofa, S. Murwani, P. Mirza Zaka (Indonesia)

12:10  THE CD38 ABSENCE AFFECTS THE SPLENIC FOXP3+CD4+ T REGULATORY CELLS DEVELOPMENT IN A MURINE MODEL
J.C. Pérez Lara, H. Romero Ramirez, G. Lopez Herrera, J.C. Rodriguez Alba (Mexico)

12:20  HIGHLY SENSITIVE DETECTION OF NEUTROPHIL ELASTASE PROTEASE ACTIVITY ON IMMUNE COMPLEX ACTIVATED CELLS
R. Akbarzadeh, C. Schultz, X. Yu, F. Petersen (Germany)

12:30-14:00  Exhibition
LUNCH BREAK, EXHIBITION, E-POSTER VIEWING
## 10:30 - 12:30

### PARALLEL SESSION 20: DIAGNOSTICS - PATHOGENESIS AND AUTOANTIBODY STANDARDIZATION

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Presenter(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30</td>
<td>WHY STANDARDIZATION ON AUTOANTIBODY TESTING IS CRITICAL FOR AUTOIMMUNITY DIAGNOSTICS</td>
<td>L.E. Andrade (Brazil)</td>
</tr>
<tr>
<td>10:50</td>
<td>IMMUNO-THERA-DIAGNOSTICS (THERANOSTICS) IN AUTOIMMUNITY AND ONCOLOGY</td>
<td>E. Matsuura (Japan)</td>
</tr>
<tr>
<td>11:10</td>
<td>P29ING4 IMMUNE COMPLEX AS MARKER FOR INFLAMMATORY JOINT INVOLVEMENT</td>
<td>N. Baerlecken, W. Torsten, G. Ralph, K. Matthias, S. Reinhold E, B. Michael (Germany)</td>
</tr>
<tr>
<td>11:20</td>
<td>SEQUENCE SPECIFICITY OF AUTOANTIBODIES AGAINST NUCLEIC ACID ANTIGENS - OPENING UP THE BLACK BOX</td>
<td>C. Macaubas, E. Fox, I. Balboni, E. Mellins, I. Solov’yov, K. Astakhova (Denmark)</td>
</tr>
<tr>
<td>11:30</td>
<td>CLINICAL ASSOCIATIONS AND ANTIGENIC SPECIFICITY OF HIGHLY POSITIVE ANTI-NUCLEOLAR AUTOANTIBODIES IN A MULTICENTRIC COHORT</td>
<td>L. De Chaisemartin, A. Roide, F. Fernani-Oukil, M.A. Dragon-Durey, C. Johanet, P. Nicaise-Roland, S. Chollet-Martin (France)</td>
</tr>
<tr>
<td>11:40</td>
<td>AUTOANTIBODIES DETECTED IN PATIENTS WITH ANKYLOSING SPONDYLITIS USING CDNA PHAGE DISPLAY</td>
<td>D. Quaden, P. Vandormael, J. Vanhoof, P. Geusens, V. Somers (Belgium)</td>
</tr>
<tr>
<td>12:00</td>
<td>DETECTION OF AUTOANTIBODIES BY INDIRECT IMMUNOFLUORESCENCE IN A PATHOLOGY DEPARTMENT.</td>
<td>J. Rajcani (Slovakia)</td>
</tr>
</tbody>
</table>
12:10  HIGH-THROUGHPUT SCREENING DISCOVERS NOVEL AUTOANTIBODIES IN AUTOIMMUNE DISEASES: THE SEROTAG APPROACH IN SYSTEMIC LUPUS, SYSTEMIC SCLEROSIS AND RHEUMATOID ARTHRITIS

P. Schulz-Knappe, A. Lueking, P. Budde, H.D. Zucht, H. Göhler, R. Brinks, J. Richter, S. Vordenbäumen, M. Schneider (Germany)

12:20  HARMONIZATION OF AUTOIMMUNE DIAGNOSTICS AND LABORATORY COMPETENCE: ANA REFLEX TEST

C. Bonaguri, A. Melegari, T. Trenti, A. Russo, L. Battistelli, A. Picanza, M. Galante, R. Aloe, G. Lippi (Italy)

12:30-14:00  Exhibition

LUNCH BREAK, EXHIBITION, E-POSTER VIEWING
PARALLEL SESSION 21: **SLE - IS IT THE CLASSICAL AUTOIMMUNE DISEASE?**

Chair: **G. Zandman-Goddard** (Israel)  
Chair: **A. Doria** (Italy)  
Chair: **Y. Levy** (Israel)  

10:30 **PITFALLS IN LUPUS**  
**M. Schneider** (Germany)  

10:50 **NEW BIOLOGIC TARGET IN SLE**  
**A. Doria** (Italy)  

11:10 **A VERY LONG TERM OBSERVATIONAL ANALYSIS ON THE EFFECTS OF AN INTENSIFIED B LYMPHOCYTE DEPLETION SCHEDULE WITHOUT IMMUNOSUPPRESSIVE MAINTENANCE IN THE TREATMENT OF LUPUS NEPHRITIS: SOME EVIDENCE OF AUTOIMMUNE PROCESS RESETTING**  
**D. Roccatello** (Italy)  

11:30 **BELIMUMAB DECREASES FLARE FREQUENCY AND HINDERS DAMAGE ACCRUAL IN PATIENTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS: DATA FROM CLINICAL PRACTICE SETTING**  

11:40 **CELIAC DISEASE COEXISTENT WITH SLE: A CASE-CONTROL STUDY**  
**S. Dahan**, D. Ben Ami Shor, H. Amital (Israel)  

11:50 **MORPHOLOGICAL AND FUNCTIONAL EYE INVOLVEMENT IN PATIENTS AFFECTED BY SYSTEMIC LUPUS ERYTHEMATOSUS AND SJOGREN SYNDROME**  

12:00 **ENHANCED VH REPLACEMENT IN ANTIBODY REPERTOIRE OF CIRCULATING PLASMABLASTS AND ITS CORRELATION WITH EPSTEIN-BARR VIRUS IN SYSTEMIC LUPUS ERYTHEMATOSUS**  

12:10 **ELUCIDATING THE PATHOGENIC ROLES OF IGG AND IGM APOPTOTIC CELL-REACTIVE ANTIBODIES ON DENDRITIC CELLS AND DETERMINANT SPREADING IN LUPUS**  
**M. Malik**, P. Arora, R. Sachdeva, V.G. Ramachandran, R. Pal (India)
12:20  SYSTEMIC LUPUS ERYTHEMATOSUS AND ANCA-ASSOCIATED VASCULITIS OVERLAP SYNDROME IN PATIENTS WITH BIOPSY-PROVEN GLOMERULONEPHRITIS


12:30-14:00  Exhibition

LUNCH BREAK, EXHIBITION, E-POSTER VIEWING
10:30 - 12:30

**Hall 3**

**PARALLEL SESSION 22: KIDNEY INVOLVEMENT IN AUTOIMMUNITY**

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30</td>
<td>KIDNEY INVOLVEMENT IN SYSTEMIC VASCULITIS</td>
<td>C. Pusey [United Kingdom]</td>
</tr>
<tr>
<td>10:50</td>
<td>KIDNEY INVOLVEMENT IN SLE</td>
<td>L. Lightstone [United Kingdom]</td>
</tr>
<tr>
<td>11:10</td>
<td>THE PROBLEM WITH PATIENTS WITH BOTH ANCA AND ANTI-GBM ANTIBODIES</td>
<td>S. McAdoo [United Kingdom]</td>
</tr>
<tr>
<td>11:25</td>
<td>IMPACT OF ANCA IN PATIENTS WITH LUPUS NEPHRITIS</td>
<td>T. Turner-Stokes [United Kingdom]</td>
</tr>
<tr>
<td>11:50</td>
<td>ANTICOAGULATION AND LONG TERM OUTCOMES IN PATIENTS WITH RENAL ARTERY STENOSIS AND ANTIPHOSPHOLIPID SYNDROME</td>
<td>A. Casian, S. Sangle, N. Jordan, S. Mannou Stathopoulou, D. D’Cruz [United Kingdom]</td>
</tr>
<tr>
<td>12:00</td>
<td>EPITOPE SPREADING IN PLA2R1 IS ASSOCIATED WITH BAD PROGNOSIS IN MEMBRANOUS NEPHROPATHY</td>
<td>B. Seitz-Polski, G. Dolla, C. Payre, S. Benzaken, V. Esnault, G. Lambeau [France]</td>
</tr>
<tr>
<td>12:10</td>
<td>THE ROLE OF OSTEOPONTIN AS A CANDIDATE BIOMARKER OF RENAL INVOLVEMENT IN SYSTEMIC LUPUS ERYTHEMATOSUS</td>
<td>C. Garufi, F.R. Spinelli, S. Truglia, F. Ceccarelli, F. Miranda, V. Pacucci, C. Alessandri, G. Valesini, F. Conti [Italy]</td>
</tr>
</tbody>
</table>
12:20  A NEW FORM OF ANTIPHOSPHOLIPID SYNDROME ASSOCIATED TO CHRONIC KIDNEY DISEASE?


12:30-14:00  Exhibition

LUNCH BREAK, EXHIBITION, E-POSTER VIEWING
10:30 - 12:30

PARALLEL SESSION 23: AUTOIMMUNITY IN DERMATOLOGY

Chair: R. Ahmed (USA) 456
Chair: A. Kuhn (Germany) 457
Chair: E. Schmidt (Germany) 458

10:30 BENEFIT OF THE COMBINATION OF IVIG AND RITUXIMAB IN TREATING BLISTERING DISEASES 459
R. Ahmed (USA)

10:45 A PEMPHIGUS PARADIGM: NEW ROLE FOR FCRN AS A DELIVERY VEHICLE FOR AUTOANTIBODIES TO INTRACELLULAR SELF-ANTIGENS 460
S.A. Grando (USA)

11:00 NEW THERAPIES IN IMMUNE-MEDIATED SKIN DISEASES 461
T. Luger (Germany)

11:15 DETECTION OF CIRCULATING AUTOANTIBODIES AND THEIR CORRELATION WITH BULLOUS PEMPHIGOID 462
M. Sardy (Germany)

11:30 MULTIVARIANT DIAGNOSIS OF AUTOIMMUNE BLISTERING DISEASES 463
E. Schmidt (Germany)

11:45 NEW TREATMENTS OF EXPERIMENTAL EPIDERMOLYSIS BULLOSA ACQUISITA 464
R. Ludwig (Germany)

12:00 EFFECT OF A CLASSICAL PATHWAY SPECIFIC INHIBITOR ON BULLOUS PEMPHIGOID SERA-INDUCED COMPLEMENT ACTIVATION 465
A. Kasprick, R. Ludwig, C. Hass, C. Kauderer, E. Dr. Schmidt, F. Petersen, S. Panicker (Germany)

12:10 FUMARIC ACID ESTERS IN CUTANEOUS LUPUS ERYTHEMATOSUS- A PROSPECTIVE, OPEN-LABEL, PHASE II PILOT STUDY 466
A. Kuhn, A. Landmann, N. Patsinakidis, V. Ruland, S. Nozinic, A.M. Perusquía Ortiz, C. Sauerland, T. Luger, A. Tsianakas, G. Bonsmann (Germany)

12:20 TBA 467
A. Gul (Turkey)

12:30-14:00

Exhibition

LUNCH BREAK, EXHIBITION, E-POSTER VIEWING
10:30 - 12:30

PARALLEL SESSION 24: EXPERIMENTAL ANIMAL MODELS OF AUTOIMMUNE DISEASES

Chair: L. Gershwin (USA) 468
Chair: M. Lidar (Israel) 469
Chair: O. Hamiel (Israel) 470

10:30
AUTOIMMUNITY IN DOMESTIC ANIMALS
L. Gershwin (USA) 471

10:50
ROLE OF SERPINB3 IN PREVENTION AND TREATMENT OF COLLAGEN INDUCED ARTHRITIS (CIA) IN BALB/C MICE
S. Bindoli, R. Luisetto, N. Bassi, M. Beggio, A. Ghirardello, L. Iaccarino, P. Pontisso, Y. Shoenfeld, A. Doria (Italy) 472

11:05
A NEW TNF-ALPHA INDUCIBLE TRANSGENIC MOUSE MODEL FOR PSORIATIC ARTHRITIS: CHARACTERIZATION OF THE PHENOTYPE REVERSIBILITY
V. Wixler (Germany) 473

11:20
ENHANCED PASSIVE TRANSFER-TRAUMA MODEL FOR COMPLEX REGIONAL PAIN SYNDROME: EVIDENCE FOR AUTOANTIBODY-PAIN
V. Tekus, Z. Helyes, J. Hawkes, A. Goebel (United Kingdom) 474

11:30
THE CD38 DEFICIENCY INDUCES AN AUTOIMMUNE-LIKE PHENOTYPE IN OLD MICE

11:40
GALECTIN-3 AMELIORATES BEHAVIORAL DISORDERS IN NZBWF1 MICE LUPUS MODEL
R. Luisetto, N. Bassi, A. Ghirardello, F. Saccon, A. Scanu, F. Leite de Oliveira, A. Doria (Italy) 476

11:50
GALECTIN-3 DELAYS THE ONSET OF GLOMERULONEPHRITIS AND PROLONGS SURVIVAL IN LUPUS-PRONE MICE (NZB/NZW F1)
F. Saccon, R. Luisetto, N. Bassi, M. Gatto, A. Ghirardello, F.L. De Oliveira, A. Doria (Italy) 477

12:00
USE OF TOLL-LIKE RECEPTOR AGONISTS FOR THE DEVELOPMENT OF EXPERIMENTAL MYASTHENIA GRAVIS MODELS WITH THYMIC HYPERPLASIA
M. Robinet, B. Villeret, S. Berrih-Aknin, R. Le Panse (France) 478
12:10  WHAT DETERMINES RELAPSING-REMITTING AUTOIMMUNE DISEASE? LESSONS FROM THE RAT MODEL OF EXPERIMENTAL AUTOIMMUNE UVEITIS (EAU)
G. Wildner, M. Diedrichs-Möhring, U. Kaufmann, C. Von Toerne, A. Kungl (Germany)

12:20  A NOVEL MOUSE MODEL FOR ANTI-LAMININ 332 MUCOUS MEMBRANE PEMPHIGOID
E.N. Heppe, F.S. Schulze, D. Zillikens, S. Goletz, E. Schmidt (Germany)

12:30-14:00  Exhibition
LUNCH BREAK, EXHIBITION, E-POSTER VIEWING

12:30 - 14:00  MP3 & 4

Industry Supported Session:
NOT INCLUDED IN MAIN EVENT CME/CPD CREDIT
14:00 - 16:00  

PARALLEL SESSION 25: PREDICTION, MONITORING AND PERSONALIZED MEDICINE  

Chair: J.M. Anaya (Colombia)  
Chair: V. Stejskal (Sweden)  
Chair: R.A. Levy (Brazil)  

14:00 PERSONALIZED MEDICINE: CLOSING THE GAP BETWEEN KNOWLEDGE AND CLINICAL PRACTICE  
J.M. Anaya (Colombia)  

14:20 INCREASED PREVALENCE OF METAL SENSITIZATION IN PATIENTS WITH MULTIPLE SCLEROSIS, PARKINSON’S DISEASE AND AMYOTROPHIC LATERAL SCLEROSIS  
V. Stejskal, B. Brunes, D. Magnusson, T. Reynolds (Sweden)  

14:30 HIGH LEVELS OF MEMORY B CELLS PREDICT ABATACEPT EFFICACY IN PATIENTS WITH RHEUMATOID ARTHRITIS  
Y. Renaudineau, P. Gazeau, G. Carvajal Alegria, V. Devauchelle-Pensec, P. Pochard, J.O. Pers, A. Saraux, D. Cornec (France)  

14:40 IMMUNOGENICITY OF TNFα INHIBITORS IN RHEUMATOID ARTHRITIS: RELATIONSHIP BETWEEN DRUG BIOAVAILABILITY/ANTI-DRUG ANTIBODIES AND CLINICAL OUTCOMES  

14:50 CLUSTERED AUTOANTIBODY REACTIVITY PROFILES AND DEFINITION OF HOMOGENEOUS SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) PATIENT GROUPS  
P. Budde, H.D. Zucht, H. Göhler, P. Rengers, S. Vordenbäumen, P. Schulz-Knappe, M. Schneider (Germany)  

15:00 A CD4 T-CELL CENTRAL MEMORY (TCM) BIOMARKER SUCCESSFULLY PREDICTS TREATMENT RESPONSE IN RECENT-ONSET TYPE 1 DIABETES (T1D)  
C. Beam, C. Maccallum, M. Peakman (USA)  

15:10 A PILOT STUDY TO BENCHMARK BIOMARKERS IN SLE: WHICH BIOMARKERS ARE ADVANTAGEOUS FOR MONITORING DISEASE ACTIVITY?  
R. Biesen, T. Rose, G.R. Burmester, A. Grutzkau, F. Hiepe (Germany)
15:20 MONITORING FUNCTIONAL B-CELL MARKERS AND SUBSETS AS BENEFICIAL TOOL TO PREDICT MULTIPLE SCLEROSIS DEVELOPMENT


15:30 IMBALANCES IN TH1/TH17 CELL SUBSETS ARE ASSOCIATED WITH DISEASE DEVELOPMENT IN EARLY MULTIPLE SCLEROSIS


15:40 USE OF A CELL-BASED REPORTER GENE ASSAY FOR THERAPEUTIC DRUG MONITORING OF PATIENTS ON ANTI-TNF-α THERAPY

S. Berthold, C. Lallemand, M. Tovey (Sweden)

15:50 SEX DIFFERENCES IN PSORIATIC ARTHRITIS: EVALUATION OF A REAL-LIFE COHORT OF 2,118 ITALIAN PATIENTS TREATED WITH METHOTREXATE

E. Generali, C. Selmi, G. Carrara, C.A. Scirè (Italy)
14:00 - 16:00  
MP3 & 4

PARALLEL SESSION 26: EASI SESSION - ANCA AND ANCA-ASSOCIATED VASCUlutIS

Chair: Y. Shoenfeld (Israel)  
Chair: N. Olschowka (Germany)  
Chair: J. Damoiseaux (Netherlands)

14:00  ANCA STUDY WITH SAMPLES FROM DIFFERENT CENTERS IN EUROPE, COMPARING DIFFERENT METHODS  
X. Bossuyt (Belgium)

14:20  THE CLINICAL PRESENTATION AND THERAPY OF DISEASE RELATED TO ANCA  
M. Segelmark (Sweden)

14:40  ANCA DIAGNOSTICS: AN EASI-SURVEY ON THE DAILY PRACTICE IN EUROPEAN COUNTRIES  
J. Damoiseaux (Netherlands)

15:00  THE NEW REFERENCE MATERIAL OF THE IRMM FOR MPO AND PR3  
J. Sheldon (United Kingdom)

15:10  ANCA DIAGNOSTICS IN AUSTRIA: EASI QUESTIONNAIRE AND QUALITY ASSESSMENT SCHEMES  
M. Herold (Austria)

15:20  ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODIES ASSOCIATED WITH INFECTIVE ENDOCARDITIS  
I. Marie (France)

15:30  SHOULD AND CAN ANCA MEASUREMENTS BE STANDARDIZED?  

15:40  ANCA DETECTION: 27 YEARS EXPERIENCE WITH FOCUS ON INFECTION AND DOUBLE POSITIVITY (PR 3 AND MPO) ANCA  
A. Chevailler (France)

15:50  PROGNOSTIC VALUES OF ANCA SPECIFICITIES  
L. Mouthon (France)
PARALLEL SESSION 27: AUTOIMMUNE ASPECTS OF NEUROLOGICAL DISEASES

Chair: A. Achiron (Israel)  
Chair: V. Somers (Belgium)  
Chair: D. Karussis (Israel)

14:00 ANTI-NMDA RECEPTOR ENCEPHALITIS  
J. Dalmau (Spain)  

14:20 FROM VGKC TO LGI1 AND CASPR2 ENCEPHALITIS: THE EVOLUTION OF A DISEASE OVER TIME  
M.J. Titulaer (Netherlands)  

14:40 B CELL ANALYSIS AND BIOMARKER DISCOVERY IN NEUROLOGIC AND AUTOIMMUNE DISEASES  
V. Somers (Belgium)  

15:00 RETT SYNDROME: AN AUTOIMMUNE DISEASE?  
J. Hayek, C. De Felice, S. Leoncini, C. Signorini, A. Cortelazzo, A.M. Papini, P. Rovero, L. Ciccoli (Italy)  

15:10 NEUROPROTECTION AFFECTED BY IMMUNOMODULATORY TREATMENT WITH GLATIRAMER ACETATE  
R. Aharoni, M. Sela, R. Arnon (Israel)  

15:20 MAPPING THE EPITOPE OF ANTIBODIES TO SURFACE DOPAMINE-2 RECEPTOR IN THE FIRST EPISODE OF ACUTE PSYCHOSIS  
N. Sinmaz, D. Pilli, J. Starling, V. Merheb, R. Dale, F. Brilot (Australia)  

15:30 REPEATED INFECTIONS INDUCE AN AUTOIMMUNE TH17 CELL PHENOTYPE IN THE BRAIN AND IMPAIR BLOOD-BRAIN BARRIER INTEGRITY: A MOUSE MODEL FOR PANS/PANDAS  
T. Cutforth, D. Knowland, E. Smith, T. Dileepan, M. Hsu, M. Platt, P.P. Cleary, D. Agalliu (USA)  

15:40 THE PROFILES OF CYTOKINES/CHEMOKINES IN THE CEREBROSPINAL FLUIDS OF PATIENTS WITH CENTRAL NERVOUS SYSTEM INVOLVEMENT OF CONNECTIVE TISSUE DISEASES  
T. Yoshio, H. Okamoto, S. Hirohata, S. Minota (Japan)
15:50 THE RELATIONSHIP BETWEEN NEUROINFLAMMATION, AUTOIMMUNE ACTIVATION, OXIDATIVE STRESS, MERCURY LEVELS, AND LOSS OF BRAIN CONNECTIVITY IN AUTISM SPECTRUM DISORDER
J. Kern, D. Geier, M. Geier (USA)

14:00 - 16:00 Hall 3
PARALLEL SESSION 28: PEPTIDES AND NEW MOLECULES IN THERAPEUTICS
Chair: V. Barak (Israel)
Chair: C. Jamin (France)
Chair: S. Gertel (Israel)

14:00 SEMAPHORIN 3A, A POTENTIAL IMMUNE REGULATOR IN FAMILIAL MEDITERRANEAN FEVER
Z. Vadasz (Israel)

14:20 IMMUNO-MODULATION OF NAIVE RHEUMATOID ARTHRITIS PATIENTS PBMC WITH A MULTI-EPITOPE PEPTIDE DELINEATED FROM CITRULLINATED AUTOANTIGENS
S. Gertel, S. Vainer, G. Serre, Y. Shoenfeld, H. Amital (Israel)

14:40 VACCINATION WITH PEPTIDE MIMOTOPES OF MOUSE CD20 ANTIGEN PROLONGS SURVIVAL IN LUPUS PRONE MICE BWF1
E. Favoino, I.E. Favia, M. Prete, G. Di Lernia, F. Perosa (Italy)

15:00 AN APTAMER FOR NEUTRALIZATION OF PATHOGENIC AUTOANTIBODIES DIRECTED AGAINST G-PROTEIN COUPLED RECEPTORS PRESENT IN PATIENTS WITH CARDIOMYOPATHY: STEPS TO A NEW TREATMENT OPTION

15:15 NOVEL PEPTIDES FOR INDUCTION OF TOLERANCE AND TREATMENT IN A LONG-TERM MOUSE MODEL OF GRAVES’ DISEASE AND ORBITOPATHY
M. Ungerer, H.P. Holthoff, Z. Li, J. Fassbender, G. Münch (Germany)

15:30 TREATMENT OF HCT116 CELLS WITH GLIADIN, TRANSGLUTAMINASES AND COMPLEXES THEREOF, IMITATING CELIAC DISEASE
P. Jeremias, B. Tanja, T. Matthias, S. Neidhoefer, A. Lerner (Germany)

15:45 NEO-EPITOPES BETWEEN GLIADIN PEPTIDES AND TISSUE / MICROBIAL TRANSGlutamatInAES SHOW STRUCTURAL MEDIATED IMMUNOREACTIVE EPITOPES IN CELIAC DISEASE PATIENTS
P. Jeremias, S. Neidhoefer, A. Lerner, T. Matthias (Germany)
14:00 - 16:00

PARALLEL SESSION 29: AUTOIMMUNE LIVER DISEASES

Chair: M.E. Gershwin (USA)  
Chair: P. Invernizzi (Italy)  
Chair: L. Muratori (Italy)

14:00 NOVEL TREATMENTS IN PRIMARY BILIARY CHOLANGITIS  
P. Invernizzi (Italy)

14:20 AUTOIMMUNE LIVER DISEASES: AN UPDATE ON IMMUNOPATHOLOGICAL ASPECTS  
D. Bogdanos (Greece)

14:40 DIAGNOSTIC AND PROGNOSTIC SIGNIFICANCE OF AUTOANTIBODIES IN AUTOIMMUNE HEPATITIS  
L. Muratori (Italy)

15:00 DYSREGULATION OF INTERFERON INTERPLAY LEADS TO FEMALE PREDOMINANT AUTOIMMUNE CHOLANGITIS: IMPLICATIONS FOR THE ETIOLOGY OF HUMAN AUTOIMMUNE CHOLANGITIS  
H. Young, J. Valencia, S. Kim, T. Back, M. Karwan, D. Feng, B. Gao, O. Park, K. Tsuneyama, P. Leung, M.E. Gershwin, H. Bae (USA)

15:20 OVERLAP SYNDROMES AND AUTOIMMUNE LIVER DISEASE: A FIVE YEAR REVISED EXPERIENCE OF AN AUTOIMMUNITY DIAGNOSIS LABORATORY  

15:30 COMBINED DETERMINATION OF AUTOIMMUNE LIVER DISEASE SPECIFIC AUTOANTIBODIES BY CYTOBEAD® ASSAY  
M. Sowa, J. Scholz, K. Grossmann, R. Hiemann, N. Röber, B. Glauche, K. Conrad, D. Roggenbuck (Germany)

15:40 DIAGNOSTIC ACCURACY OF TWO TESTS FOR DETERMINATION OF ANTI-M2 IN THE DIAGNOSIS OF PRIMARY BILIARY CIRRHOSIS. IS POSSIBLE TO PREDICT THE COURSE OF THE DISEASE?  
A.M. Alfano, M. Battistini, G. Crotti, A. Ferrini, C. Mancinetti, T. Manetta, C. Marchese, P. Mertlach, A. Romito, M.T. Tambuzzo (Italy)

15:50 FRUCTOSYLATION OF HUMAN SERUM ALBUMIN AND ITS POSSIBLE ROLE IN LIVER DISEASES  
A. Zaman, K. Alam (India)
14:00 - 16:00

PARALLEL SESSION 30: TYPE 1 DIABETES MELLITUS

Chair: M. von Herrath (USA)
Chair: I. Lazurova (Slovakia)
Chair: C. Dias (Portugal)

14:00 PATHOLOGY OF HUMAN TYPE 1 AND 2 DIABETES: SURPRISING NEW FINDINGS AND PARADIGM SHIFTS
M. Von Herrath (USA)

14:20 PANCREATITIS AFTER HUMAN PAPILLOMAVIRUS VACCINATION: A CASE OF MOLECULAR MIMICRY
M. Bizjak, O. Bruck (Slovenia)

14:40 A PANEL OF CIRCULATING IMMUNE-RELATED AND ISLET-SPECIFIC MIRNAS AS BIOMARKERS OF EARLY DISEASE PROGRESS AND BETA CELL LOSS IN NOD MICE
Z. Guo, R. Roat, J. Christopherson, C. Free, M. Hossain (USA)

14:50 MODULATION OF AUTOIMMUNE T CELL REACTION IN PATIENTS WITH TYPE 1 DIABETES BY TOLERGENIC DENDRITIC CELLS

15:00 ANTIBODIES TO POST-TRANSLATIONALLY MODIFIED INSULIN IN TYPE 1 DIABETES
R. Strollo (Italy)

15:10 CAN AUTOIMMUNE TYPE-1-DIABETES BE PREVENTED BY ANTI-IDIOPTYPIC ANTIBODIES?

15:20 GLYCO-OXIDATIVE DAMAGE TO HUMAN DNA: A POSSIBLE REASON FOR TYPE I DIABETES AUTOIMMUNITY
Moinuddin, S. Ahmad (India)

15:30 COMORBIDITY OF CHILDHOOD COELIAC DISEASE AND TYPE 1 DIABETES: AN IMMUNOLOGICAL STUDY
R. Uibo, T. Vorobjova, K. Metsküla, O. Uibo (Estonia)
15:40  EFFECT OF P21 DEFICIENCY ON MURINE AUTOIMMUNE PANCREATITIS  G.M. Seleznik, T. Reding, L. Peter, A. Zabel, S. Sonda, R. Graf  (Switzerland)

15:50  FOLLOW UP OF VALUE OF THE INTRARENAL RESISTIVITY INDICES AND DIFFERENT RENAL BIOMARKERS FOR EARLY IDENTIFICATION OF DIABETIC NEPHROPATHY IN TYPE 1 DIABETIC PATIENTS  S.M.A. El Dayem, A.A. Battah, A.E.M. El Bohy, M. Hamed (Egypt)
14:00 - 16:00 Station 8

PARALLEL SESSION 30B: NEW HORIZONS IN AUTOIMMUNE THERAPY

Chair: P.L. Meroni (Italy) 553
Chair: D. Roggenbuck (Germany) 554
Chair: C. Blandizzi (Italy) 555

14:00 CONSISTENCY OF MONOCLONAL ANTIBODIES: FROM PRODUCTION TO CLINICAL PRACTICE
C. Blandizzi (Italy) 556

14:20 CARDIOVASCULAR COMORBIDITIES IN INFLAMMATORY ARTHRITIS: THE ROLE OF TNF INHIBITORS
P.L. Meroni, N. Ronda, I. Hollan (Italy) 557

14:40 THE ZIKA VIRUS ASSOCIATED WITH AUTOIMMUNITY: GBS AS A CASE IN POINT
C. Chang (USA) 558

15:00 THE ROLE OF LIPOPROTEIN OXIDATIVE INFLAMMATION AND β2-GLYCOPROTEIN I IN INNATE IMMUNITY OF EARLY ATHEROSCLEROSIS
E. Matsuura, L. Lopez (USA) 559

15:10 SUCCESSFUL TREATMENT OF EOSINOPHILIC FASCIITIS USING EXTRACORPOREAL PHOTOPHERESIS
J. Végh (Hungary) 560

15:20 CANNABIS AS AN ANTI INFLAMMATORY TREATMENT
T. Naftali (Israel) 561

15:30 ANTIGEN-SPECIFIC DOWNREGULATION OF IMMUNOPATHOLOGICAL EVENTS IN AN EXPERIMENTAL AUTOIMMUNE KIDNEY DISEASE
A.Z. Barabas, C. Cole, R. Lafreniere (Canada) 562

15:40 VITAMIN D SUPPLEMENTATION EFFECTS ON FOXP3 EXPRESSION IN T CELLS AND FOXP3+/IL-17A RATIO AND CLINICAL COURSE IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS: STUDY IN A PORTUGUESE COHORT.

15:50 A TALE OF TWO ANTIBODIES: BETA ADRENERGIC AND MUSCARINIC CHOLINERGIC ANTIBODIES ASSOCIATED WITH SIMULTANEOUS ERYTHROMELALGIA AND RAYNAUD’S PHENOMENON
J. Schofield, C. Scheibenbogen, M. Nagel, H. Heidecke (USA) 564
16:00-16:30   Exhibition

COFFEE BREAK & EXHIBITION

16:00 - 16:30   Station 1

EPD25: TYPE 1 DIABETES MELLITUS: THE SWEET AND THE AUTOIMMUNE

Chair: D. Kulshrestha (Taiwan)

16:00  RELATIONSHIP BETWEEN HYPERGLYCEMIA LEVELS AND INTERLEUKIN 6 (IL-6) IN PATIENTS WITH DIABETES MELLITUS  
A. Amir (Indonesia)  

16:05  PREDICTIVE BIOMARKERS FOR DIABETES REVERSAL IN NOD MICE BY CLINICAL-GRADE PRO-INSULIN AND IL-10 SECRETING LACTOCOCCUS LACTIS IN COMBINATION WITH LOW-DOSE ANTI-CD3.  
T. Takiishi, D. Cook, H. Korf, G. Sebastiani, F. Mancarella, C. Wasserfall, L. Steidler, P. Rottiers, F. Dotta, G. Conny, C. Mathieu (Belgium)  

16:10  RELATIONSHIPS BETWEEN CAROTID ARTERY INTIMA MEDIA THICKNESS AND INTERLEUKIN-6 LEVELS IN YOUNG PATIENTS WITH TYPE 1 DIABETES MELLITUS  
V. Gurevich, S. Sayganov, E. Minadze (Russia)  

16:15  LOW CD25 EXPRESSION ON T REGULATORY CELLS DEFINES THE REGULATORY COMPARTMENT IN PATIENTS WITH TYPE 1 DIABETES  
J. Kayserova, Z. Parackova, K. Sismova, Z. Sumnik, S. Kolouskova, J. Lebl, A. Sediva (Czech Republic)  

16:20  TRANSGENIC EXPRESSION OF AUTOIMMUNE REGULATOR (AIRE) IN DENDRITIC CELLS ATTENUATES AUTOIMMUNE DIABETES IN NOD MICE BY SUPPRESSING PROINFLAMMATORY CYTOKINES SECRETING T CELLS  
D. Kulshrestha, H.K. Sytwu (Taiwan)  

16:25  ASSOCIATION OF TYPE 1 DIABETES WITH ORGAN SPECIFIC AUTOIMMUNE DISEASE  
N. Ouikhlef, Y. Bouali, A. Louail, S. Djemi, A. Benhalima (Algeria)
16:00 - 16:30  Station 2

**EPD26: EXPERIMENTAL MODELS: FROM MICE TO MEN**

Chair: Y. Sofyan (Indonesia)

16:00 ETANERCEPT, INFlixIMAB AND TNF ABLATION IN MACROPHAGES EFFECTIVELY AMELIORATE EXPERIMENTAL ARTHRITIS IN HUMANIZED TNF KNOCK-IN MICE

M. Drutskaya, R. Zvartsev, E. Gorshkova, A. Zhdanova, K.S. Atretkhany, G. Efimov, A. Kruglov, S. Nedospasov (Russia)

16:05 HUMAN PERIPHERAL BLOOD LYMPHOCYTES MAINTAIN POLYCLONAL AND ANTIGEN-SPECIFIC REACTIVITY AFTER ENGRAFTMENT INTO NOD-SCID IL2RγNULL MICE: FIRST STEPS TOWARDS A HUMANIZED MODEL OF AUTOIMMUNE ARTHRITIS

K. Schinnerling, C. Schäfer, M. Jaxaira, L. Soto, J.C. Aguillón (Chile)

16:10 THE EFFECTS OF GENISTEIN SOYBEAN TOWARD SERUM FIBROBLAST GROWTH FACTOR 2 LEVELS AND KIDNEY FIBROSIS IN DIABETIC NEPHROPATHY RATS

Y. Sofyan (Indonesia)

16:15 NEONATAL CORTICOSTERONE ADMINISTRATION REDUCES THE BEHAVIOURAL AND BRAIN WHITE MATTER ALTERATIONS ASSOCIATED WITH EXPOSURE TO GROUP-A-BETA-HAEMOLITIC STREPTOCOCCUS IN MICE

C. Spinello, S. Macrì, R. Magliozzi, G. Laviola (Italy)

16:20 SOMATIC MUTATIONS IN CLONALLY EXPANDED LYMPHOCYTES IN PATIENTS WITH NEWLY DIAGNOSED RHEUMATOID ARTHRITIS

16:00 - 16:30

Station 3

**EPD27: SLE: NOVEL ASPECTS**

Chair: C.H. Suh [Republic of Korea]

16:00 OUTCOME OF FILIPINO CHILDREN WITH LUPUS NEPHRITIS TREATED WITH A MODIFIED TREATMENT REGIMEN USING CYCLOPHOSPHAMIDE

M.T. Collante, C. Bernal [Philippines]

16:05 THE ANTI-INFLAMMATORY COMPOUND OXACYCLODODECINDIONE COULD SERVE AS A LEAD STRUCTURE FOR THE DEVELOPMENT OF NEW THERAPEUTICS IN THE TREATMENT OF SLE


16:10 ANTI-TNF-INDUCED LUPUS - A DISTINCT CLINICAL ENTITY

O. Shovman, T. Shalev, Y. Shoenfeld [Israel]

16:15 NEUTROPHIL CYTOPLASMIC ANTIBODIES (ANCA) IN PEDIATRIC LUPUS: PREVALENCE, CLINICAL ASSOCIATIONS AND CORRELATION WITH OTHER AUTOANTIBODIES

M. Smara, Y. Meddour, S. Chaib-Mamouzi [Algeria]

16:20 VITAMIN D AND BONE MINERAL DENSITY IN SYSTEMIC LUPUS ERYTHEMATOSUS AND RHEUMATOID ARTHRITIS


16:25 TACROLIMUS-BASED REGIMENS IN THE TREATMENT FOR LUPUS NEPHRITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS

Y.K.O. Teng, T. Kraaij, O.W. Bredewold, T.W.J. Huizinga, T.J. Rabelink [Netherlands]
16:00 - 16:30  Station 4

**EPD28: METHODS IN AUTOIMMUNE DIAGNOSTICS**

**Chair:** B. Torres Rives (Cuba)

16:00  **TITLE ANTI-HMGCR ANTIBODY DETECTION METHODS: IN-HOUSE VS COMMERCIAL ELISA**

M. Alvarado, A. Marín, D. Alvarez-De la Sierra, C. Franco, E. Balada, M.A. Martínez, M. Labrador Horrillo, I. Pinal Fernandez, C. Juárez, A. Selva O´Callaghan (Spain)

16:05  **COMPARISON OF TWO ANTI-DoublesTRAND-DNA ANTIBODIES ASSAYS : CRITHIDIA LUCILIAE SUBSTRATE READ BY AUTOMATED FLUORESCENT MICROSCOPE VERSUS CHEMILUMINESCENT IMMUNOASSAY**

T. Belmondo, S. Harzoun, M. Nasser, S. Hue (France)

16:10  **DIFFERENTIAL CYTOKINE AND REGULATORY CELLS IN DISCOID AND SUBACUTE CUTANEOUS LUPUS**


16:15  **EVALUATION OF NOVEL ANA SCREENING METHOD: COMBINED USE OF AUTOMATED IIF AND CTD SCREEN CHEMILUMINESCENT IMMUNOASSAY**

N. Gallo, M. Arzenton, L. Penello, M. Seguso, M. Plebani (Italy)

16:20  **AUTOMATED IFA METHODS COMPARE WELL WITH ESTABLISHED MANUAL IFA SCREENING AND TITRATION FOR ANA HEP-2**

J. Blecken, T. Matthias, A. Frey, M. Daves, A. Joos, S. Platzgummer (Italy)

16:25  **IMMUNOLOGICAL MARKERS IN CUBAN PATIENTS WITH NON-INFECTIOUS UVEITIS**

### Station 5

#### 16:00 - 16:30

**EPD29: CELIAC - DON’T MISS THE DIAGNOSIS**

<table>
<thead>
<tr>
<th>Time</th>
<th>Presentation</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:00</td>
<td>CELIAC DISEASE SCREENING IN AN ALGERIAN COHORT OF CHILDREN WITH TYPE 1 DIABETES</td>
<td>I. Allam, R. Djidjik (Algeria)</td>
</tr>
<tr>
<td>16:05</td>
<td>ISOLATION AND LONG-TERM PRIMARY CULTURE OF SMALL INTESTINAL EPITHELIAL CELLS AS A MODEL FOR FURTHER STUDIES</td>
<td>J. LukačBajalo, D. Cerne, M. Hadzija, G. Majdič, R. Orel, B. Bozic (Slovenia)</td>
</tr>
<tr>
<td>16:10</td>
<td>SERUM IGA ANTI-TGT NEGATIVE CASES IN CELIAC DISEASE SUSPECTED ADULT PATIENTS. THE NEED OF A POPULATION-SPECIFIC CUT-OFF VALUE</td>
<td>J.A. Garrote, V. Ruiperez, H. Nunez, S. Perez-Zaragoza, F. Sanchez-Martin, E. Arranz (Spain)</td>
</tr>
<tr>
<td>16:15</td>
<td>ANTI-ENTEROCYTE AUTOANTIBODIES IN PEDIATRIC CELIAC DISEASE</td>
<td>A. Lerner, R. Kushak, J. Patricia, T. Matthias, H. Winter (Germany)</td>
</tr>
</tbody>
</table>
16:00 - 16:30 Station 6

EPD30: SJÖGREN’S SYNDROME: THE ULTIMATE B CELL STIMULATION

Chair: K. Malyavantham (USA)

16:00 SJÖGREN SYNDROME - A CASE OF SPASTIC PARAPARESIS
R. Alves, F. Correia, C. Soares, L. Afonso (Portugal)

16:05 THE PRESENTATION OF SJÖGREN’S SYNDROME AS UNEXPLAINED COUGH - A PROSPECTIVE STUDY OF A FOCUSED EVALUATION
M. Koslow, S. Kivity, V. Vishnevska-Dai, I. Ben-Dov (Israel)

16:10 INVESTIGATION OF ANTI-NUCLEAR AUTOANTIBODIES (ANAS) IN A CHINESE PRIMARY SJÖGREN’S SYNDROME (PSS) COHORT USING MULTIPLEX LINE IMMUNOASSAYS (LIAS)
K. Malyavantham, G. Shi, Y. Wang, Y. Liu, C. Dynski-Trumble, L. Shen, L. Suresh (USA)

16:15 RHEUMATOID FACTOR ISOTYPES AND ANTI-RO 52/60 AUTOANTIBODIES IN PRIMARY SJÖGREN’S SYNDROME WITH EXTRAGLANDULAR MANIFESTATIONS
B. Meek, H. Kelder, A. Claessen, A.J. Van Houte, E.J. Ter Borg (Netherlands)

16:20 AN EVALUATION OF SERUM AUTOANTIBODIES REVEALS TWO MAIN GROUPS IN PATIENTS WITH PRIMARY SJÖGREN’S SYNDROME

16:25 A CASE OF PULMONARY ALVEOLAR HEMORRHAGE WITH PRIMARY SJÖGREN’S SYNDROME
S. Ugurlu, K. Erdam (Turkey)
16:00 - 16:30

EPD31: MYASTHENIA GRAVIS & MULTIPLE SCLEROSIS

Chair: C. Pistono (Italy)

16:00 INVARIANT NATURAL KILLER T CELLS FROM PATIENTS WITH PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS DISPLAY A PROINFLAMMATORY PHENOTYPE


16:05 MAY AHR BE INVOLVED IN AUTOIMMUNE MYASTHENIA GRAVIS?

N. Dragin, J.A. Villegas, R. Khansa, R. Marieke, L.P. Rozen, B.A. Sonia (France)

16:10 INVOLVEMENT OF OXIDATIVE STRESS ON HSP70-2 PROTEIN EXPRESSION IN MULTIPLE SCLEROSIS (MS)

C. Pistono, C. Boiocchi, C. Monti, G. Nosari, M. Cuccia, C. Montomoli, R. Bergamaschi (Italy)

16:15 HLA GENES AS MODIFIERS OF RESPONSE TO IFN-β-1A THERAPY IN RELAPSING-REMITTING MULTIPLE SCLEROSIS

M. Taheri, A. Sayad, G. Solgi, A. Movafagh, M.D. Omrani, M. Mazdeh (Iran)

16:20 MONITORING AND ITS CLINICAL RELEVANCE OF LYMPHOCYTE SUBSETS DURING INNOVATIVE MULTIPLE SCLEROSIS TREATMENT STRATEGIES

K. Thomas, M. Kaufmann, J. Blankenburg, J. Eisele, T. Ziemssen (Germany)

16:25 CYTOKINE PRODUCTION IN PERIPHERAL BLOOD CELLS OF PATIENTS WITH MULTIPLE SCLEROSIS

S. Zivancevic Simonovic, O. Mihaljevic, G. Toncev, I. Kostic, I. Majstorovic, O. Milosevic-Djordjevic (Serbia)
16:00 - 16:30
Station 8

**EPD32: IVIG, INNATE IMMUNITY: HOW TO RESTORE THE IMMUNE SYSTEM TO NORMAL**

Chair: Y. Kronimus (Germany)

16:00  
**GENERATION OF MONOCLONAL AUTOANTIBODIES FOR EFFECTIVE IMMUNIZATION IN PATIENTS WITH ALZHEIMER’S AND PARKINSON’S DISEASE**

A. Albus, M. Jördens, M. Möller, R. Dodel (Germany)

16:05  
**THE EFFECT OF MICROBIOME/TOLL-LIKE RECEPTOR INTERACTIONS ON SUSCEPTIBILITY TO TYPE 1 DIABETES**

A. Baxter, M. Jordan, D. Stanley, R. Moore, B. Crowley (Australia)

16:10  
**MANAGEMENT OF ADVERSE EVENTS IN THE TREATMENT OF PATIENTS WITH IMMUNOGLOBULIN THERAPY: A REVIEW OF EVIDENCE**

P. Cherin, I. Marie, M. Michallet, E. Pelus, J. Dantal, J.C. Crave, J.C. Delain, J.F. Viallard (France)

16:15  
**FC GLYCOSYLATION OF NATURALLY OCCURRING AUTOANTIBODIES IN PARKINSON’S AND ALZHEIMER’S DISEASE**

Y. Kronimus, I. Kuhn, R. Dodel (Germany)

16:20  
**CLINICAL SIGNIFICANCE OF COMPLEMENT SYSTEM ANALYTICS EXTRACTED FROM BIG DATA BANKS**

U. Nydegger, P. Medina Escobar, L. Risch, T. Lung (Switzerland)

16:25  
**INCREASED NLRC4 INFLAMMASOMES AND THEIR CORRELATIONS WITH DISEASE ACTIVITY IN AUTOIMMUNE HEPATITIS**

L. Wang, W. Jiao, K. Zhang, F.S. Wang (China)
16:30 - 18:30

Hall 1

PARALLEL SESSION 31: ENVIRONMENTAL FACTORS AND SEX HORMONES IN AUTOIMMUNITY

Chair: A. Vojdani (USA) 620
Chair: U. Sack (Germany) 621
Chair: M. Cutolo (Italy) 622

16:30 ENVIRONMENTAL BASIS OF AUTOIMMUNITY
M.E. Gershwin (USA) 623

16:50 XENOBIO蒂CS AND AUTOIMMUNITY
A. Vojdani, J. Lambert (USA) 624

17:10 ESTROGENS AS ENHANCERS OF THE IMMUNE RESPONSE AND AUTOIMMUNITY
M. Cutolo (Italy) 625

17:30 CORRELATION OF TISSUE AUTOANTIBODIES AND FOOD IMMUNE REACTIVITY IN RANDOMLY SELECTED PATIENT SPECIMENS
J. Lambert, A. Vojdani (USA) 626

17:45 GENDER AND AUTOIMMUNITY: A SPOTLIGHT ON THE ROLE OF PROGESTOGENS
I. Tan (USA) 627

18:00 GENE SHARING BETWEEN EPSTEIN-BARR VIRUS AND HUMAN IMMUNE-RESPONSE GENES
D. Dreyfus (USA) 628

18:10 A HIGH FIBRE DIET CAN MODULATE HALLMARKS OF INFLAMMATION AND AUTOIMMUNITY CULMINATING IN REDUCED NEPHRITIS IN A MODEL OF SYSTEMIC LUPUS ERYTHEMATOSUS
T. Gottschalk, E. Tsantikos, M. Hibbs (Australia) 629

18:20 SOLUBLE SYNDIEAN-1: A POTENTIAL NOVEL BIOMARKER OF SMALL BOWEL MUCOSAL DAMAGE IN CHILDREN WITH CELIAE DISEASE
D. Yablecovitch, A. Oren, S. Ben-Horin, E. Fudim, R. Eliakim, F.M. Konikoff, U. Kopylov, T. Matthias, A. Lerner (Germany) 630
16:30 - 18:30  MP3 & 4

PARALLEL SESSION 32: RHEUMATOID ARTHRITIS - CHALLENGES IN THE NEW ERA

Chair: F. Atzeni (Italy) 631
Chair: S.B Abramson (USA) 632
Chair: P. Langevitz (Israel) 633

16:30  INFECTIONS AND BIOLOGIC AGENTS IN RA
F. Atzeni (Italy) 634

16:50  CARDIAC IMPAIRMENT IN RHEUMATOID ARTHRITIS AND INFLUENCE OF ANTI TNF-ALPHA THERAPY
I. Lazurova, L. Tomáš (Slovakia) 635

17:10  PREVENTION OF CARDIOVASCULAR DISEASE IN RHEUMATOID ARTHRITIS
N. Ronda, I. Hollan (Italy) 636

17:25  ISCHEMIC HEART DISEASE IN RHEUMATOID ARTHRITIS PATIENTS: CASE-CONTROL STUDY
A. Watad (Israel) 637

17:40  ASSOCIATION BETWEEN DUFFY GENOTYPE AND THE ACTIVITY OF RHEUMATOID ARTHRITIS IN COLOMBIAN PATIENTS
C. Saavedra-Díaz, F.E. Ospina, A. Hormaza, C.A. Cañas, C. Fong, G. Barreto, G. Tobón, F. Bonilla-Abadía (Colombia) 638

17:50  GENETIC ASSOCIATION OF ANGIOTENSIN CONVERTING ENZYME-INDEL POLYMORPHISM WITH RHEUMATOID ARTHRITIS SUSCEPTIBILITY IN SOUTH GUJARAT POPULATION OF INDIA
D. Patel, A. Dhangar, R. Shah, N. Laddha, P. Kumar, M. Dwivedi (India) 639

18:00  RHEUMATOID ARTHRITIS PATIENTS HAVE ALTERATIONS IN INHERENTLY AUTOREACTIVE 9G4+ B CELLS IN PERIPHERAL BLOOD
R.A. Moura, M.J. Leandro, V. Reddy, J.E. Fonseca, G. Cambridge (United Kingdom) 640

18:10  REDUCTION OF AUTOPHAGY CORRELATES WITH A FAVORABLE CLINICAL OUTCOME IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH DMARDS
M. Vomero, C. Alessandri, M. Pendolino, C. Barbati, T. Colasanti, M. Di Franco, C. Iannuccelli, M. Sorice, A. Capozzi, E. Ortona, M. Pierdominici, W. Malorni, F. Conti, G. Valesini (Italy) 641
18:20  IL-18 BINDING PROTEIN FROM BENCH TO BEDSIDE: IL-18/IL-18BP IMBALANCE IN SECONDARY HEMOPHAGOCYTIC SYNDROME PATIENTS. A COMPLETE REMISSION IN A BABY TREATED WITH IL-18 BINDING PROTEIN

D. Novick, C.A. Dinarello, G. Kaplanski (Israel)
16:30 - 18:30  Hall 2

PARALLEL SESSION 33: GENETICS AND EPIGENETICS OF AUTOIMMUNE DISEASES

Chair: Q. Lu (China)  
Chair: Y. Tomer (USA)  
Chair: K. Yamamoto (Japan)

16:30  THE REAL CULPRIT IN SYSTEMIC LUPUS ERYTHEMATOSUS: ABERRANT DNA METHYLATION  
Q. Lu (China)  

16:50  THE COMMON MECHANISMS OF AUTOIMMUNITY  
J.M. Anaya (Colombia)  

17:10  GENETICS AND ENVIRONMENT SHAPE PHENOTYPES OF ANCA VASCULITIDES  
W.L. Gross (Germany)  

17:30  AN IN SILICO APPROACH REVEALS, IN B CELLS FROM PRIMARY SJOGREN’S SYNDROME PATIENTS, ASSOCIATIONS BETWEEN GENETIC AND EPIGENETIC FACTORS  

17:40  EXPLORING AUTOIMMUNITY IN A COHORT OF CHILDREN WITH GENETICALLY-CONFIRMED AICARDI-GOUTIERES SYNDROME  

17:50  FUNCTIONAL AND MULTI-OMIC APPROACHES TO THE SHARED GENETIC BASIS ACROSS PEDIATRIC AUTOIMMUNITY  
Y.R. Li, J. Li, D. Zhao, R.N. Baldassano, E.T.L. Prak, H. Li, B.J. Keating, H. Hakonarson (USA)  

18:00  DNA METHYLATION AND GENE EXPRESSION CHANGES IN MONOZYGOTIC TWINS REVEAL THE CONTRIBUTION OF THE INNATE IMMUNE SYSTEM IN MYASTHENIA GRAVIS  
S. Mamrut, N. Avidan, F. Truffault, E. Staun-Ram, M. Frenkian, S. Berrih-Aknin, A. Miller (Israel)
18:10  PREDICTIVE VALUE OF POLYMORPHISMS OF GENES INVOLVED IN INVOLVED IN INFLAMMATION FOR THE CLINICAL RESPONSE TO TNFA INHIBITORS IN RHEUMATOID ARTHRITIS

18:20  COMPUTATIONAL ANALYSIS OF AUTOIMMUNE DISEASES RELATED GENES SNPS
A. Tekcan (Turkey)
16:30 - 18:30

PARALLEL SESSION 34: EUROPEAN FORUM ON ANTIPHOSPHOLIPID ANTIBODIES

Chair: R. Cervera (Spain)
Chair: D. Wahl (France)

16:30 INTRODUCTION
R. Cervera (Spain)

16:35 LONG STANDING APS
A. Tincani (Italy)

16:50 BETA-2 GLYCOPROTEIN I STANDARD
P.L. Meroni (Italy)

17:05 TRAPS TRIAL
V. Pengo, A. Hoxha, A. Banzato, E. Bison, G. Zoppellaro, J.S. Padayatti, G. Denas, A. Ruffatti (Italy)

17:20 HYDROXYCHLOROQUINE AS SECONDARY THROMBOPROPHYLAXIS IN PRIMARY APS
C. Belizna (France)

17:25 ADDITIONAL TREATMENTS IN HIGH RISK OBSTETRIC ANTIPHOSPHOLIPID SYNDROME. A EUROPEAN FORUM ON ANTIPHOSPHOLIPID PROJECT
A. Ruffatti, A. Hoxha, M. Favaro, A. Banzato, V. Pengo (Italy)

17:35 UPDATE FROM THE PEDIATRIC APS REGISTRY
T. Avcin (Slovenia)

17:50 APS ACTION
P.L. Meroni (Italy)

18:05 10TH MEETING OF THE EUROPEAN FORUM ON ANTIPHOSPHOLIPID ANTIBODIES
D. Wahl (France)

18:20 DISCUSSION
16:30 - 18:30

Parallel Session 35: Big Data Analysis, Registries, and Epidemiological Studies in Autoimmunity

Chair: M. Praver (USA) 666
Chair: X. Zeng (China) 667
Chair: H. Amital (Israel) 668

16:30 BIG DATA ANALYSIS IN HEALTH RESEARCH
M. Praver (USA) 669

16:50 THE REGISTRY OF RHEUMATIC DISEASES IN CHINA
X. Zeng (China) 670

17:10 THE REGISTRY OF TAKAYASU ARTERITIS IN CHINA
X. Tian (China) 671

17:30 WHAT CAN WE LEARN FROM REAL LIFE DATABASES?
H. Amital (Israel) 672

17:50 REGISTRIES IN RHEUMATOID ARTHRITIS
P. Sarzi-Puttini (Italy) 673

18:10 THE ANNUAL INCIDENCE/PREVALENCE OF AUTOIMMUNE DISEASES IS INCREASING WORLDWIDE
A. Lerner, P. Jeremias, T. Matthias (Germany) 674

18:20 HYPOGONADAL PATIENTS WITH AUTOIMMUNE DISEASES (CROHN’S DISEASE, PSORIASIS) BENEFIT FROM LONG-TERM TREATMENT WITH TESTOSTERONE - REAL-LIFE DATA FROM A REGISTRY STUDY
F. Saad, A. Haider, A. Traish, L. Gooren (Germany) 675
PARALLEL SESSION 36: SYSTEMIC ONSET JUVENILE IDIOPATHIC ARTHRITIS AND HEREDITARY PERIODIC FEVER SYNDROME

16:30 SYSTEMIC ONSET JUVENILE IDIOPATHIC ARTHRITIS
   R. Cimaz (Italy)

16:50 HEREDITARY PERIODIC FEVER SYNDROMES
   L. Cantarini (Italy)

17:10 AUTOPHAGY AND AUTOIMMUNITY
   G. Valesini (Italy)

17:30 THE CONTINUUM OF AUTOIMMUNITY AND AUTOINFLAMMATION
   E. Pras (Israel)

17:50 THE CHOLINERGIC ANTI-INFLAMMATORY PATHWAY: A POSSIBLE MECHANISM OF ACTION OF ANTI-CHOLINESTERASES IN AN ANIMAL MODEL OF AUTOIMMUNE ARTHRITIS
   M. Gowayed, R. Refaat, A. Attia, H. El-Abhar, C. Baerwald (Egypt)

18:00 AUTOIMMUNE FAMILY - A GLANCE IN THE CLINIC

18:10 COEXISTENCE OF FAMILIAL MEDITERRANEAN FEVER (FMF), JUVENILE PSORIATIC ARTHRITIS (JPSA) AND SECONDARY HYPOGONADISM
   H. Sargsyan (Armenia)

18:20 DISCUSSION
SCIENTIFIC PROGRAM
SATURDAY, APRIL 9, 2016

10TH INTERNATIONAL CONGRESS ON AUTOIMMUNITY
APRIL 6-10, 2016, LEIPZIG, GERMANY
Autoimmunity Reviews

Co-Editors-in-Chief

Y. Shoenfeld • M.E. Gershwin

2014 Impact Factor*

7.933

*Journal Citation Reports published by Thomson Reuters 2015

Supports Open Access

For the full aims & scope, visit:

journals.elsevier.com/autoimmunity-reviews
SATURDAY, APRIL 9, 2016

8:00 - 10:00  Hall 1

PLENARY SESSION 3

Chair: J. Dayer (Switzerland)  686
Chair: M.E. Gershwin (USA)  687
Chair: C. Vasconcelos (Portugal)  688

8:00  THE INTERRELATIONSHIP OF MICROBIOME AND AUTOIMMUNITY  689
S.B. Abramson (USA)

8:30  MEMBRANOS NEPHROPATHY AS A CLASSICAL AUTOIMMUNE DISEASE  690
P. Ronco (France)

9:00  THE MOSAIC OF AUTOIMMUNITY IN 2016: NEW FACTORS AND NOVEL IMMUNOMODULATIONS  691
Y. Shoenfeld (Israel)

9:30  THE SKIN IN SYSTEMIC AUTOIMMUNE DISEASES - UNMET NEEDS!  692
A. Kuhn (Germany)
10:00 - 10:30

Station 1

**EPD33: APS: NOVELTIES**

**Chair:** G. Medina (Mexico)

10:00 **AUTOANTIBODY PROFILE AND CLINICAL ASSOCIATIONS IN 176 ADULT ITALIAN SYSTEMIC SCLEROSIS PATIENTS**

T. Schioppo, L. Cesana, F. Ingegnoli, P.L. Meroni, C. Bentow, M. Mahler, S. Vettori, G. Valentini (Italy)

10:05 **RIVAROXABAN IN PATIENTS WITH ANTIPHOSPHOLIPID SYNDROME (APS) - OWN EXPERIENCE IN 23 CASES**

E. Haladyj, M. Olesińska (Poland)

10:10 **CLINICAL OUTCOME AFTER ANTIPHOSPHOLIPID ANTIBODIES NEGATIVIZATION IN PRIMARY ANTIPHOSPHOLIPID SYNDROME. A 5-YEAR FOLLOW-UP STUDY**

G. Medina, E. Briones García, M.P. Cruz-Domínguez, O.I. Florez-Durante, L.J. Jara (Mexico)

10:15 **EFFICACY OF HYDROXYCHLOROQUINE ON MESENTERIC AND CAROTID ARTERIAL THROMBOSIS IN A MOUSE MODEL OF ANTIPHOSPHOLIPID SYNDROME**

S. Miranda, M. Lebesnerais, Y. Benhamou, L. Galas, D. Schapman (France)

10:20 **TITLE: ANTI-PHOSPHOLIPID ANTIBODIES AND PARATHYROID HORMONE: A GENDER STUDY**

A. Vitagliano, A.M. D’ursi, P. Amato, A. Sorrentino, C. Mirello, P. Sabatini (Italy)

10:25 **BUDD-CHIARI SYNDROME AS THE PRESENTING MANIFESTATION OF ANTIPHOSPHOLIPID SYNDROME**

A. Mota, C. Eira, R. Silvério, N. Ribeiro, A. Monteiro (Portugal)
10:00 - 10:30  Station 2

EPD34: GENE, FAMILIES, RNA

Chair: A. Paradowska-Gorycka (Poland) 700

10:00  ASSOCIATION OF PTPN22 GENE POLYMORPHISMS WITH AUTOIMMUNE DISEASE IN PEDIATRIC PATIENTS WITH TYPE 1 DIABETES FROM ALGERIA 701
H. Mesbah-Amroun, A. Boukercha, A. Bouzidi, K. Ait-Abdesslam, D. Bouziane, C. Touil-Boukoffa (Algeria)

10:05  DNA DEMETHYLATION OF THE TIM-3 PROMOTER IS CRITICAL FOR ITS STABLE EXPRESSION ON T CELLS 702

10:10  MICRORNA-146A EXPRESSION AS PUTATIVE BIOMARKER IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS 703
C. Carvalho, B. Leal, A. Bettencourt, A. Marinho, I. Almeida, F. Farinha, P. Pinho e Costa, C. Vasconcelos, B. Martins da Silva (Portugal)

10:15  ASSOCIATION OF HLA-DRB1 ALLELES WITH MIXED CONNECTIVE TISSUE DISEASE (MCTD) 704

10:20  THE GENETICS OF AUTOIMMUNITY: A PROTOTYPE OF MULTIFACTORIAL INHERITANCE 705
E. Pras (Israel)
10:00 - 10:30

**Station 3**

**EPD35: SLE: THE LEADING AUTOIMMUNE CONDITION**

Chair: **S. Vento** (Botswana)

10:00 **DECREASED FREQUENCY AND ACTIVATED PHENOTYPE OF BLOOD CD27+IGG+B LYMPHOCYTES IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS**

**Z. Chen**, H.H. Zhang, M.T. Li, X.F. Zeng (China)

10:05 **SURVIVAL OF PREDNISONE-FREE REMISSION IN SLE PATIENTS WITH SEROLOGICALLY ACTIVE CLINICAL QUIESCENT DISEASE**


10:10 **AUTOIMMUNE DISEASES IN LOW AND MIDDLE INCOME COUNTRIES: A NEGLECTED, YET IMPORTANT ISSUE IN GLOBAL HEALTH**

**S. Vento**, F. Cainelli (Botswana)

10:15 **THYMIC EPITHELIAL PROGENITOR/STEM CELLS TRANSPLANTATION IN AUTOIMMUNE DISEASES**

**B. Wozniewicz**, M. Wozniewicz, R. Swierzewski, I. Nawrot, R. Janas (Poland)

10:20 **A RARE CASE OF SYSTEMIC LUPUS ERYTHEMATOSUS WITH SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS AND MORPHEA**

**S. Wydywa Yenny**, I. Isramiharti, G. Akhyar, P. Kampar, Y. Yenita, N. Najirman (Indonesia)
10:00 - 10:30

Station 4

EPD36: **DIAGNOSTICS: FROM THE LAB TO THE CLINIC**

Chair: **S. Kivity** (Israel)

10:00 ROLE OF VOLATILE COMPOUNDS RELEASED BY SYNOVIAL FLUID IN THE EVALUATION OF OSTEOARTHRITIS AND INFLAMMATORY DISEASES OF THE KNEE JOINT

A. Bergamini, R. Perricone, **M.S. Chimenti**, G.L. Fonti, C. Canofari, E. Martinelli, C. Di natale, R. Capuano, L. Lugari (Italy)

10:05 REAL-WORLD VALIDATION OF AN AUTOMATED INDIRECT IMMUNOFLUORESCENCE ANTI-NUCLEAR ANTIBODY SYSTEM

**R.A. Booth** (Canada)

10:10 ANCA TESTING IN AUSTRIA - SOME MORE RESULTS OF THE EASI QUESTIONNAIRE

**M. Herold**, W. Klotz, T. Horn, Members of EASI Austria (Austria)

10:15 NEUTROPHIL LYMPHOCYTE RATIO IN PATIENTS WITH AUTOIMMUNE DISEASES

A. Israeli, E. Maor, S. Gad, O. Har-Noy, Y. Sidi, R. Brenner, **S. Kivity** (Israel)

10:20 ANTI-PHOSPHOLIPASE A2 RECEPTOR ANTIBODIES IN DANISH PATIENTS WITH MEMBRANOUS NEPHROPATHY


10:25 EVALUATION OF DIAGNOSTIC PRACTICE ON TESTING AND REPORTING ANTINEUTROPHIL CYTOPLASMATIC AUTOANTIBODIES (ANCA) IN NORTH ESTONIAN MEDICAL CENTRE

**M. Mägi**, M. Kütt (Estonia)
10:00 - 10:30

Station 5

**EPD37: CNS: BRAIN, AUTOIMMUNITY AND BEYOND**

Chair: C. Hoffmann (Netherlands)

10:00 ASSOCIATION OF ANTI-YO, ANTI-HU AND ANTI-SOX1 ANTIBODIES IN CSF IN PATIENT WITH LIMBIC AND PARALIMBIC ENCEPHALITIS IN THE SETTING OF SMALL CELL LUNG CARCINOMA

I. Gañán Nieto, P. González Urra, A. Tejeda Velarde, A. Carrasco Sayalero, A. Jiménez-Escrig (Spain)

10:05 MRNA ELECTROPORATION IS AN EFFECTIVE TOOL TO INDUCE LONG-TERM MYELIN EXPRESSION BY HUMAN TOLEROGENIC DENDRITIC CELLS

J. Derdelinckx, W.P. Lee, M. De Laere, P. Cras, B. Willekens, Z.N. Berneman, N. Cools (Belgium)

10:10 INTIMATE RELATIONSHIPS, DISEASE’S BURDEN AND IMMUNE STATUS - A LONGITUDINAL STUDY IN WOMEN WITH SLE

M. Figueiredo-Braga, M. Figueiredo, M. Bernardes, G. Terroso, L. Costa (Portugal)

10:15 ANALYSIS OF AUTO-ANTIBODIES IN PSYCHOTIC DISORDER


10:20 HUMAN MONOCLONAL NMDA RECEPTOR AUTO-ANTIBODIES ARE SUFFICIENT FOR ENCEPHALITIS PATHOGENESIS

J. Kreye, N. Wenke, M. Chayka, J. Leubner, R. Murugan, N. Maier, H. Wardemann, H. Prüss (Germany)

10:25 THE NEW M23-BASED ELISA ASSAY FOR ANTI-AQUAPORIN 4 AUTOANTIBODIES: SENSITIVITY, SPECIFICITY AND DIRECT COMPARISON WITH IIF METHOD

M. Tampoia, F. Marnetto, L. Abbracciavento, L. Granieri, P. Valentino, A. Bertolotto, R. Fumarulo (Italy)
10:00 - 10:30
Station 6

EPD38: VASCULITIS: A SYSTEMIC AUTOIMMUNE CONDITION
Chair: N. Lorenzo Villalba (Spain)

10:00 AUTOIMMUNE ASSOCIATED ORBITAL INFLAMMATORY MASSES AND RESPONSE TO IMMUNOSUPPRESSIVE THERAPY
A. Casian, S. Sangle, R. Malaiya, P. Lutalo, L. Nel, B. Menon, H. Varma, M. Stanford, D. D’Cruz (United Kingdom)

10:05 DESCRIPTION OF CLINICAL JOINT MANIFESTATION OF HYPOVITAMINOSIS D PATIENTS AT RHEUMATOLOGY OUTPATIENT CLINIC OF DR. HASAN SADIKIN GENERAL HOSPITAL IN WEST JAVA INDONESIA 2012 -2015
S. Dewi, R.H. Malik (Indonesia)

10:10 MICROHEMATURIA AND MILD PROTEINURIA IN A PREVIOUS HEALTHY YOUNG MAN
N. Lorenzo Villalba, N. Sablon, Y. Parodis, M.B. Alonso, M. Kechida, Z. Cordoba, J.C. Rodriguez (Spain)

10:15 THE CLINICAL RELEVANCE OF ALPHA-1-ANTITRYPSIN PHENOTYPE IN PATIENTS WITH GRANULOMATOSIS WITH POLYANGIITIS
M. Pervakova, V. Emanuel, S. Lapin, O. Titova, I. Belyaeva, A. Chudinov, T. Blinova, O. Napalkova, T. Bulgakova (Russia)

10:20 A RARE CASE OF MICROSCOPIC POLYANGIITIS IN CHILDHOOD
P. Miteva, D. Roussinov, T. Tzanova, S. Monov, R. Shumnalieva (Bulgaria)

10:25 GRANULOMATOSIS WITH POLYANGIITIS AND NEUROENDOCRINE INTESTINAL TUMOR: AN UNIQUE AND CHALLENGING COMBINATION
A.I. Reis, A. Watts Soares, M. Lobo Antunes, C. Noronha, J. Espirito Santo, A. Grilo (Portugal)
10:00 - 10:30  
Station 7

**EPD39: IL17 - WHY MIOSSSEC IS RIGHT**

**Chair: H. Kalim** (Indonesia)

10:00  
**IL-6/IL-17A PRODUCTION CORRELATE WITH NO SYNTHASE 2 EXPRESSION DURING PRIMARY SJOGREN’S SYNDROME: THEIR INVOLVEMENT IN DISEASE IMMUNOPATHOGENESIS**  
S. Benchabane, A. Boudjelida, R. Toumi, H. Belguendouz, P. Youinou, **C. Touil-Boukoffa** (Algeria)

10:05  
**ARE MESENCHYMAL STEM CELLS (MSCS) ABLE TO CONTROL PRO-INFLAMMATORY T CELLS?**  
G. Almanzar, M. Riekert, J. Heim, K. Hofner, M. Schmalzing, H.P. Tony, N. Schutze, M. Prelog (Germany)

10:10  
**REDUCTION OF IL-1β AND IL-17 IN NICOTINE-TREATED PBMC OF MULTIPLE SCLEROSIS PATIENTS**  
E. Costantini, M. Reale, C. D'Angelo, M. Di Nicola, A.M. Tata, M. Di Bari (Italy)

10:15  
**SERUM LEVEL OF INTERLEUKIN-17 (IL-17) AND TRANSFORMING GROWTH FACTOR-β (TGF-β) ON GRAVES’ DISEASE PATIENTS**  
E. Darwin, D. Elvira (Indonesia)

10:20  
**CORRELATION OF IL-17 URINARY EXCRETION WITH ACTIVITY INDEX, CHRONICITY INDEX, AND DISEASE ACTIVITY IN LUPUS NEPHRITIS**  
H. Kalim, **H. Kusworini**, A. Gunawan, M. Suyoso (Indonesia)

10:25  
**INTRATHECAL IL-17/IL-6 AXIS ACTIVATION IN ANTI-NMDA RECEPTOR ENCEPHALITIS**  
10:00 - 10:30

Station 8

**EPD40: IVIG: THE BIOLOGIC OF PREFERENCE**

Chair: S. Dahan (Israel)

10:00 **EFFICACY OF HIGH DOSE INTRAVENOUS IMMUNOGLOBULINS IN A DIFFICULT CASE OF DERMATOMYOSITIS OVERLAPPING NECROTIZING AUTOIMMUNE MYOSITIS**

C. Canofari, F. Sunzini, C. Barbato, G. Fonti, P. Conigliaro, A. Bergamini, R. Perricone (Italy)

10:05 **THE EFFECT OF INTRAVENOUS IMMUNOGLOBULIN ON EX VIVO ACTIVATION OF HUMAN LEUKOCYTES**

S. Gusev, S. Dahan, D. Ben-Ami Shor, M. Blank, Y. Shoenfeld (Israel)

10:10 **INTRAVENOUS IMMUNOGLOBULIN AS MONOTHERAPY FOR MYASTHENIA GRAVIS DURING PREGNANCY**

J. Gamez, M. Salvado, M. Casellas, S. Manrique, F. Castillo (Spain)

10:15 **EFFICACY AND SAFETY OF I10, A NOVEL 10% INTRAVENOUS IMMUNOGLOBULIN IN PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA: AN OPEN-LABEL MULTICENTRE STUDY**

A. Salama, M. Stulginskis, Y. Popovych, D. Woszczyk, B. Slama, M. Kappler, A. Sadoun, F. Rodeghiero (France)

10:20 **OPTIMISING THE EFFECTOR FUNCTION BALANCE OF FC-MULTIMERS FOR TREATMENT OF AUTO-ANTIBODY MEDIATED DISEASE**

T. Rowley, F. Fallah-Arani, D. Humphreys (United Kingdom)
10:30 - 12:30  
**PARALLEL SESSION 37: SYSTEMIC LUPUS ERYTHEMATOSUS - THE CHALLENGE**

**Chair:** S. Navarra (Philippines)  
**Chair:** Y. Naparstek (Israel)  
**Chair:** H. Young (USA)  

10:30  
**CASE STUDIES IN DIFFICULT LUPUS**  
S. Navarra (Philippines)  

10:50  
**TIME RELATED SYSTEM FOR GLOBAL VIEW OF SLE PATIENTS (TOAD)**  
C. Vasconcelos (Portugal)  

11:10  
**ANTI-PTX3 ANTIBODIES DELAY GLOMERULONEPHRITIS AND IMPROVE SURVIVAL IN NZB/NZW F1 MICE**  
M. Gatto, A. Ghirardello, R. Luisetto, M. Beggio, N. Bassi, D. Del Prete, L. Iaccarino, A. Doria (Italy)  

11:20  
**A META-ANALYSIS OF SERUM AND CEREBROSPINAL FLUID AUTOANTIBODIES IN NEUROPSYCHIATRIC SYSTEMIC LUPUS ERYTHEMATOSUS**  
R. Ho, Y. Lu, C. Ho, M. Zhang (Singapore)  

11:30  
**IMPAIRMENT OF GAS6/MERTK SYSTEM IN LUPUS NEPHRITIS**  
M. Bellan, F. Goegan, S. Pagani, L. Salmi, L. Castello, G.C. Avanzi, M. Quaglia, P. Stratta, M. Pirisi, P.P. Sainaghi (Italy)  

11:40  
**A META-ANALYSIS OF TACROLIMUS USE IN LUPUS NEPHRITIS**  
J. Hannah, A. Casian, D. D’Cruz (United Kingdom)  

11:50  
**OVERLAP SYNDROME BETWEEN FAMILIAL MEDITERRANEAN FEVER AND SYSTEMIC LUPUS ERYTHEMATOSUS IN 12-YEARS OLD FEMALE PATIENT**  
A. Gagro, V. Drkulec, J. Cepin-Bogovic, I. Skaric, K. Kondza, G. Roic, V. Herceg-Cavrak, A. Tesija Kuna, I. Vukasovic (Croatia)  

12:00  
**DISCOVERY AND INITIAL VALIDATION OF AUTOANTIBODIES AGAINST THE MAJOR VAULT PROTEIN (MVP) IN SYSTEMIC LUPUS ERYTHEMATOSUS**  
P. Budde, S. Vordenbäumen, H.D. Zucht, P. Schulz-Knappe, S. Matthias (Germany)  

12:10  
**CHIKUNGUNYA FEVER PRESENTING AS A SYSTEMIC DISEASE WITH FEVER, ARTHRITIS AND RASH- OUR EXPERIENCE IN ISRAEL**  
A. Tanay (Israel)  

12:20  
**DISCUSSION**  

12:30-14:00  
**Exhibition**  

**LUNCH BREAK, EXHIBITION, E-POSTER VIEWING**
10:30 - 12:30 MP3 & 4

PARALLEL SESSION 38: INFECTION AND AUTOIMMUNITY - TWO EDGES OF THE SWORD

Chair: C. Lunardi (Italy) 758
Chair: D. Bogdanos (Greece) 759
Chair: M. Sticherling (Germany) 760

10:30 EMERGING ISSUES: FROM MICROBIOME TO INFECTOME IN AUTOIMMUNITY
D. Bogdanos (Greece) 761

10:50 AUTOIMMUNITY AND INFECTION IN COMMON VARIABLE IMMUNODEFICIENCY (CVID)
C. Lunardi (Italy) 762

11:10 AUTOANTIGEN DISCOVERY IN PATIENTS WITH ANTIBIOTIC-REFRACTORY LYME ARTHRITIS
A. Steere, J.T. Crowley, A. Pianta, K. Strle, Q. Wang, E.E. Drouin, C.E. Costello (USA) 763

11:20 EPSTEIN-BARR VIRUS INFECTION REACTIVATION AS A RISK FACTOR FOR THE DEVELOPMENT OF DRYNESS SYMPTOMS AND POTENTIAL FACTOR IN THE DEVELOPMENT OF PRIMARY SJOGREN’S SYNDROME
M. Maslinska, B. Kwiatkowska (Poland) 764

11:30 EPSTEIN-BARR VIRUS INFECTION IN THE PATIENT WITH SYSTEMIC LUPUS ERYTHEMATOSUS
P. Sierzputowski, J. Ruivo, P. Alcantara (Portugal) 765

11:40 UPSCALE RHEUMONOLOGY: FROM MICROBES TO MICROBIOME TO MICROTECHNOLOGIES: ENRICHING BEDSIDE P4 RHEUMATOLOGY
P. Pispati (India) 766

11:50 A PROSPECTIVE STUDY OF DIRECT-ACTING ANTIVIRAL AGENTS FOR HEPATITIS C VIRUS-ASSOCIATED MIXED CRYOGLOBULINEMIA
M. Visentini, S. Colantuono, M. Mitrevski, M. Del Padre, A. De Santis, M. Fiorilli, A. Pulsoni, M. Casato (Italy) 767

12:00 ARE ENDOGENOUS RETROVIRUSES IMPORTANT IN HUMAN AUTOIMMUNITY?
B.A. Nexø, M.J. Laska (Denmark) 768
12:10 VIRAL NONSTRUCTURAL PROTEIN 1 (NS1) STIMULATES AUTOIMMUNITY BY DESTRUCTION OF SELF-TOLERANCE
K. Puttaraksa, H. Pirttinen, R. Lagier, S. Naides, L. Gilbert (Finland)

12:20 EVIDENCE FOR AUTOIMMUNE ENCEPHALITIS IN PEDIATRIC AUTOIMMUNE NEUROPSYCHIATRIC DISORDER ASSOCIATED WITH STREPTOCOCCAL INFECTIONS (PANDAS)
S. Swedo (USA)

12:30-14:00 Exhibition
LUNCH BREAK, EXHIBITION, E-POSTER VIEWING
10:30 - 12:30

PARALLEL SESSION 39: HIGHLIGHTS IN DIAGNOSTICS

Chair: K. Conrad (Germany) 771
Chair: M. Sowa (Germany) 772
Chair: M. Mahler (USA) 773

10:30 NEXT GENERATION AUTOANTIBODY DETECTION BY HIGHLY FLEXIBLE CYTOBEAD® TECHNOLOGY
M. Sowa, R. Hiemann, J. Scholz, K. Grossmann, D. Reinhold, K. Conrad, D. Roggenbuck (Germany) 774

10:50 CELLULAR IMMUNE DIAGNOSTICS IN AUTOIMMUNITY
U. Sack (Germany) 775

11:10 ANTI-PAD3 ANTIBODIES AS A PROMISING MARKER TO MEASURE JOINT DAMAGE IN PATIENTS WITH RHEUMATOID ARTHRITIS
A. Seaman, E. Darrah, M. Infantino, M. Benucci, M. Manfredi, F. Meacci, M. Mahler (USA) 776

11:30 INCIDENCE OF AQP4-IGG SEROPOSITIVE NEUROMYELITIS OPTICA SPECTRUM DISORDERS IN THE NETHERLANDS: ONE IN A MILLION

11:40 DIFFERENTIAL DIAGNOSIS OF AUTOIMMUNE LIMBIC ENCEPHALITIS BY MULTIPARAMETRIC SEROLOGICAL TESTING
S. Lederer, B. Teegen, L. Komorowski, J. Fraune, K. Fechner, W. Stöcker, C. Probst (Germany) 778

11:50 DO ANTI-SMOOTH MUSCLE ANTIBODIES PREDICT DEVELOPMENT OF AUTOIMMUNE HEPATITIS IN ASYMPOTOMATIC INDIVIDUALS? - A RETROSPECTIVE COHORT REVIEW
R. Healey, L. Corless, P. Gordins, S. Holding (United Kingdom) 779

12:00 THE SEROTAG® APPROACH: FROM DISCOVERY TO VALIDATED ASSAYS IN LESS THAN THREE YEARS. A CASE STUDY ON NOVEL SYSTEMIC SCLEROSIS AUTOANTIGENS
J. Schulte-Pelkum, P. Budde, H.D. Zucht, D. Wirtz, P. Schulz-Knappe, N. Hunzelmann, B. Maurer, K. Conrad, M. Schneider (Germany) 780
12:10  GOODPASTURE’S SYNDROME: INDIRECT IMMUNOFLUORESCENCE AS AN ESSENTIAL TEST FOR THE DETECTION OF CIRCULATING ANTI-GLOMERULAR BASEMENT MEMBRANE ANTIBODIES

C. Dumestre-Perard, A. Gauthier, G. Clavarino, P.L. Carron, D. Giovannini, S. Colliard, J.Y. Cesbron (France)

12:20  VERIFICATION OF CRYOGLOBULINS IN CRYOPRECIPITATES BY NEPHELOMETRY

I. Francova, K. Maličková, M. Hinoďoš (Czech Republic)

12:30-14:00  Exhibition

LUNCH BREAK, EXHIBITION, E-POSTER VIEWING
10:30 - 12:30

PARALLEL SESSION 40: INNATE IMMUNITY AND NATURAL AUTOANTIBODIES (IVIG)

Chair: A. Issekutz (Canada)  
Chair: A. Zuercher (Switzerland)  
Chair: Z. Sthoeeger (Israel)

10:30  INTRODUCTION TO IVIG EFFECTS ON INNATE IMMUNE CELLS
S. Kaveri (France)

10:40  POTENTIATION BY IVIG OF NK CELL PROLIFERATION IN RESPONSE TO CYTOKINES AND DURING T CELL ACTIVATION
B. Derfalvi, D. Rowter, A. Issekutz, F. Kaebermann (Canada)

11:00  EXPERIENCE IN IVIG THERAPY FOR SELECTED WOMEN WITH RECURRENT REPRODUCTIVE FAILURE AND NK CELL EXPANSION
S. Sanchez-Ramon (Spain)

11:20  IVIG MODULATION OF DENDRITIC CELL/APC FUNCTION AND/OR ON IL-33 RELATED CYTOKINE NETWORK
J. Kwekkeboom (Netherlands)

11:40  USE OF IVIG FOR THE PREVENTION OF GVHD IN NSG MICE: THE ROLE OF NK CELLS
J. Gregoire-Gauthier, F. Fontaine, L. Benchimol, M.M. Dieng, E. Haddad (Canada)

11:50  PERIPHERAL BLOOD AND SPLENIC NATURAL KILLER CELLS IN PRIMARY IMMUNE THROMBOCYTOPENIA: PHENOTYPE, FUNCTION AND EFFECT OF IVIG
M. Ebbo, A. Grados, L. Benarous, S. Audonnet, M. Mahevas, B. Godeau, J.F. Viallard, C. Piperoglou, C. Cognet, C. Farnarier, J.R. Harlé, F. Vely, N. Schleinitz (France)

12:00  ALTERED B CELL HOMEOSTASIS AND TOLL-LIKE RECEPTOR 9-DRIVEN RESPONSE IN PATIENTS AFFECTED BY AUTOIMMUNE POLYGLANDULAR SYNDROME TYPE 1 (APECED)
12:10  IL-37: THERAPEUTIC POTENTIAL OF A NATURAL INHIBITOR OF INNATE IMMUNITY DURING EXPERIMENTAL ARTHRITIS
M. Koenders, L. Joosten, P. Van der Kraan, W. Van den Berg, C. Dinarello  (Netherlands)

12:20  ANIMAL MODELS OF TYPE I INTERFERONOPATHIES

12:30-14:00  Exhibition

LUNCH BREAK, EXHIBITION, E-POSTER VIEWING
10:30 - 12:30

PARALLEL SESSION 41: UCTD, MCTD AND OTHER CONNECTIVE TISSUE DISEASES

Chair: M. Mosca (Italy)  
Chair: M. Olesinska (Poland)  
Chair: C. Belizna (France)  

10:30 PREDICTING, MONITORING AND PREVENTING: UNDIFFERENTIATED CONNECTIVE TISSUE DISEASES AND EARLY LUPUS  
M. Mosca (Italy)  

10:50 PREDICTING, MONITORING AND PREVENTING - ACTIVITY AND DAMAGE IN MCTD  
M. Olesinska (Poland)  

11:10 ASSESSMENT OF CYTOMEGALOVIRUS-SPECIFIC CELL-MEDIATED IMMUNITY FOR THE PREDICTION OF CYTOMEGALOVIRUS SPONTANEOUS CLEARANCE IN HIGH-RISK KIDNEY TRANSPLANT RECIPIENTS WITH CYTOMEGALOVIRUS VIREMIA  
M. Lochouarn Andreani, S. Benzaken, L. Albano, E. Cassuto, A. Jeribi, A. Caramella, V. Giordanengo, G. Bernard, V. Esnault, B. Seitz-Polski (France)  

11:20 POST-STEROID NEUROPSYCHIATRIC MANIFESTATIONS ARE SIGNIFICANTLY MORE FREQUENT IN SLE COMPARED WITH OTHER AUTOIMMUNE DISEASES AND PREDICT BETTER PROGNOSIS COMPARED WITH DE NOVO NPSLE  

11:30 FAST AND COMPLETE RESTORATION OF HAIR GROWTH BY SELECTIVE JAK1 INHIBITION IN THE C3H/HEJ MOUSE MODEL OF ALOPECIA AREATA  

11:40 THE AUTOIMMUNE DISEASES OF THE EYES  
F.A. De Andrade (Brazil)
11:50  STAT6 DEFICIENCY AMELIORATES SEVERITY OF GRAVES’ DISEASE BY SUPPRESSING THYROID EPITHELIUM HYPERPLASIA
L. Wang, X. Jiang, Y. Chu (China)

12:00  THE AVIDITY OF PR3-ANCA IN PATIENTS WITH GRANULOMATOSIS WITH POLYANGIITIS DURING FOLLOW-UP
M. Kemna, W. Schlumberger, P. Van Paassen, C. Dähnrich, J. Damoiseaux, J.W. Cohen Tervaert (Netherlands)

12:10  NEUTROPHIL-EXTRACELLULAR TRAPS CAUSE ANCA-INDUCED GLOMERULONEPHRITIS IN A COMPLEMENT DEPENDENT MANNER AND IS CONTROLLED BY THE NECROPTOSIS PATHWAY
A. Schreiber, A. Linkermann, S. Krautwald, U. Jerke, R. Kettritz (Germany)

12:20  FREQUENCY OF GARDASIL-SPECIFIC MEMORY LYMPHOCYTES IS INCREASED IN PATIENTS WITH SELF-REPORTED HEALTH EFFECTS AFTER GARDASIL VACCINATION
V. Stejskal, D. Downing, C. Plothe, K. Viborg (Sweden)

12:30-14:00  Exhibition
LUNCH BREAK, EXHIBITION, E-POSTER VIEWING
PARALLEL SESSION 42: PREGNANCY AND AUTOIMMUNITY

Chair: A. Tincani [Italy] 808
Chair: P.L. Meroni [Italy] 809
Chair: S. De Carolis [Italy] 810

10:30 THE USE OF SYNTHETIC AND BIOLOGIC DMARDS IN PREGNANCY

10:50 IVIG AND RECURRENT AUTOIMMUNE PREGNANCY LOSS
H. Carp [Israel] 812

11:10 MANAGEMENT OF PREGNANCY IN SLE AND APS
C. Dias [Portugal] 813

11:30 THE ROLE OF COMPLEMENT IN THE PHYSIOLOGY AND PATHOLOGY OF THE REPRODUCTIVE SYSTEM
F. Tedesco [Italy] 814

11:50 ANGIogenic FACTORS AND CLINICAL CHARACTERISTICS IN PREGnant WOMEN WITH OBSTETRIC AND THROMBOTIC ANTIPHOSPHOLIPID SYNDROME
K. Mayer-Pickel [Austria] 817

12:10 SAFETY OF ANTI TNF-α AGENTS IN PATIENTS WITH CHRONIC ARTHRITIDES DURING PREGNANCY AND BREASTFEEDING: A CASE-CONTROL MONOCENTRIC STUDY

12:30-14:00 Exhibition

LUNCH BREAK, EXHIBITION, E-POSTER VIEWING
14:00 - 16:00

PARALLEL SESSION 43: ANA DIAGNOSTICS AND IMMUNOFUORESCENCE

Chair: J. Damoiseaux (Netherlands) 818
Chair: L.E. Coelho Andrade (Brazil) 819
Chair: E. Chan (USA) 820

14:00 AUTOANTIBODIES AS BIOMARKERS IN MYOSITIS

G. Pruijn (Netherlands) 821

14:20 ANA AND ANCA DETECTION IN DAILY CLINICAL PRACTICE: EUROPATTERN VERSUS CONVENTIONAL MICROSCOPY

J. Damoiseaux (Netherlands) 822

14:40 THE INCREDIBLE SUCCESS STORY OF IMMUNOFUORESCENCE

W. Stoecker (Germany) 823

15:00 COMBINED ANTINUCLEAR ANTIBODY AND ANTI-R052 ANTIBODY ASSAYS IMPROVE THE SEROLOGICAL DIAGNOSIS OF IDIOPATHIC INFLAMMATORY MYOPATHIES


15:10 THE MAJORITY OF PATIENTS NEGATIVE FOR ANA-IIFA AND POSITIVE FOR ANA-MULTIPLEX BECOME IIFA POSITIVE IN THREE YEARS


15:20 FLUORESCENCE ENZYME IMMUNOASSAY IN THE DETECTION OF PARIETAL CELL AND INTRINSIC FACTOR AUTOANTIBODIES: WHAT’S NEW?

G. Pesce, M. Bagnasco, M.P. Panozzo, D. Villalta, A. Antico, N. Bizzaro (Italy) 826

15:30 ANTI-CN-1A (MUP44, NT5C1A) IGG SEROLOGIC ASSAY FOR THE DIAGNOSIS OF SPORADIC INCLUSION BODY MYOSITIS (SIBM)

E. Cho, G. Shen, D. Karayev, A.L. Metzger, R.I. Morris, S.L. Kramp, C. Dähnrich, W. Schlumberger (Germany) 827

15:40 THE CHOICE OF ANA AUTOMATED SCREENING: IMPACT AND BENEFIT

A. Melegari, C. Bonaguri, A. Russo, C. Vezzosi, B. Venturelli, E. De Santis, T. Trenti (Italy) 828

15:50 COMPARISON OF THE CLINICAL UTILITY IN THE DETECTION OF ANTI-NUCLEAR ANTIBODIES BETWEEN THE ELIA CTD SCREEN AND INDIRECT IMMUNOFUORESCENCE ON HEP-2 CELLS

C. Robier, O. Amouzadeh-Ghadikolai, M. Stettin, G. Reicht (Austria) 829
12:30 - 14:00  MP3 & 4

Industry Supported Session:
NOT INCLUDED IN MAIN EVENT CME/CPD CREDIT

14:00 - 16:00  Hall 1

PARALLEL SESSION 44: **T-REG, B-REG, TOLERANCE AND AUTOIMMUNITY**

**Chair:** E. Toubi (Israel) 830
**Chair:** D. D’Cruz (United Kingdom) 831
**Chair:** J.E. Fonseca (Portugal) 832

**14:00** MOLECULAR MASCULINIZATION OF REGULATORY T CELLS
**G.C. Tsokos** (USA)

**14:20** FOXP3 HIGHIL-10 HIGH B REGULATORY CELLS IN SLE
**E. Toubi** (Israel)

**14:40** REGULATORY B LYMPHOCYTES IN ISOLATED HASHIMOTO THYROIDITIS (HT) AND/OR ASSOCIATED WITH CELIAC DISEASE (CD)
I. Gatto, M.G. Santaguidia, G. Mangino, C. Virili, G. Romeo, **M. Centanni** (Italy)

**14:50** ROLE OF CD38 IN THE HUMAN CD4+CD25+FOXP3+CD127- PERIPHERAL T REGULATORY LYMPHOCYTES

**15:00** REDUCED FREQUENCIES AND ALTERED PHENOTYPES OF REGULATORY B CELLS IN PATIENTS WITH ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY (ANCA)-ASSOCIATED VASCULITIS
**D. Söderberg**, P. Eriksson, J. Ernerudh, M. Segelmark (Sweden)

**15:10** GRANZYME B PRODUCING B-CELLS HAVE IMMUNOREGULATORY FUNCTION AND ARE DIMINISHED IN PATIENTS WITH ANCA-VASCULITIS

**15:20** REGULATORY CD19+CD24HIGHCD38HIGH B CELLS ARE SIGNIFICANTLY DEPLETED IN PATIENTS WITH ATHEROSCLEROSIS AND HAVE ALTERED INTERLEUKIN-10 PRODUCTION
**I.E. Dumitriu**, P. Baruah, J.C. Kaski (United Kingdom)
15:30 THE ROLE OF T-REGULATOR EXPRESSION IN AUTOIMMUNE THYROID DISEASE AND ITS ASSOCIATION WITH THYROID ANTIBODY  
D. Elvira (Indonesia)

15:40 GLUCOCORTICOID HORMONE INFLUENCE IN VIVO DIFFERENTIATION AND ENHANCE IN VITRO EXPANSION OF FUNCTIONAL REGULATORY T CELLS  
T. Berki, E. Ugor, R. Pap, L. Prenek, F. Boldizsár, P. Németh (Hungary)

15:50 STUDY ON THE RELATIONSHIP BETWEEN REGULATORY B CELLS AND THE ACTIVITY OF RHEUMATOID ARTHRITIS  
G. Wu (China)
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00</td>
<td>THE ASSOCIATION OF OTHER AUTOIMMUNE DISEASES IN PATIENTS WITH THYROID AUTOIMMUNE DISORDERS</td>
<td>A. Antonelli, S.M. Ferrari, D. Giuggioli, M. Colaci, C. Ferri, P. Fallahi (Italy)</td>
</tr>
<tr>
<td>14:20</td>
<td>TYPE 1 DIABETES AND MULTIPLE ENDOCRINE AUTOIMMUNE DISORDERS</td>
<td>G. Kahaly (Germany)</td>
</tr>
<tr>
<td>14:40</td>
<td>AUTOIMMUNE THYROID DISEASES: FROM GENE MAPPING TO NOVEL DRUG TARGETS</td>
<td>Y. Tomer (USA)</td>
</tr>
<tr>
<td>14:55</td>
<td>HOW SOME TSH RECEPTOR ANTIBODIES DICTATE THYROCYTE DEATH - IMPLICATIONS FOR AUTOIMMUNITY</td>
<td>T. Davies, S. Morshed (USA)</td>
</tr>
<tr>
<td>15:10</td>
<td>CIRCULATING CXCL10 IS INCREASED IN NON-SEGMENTAL VITILIGO, IN PRESENCE OR ABSENCE OF AUTOIMMUNE THYROIDITIS</td>
<td>S.M. Ferrari, P. Fallahi, G. Santaguida, C. Virili, I. Ruffilli, F. Ragusa, M. Centanni, A. Antonelli (Italy)</td>
</tr>
<tr>
<td>15:20</td>
<td>INCIDENCE OF THYROID DISORDERS IN MIXED CRYOGLOBULINEMIA: RESULTS FROM A LONGITUDINAL FOLLOW-UP</td>
<td>P. Fallahi, S.M. Ferrari, I. Ruffilli, G. Elia, D. Giuggioli, M. Colaci, C. Ferri, A. Antonelli (Italy)</td>
</tr>
<tr>
<td>15:30</td>
<td>SERUM THYROID HORMONE AUTOANTIBODIES IN SUBJECTS WITH CHRONIC HEPATITIS C, AND WITH GRAVES’ DISEASES OR HASHIMOTO’S THYROIDITIS</td>
<td>S. Benvenga, R. Vita, M.R. Galletti, M. Mandolfino, F. Di Bari, S.M. Ferrari, P. Fallahi, A. Antonelli (Italy)</td>
</tr>
<tr>
<td>15:40</td>
<td>TSH RECEPTOR A SUBUNIT IMMUNIZATION OF MICE LEADS TO A LONG-TERM MODEL OF GRAVES’ ORBITOPATHY</td>
<td>M. Ungerer, H.P. Holthoff, M. Lohse, G. Muench (Germany)</td>
</tr>
<tr>
<td>15:50</td>
<td>THE IMPORTANCE OF IMMUNOMODULATORY TREATMENT IN THYROID AUTOIMMUNITY REPRODUCTIVE FAILURE PATIENTS</td>
<td>G. Gabriela, F. Leila, J. Gisela, G. Maria, M. Soledad, V. Gustavo, P. Sergio (Argentina)</td>
</tr>
</tbody>
</table>
PARALLEL SESSION 46: **NOVEL STUDIES IN AUTOIMMUNE DISEASES**

**Chair:** J.W. Cohen Tervaert (Netherlands)  
**Chair:** B.S. Porat Katz (Israel)  
**Chair:** F. Tedesco (Italy)

**14:00 CANNABINOIDS AND AUTOIMMUNE DISEASES: A SYSTEMATIC REVIEW**  
V. Katchan (Spain)  

**14:20 SOME LIKE IT HOT: SPICY FOOD (CAPSAICIN) AND AUTOIMMUNITY**  
S. Dahan (Israel)  

**14:40 IRREGULAR ANTIBODIES IN NO HEMOLYTIC AUTOIMMUNE DISEASES ARE ABLE TO INDUCE ERYTHROCYTE LYSIS MEDIATED BY COMPLEMENT AND MACROPHAGES**  

**14:50 PHOSPHATIDYLCHOLINE SUPPLEMENTATION ATTENUATES SIDE EFFECTS OF HUMAN PAPILLOMAVIRUS VACCINE IN MICE**  
**M. Arango,** S. Kivity, L. Tomijenovic, M. Blank, Y. Shoenfeld (Israel)  

**15:00 BLOOD BRAIN BARRIER DISRUPTION BY LIPOPOLYSACCHARIDE IN MICE: A USEFUL APPROACH FOR EVALUATION OF NEUROPSYCHIATRIC-LUPUS.**  
M.T. Arango, S. Goldman, Y. Mardor, Y. Shoenfeld, M. Blank, I. Cooper, **S. Kivity** (Israel)  

**15:10 BELIMUMAB IN PATIENTS WITH SLE AND PERSISTENT PROTEINURIA DESPITE THE STANDARD THERAPY**  

**15:20 TOLEROGENIC EFFECT OF ACTIVE VITAMIN D IN EXPERIMENTAL MODELS OF RHEUMATOID ARTHRITIS AND MULTIPLE SCLEROSIS**  
**L.L. Ishikawa,** L.A. Mimura, T.F. Fraga-Silva, A. Missio, S.F. Zorzella-Pezavento, F. Chiuso-Minicucci, A. Sartori (Brazil)  

**15:30 DISTINCT DISTRIBUTION PATTERNS OF LARGE VESSEL VASCULITIS ASSESSED WITH 18F-FDG PET/CT: A CLUSTER AND PRINCIPAL COMPONENT ANALYSIS STUDY**  
**A. Soriano,** G. Pazzola, L. Boiardi, F. Muratore, P. Macchioni, R. Aldigeri, M. Casali, A. Versari, C. Salvarani (Italy)
15:40  CHURG-STRAUSS SYNDROME: SILICONE IMPLANT OR SINGULAIR (OR COULD BE BOTH?)

P. David, A. Dagan, Y. Shoenfeld, J.W. Cohen Tervaert, M. Colaris, M. De Boer (Brazil)

15:50  DISCUSSION
14:00 - 16:00

PARALLEL SESSION 47: EPSTEIN-BARR VIRUS DRIVEN INFLAMMATORY DISEASES: FROM PRIMARY IMMUNODEFICIENCIES TO AUTOIMMUNE DISEASES (NEDAI SESSION)

Chair: C. Vasconcelos (Portugal) 867
Chair: B. Martins da Silva (Portugal) 868
Chair: A. Marinho (Portugal) 869

14:00 IMMUNOGENETIC PREDISPOSING FACTORS FOR CHRONIC EBV INFECTION - SESSION 1
B. Leal (Portugal) 870

14:20 IMMUNOGENETIC PREDISPOSING FACTORS FOR CHRONIC EBV INFECTION - SESSION 2
C. Carvalho (Portugal) 871

14:40 EBV CHRONIC INFECTION AND AUTOIMMUNITY: LESSON FROM A PRIMARY IMMUNODEFICIENCY - CASE 1
R. Costa (Portugal) 872

14:55 EBV CHRONIC INFECTION AND AUTOIMMUNITY: LESSON FROM LYMPHOHISTIOCYTOSIS - CASE 2
R. Alves (Portugal) 873

15:10 EBV CHRONIC INFECTION: CASE REPORTS DISCUSSION
A. Marinho (Portugal) 874

15:30 STEM CELL THERAPY FOR AUTOIMMUNE AND PRIMARY IMMUNODEFICIENCIES: STRATEGIES TO AVOID EBV
R. Handgretinger (Germany) 875

15:50 DISCUSSION
14:00 - 16:00
Hall 5

PARALLEL SESSION 48: PEARLS IN AUTOIMMUNITY: TOP CANDIDATES FOR THE MAI AWARD 2016

Chair: **A. Kuhn** (Germany)
Chair: **Z. Tellier** (France)
Chair: **D. Roccatello** (Italy)

14:00 VITAMIN D STATUS IS ASSOCIATED WITH IMPROVED CLINICAL AND IMMUNOLOGICAL OUTCOME IN RELAPSING REMITTING MULTIPLE SCLEROSIS
**J. Smolders**, R. Hupperts, J. Damoiseaux (Netherlands)

14:15 MELATONIN CONTRIBUTES TO THE SEASONALITY OF MULTIPLE SCLEROSIS RELAPSES
**M. Farez** (Argentina)

14:30 ANTI-MYELIN OLIGODENDROCYTE GLYCOPROTEIN AUTOANTIBODIES AS BIOMARKERS OF DEMYELINATING DISEASES IN HUMANS
F. Tea, S. Ramanathan, T.K. Nguyen, V. Merheb, R.C. Dale, **F. Brilot** (Australia)

14:45 AUTOANTIBODIES TO COMPLEMENT FACTOR H IN PATIENTS WITH NEUROMYELITIS OPTICA

15:00 THE NUCLEOLUS AND INACTIVE X CHROMOSOME NEXUS - A MECHANISM FOR CREATION OF AUTOANTIGENS
**W. Brooks**, Y. Renaudineau (USA)

15:15 ENHANCED SENSITIVITY OF TREX1-DEFICIENT CELLS TO COLD AND UV-IRRADIATION PREDISPOSES TO AUTOIMMUNITY
F. Schmidt, N. Berndt, N. Zimmermann, P. Knuschke, M.A. Lee-Kirsch, **C. Günther** (Germany)

15:30 EFFECT OF EXPERIMENTAL ANTIPHOSPHOLIPID SYNDROME ON WHITE MATTER, HIPPOCAMPUS DENTATE GYRUS CELL PROLIFERATION AND NEUROBLAST DIFFERENTIATION
15:40 NEUROPEPTIDE Y AS REGULATOR OF MACROPHAGE PHENOTYPE AND FUNCTIONS: A NEUROIMMUNE CUE IN ATHEROSCLEROSIS REGRESSION? B. Buttari, E. Profumo, R. Businaro, I.J. Elenkov, R. Riganò (Italy)

15:50 COGNITIVE DYSFUNCTION IN SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS OF A 10 YEARS PROSPECTIVE COHORT STUDY F. Ceccarelli, C. Perricone, C. Pirone, L. Massaro, C. Alessandri, C. Mina, M. Marianetti, F.R. Spinelli, G. Valesini, F. Conti (Italy)
16:00-16:30 Exhibition

COFFEE BREAK & EXHIBITION BREAK

16:00-16:30 Station 1

**EPD41: THYROID: AVENUES IN DISEASE DIAGNOSTICS**

*Chair: U. Gul (Turkey)*

**16:00** AUTOIMMUNE THYROID DISORDERS IN PATIENTS WITH PSORIASIS  
**U. Gul, M. Gonul (Turkey)**  

**16:05** ENHANCING EFFECT OF TOTAL IMMUNOGLOBULIN E LEVELS ON GRAVES’ HYPERTHYROIDISM  
**I. Molnár, S.V. Eva (Hungary)**  

**16:10** THE CHARACTERISTIC OF AUTOIMMUNITY IN HASHIMOTO’S THYROIDITIS  
**P. Sobolevskaia, Y. Stroev, V. Utekhin, L. Churilov, D. Baranov, A. Yakovenko (Russia)**  

**16:15** A CLINICALLY PRACTICAL APPROACH FOR THE DIAGNOSIS AND TREATMENT OF HASHIMOTO’S ENCEPHALOPATHY  

**16:20** DETECTION OF ORGAN-SPECIFIC ANTI-THYROID AUTOANTIBODIES IN PATIENTS WITH NON-ORGAN-SPECIFIC AUTOIMMUNE DISEASES  

**16:25** APPLICATION OF RECOMBINANT PROTEINS IN THE ANALYSIS OF THE EPITOPES OF THYROID AUTOANTIGENS  
**A. Zubkov, E. Shamkina, N. Kuzmina (Russia)**
16:00 - 16:30
Station 2

**EPD42: CITRULLINATION: AN IMPORTANT FACTOR IN AUTOIMMUNE CONDITIONS**

**Chair: C. Bentow (USA)**

16:00  **ADDED VALUE OF IGA ISOTYPE FOR ANTI-CITRULLINATED PROTEIN ANTIBODIES IN THE DIAGNOSIS FOR RHEUMATOID ARTHRITIS**
M. Mahler, **C. Bentow**, T. Webb, L. Cesana, P. Roux-Lombard, M. Nissen, C. Lamacchia, C. Gabay (USA)

16:05  **COMPARATIVE EVALUATION OF 3 ASSAYS FOR THE DETECTION OF ANTI-CCP ANTIBODIES**
**F. Coutant**, S. Genebrier, K. Messaoudi, N. Fabien, B. Evrard, P. Rouzaire (France)

16:10  **CYCLIC CITRULLINATED PEPTIDES AS ACPA-NEUTRALIZERS IN RHEUMATOID ARTHRITIS**
**C. Eriksson**, C. Fernandes-Cerqueira, S. Gunasekera, U. Göransson, P.J. Jakobsson (Sweden)

16:15  **HYPOXIA PROMOTES C5A-ASSOCIATED INFLAMMATION VIA MIR-342-3P**
**S. Liu**, L. Song, L. Yi, X. Cao (China)

16:20  **EVALUATION OF ANTI-CITRULLINATED PROTEIN ANTIBODY ASSAY IN AN ITALIAN REFERENCE CENTER FOR THE DIAGNOSIS OF RHEUMATOID ARTHRITIS**

16:25  **ANTI-MUTATED CITRULLINATED VIMENTIN ANTIBODIES IN ANTIPHOSPHOLIPID SYNDROME: DIAGNOSTIC VALUE AND RELATIONSHIP WITH CLINICAL FEATURES**
16:00 - 16:30

Station 3

EPD43: **LIVER: A PIECE OF THE MOSAIC OF AUTOIMMUNITY**

**Chair:** C. Bonaguri (Italy)

16:00  
**EVOLUTION OF AUTOIMMUNE HUMORAL RESPONSE AND LIVER BIOCHEMISTRY PROFILE IN ASYMPTOMATIC INDIVIDUALS WITH ANTIMITOCHONDRIAL ANTIBODIES**  
D. Baldo, A. Dellavance, M.L.G. Ferraz, L.E.C. Andrade (Brazil)

16:05  
**MULTICENTER ITALIAN STUDY ABOUT AN AUTOIMMUNE PROFILE TESTING FOR CLINICAL MANAGEMENT OF PRIMARY BILIARY CIRRHOSIS**  

16:10  
**NEUROLOGICAL MANIFESTATIONS IN PATIENTS WITH PRIMARY BILIARY CIRRHOSIS**  
C. Kaliouli-Antonopoulou, X. Koufomichali, O. Boulamatsi, S. Kokkoris, M. Agrogiai, A. Ioannidou, E. Pappa, C. Drakoulis (Greece)

16:15  
**EVALUATION OF A NEW TEST FOR THE DETECTION OF AMA-M2 ANTIBODIES**  
A. Mendes, I. Baptista-Fernandes, A. Valente, J. Faro-viana (Portugal)

16:20  
**ANTIBODY-NEGATIVE AUTOIMMUNE HEPATITIS IN AN 11 YEAR OLD BOY**  
A. Sauerbrey, K. Luecke, H. Kosmehl (Germany)
16:00 - 16:30  

**Station 4**

**EPD44: ANA DIAGNOSTICS: THE ULTIMATE PROCEDURE**

Chair: A. Radice (Italy)

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:05</td>
<td>THE DIAGNOSTIC PERFORMANCE OF AN AUTOMATED FLUORESCENCE ENZYME IMMUNOASSAY FOR ANTI-DSDNA ANTIBODIES IN A CLINICAL ROUTINE SETTING WITH RHEUMATOLOGIC OUTPATIENTS</td>
<td>B. Schlueter (Germany)</td>
</tr>
<tr>
<td>16:10</td>
<td>NEW ALGORITHM FOR NEGATIVE/POSITIVE DISCRIMINATION OF ANTI-NUCLEAR ANTIBODIES DETECTION ON AUTOMATED FLUORESCENCE MICROSCOPE</td>
<td>V. Stojkovic, L. Lutteri, E. Cavalier (Belgium)</td>
</tr>
</tbody>
</table>
16:00 - 16:30

Station 5

EPD45: ADDITIONAL ASPECTS OF GASTROINTESTINAL AUTOIMMUNITY

Chair: D. Bogdanos (Greece)

16:00 MYCOBACTERIUM AVIUM INDUCED PARATUBERCULOSIS AND CROHN’S DISEASE SHARE COMMON ANTIBODY PROFILES

16:05 A PATIENT WITH AUTOIMMUNE HEPATITIS AND AUTOIMMUNE PANCREATITIS; A CASE REPORT OF AN UNCOMMON AUTOIMMUNE DISEASE ASSOCIATION IN PATIENT WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
D. Dajcman, N. Potocnik Dajcman (Slovenia)

16:10 DISTINCT ANTI-IFI16 AND ANTI-GP2 ANTIBODIES IN INFLAMMATORY BOWEL DISEASE AND THEIR VARIATION WITH INFLIXIMAB THERAPY
M. De Andrea, V. Caneparo, L. Pastorelli, L.F. Pisani, B. Bruni, F. Prodam, D. Roggenbuck, M. Vecchi, S. Landolfo, M. Gariglio (Italy)

16:15 ANTI-SACCHAROMYCES CEREVISIAE ANTIBODIES IN PATIENTS WITH ANTI-β2 GLYCOPROTEIN I ANTIBODIES
A. Mankai, S. Layouni, M. Ghozzi, I. Ghedira (Tunisia)

16:20 DIGESTIVE TRACT SARCOIDOSIS
E. Ghrenassia, A. Mekinian, O. Fain (France)

16:25 THE ROLE OF IL-22 IN CHRONIC GUT INFLAMMATION INDUCED BY INFECTION WITH SALMONELLA ENTERICA
A. Seydel, M. Hoffmann, H. Petruschke, U. Schwertassek, J. Lehmann (Germany)
16:00 - 16:30

**Station 6**

**EPD46: VASCULITIS: THE GREAT IMITATOR**

**Chair:** S. Ohlsson [Sweden]

16:00 **GRANULOMATOSIS WITH POLYANGIITIS AND FACIAL PALSY: INSIGHT IN THE AUTOIMMUNE PATHOGENESIS** 920

G. Iannella, A. Greco, G. Granata, A. Manno, B. Pasquariello, D. Angeletti, D. Didona, G. Magliulo [Italy]

16:05 **LONG TERM OUTCOME OF PATIENTS WITH LOW LEVEL OF CRYOglobulin (< 0.05 G/L)** 921

I. Marie [France]

16:10 **PROPylthIOuRACIL ANCA ASSOCIATED VASCULITIS - INDUCED OR NOT?** 922


16:15 **NEUTROPHILS FROM ANCA-ASSOCIATED VASCULITIS PATIENTS SHOW AN INCREASED CAPACITY TO ACTIVATE THE COMPLEMENT SYSTEM VIA THE ALTERNATIVE PATHWAY** 923

S. Ohlsson, L. Holm, L. Skattum, T. Hellmark [Sweden]

16:20 **A CASE OF REFRACtORY TAKAYASU ARTERITIS AND PSORIATIC ARTHRITIS: ACHIEVING REMISSION WITH TNFA INHIBITOR [ADALIMUMAB]** 924

F. Sunzini, L. Novelli, C. Barbato, C. Canofari, G.L. Fonti, M.S. Chimenti, R. Perricone [Italy]
16:00 - 16:30

Station 7

EPD47: PERSONALIZED AND PRECISION TRENDS IN AUTOIMMUNITY

Chair: B. Gundogdu (Turkey)

16:00  LONG TERM SURVIVAL OF HALF DOSE ETANERCEPT: EXTENDED FOLLOW-UP OF A PROSPECTIVE CLINICAL STUDY

F. Ometto, B. Raffeiner, C. Botsios, L. Friso, D. Astorri, L. Bernardi, L. Punzi, A. Doria (Italy)

16:05  THERAPEUTIC DRUG MONITORING OF USTEKINUMAB IN SERUM OF PSORIATIC PATIENTS: SENSE OR NONSENSE?

E. De Keyser, C. Busard, E. Coussens, L. Grine, E. Botti, L. Meuleman, M. Van De Kerckhove, H. Boonen, A. Stockman, A. Costanzo, J. Lambert, P. Spuls (Belgium)

16:10  NON-INTERVENTIONAL STUDY TO DESCRIBE THE SAFETY, TOLERABILITY AND EFFICACY OF TOCILIZUMAB IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS WHO HAVE AN INADEQUATE RESPONSE TO NON-BIOLOGIC DMARD

S. Aligrudic, K. Kazic, N. Miketic, A. Bulatovic, D. Lutovac, N. Sjekloca, A. Kovacevic (Montenegro)

16:15  ABNORMAL B-CELL SUBSET DISTRIBUTION IN PATIENTS WITH POLYMYALGIA RHEUMATICA IS CORRECTED UNDER TOCILIZUMAB MONOTHERAPY


16:20  FACTORS ASSOCIATED WITH RESPONSE TO ABATACEPT IN RHEUMATOID ARTHRITIS: A SYSTEMATIC LITERATURE REVIEW

J.C. Sarmiento-Monroy, C. Villota-Eraso, R.D. Mantilla (Colombia)

16:25  REFRACTORY ADULT-ONSET STILL'S DISEASE SUCCESSFULLY TREATED WITH ETANERCEPT: A CASE REPORT

B. Gundogdu (Turkey)
16:00 - 16:30 Station 8

**EPOSTERS**

**16:00**
**EPD48: THE SKIN AS THE MIRROR OF AUTOIMMUNITY**
Chair: R. Slezak (Czech Republic)

**16:00**
A CASE OF GENERALIZED MORPHEA LOCATED ON INSTEP, MEDIAL AND LATERAL ANKLES IN A 9-YEAR OLD GIRL
G. Akhyar, I. Isramiharti, A. Fadilla (Indonesia)

**16:05**
REDUCED SKIN BLISTERING IN EXPERIMENTAL EPIDERMOLYSIS BULLOSA ACQUITISTA AFTER ANTI-TNF TREATMENT

**16:10**
CARDIOVASCULAR RISK IN BEHÇET’S DISEASE- A CASUISTIC STUDY

**16:15**
TREATMENT WITH STATIN REVERSES ALOPECIA AREATA IN THE MOUSE MODEL

**16:20**
CLINICAL FACTORS AFFECTING THE EFFECTIVENESS OF THE THERAPY OF PEMPHIGUS VULGARIS - A RETROSPECTIVE STUDY
R. Slezak, O. Kopecky, V. Radochova, I. Drizhal (Czech Republic)
16:30 - 18:30

PARALLEL SESSION 49: NEW THERAPEUTIC AVENUES IN AUTOIMMUNE DISEASES

Chair: M. Galeazzi (Italy) 939
Chair: G. Pruijn (Netherlands) 940
Chair: D. Naor (Israel) 941

16:30 DEFINITE RESULTS OF THE THERAPY WITH DEKAVIL IN RHEUMATOID ARTHRITIS
M. Galeazzi (Italy) 942

16:50 IS THE SPECIFIC DEPLETION OF AUTOANTIBODY-SECRETING PLASMA CELLS A REALISTIC THERAPEUTIC APPROACH?
F. Hiepe (Germany) 943

17:10 NOVEL THERAPEUTIC TARGETS IN AUTOIMMUNITY - TGF-BETA3 AS A NOVEL TARGET OF IMMUNOTHERAPY
K. Yamamoto (Japan) 944

17:30 ANTI-INFLAMMATORY REGENERATIVE ACTIVITY OF A CD44-DERIVED PEPTIDE
D. Naor, L. Eshkar Sebban, K.O. Amar, S. Cohen (Israel) 945

17:50 COMPARATIVE EFFECTIVENESS OF IMMUNE-CELL DEPLETION AND A TARGETED THERAPY AGAINST LT LTBR-SIGNALING IN THE TREATMENT OF AUTOIMMUNE PANCREATITIS
G.M. Seleznik, R. Theresia, S. Sabrina, S. Stephan, B. Jeffrey, H. Mathias, G. Rolf (Switzerland) 946

18:05 SM101, A NOVEL RECOMBINANT, SOLUBLE, HUMAN FCGIIIB RECEPTOR, IN THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): RESULTS OF A DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY
S. Tillmanns, C. Kolligs, D. D’Cruz, A. Doria, E. Hachulla, R. Voll, M. Tansey (Germany) 947

18:20 LONG TERM USE OF HYDROXYCHLOROQUINE REDUCES ANTIPHOSPHOLIPID ANTIBODIES TITRES IN PATIENTS WITH PRIMARY ANTIPHOSPHOLIPID SYNDROME
E. Nuri, M. Taraborelli, L. Andreoli, M. Gerosa, L. Argolini, P.L. Meroni, A. Tincani (Italy) 948
16:30 - 18:30  MP3 & 4

PARALLEL SESSION 50: ANTIPHOSPHOLIPID SYNDROME (APS) - DIAGNOSTICS AND CHALLENGES FOR THE FUTURE

Chair: S.R. Binder (USA)  949
Chair: T. Koike (Japan)  950
Chair: V. Pengo (Italy)  951

16:30  INTRODUCTION
V. Pengo (Italy)  952

16:40  COMPLEMENT AND THROMBOSIS IN THE ANTIPHOSPHOLIPID SYNDROME  953
T. Atsumi (Japan)

17:00  CIGARETTE SMOKING AND ANTI-PHOSPHOLIPID ANTIBODIES - WHAT IS THE CONNECTION?  954
S.R. Binder (USA)

17:20  ANTI-BETA2GPI ANTIBODIES: IS THE DOMAIN SPECIFICITY REALLY IMPORTANT?  955
P.L. Meroni (Italy)

17:40  IMMUNOMODULATION OF EXPERIMENTAL APS WITH DOMAIN 1 OF B2GPI  956
M. Blank (Israel)

17:50  ANTIPHOSPHOLIPID ANTIBODY-MEDIATED INCREASE OF TISSUE FACTOR IN ARTERIAL WALL IS RELATED TO INCREASED THROMBUS SIZE IN A MOUSE MODEL  957
R. Willis, P. Grant, Z. Romay-Penabad, E. Papalardo, M. Jamaluddin, R. Rudrangi, E.B. Gonzalez, A.R. Brasier (USA)

18:00  THE EFFICACY OF HYDROXYCHLOROQUINE FOR OBSTETRICAL OUTCOME IN ANTI-PHOSPHOLIPID SYNDROME: DATA FROM A EUROPEAN MULTICENTER RETROSPECTIVE STUDY  958

V. De Filippis, D. Peterle, S. Tes scary, N. Pozzi, A. Banzato, V. Pengo, R. De Cristofaro, L. Acquasaliente (Italy)

18:20  THE ROLE OF MICROBIOTA IN THE PATHOGENESIS OF ANTIPHOSPHOLIPID SYNDROME  960
M. Versini, P.Y. Jeandel, T. Piche, E. Rosenthal (France)
PARALLEL SESSION 51: AUTOIMMUNE SYNDROME INDUCED BY ADJUVANTS (ASIA - SHOENFELD’S SYNDROME)

Chair: L.J. Jara Quezada (Mexico)  
Chair: L. Andreoli (Italy)  
Chair: J. Alijotas-Reig (Spain)

16:30 SEVERE MANIFESTATIONS OF AUTOIMMUNE SYNDROME INDUCED BY ADJUVANTS (ASIA)  
L.J. Jara Quezada, G. Garcia-Collinot, G. Medina, M.D.P. Cruz-Dominguez, R.A. Carranza-Muleiro, O.L. Vera-Lastra, M.A. Saavedra (Mexico)

16:45 THE ROLE OF VITAMIN D IN ASIA SYNDROME  
J.W. Cohen Tervaert (Netherlands)

17:00 AUTOINFLAMMATORY/ AUTOIMMUNE SYNDROME INDUCED BY ADJUVANTS (ASIA) RELATED TO SILICONE AND NON-SILICONE BIOIMPLANTS. ANALYSIS OF A LARGE SPANISH COHORT  
J. Alijotas-Reig, E. Esteve-Valverde (Spain)

17:15 ARE THE AUTOIMMUNE/INFLAMMATORY SYNDROME INDUCED BY ADJUVANTS (ASIA) AND THE UNDIFFERENTIATED CONNECTIVE TISSUE DISEASE (UCTD) RELATED TO EACH OTHER? A CASE-CONTROL STUDY OF ENVIRONMENTAL EXPOSURES  

17:30 EXPLANTATION OF SILICONE BREAST IMPLANTS AS A TREATMENT OF ASIA DUE TO SILICONE IMPLANT INCOMPATIBILITY SYNDROME (SIIS): AN OUTCOME ANALYSIS  
M. De Boer, M.J. Colaris, R. Van der Hulst, J.W. Cohen Tervaert (Netherlands)

17:40 NEW INSIGHTS IN OVINE ASIA SYNDROME: CLINICOPATHOLOGICAL CHANGES IN EXPERIMENTALLY INDUCED ANIMALS  
L. Luján (Spain)

17:50 ANIMAL MODELS OF ADJUVANT AND VACCINE-INDUCED AUTOIMMUNE DISEASES  
J. Torres-Ruiz, Y. Shoenfeld, M. Blank (Mexico)
18:00  GELBLEED AND RUPTURE OF SILICONE BREASTIMPLANTS INVESTIGATED BY LIGHT-, ELECTRONMICROSCOPY AND ENERGY DISPERSIVE X-RAY ANALYSIS OF INTERNAL ORGANS AND NERVOUS TISSUE IN A DECEASED WOMAN
   R. Kappel, L. Boer, H. Dijkman (Netherlands)  971

18:10  PHOSPHATIDYLCHOLINE ALLEVIATES ASIA; AUDIT AND CASE STUDIES
   D. Downing, P. Kane, V. Stejskal (United Kingdom)  972

18:20  PHOSPHORYLCHOLINE - A MIRACULOUS COMPOUND IN IMMUNOLOGY AND AUTOIMMUNITY
   J. Omersel, Y. Shoenfeld (Slovenia)  973
16:30 - 18:30

PARALLEL SESSION 52: THE AUTOIMMUNE ASPECTS OF PSORIASIS, MYOSITIS AND ATHEROSCLEROSIS

Chair: Z. Szekanecz (Hungary) 974
Chair: G. Valesini (Italy) 975
Chair: S. Kaveri (France) 976

16:30 GENETICS OF INFLAMMATORY ATHEROSCLEROSIS

16:50 PSORIASIS AND AUTOIMMUNITY
M. Sticherling (Germany) 978

17:10 THE CLINICAL UTILITY OF ANTI-HMGCR ANTIBODIES IN IMMUNE MEDIATED NECROTIZING MYOPATHY FOLLOWING STATIN EXPOSURE
O. Shovman, B. Gilburd, C. Chayat, C. Bentow, M. Mahler, Y. Shoenfeld (Israel) 979

17:25 SERUM HMW ADIPONECTIN, RBP-4, VISFATIN, APELIN AND HMGB1 LEVELS IN MILD PSORIATIC PATIENTS
M. Auriemma, A. Capo, E. Costantini, C. D’Angelo, P. Amerio, M. Reale (Italy) 980

17:40 OSMOREGULATORY PATHWAYS ARE ACTIVATED IN POLYMYOSITIS: INCREASED EXPRESSION OF OSMOLYTE ACCUMULATORS IN MUSCLE FIBERS AND IMMUNE CELLS
B. De Paepe, J. Ronnelid, S. Jens, J. De Bleecker (Belgium) 981

17:50 IMPACT OF B1-ADRENERGIC RECEPTOR POLYMORPHISMS ON THE INTERACTION WITH AGONISTIC AUTOANTIBODIES IN DILATED CARDIOMYOPATHY
F. Boege, B. Bornholz (Germany) 982

18:00 HIGH SENSITIVITY C-REACTIVE PROTEIN AS AN INDEPENDENT RISK FACTOR COMPARED TO CLASSIC CARDIOVASCULAR RISK FACTORS IN ACUTE MYOCARDIAL INFARCTION
E.F. Elfi, P. Mayorita (Indonesia) 983
18:10 ANTI-TNF-ALPHA DRUGS DIFFERENTLY AFFECT TNF-ALPHA/STNF-R SYSTEM AND MONOCYTE SUBSETS IN PATIENTS WITH PSORIASIS


18:20 THE ROLE OF VITAMIN D IN AUTOIMMUNITY RELATED ATHEROSCLEROSIS AND HEART DISEASE

S. Sokolovic, R. Alimanovic-Alagic, L. Dzananovic (Bosnia and Herzegovina)
16:30 - 18:30
PARALLEL SESSION 53: THE AUTOIMMUNE SIDE OF INFLAMMATORY ARTHRITIS AND AUTOINFLAMMATION

Chair: R. Perricone (Italy)  
Chair: A. Doria (Italy)  
Chair: Y. Levo (Israel)

16:30 AUTOANTIBODIES IN INFLAMMATORY ARTHRITIS  
R. Perricone (Italy)

16:50 A LIPOSOMAL STEROID NANO-DRUG: A NEW APPROACH FOR THE TREATMENT OF AUTOIMMUNE INFLAMMATORY DISEASES  
Y. Naparstek (Israel)

17:05 AUTOANTIBODY PROFILE OF ADULT PATIENTS WITH CHILDHOOD ONSET TYPE 2 AUTOIMMUNE HEPATITIS  
M. Woynarowski, M. Wozniak, B. Cukrowska, A. Wierbicka, S.D. Lytton (Germany)

17:20 TOLL-LIKE RECEPTOR 2 IS OVER EXPRESSED IN FAMILIAL MEDITERRANEAN FEVER PATIENTS AND IS INHIBITED BY TREATMENT WITH COLCHICINE  
I. Ben Zvi, V. Hornung, A. Livneh, H. Ben-David (Israel)

17:30 NEUROSYPHILIS: FROM INFECTION TO AUTOINFLAMMATION? ROLE OF REGULATORY T CELLS  
S. Javor, A. Parodi, G. Ciccarese, F. Drago (Italy)

17:40 ASSOCIATIONS BETWEEN ICAM-1 GENE POLYMORPHISMS AND THE FIRST STAGE OF CKD WITH DAMP-HEAT CONSTITUTION  

17:50 IDENTIFICATION OF CARBAMYLATED ALPHA-1-ANTI-TRYPSIN AS AN ANTIGENIC TARGET OF ANTI-CARBAMYLATED PROTEIN ANTIBODIES IN RHEUMATOID ARTHRITIS PATIENTS  

18:00 IN DEPTH IMMUNOPHENOTYPIC ANALYSIS IN JUVENILE IDIOPATHIC ARTHRITIS (JIA) I: A CROSSSECTIONAL STUDY  
E. Quesada-Masachs, D. Alvarez-de la Sierra, M. Garcia Prat, V. Bittermann, A. Marin Sanchez, C. Modesto Caballero, M. Martinez Gallo (Spain)
18:10  SERUM MATRIX METALLOPROTEINASE 3 ELEVATED FROM NORMAL PREDICTING FLARE IN PATIENTS WITH RHEUMATOID ARTHRITIS 997
J. Ma, J. Lin, D. Zheng, Y. Mo, L. Chen, L. Dai (China)

18:20  A NOVEL NFAT5 INHIBITOR FOR SUPPRESSION OF CHRONIC ARTHRITIS 998
Y.J. Park, H. Eun-Jin, L. Naeun, C. Chul-Soo, K. Wan-Uk (Republic of Korea)
**16:30 - 18:30**

**Hall 5**

**PARALLEL SESSION 54: CYTOKINES AND AUTOIMMUNITY**

**Chair: T. Avcin** (Slovenia)  
999

**Chair: M. Lee-Kirsch** (Germany)  
1000

**Chair: R. Gerli** (Italy)  
1001

**16:30**  
SYSTEMIC EFFECTS OF IL-17  
P. Miossec (France)  
1002

**16:50**  
TYPE I INTERFERONOPATHIES - AN EXPANDING SPECTRUM OF IMMUNE DYSREGULATION  
M. Lee-Kirsch (Germany)  
1003

**17:10**  
THE ROLE OF STAT SIGNALLING PATHWAYS IN THE PATHOGENESIS OF SLE  
T. Avcin (Slovenia)  
1004

**17:30**  
IL-17A GOVERNS TISSUE DESTRUCTION IN BULLOUS PEMPHIGOID  
L. Chakievska, S. Roy, S. Goletz, C. Hölscher, D. Zillikens, E. Schmidt, F. Schulze (Germany)  
1005

**17:40**  
GM-CSF IS THE MAJOR INFLAMMATORY CYTOKINE DRIVING EAE PATHOGENESIS AND IS REGULATED BY MICRO-RNA 223 (MIR-223)  
S. Miller, I. Ifergan, T. Davidson, C. Jones, M. Sleeman (USA)  
1006

**17:50**  
THE TWO FACES OF IL-22: MORE THAN A PATHOGENIC CYTOKINE IN EXPERIMENTAL ARTHRITIS  
D. Roeleveld, F. Apparailly, L. Parga, F. Van de Loo, C. Jorgensen, M. Koenders (Netherlands)  
1007

**18:00**  
TARGETED THERAPY OF AUTOIMMUNE ARTHRITIS USING IL-27, A NEW MEMBER OF THE IL-12 FAMILY  
K. Moudgil, R. Meka, S. Venkatesha, B. Acharya, E. Ruoslahti (USA)  
1008

**18:10**  
SIGNIFICANCE OF INTERLEUKIN-6/STAT PATHWAY FOR THE GENE EXPRESSION OF REG I ALPHA, A NEW AUTO-ANTIGEN IN SJOGREN’S SYNDROME PATIENTS, IN SALIVARY DUCT EPITHELIAL CELLS  
1009

**18:20**  
ACTIVE IMMUNIZATION AGAINST IL-17A COULD PREVENT THE PROGRESSIVITY OF AUTOANTIBODY PRODUCTION IN PRISTANE INDUCED LUPUS MICE MODEL  
H. Kalim, K. Handono, D. Hasanah, M. Zaka Pratama (Indonesia)  
1010
SCIENTIFIC PROGRAM
SUNDAY, APRIL 10, 2016
SUNDAY, APRIL 10, 2016

8:00 - 10:00

PLENARY SESSION 4

Chair: J. Kalden [Germany] 1011
Chair: S. Navarra [Philippines] 1012
Chair: R. Perricone [Italy] 1013

8:00 BIOLOGIC VS. CLINICAL TARGETS IN SLE MANAGEMENT 1014
A. Doria [Italy]

8:30 SILICONE AND AUTOIMMUNITY 1015
J.W. Cohen Tervaert [Netherlands]

9:00 AUTOIMMUNE ATHEROSCLEROSIS IN 3D: HOW IT DEVELOPS, HOW TO DIAGNOSE AND WHAT TO DO 1016
Z. Szekanecz [Hungary]

9:30 TARGETING B CELLS IN AUTOIMMUNE DISEASES 1017
T. Dörner [Germany]

10:00-10:30
Foyer Area Level 1

COFFEE BREAK
<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker(s)</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30</td>
<td>CLINICAL COMPLICATIONS IN PRIMARY SJOGREN’S SYNDROME</td>
<td>R. Gerli (Italy)</td>
<td>1021</td>
</tr>
<tr>
<td>10:50</td>
<td>CUTTING EDGE RX IN SJOGREN’S SYNDROME</td>
<td>S. Naguwa (USA)</td>
<td>1022</td>
</tr>
<tr>
<td>11:10</td>
<td>THERAPY OF SJOGREN’S SYNDROME: CURRENT KNOWLEDGE AND FUTURE PROSPECTS</td>
<td>A. Tzioufas (Greece)</td>
<td>1023</td>
</tr>
<tr>
<td>11:30</td>
<td>THE ROLE OF SPECKLE TRACKING ECHOCARDIOGRAPHY TO DETECT EARLY MYOCARDIAL ALTERATION IN PRIMARY SJOGREN SYNDROME</td>
<td>L. Gianturco, F. Atzeni, P. Sarzi Puttini, M. Turiel (Italy)</td>
<td>1024</td>
</tr>
<tr>
<td>11:45</td>
<td>ASSOCIATION BETWEEN SJOGREN SYNDROME, FIBROMYALGIA, AND ORGAN SPECIFIC NOVEL AUTOANTIBODIES</td>
<td>A. Lichtbroun (USA)</td>
<td>1025</td>
</tr>
<tr>
<td>12:00</td>
<td>HYPOTHYROIDISM AMONG SLE PATIENTS: A CASE-CONTROL STUDY</td>
<td>A. Watad (Israel)</td>
<td>1026</td>
</tr>
<tr>
<td>12:10</td>
<td>NEUROLOGICAL INVOLVEMENT AS THE INITIAL MANIFESTATION IN PRIMARY SJOGREN’S SYNDROME</td>
<td>M. Polo-Trujillo, J.C. Naranjo, J.P. Suso, A. Echeverri, G. Tobón (Colombia)</td>
<td>1027</td>
</tr>
<tr>
<td>12:20</td>
<td>DISCUSSION</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
10:30 - 12:30 Hall 2

PARALLEL SESSION 56: IMMUNOMANIPULATION

Chair: G. Wick (Austria)  1028
Chair: C. Belizna (France)  1029
Chair: P. Cherin (France)  1030

10:30 HYDROXYCHLOROQUINE IN ANTIPHOSPHOLIPID SYNDROME  1031
C. Belizna (France)

10:50 MYOPATHY AND NEUROPATHY EXPERIENCE FOR IMMUNOGLOBULINS  1032
P. Cherin (France)

11:10 ORAL TOLERIZATION AGAINST MYCOBACTERIAL HSP65 FOR PREVENTION OF Atherosclerosis - DEFINITION OF Atherogenic PEPTIDES  1033
G. Wick (Austria)

11:30 THE IMPACT OF CONVENTIONAL AND BIOLOGICAL DMARDS ON BONE BIOLOGY  1034
J.E. Fonseca (Portugal)

11:45 NOVEL APPROACHES FOR IMMUNOTHERAPY IN MS AND RELATED AUTOIMMUNE NEUROLOGICAL DISEASES  1035
D. Karussis (Israel)

12:00 USE OF LONG TERM SUBCUTANEOUS IMMUNOGLOBULINS IN INFLAMMATORY MYOPATHIES: A RETROSPECTIVE ANALYSIS OF 19 PATIENTS  1036
P. Cherin, B. Cristina, O. Cartry, G. Lascu-Dubos, C. De Jaeger, J.C. Crave, J.C. Delain, E. Hachulla (France)

12:10 PROTEIN AND RNA-IMMUNOPRECIPITATION FOR THE IDENTIFICATION OF RARE AUTOANTIBODIES IN SYSTEMIC AUTOIMMUNE RHEUMATIC DISEASES  1037
N. Isailovic, A. Ceribelli, E. Generali, M. De Santis, M. Massarotti, M. Satoh, C. Selmi (Italy)

12:20 SUBCUTANEOUS IMMUNOGLOBULIN THERAPY IN A WOMEN WITH ABORTION AND MULTIPLE SCLEROSIS  1038
J.A. Carbone Campoverde, E. Sarmiento, E. Fernandez-Cruz (Spain)
10:30 - 12:30

PARALLEL SESSION 57: THE AUTOIMMUNE ORIGIN OF CELIAC AND GASTROINTESTINAL DISEASES

Chair: N. Bizzaro (Italy) 1039
Chair: N. Gallo (Italy) 1040
Chair: E. Capoluongo (Italy) 1041

10:30 ANTI-TRANSGLUTAMINASE ANTIBODIES BY CLIA: PERFORMANCE CHARACTERISTICS AND HARMONIZATION N. Gallo (Italy) 1042

10:50 LABORATORY TESTING IN CELIAC DISEASE: NAVIGATING BETWEEN QUALITY AND EFFICIENCY E. Capoluongo (Italy) 1043

11:10 HLA-DQ GENOTYPING COMBINED WITH SEROLOGICAL MARKERS FOR THE DIAGNOSIS OF COELIAC DISEASE M.J. Sousa, R. Ribeiro, M. Albuquerque, J.G. Sousa, M.F. Menezes, G. Sousa (Portugal) 1044


11:30 FECAL CALPROTECTIN IN SYSTEMIC SCLEROSIS I. Marie (France) 1046

11:40 ASSOCIATION OF MICROSCOPIC COLITIS WITH AUTOIMMUNE DISEASES IN A SERIES OF 97 CASES W.A. Sifuentes Giraldo, M. Llop Vilaltella, C. Bouruncle Alaluna, C. González-García, E. Loza Santamaría, J.L. Morell Hita, A. López San Román (Spain) 1047

11:50 FREQUENCY OF ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES (ANCAS) IN PRIMARY SCLEROSING CHOLANGITIS (PSC) WITH OR WITHOUT INFLAMMATORY BOWEL DISEASES (IBD) AND IN SUBTYPES OF AUTOIMMUNE HEPATITIS (AIH) J. Goldbaum Crescente, A. Dellavance, C. Pires Abrantes-Lemos, M. Augusto Diniz, F. Jose Carrilho, L.E. Coelho Andrade, E.L. Rachid Cancado (Brazil) 1048
12:00  UTILIT Y OF SERUM AND MORPHOLOGICAL MARKERS IN THE DETECTION OF CHRONIC ATROPHIC GASTRITIS  
M.P. Panozzo, M. Franceschi, G. Baldassarre, A. Morini, A. Visona', D. Villalta, A. Antico, N. Bizzaro (Italy)

12:10  EFFICACY OF ARYL HYDROCARBON RECEPTOR-ACTIVATING PHYTOSUBSTANCES IN A REFINED CHRONIC DEXTRAN SULFATE SODIUM-INDUCED COLITIS MODEL  
M. Hoffmann, A. Seydel, S. Riemschneider, J. Kohlschmidt, U. Schwertassek, J. Lehmann (Germany)

12:20  FECAL BIOMARKERS AND AUTOANTIBODIES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE (IBD)  
T. Bulgakova, S. Lapin, O. Shukina, A. Haritonov, A. Kharitidis, H. Bang, A. Krämer (Russia)
10:30 - 12:30

**PARALLEL SESSION 58: NEW AUTOIMMUNE DISEASES, CANCER AND AUTOIMMUNITY**

**Chair:** I. Ben Zvi (Israel)  
**Chair:** C. Perricone (Italy)  
**Chair:** J.W. Cohen Tervaert (Netherlands)

**10:30**  
THE AUTOIMMUNE SIDE OF RHEUMATIC FEVER  
C. Perricone (Italy)

**10:50**  
A UNIFYING HYPOTHESIS FOR IGG4-MEDIATED AUTOIMMUNITY  
M. Huijbers, S. Van der Maarel, E. Niks, J. Plomp, J. Verschuuren (Netherlands)

**11:05**  
AUTOIMMUNITY AND CANCER INTER RELATIONSHIPS: 2016  
E. Giat, M. Ehrenfeld (Israel)

**11:20**  
AORTIC ANEURYSM ASSOCIATED WITH SLE: AN AUTOIMMUNE DISEASE AGGRAVATING AN ATHEROSCLEROTIC PROCESS- A CASE-CONTROL STUDY  
H. Amital (Israel)

**11:30**  
EXACERBATION OF ACUTE EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS BY ENHANCING SERUM LEVEL OF LACTIC ACID AS A POTENTIAL BIOMARKER OF MULTIPLE SCLEROSIS PROGRESSION FOLLOWING ADMINISTRATION OF MELATONIN  
S. Dokoohaki, M. Gharghani, H. Sadeghi, A. Ghanbari, N. Farhadi, M.A. Dokoohaki (Iran)

**11:40**  
AUTOIMMUNITY PREFERENTIALLY TARGETS THE RNA-PROTEIN SYNTHESIZING MACHINERY IN BREAST CANCER  
M.C. Maroun, L. Grossman, R. Arshad, F. Fernández-Madrid (USA)

**11:50**  
THE AUTOANTIBODY PROFILE IN BREAST CANCER SERA SUGGESTS THAT AUTOIMMUNITY MAY BE INVOLVED IN ITS PATHOGENESIS  
F. Fernandez-Madrid, L. Grossman, R. Arshad, M.C. Maroun (USA)

**12:00**  
HALLMARKS OF AUTOANTIBODIES IN CANCER. GD3 DISIALYLATED GLYCOSPHINGOLIPID AND CD34 ANTIGEN REVEALING PATTERN FOUND IN THE MELANOMA IMMUNOGLOBULIN REPERTOIRE  
12:10  A NOVEL MOUSE MODEL OF PRIMARY SJÖGREN’S SYNDROME WITH INTERSTITIAL LUNG DISEASE  
J. Zheng, Q. Huang, F. Deng, R. Huang, W. Zhao, X. Yue, F. Petersen, X. Yu  
(Germany)  

12:20  IMPROVEMENT OF LIPOPROTEIN FUNCTIONS RELATED TO CELL CHOLESTEROL TRAFFICKING IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH TOCILIZUMAB  
N. Ronda, D. Greco, M.P. Adorni, F. Zimetti, R. Gualtierotti, F. Ingegnoli, O. Borghi, F. Bernini, P. Meroni (Italy)
10:30 - 12:30

Hall 5

PARALLEL SESSION 59: IL-6 AND JAK INHIBITION: NEW ACHIEVEMENTS

Chair: F. Atzeni (Italy) 1065
Chair: D. Novick (Israel) 1066
Chair: M. Benucci (Italy) 1067

10:30
IL-6 INHIBITION: LONG-TERM RESULTS IN RHEUMATOID ARTHRITIS
P. Sarzi-Puttini (Italy) 1068

10:50
IMMUNOGENICITY AND IL-6 INHIBITION (OR TOCILIZUMAB)
M. Benucci, F. Meacci, M. Infantino, P. Sarzi-Puttini, F. Atzeni, M. Manfredi, V. Grossi (Italy) 1069

11:10
TOCILIZUMAB THERAPY IN ISRAELI PATIENTS WITH RHEUMATOID ARTHRITIS
M. Abou Shakra (Israel) 1070

11:30
JAK INHIBITORS IN AUTOIMMUNITY
P.C. Taylor (United Kingdom) 1071

11:50
MELATONIN ENHANCES INTERLEUKIN-10 EXPRESSION AND REPRESSES CHEMOTAXIS TO INHIBIT INFLAMMATION IN SITU AND AMELIORATE THE SEVERITY OF EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS
S.J. Chen (Taiwan) 1072

12:05
SERUM LEVELS OF IL-6 AND IL-10 IN PATIENTS WITH INHERITED EPIDERMOLYSIS BULLOSA
M. Tampoia, L. Abbracciavento, R. Fumarulo (Italy) 1073

12:20
CYTOKINE LEVELS ARE ASSOCIATED WITH THE SEVERITY OF SYMPTOMS IN MAJOR DEPRESSION
V. Barak, Y. Madi, A. Yogev, M. Bar-Gad, H. Amital, Y. Shoenfeld, D. Amital (Israel)
INDEX OF AUTHORS
The Journal of Innate Immunity is a bimonthly journal covering all aspects in the area of innate immunity, including evolution of the immune system, molecular biology of cells involved in innate immunity, pattern recognition and signals of ‘danger’, microbial corruption, host response and inflammation, mucosal immunity, complement and coagulation, sepsis and septic shock, molecular genomics, and development of immunotherapies.

The journal publishes original research articles, short communications and reviews.

Benefits for Authors

• Cost-effective publishing (no submission fee and no page charges for papers of 5 or fewer printed pages)
• Free online color figures
• Rapid and fair peer-review process
• Full listing in all relevant bibliographic databases (PubMed/MEDLINE, Web of Science etc.)
• Author’s choice for open access publishing

Find out more: www.karger.com/jin
<table>
<thead>
<tr>
<th>Name</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bitton, A.</td>
<td>304</td>
</tr>
<tr>
<td>Bizjak, M.</td>
<td>291, 361, 544</td>
</tr>
<tr>
<td>Bizzaro, N.</td>
<td>118, 122, 207, 211, 824, 826, 1 039, 1 049</td>
</tr>
<tr>
<td>Bjartell, A.</td>
<td>250</td>
</tr>
<tr>
<td>Bjorhall, K.</td>
<td>802</td>
</tr>
<tr>
<td>Bjursell, M.</td>
<td>94</td>
</tr>
<tr>
<td>Blanchard Delaunay, C.</td>
<td>281</td>
</tr>
<tr>
<td>Blandizzi, C.</td>
<td>555, 556</td>
</tr>
<tr>
<td>Blank, M.</td>
<td>114, 153, 157, 286, 304, 348, 742, 861, 862, 956, 970, 1 062</td>
</tr>
<tr>
<td>Blankenburg, J.</td>
<td>611</td>
</tr>
<tr>
<td>Blecken, J.</td>
<td>590</td>
</tr>
<tr>
<td>Blinova, T.</td>
<td>730</td>
</tr>
<tr>
<td>Boccassini, L.</td>
<td>58</td>
</tr>
<tr>
<td>Böcher, O.</td>
<td>56</td>
</tr>
<tr>
<td>Böckle, B.</td>
<td>218, 219</td>
</tr>
<tr>
<td>Bodio, C.</td>
<td>487, 653</td>
</tr>
<tr>
<td>Boege, F.</td>
<td>982</td>
</tr>
<tr>
<td>Boekhorst, J.</td>
<td>161</td>
</tr>
<tr>
<td>Boer, L.</td>
<td>971</td>
</tr>
<tr>
<td>Bogdanos, D.</td>
<td>154, 533, 759, 761, 913, 914</td>
</tr>
<tr>
<td>Bohgaki, T.</td>
<td>356, 801</td>
</tr>
<tr>
<td>Boiardi, L.</td>
<td>865</td>
</tr>
<tr>
<td>Boiocchi, C.</td>
<td>609</td>
</tr>
<tr>
<td>Bojinca, M.</td>
<td>227</td>
</tr>
<tr>
<td>Bojinca, V.</td>
<td>242, 684</td>
</tr>
<tr>
<td>Boldizsár, F.</td>
<td>841</td>
</tr>
<tr>
<td>Boleixa, D.</td>
<td>563</td>
</tr>
<tr>
<td>Bonaguri, C.</td>
<td>431, 828, 902, 904</td>
</tr>
<tr>
<td>Boniovanni, S.</td>
<td>58</td>
</tr>
<tr>
<td>Boni, A.</td>
<td>184</td>
</tr>
<tr>
<td>Bonilla-Abadía, F.</td>
<td>70, 638</td>
</tr>
<tr>
<td>Bonometti, R.</td>
<td>59</td>
</tr>
<tr>
<td>Bonroy, C.</td>
<td>241</td>
</tr>
<tr>
<td>Bonsmann, G.</td>
<td>466</td>
</tr>
<tr>
<td>Bony, C.</td>
<td>204</td>
</tr>
<tr>
<td>Boonen, H.</td>
<td>928</td>
</tr>
<tr>
<td>Booth, R.A.</td>
<td>714</td>
</tr>
<tr>
<td>Bor, S.</td>
<td>59</td>
</tr>
<tr>
<td>Borangiu, A.</td>
<td>684</td>
</tr>
<tr>
<td>Bordron, A.</td>
<td>247, 649</td>
</tr>
<tr>
<td>Borghi, M.O.</td>
<td>127, 203, 487, 653, 909</td>
</tr>
<tr>
<td>Borghi, O.</td>
<td>1 064</td>
</tr>
<tr>
<td>Borgiani, P.</td>
<td>317</td>
</tr>
<tr>
<td>Boric, K.</td>
<td>306</td>
</tr>
<tr>
<td>Börjesson, J.</td>
<td>94</td>
</tr>
<tr>
<td>Bornholz, B.</td>
<td>982</td>
</tr>
<tr>
<td>Borro, M.</td>
<td>229</td>
</tr>
<tr>
<td>Bosques, C.J.</td>
<td>113</td>
</tr>
<tr>
<td>Bossuyt, X.</td>
<td>142, 498</td>
</tr>
<tr>
<td>Botsios, C.</td>
<td>927</td>
</tr>
<tr>
<td>Botta, A.</td>
<td>326</td>
</tr>
<tr>
<td>Botti, E.</td>
<td>928</td>
</tr>
<tr>
<td>Bouali, Y.</td>
<td>571</td>
</tr>
<tr>
<td>Boudjeldia, A.</td>
<td>734</td>
</tr>
<tr>
<td>Bougias, D.</td>
<td>893, 912</td>
</tr>
<tr>
<td>Boukercha, A.</td>
<td>701</td>
</tr>
<tr>
<td>Boulmatsi, O.</td>
<td>905</td>
</tr>
<tr>
<td>Bourruncle Alaluna, C.</td>
<td>1 047</td>
</tr>
<tr>
<td>Bouterea, W.</td>
<td>74</td>
</tr>
<tr>
<td>Bouziane, D.</td>
<td>701</td>
</tr>
<tr>
<td>Bouzidi, A.</td>
<td>701</td>
</tr>
<tr>
<td>Boyer, O.</td>
<td>338</td>
</tr>
<tr>
<td>Boštela Cukrowska</td>
<td>991</td>
</tr>
<tr>
<td>Bozic, B.</td>
<td>594</td>
</tr>
<tr>
<td>Bozic, I.</td>
<td>306</td>
</tr>
<tr>
<td>Brachvogel, B.</td>
<td>363</td>
</tr>
<tr>
<td>Brahim, I.</td>
<td>366</td>
</tr>
<tr>
<td>Brakopp, S.</td>
<td>303</td>
</tr>
<tr>
<td>Branch, .</td>
<td>220</td>
</tr>
<tr>
<td>Branch, D.R.</td>
<td>106, 110</td>
</tr>
<tr>
<td>Brändén, L.</td>
<td>94</td>
</tr>
<tr>
<td>Braschi, F.</td>
<td>389</td>
</tr>
<tr>
<td>Brascia, C.</td>
<td>597</td>
</tr>
<tr>
<td>Brasier, A.R.</td>
<td>957</td>
</tr>
<tr>
<td>Bravo, J.C.</td>
<td>70</td>
</tr>
<tr>
<td>Bredenberg, J.</td>
<td>302</td>
</tr>
<tr>
<td>Bredewold, O.W.</td>
<td>584</td>
</tr>
<tr>
<td>Breken, R.</td>
<td>33</td>
</tr>
<tr>
<td>Bremme, K.</td>
<td>958</td>
</tr>
<tr>
<td>Brenner, R.</td>
<td>716</td>
</tr>
<tr>
<td>Briasoulis, C.</td>
<td>893</td>
</tr>
<tr>
<td>Brilot, F.</td>
<td>515, 881</td>
</tr>
<tr>
<td>Brinks, R.</td>
<td>430</td>
</tr>
<tr>
<td>Briones García, E.</td>
<td>696</td>
</tr>
<tr>
<td>Brocke, S.</td>
<td>396</td>
</tr>
<tr>
<td>Brodmann, M.</td>
<td>354</td>
</tr>
<tr>
<td>Brogna, C.</td>
<td>382</td>
</tr>
<tr>
<td>Brogren, C.H.</td>
<td>548</td>
</tr>
<tr>
<td>Brooks, W.</td>
<td>883</td>
</tr>
<tr>
<td>Brooks, W.H.</td>
<td>649</td>
</tr>
<tr>
<td>Bruck, O.</td>
<td>544</td>
</tr>
<tr>
<td>Brugnano, R.</td>
<td>243</td>
</tr>
<tr>
<td>Brun, M.</td>
<td>341</td>
</tr>
<tr>
<td>Brunes, B.</td>
<td>485</td>
</tr>
<tr>
<td>Bruni, B.</td>
<td>916</td>
</tr>
<tr>
<td>Bruni, C.</td>
<td>389</td>
</tr>
<tr>
<td>Bruno, V.</td>
<td>328</td>
</tr>
<tr>
<td>Budde, P.</td>
<td>428, 430, 488, 756, 780</td>
</tr>
<tr>
<td>Budkova, A.</td>
<td>234</td>
</tr>
<tr>
<td>Bulatovic, A.</td>
<td>929</td>
</tr>
<tr>
<td>Bulgakova, T.</td>
<td>730, 1 051</td>
</tr>
<tr>
<td>Buonocore, R.</td>
<td>904</td>
</tr>
<tr>
<td>Burke-Murphy, E.</td>
<td>110</td>
</tr>
<tr>
<td>Burlingame, R.W.</td>
<td>65</td>
</tr>
<tr>
<td>Burmester, G.</td>
<td>179</td>
</tr>
<tr>
<td>Burmester, G.R.</td>
<td>147, 490</td>
</tr>
<tr>
<td>Busard, C.</td>
<td>928</td>
</tr>
<tr>
<td>Businaro, R.</td>
<td>886</td>
</tr>
<tr>
<td>Buttari, B.</td>
<td>886</td>
</tr>
<tr>
<td>Buttmann, M.</td>
<td>303</td>
</tr>
<tr>
<td>Buurman, W.A.</td>
<td>723</td>
</tr>
<tr>
<td>BYUN, J.I.</td>
<td>381, 739</td>
</tr>
<tr>
<td>C. Bentow</td>
<td>216</td>
</tr>
<tr>
<td>Cabrera-Marante, O.</td>
<td>825</td>
</tr>
<tr>
<td>Cadusseau, J.</td>
<td>4, 8</td>
</tr>
<tr>
<td>Caielli, F.</td>
<td>709</td>
</tr>
<tr>
<td>Cambridge, G.</td>
<td>640</td>
</tr>
<tr>
<td>Cañas, C.A.</td>
<td>70, 180, 638</td>
</tr>
<tr>
<td>Candore, G.</td>
<td>367</td>
</tr>
<tr>
<td>Caneparo, V.</td>
<td>916</td>
</tr>
<tr>
<td>Canhão, H.</td>
<td>259</td>
</tr>
<tr>
<td>cannella, A.C.</td>
<td>441</td>
</tr>
<tr>
<td>Canofari, C.</td>
<td>713, 741, 440, 925</td>
</tr>
<tr>
<td>Cantaert, T.</td>
<td>126</td>
</tr>
<tr>
<td>Cantarini, L.</td>
<td>680</td>
</tr>
<tr>
<td>Cantil, V.</td>
<td>339, 958</td>
</tr>
<tr>
<td>Cao, S.</td>
<td>51</td>
</tr>
<tr>
<td>Cao, X.</td>
<td>899</td>
</tr>
<tr>
<td>Capaldo, C.</td>
<td>604</td>
</tr>
<tr>
<td>Capo, A.</td>
<td>980</td>
</tr>
<tr>
<td>Capoluongo, E.</td>
<td>1 041, 1 043</td>
</tr>
<tr>
<td>Caporali, R.</td>
<td>487, 653</td>
</tr>
<tr>
<td>Capozzi, A.</td>
<td>641, 901</td>
</tr>
<tr>
<td>Cappa, M.</td>
<td>792</td>
</tr>
<tr>
<td>Capuano, R.</td>
<td>713</td>
</tr>
<tr>
<td>Carabellessi, N.</td>
<td>650, 967</td>
</tr>
<tr>
<td>Caramella, A.</td>
<td>800</td>
</tr>
<tr>
<td>Carballo, G.</td>
<td>123</td>
</tr>
<tr>
<td>Carbillon, L.</td>
<td>958</td>
</tr>
<tr>
<td>Carbone</td>
<td>410, 1 038</td>
</tr>
<tr>
<td>Campoverde, J.A.</td>
<td>375</td>
</tr>
<tr>
<td>Carmen, H.D.L.</td>
<td>375</td>
</tr>
<tr>
<td>Name</td>
<td>Pages</td>
</tr>
<tr>
<td>-------</td>
<td>-------</td>
</tr>
<tr>
<td>Corless, L.</td>
<td>779</td>
</tr>
<tr>
<td>Cornec, D.</td>
<td>178, 182, 486, 930</td>
</tr>
<tr>
<td>Coronado, P.</td>
<td>223</td>
</tr>
<tr>
<td>Correia, F.</td>
<td>600</td>
</tr>
<tr>
<td>Cortelazzo, A.</td>
<td>513</td>
</tr>
<tr>
<td>Cossarizza, A.</td>
<td>607, 984</td>
</tr>
<tr>
<td>Costa, L.</td>
<td>722</td>
</tr>
<tr>
<td>Costa, P.P.</td>
<td>563</td>
</tr>
<tr>
<td>Costa, R.</td>
<td>872</td>
</tr>
<tr>
<td>Costa, S.</td>
<td>182</td>
</tr>
<tr>
<td>Costantini, E.</td>
<td>736, 980</td>
</tr>
<tr>
<td>Costanzo, A.</td>
<td>928</td>
</tr>
<tr>
<td>Costello, C.E.</td>
<td>763</td>
</tr>
<tr>
<td>Cotter, J.</td>
<td>936</td>
</tr>
<tr>
<td>Coussens, E.</td>
<td>928</td>
</tr>
<tr>
<td>Coutant, F.</td>
<td>897</td>
</tr>
<tr>
<td>Cras, P.</td>
<td>721</td>
</tr>
<tr>
<td>Crave, J.C.</td>
<td>616, 1036</td>
</tr>
<tr>
<td>Creange, A.</td>
<td>384</td>
</tr>
<tr>
<td>Crinò, A.</td>
<td>792</td>
</tr>
<tr>
<td>Crisostomo, M.</td>
<td>63, 67, 374</td>
</tr>
<tr>
<td>Crisostomo, M.E.</td>
<td>62</td>
</tr>
<tr>
<td>Cristina, B.</td>
<td>1036</td>
</tr>
<tr>
<td>Crotti, G.</td>
<td>538</td>
</tr>
<tr>
<td>Crowley, B.</td>
<td>615</td>
</tr>
<tr>
<td>Crowley, J.T.</td>
<td>763</td>
</tr>
<tr>
<td>Cruz-Dominguez, M.D.P.</td>
<td>964</td>
</tr>
<tr>
<td>Cruz-Dominguez, M.P.</td>
<td>696</td>
</tr>
<tr>
<td>Csuka, O.</td>
<td>1062</td>
</tr>
<tr>
<td>Csumita, M.</td>
<td>977</td>
</tr>
<tr>
<td>Cuccia, M.</td>
<td>609</td>
</tr>
<tr>
<td>Dulińska, S.</td>
<td>378</td>
</tr>
<tr>
<td>Cui, L.</td>
<td>55</td>
</tr>
<tr>
<td>Cunha, C.</td>
<td>936</td>
</tr>
<tr>
<td>Cunha, M.</td>
<td>936</td>
</tr>
<tr>
<td>Cunha, P.</td>
<td>936</td>
</tr>
<tr>
<td>Cunill Monjo, V.</td>
<td>36</td>
</tr>
<tr>
<td>Cunningham, J.L.</td>
<td>319</td>
</tr>
<tr>
<td>Curcio, F.</td>
<td>31</td>
</tr>
<tr>
<td>Durila, K.</td>
<td>60</td>
</tr>
<tr>
<td>Cutforth, T.</td>
<td>516</td>
</tr>
<tr>
<td>Cutolo, M.</td>
<td>622, 625</td>
</tr>
<tr>
<td>Czirbesz, K.</td>
<td>1062</td>
</tr>
<tr>
<td>D. Rolla</td>
<td>451</td>
</tr>
<tr>
<td>D. Santoro</td>
<td>451</td>
</tr>
<tr>
<td>Dagan, A.</td>
<td>866</td>
</tr>
<tr>
<td>Dahan, S.</td>
<td>439, 740, 742, 859</td>
</tr>
<tr>
<td>Dähnrich, C.</td>
<td>805, 827</td>
</tr>
<tr>
<td>Dai, L.</td>
<td>997</td>
</tr>
<tr>
<td>Daia, S.</td>
<td>242</td>
</tr>
<tr>
<td>Daia-Iliescu, S.</td>
<td>684</td>
</tr>
<tr>
<td>Dajcman, D.</td>
<td>915</td>
</tr>
<tr>
<td>Dale, R.</td>
<td>515</td>
</tr>
<tr>
<td>Dale, R.C.</td>
<td>881</td>
</tr>
<tr>
<td>Dalmau, J.</td>
<td>510</td>
</tr>
<tr>
<td>Dalton, J.</td>
<td>159</td>
</tr>
<tr>
<td>D’Amico, M.</td>
<td>243</td>
</tr>
<tr>
<td>Damoiseaux, J.</td>
<td>123, 188, 497, 500, 805, 818, 822, 879</td>
</tr>
<tr>
<td>D’Angelo, C.</td>
<td>736, 980</td>
</tr>
<tr>
<td>Daniel, L.</td>
<td>443</td>
</tr>
<tr>
<td>Danieli, M.G.</td>
<td>107, 116</td>
</tr>
<tr>
<td>Dăduvá, K.</td>
<td>546</td>
</tr>
<tr>
<td>Dantal, J.</td>
<td>616</td>
</tr>
<tr>
<td>Danza, A.</td>
<td>401</td>
</tr>
<tr>
<td>Dapcevic, M.</td>
<td>221</td>
</tr>
<tr>
<td>Dario Roccioletto</td>
<td>437</td>
</tr>
<tr>
<td>Darrah, E.</td>
<td>776</td>
</tr>
<tr>
<td>Darwin, E.</td>
<td>79, 737, 937</td>
</tr>
<tr>
<td>Daugas, E.</td>
<td>443</td>
</tr>
<tr>
<td>D’Aurizio, F.</td>
<td>892</td>
</tr>
<tr>
<td>Daves, M.</td>
<td>590</td>
</tr>
<tr>
<td>David, P.</td>
<td>342, 866</td>
</tr>
<tr>
<td>Davidson, T.</td>
<td>1006</td>
</tr>
<tr>
<td>Davies, T.</td>
<td>845, 849</td>
</tr>
<tr>
<td>Dayer, J.</td>
<td>686</td>
</tr>
<tr>
<td>D’Cruz, D.</td>
<td>754, 275, 278, 446, 452, 727, 831, 947</td>
</tr>
<tr>
<td>de Andrade, F.A.</td>
<td>803</td>
</tr>
<tr>
<td>De Andrea, M.</td>
<td>916</td>
</tr>
<tr>
<td>De Baets, M.H.</td>
<td>723</td>
</tr>
<tr>
<td>De Biasi, S.</td>
<td>607, 984</td>
</tr>
<tr>
<td>De Blecker, J.</td>
<td>981</td>
</tr>
<tr>
<td>de Boer, M.</td>
<td>194, 866, 968</td>
</tr>
<tr>
<td>De Carolis, C.</td>
<td>322, 325</td>
</tr>
<tr>
<td>De Carolis, S.</td>
<td>326, 339, 810</td>
</tr>
<tr>
<td>De Chaisemartin, L.</td>
<td>426</td>
</tr>
<tr>
<td>De Craemer, A.S.</td>
<td>353</td>
</tr>
<tr>
<td>De Cristofaro, R.</td>
<td>959</td>
</tr>
<tr>
<td>De Felice, C.</td>
<td>513</td>
</tr>
<tr>
<td>De Filippis, V.</td>
<td>959</td>
</tr>
<tr>
<td>De Haan, P.</td>
<td>294</td>
</tr>
<tr>
<td>De Haard, H.</td>
<td>398</td>
</tr>
<tr>
<td>De Haro Muñoz, T.</td>
<td>246</td>
</tr>
<tr>
<td>De Hert, M.</td>
<td>723</td>
</tr>
<tr>
<td>de Jaeger, C.</td>
<td>1036</td>
</tr>
<tr>
<td>De Jaureguiberry, J.P.</td>
<td>341</td>
</tr>
<tr>
<td>de Jesus, G.</td>
<td>220</td>
</tr>
<tr>
<td>De Keyser, E.</td>
<td>928</td>
</tr>
<tr>
<td>de la Puente Bujidos, C.</td>
<td>205</td>
</tr>
<tr>
<td>De Laere, M.</td>
<td>721</td>
</tr>
<tr>
<td>de Las Heras Alonso, E.</td>
<td>205</td>
</tr>
<tr>
<td>De Los Santos, I.</td>
<td>53</td>
</tr>
<tr>
<td>De Lunardo, F.</td>
<td>901</td>
</tr>
<tr>
<td>de Melo Cruvinel, W.</td>
<td>123</td>
</tr>
<tr>
<td>de Oliveira, F.L.</td>
<td>477</td>
</tr>
<tr>
<td>De Paepe, B.</td>
<td>981</td>
</tr>
<tr>
<td>de Ru, A.</td>
<td>995</td>
</tr>
<tr>
<td>De Santis, A.</td>
<td>767</td>
</tr>
<tr>
<td>De Santis, E.</td>
<td>828</td>
</tr>
<tr>
<td>De Santis, M.</td>
<td>1037</td>
</tr>
<tr>
<td>De Santis, R.</td>
<td>382</td>
</tr>
<tr>
<td>De Spirito, M.</td>
<td>328</td>
</tr>
<tr>
<td>De Wazieres, B.</td>
<td>281</td>
</tr>
<tr>
<td>De Winter, L.M.</td>
<td>372, 373</td>
</tr>
<tr>
<td>Degandt, S.</td>
<td>68</td>
</tr>
<tr>
<td>Degli Esposti, C.</td>
<td>249</td>
</tr>
<tr>
<td>Dehoulle, C.</td>
<td>384</td>
</tr>
<tr>
<td>Dekel, N.</td>
<td>286</td>
</tr>
<tr>
<td>Del Padre, M.</td>
<td>767</td>
</tr>
<tr>
<td>Del Prete, D.</td>
<td>751</td>
</tr>
<tr>
<td>Del Ross, T.</td>
<td>339</td>
</tr>
<tr>
<td>Del Sordo, G.</td>
<td>326</td>
</tr>
<tr>
<td>Delain, J.C.</td>
<td>616, 1036</td>
</tr>
<tr>
<td>DelCanto, G.</td>
<td>937</td>
</tr>
<tr>
<td>Deligny, C.</td>
<td>281</td>
</tr>
<tr>
<td>Dellavance, A.</td>
<td>369, 376, 903, 1048</td>
</tr>
<tr>
<td>Demel, U.</td>
<td>354</td>
</tr>
<tr>
<td>Demircan, N.</td>
<td>388</td>
</tr>
<tr>
<td>demirpehlivan, E.</td>
<td>230</td>
</tr>
<tr>
<td>Demoersman, J.</td>
<td>178</td>
</tr>
<tr>
<td>Deng, F.</td>
<td>1063</td>
</tr>
<tr>
<td>Denno, Y.</td>
<td>303</td>
</tr>
<tr>
<td>Denton, C.</td>
<td>389</td>
</tr>
<tr>
<td>Derdelinckx, J.</td>
<td>721</td>
</tr>
<tr>
<td>Derfalvi, B.</td>
<td>787</td>
</tr>
<tr>
<td>Dessouki, O.</td>
<td>235</td>
</tr>
<tr>
<td>Detry, J.</td>
<td>147</td>
</tr>
<tr>
<td>Devalayara, M.</td>
<td>802</td>
</tr>
<tr>
<td>Devauchelle-Pensec, V.</td>
<td>178, 182, 486, 604, 930</td>
</tr>
<tr>
<td>Devilliers, H.</td>
<td>279</td>
</tr>
<tr>
<td>Devos, H.</td>
<td>68</td>
</tr>
</tbody>
</table>
Gazeau, P. 486
Geier, D. 12, 518
Geier, M. 12, 518
Gelardi, C. 116
Genebrier, S. 897
Generali, E. 494, 1037
Gentian Denas 660
Georgiou, C. 912
Gerbaulet, A. 794
Gerl, V. 126
Gerli, R. 409, 909, 1037, 1021
Gerosa, M. 948
Gershwin, L. 468, 471
Gershwin, M.E. 529, 535, 623, 687
Gertel, S. 144, 520, 523
Geusens, P. 373, 427
Ghaly, M. 235
Ghanbari, A. 1059
Gharghani, M. 1059
Ghazouani, E. 352
Ghiggeri, G. 243
Ghillani-Dalbin, P. 65
Ghirardello, A. 368, 472, 476, 477, 708, 751, 909
Ghobaralipoor, S. 80
Ghozzi, M. 917
Ghrenassia, E. 918
Giaccomo Zoppellaro 660
Giacomelli, R. 409
Giacomello, R. 31
Giancchecchi, E. 792
Gianniki, M. 893, 912
Giannotta, G. 290
Gianturco, L. 58, 1024
Giat, E. 1057
Gibbon, A. 59
Gibellini, L. 607, 984
Gilbert, L. 769
Gilburd, B. 120, 213, 979
Gilianu, S. 44
Gioia, B.G. 367
Giorda, E. 792
Giordanengo, V. 800
Giordano, A. 160
Giordano, L. 44
Giovanella, L. 892
Giovanelli, L. 909
Giovannini, D. 781
Giovannoni, G. 260
Gisela, J. 854, 1045
Gudziz, M.G. 909
Giorgi, D. 846, 851
Giulietta, B. 73
Glaeser, R. 88
Glaser, R. 268
Glauche, B. 537
Gleon, C. 35
Gobor, L. 1062
Godeau, B. 791, 279
Godeny, M. 1062
Goebl, V. 182
Goebel, A. 474
Goegang, F. 753
Goehler, H. 147
Goettel, P. 525
Göhler, H. 430, 488
Gold, H. 303
Goldbaum Crescente, J.
Goldman, S. 862
Goletz, S. 480, 1005
Gomes, M.J. 256
Gomez-Cruz, O. 266
Gonzalez-Ruiz, J.M. 53
Gonçalves, I. 256
Gonçalves, M. 936
Gonçalves, M.J. 259
Gondran, G. 281
Goñi, M. 401
Gonul, M. 889
González Urra, P. 720
González, E. 455, 36
González, E.B. 35, 957
González-García, C. 1047
Gooren, L. 675
Göransson, U. 898
Gordins, P. 779
Gorla, R. 487, 653, 817
Gorshkova, E. 573
Gottschalk, T. 629
Gowayed, M. 683
grados, A. 791
Graf, R. 551
Graña, D. 401
Granata, G. 921
Grando, S.A. 460
Grange, C. 391
Grange, L. 150
Grange, S. 338
Granieri, L. 725
Grant, P. 957
Graslunds, A. 281
Grassi, F. 411
Gräffler, A. 214
Greco, A. 921
Greco, D. 1064
Greer, J. 159
Greger, J.W. 717
Gregor, P. 60
Grigoriou, A. 354
Grilo, A. 732
Grindebacke, H. 413
Grine, L. 928
Groenestein, R. 269
Grohová, A. 546
Grondona, A.G. 383
Groseanu, L. 242, 684
Gruss, W.L. 271, 276, 648
Grossi, C. 487, 653
Grossi, V. 124, 374, 824, 1069
Grossman, L. 1060, 1061
Grossmann, K. 537, 774
Grosso, V. 487, 653
Gruber, N. 286
Grüngreiff, K. 396
Grutzkau, A. 490
Gu, J. 51
Guattieriotti, R. 411, 1064
Guaschino, G. 59
GUBERT, I.C. 316
Guggino, G. 367
Guido, V. 87
Guiducci, S. 389
Guillaume, L. 337
Guillevin, L. 279
Guilpain, P. 204
Guimarães, J. 563
Guis, L. 52
Gul, A. 467
Gul, U. 888, 889
Gunasekera, S. 898
Gunawan, A. 738
Gundin, S. 215
Gundogdu, B. 926, 932
Gunnarsson, I. 237
Günther, C. 138, 884
Guo, Z. 545
Gurevich, M. 300
Gurevich, V. 314, 568
Gurrieri, F. 146
Gusev, S. 742
Gustavo, V. 854, 1 045
Guttek, K. 396
Guy, A. 213
GUZMÁN-LÓPEZ, K. 103
H. El Hilali 117
Haberland, A. 525
Hábová, V. 60
Hachulla, E. 182, 281, 947, 1 036
Hadzija, M. 594
Häggmark, A. 250, 319
Hahn, S. 303
Haider, A. 675
Hajjej, Z. 352
Hakonarson, H. 651
Hamann, D. 777
Hamid Mazou 117
Hamidou, M. 279, 281, 443
Hamiel, O. 13, 470
Hammami, S. 74
HAMMERS, C.M. 88
Han, E.J. 402
Handgretinger, R. 875
Handono, K. 416, 1 010
Hannah, J. 754
Hardwick, T. 39
Haritonov, A. 1 051
Harlé, J.R. 341, 791
Har-Noy, O. 716
Harzoun, S. 587
Hasanah, D. 1 010
Hasenclever, D. 105
Hass, C. 465
Hatron, P.Y. 182
Hawkes, J. 474
Hayek, J. 513
Hazime, R. 366
Healey, R. 779
Hearth-Holmes, M. 441
Heidecke, H. 202, 564
Heim, J. 735
Hejazenia, F. 54
Hellmark, T. 924
Hellström, C. 66
Helyes, Z. 474
Henjes, F. 250
Henke, J. 580
Hennig, A. 794
Heppe, E.N. 480
Herath, K.H.I.N.M. 402
Herceg-Cavark, V. 755
Hernandez, J. 77
Hernández-Molina, G. 588
Hernández-Osorio, L.A. 860
Herold, M. 123, 212, 502, 715
Herraraiz, M.A. 223
Hershberg, U. 88
Hervier, B. 443
Hibbs, M. 629
Hie, M. 279
Hiemann, R. 537, 774
Hiepe, F. 179, 490, 943
Hiller, B. 794
HinGs, M. 782
Hintzen, R.Q. 491, 492, 777
Hirohata, S. 43, 45, 517
Hirose, M. 935
Hisada, R. 801
Ho, C. 752
Ho, R. 752
Hoövar, A. 378
Hoffmann, C. 719, 723
Hoffmann, M. 919, 1 050
Hoffmanová, I. 60
Hofner, K. 735
Hogervorst, J.M. 491
Hoglund, P. 280
Hokstad, I. 264
Holding, S. 64, 779
Hollan, I. 264, 487, 557, 636
Holl-Ulrich, K. 38
Holm, L. 924
Hölscher, C. 1 005
Holthoff, H.P. 526, 853
Holy, B. 958
Hong, M.G. 250
Hooijkaas, H. 312
Höpner, U. 214
Horita, T. 356, 801
Hormaza, A. 70, 638
Horn, S. 354
Horn, T. 715
Hornberg, J. 94
Hornung, V. 992
Horvath, S. 1 062
Horvai, K.D. 42
Hossain, M. 545
Hot, A. 391
Hotta Osamu Clinic, 14
Hotta, O. 287
Hoxha, A. 662
Hoyer, B. 179
Hsu, M. 516
Huang, C. 320, 323, 329
Huang, C.Y. 313
Huang, Q. 1 063
Huang, R. 1 063
Huang, X. 33
Huanjian, F. 994
Hue, S. 384, 587
Hughes, G. 23
Huijbers, M. 1 056
Huizinga, T. 145
Huizinga, T.W.J. 584
Humphreys, D. 745
Hunzelmann, N. 780
Hupperts, R. 879
Hutsebaut, M. 68
Hutu, D.P. 504
Hyvarinen, S. 882
Iaccarino, L. 233, 368, 438, 472, 708, 751, 863
IAGSA, S.G. 650
Iaiani, G. 160
Iannella, G. 921
Iannuccelli, C. 641
Ibañez, M. 36
Ibrahim, S. 81
Ibrahim, S.M. 88, 268
Idborg, H. 237
Ieiri, N. 287
Irgan, I. 1 006
Illes, Z. 882
Imai, K. 287
Imperiali, M. 892
Indriyaningrum, N. 46
Infantino, M. 124, 211, 374, 776, 824, 1 069
Ingegnoli, F. 203, 694, 1 064
Invernizzi, P. 530, 532
Ioannidou, A. 905
Ionescu, R. 242, 684
Irure-ventura, J. 104, 215, 355
<table>
<thead>
<tr>
<th>Name</th>
<th>Page Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Isabelle, L.</td>
<td>337</td>
</tr>
<tr>
<td>Isailovic, N.</td>
<td>1 037</td>
</tr>
<tr>
<td>Ishikawa, L.</td>
<td>400</td>
</tr>
<tr>
<td>Ishikawa, L.L.</td>
<td>403, 864</td>
</tr>
<tr>
<td>IslasJacome, F.</td>
<td>394</td>
</tr>
<tr>
<td>Israel, A.</td>
<td>716</td>
</tr>
<tr>
<td>Isramiharti, I.</td>
<td>711, 934</td>
</tr>
<tr>
<td>Issekutz, A.</td>
<td>783, 787</td>
</tr>
<tr>
<td>Itaya-Hironaka, A.</td>
<td>1 009</td>
</tr>
<tr>
<td>Ivanova-Todorova, E.</td>
<td>598</td>
</tr>
<tr>
<td>Ivarsen, P.</td>
<td>717</td>
</tr>
<tr>
<td>Jaatinen, T.</td>
<td>577</td>
</tr>
<tr>
<td>Jackson, S.</td>
<td>802</td>
</tr>
<tr>
<td>Jacques, P.</td>
<td>281</td>
</tr>
<tr>
<td>Jakobsson, P.J.</td>
<td>237, 898</td>
</tr>
<tr>
<td>Jamaluddin, M.</td>
<td>957</td>
</tr>
<tr>
<td>Janas, R.</td>
<td>710</td>
</tr>
<tr>
<td>Janket, S.</td>
<td>130</td>
</tr>
<tr>
<td>Janssen, G.</td>
<td>995</td>
</tr>
<tr>
<td>Janssen, M.</td>
<td>492</td>
</tr>
<tr>
<td>Jara Quezada, L.J.</td>
<td>15, 961, 964</td>
</tr>
<tr>
<td>Jara, L.</td>
<td>266</td>
</tr>
<tr>
<td>Jara, L.J.</td>
<td>696</td>
</tr>
<tr>
<td>Jarius, S.</td>
<td>303</td>
</tr>
<tr>
<td>Jarrot, P.A.</td>
<td>443</td>
</tr>
<tr>
<td>Jaume Alijotas-Reig</td>
<td>966</td>
</tr>
<tr>
<td>Javor, S.</td>
<td>993</td>
</tr>
<tr>
<td>Jaxaira, M.</td>
<td>574</td>
</tr>
<tr>
<td>Jayne, D.</td>
<td>280</td>
</tr>
<tr>
<td>Jean Emmanuel, K.</td>
<td>337</td>
</tr>
<tr>
<td>Jean Francois, D.</td>
<td>337</td>
</tr>
<tr>
<td>Jeandel, P.Y.</td>
<td>960</td>
</tr>
<tr>
<td>Jee, Y.</td>
<td>402</td>
</tr>
<tr>
<td>Jeffrey, B.</td>
<td>946</td>
</tr>
<tr>
<td>Jens, S.</td>
<td>981</td>
</tr>
<tr>
<td>Jensen, K.L.</td>
<td>548</td>
</tr>
<tr>
<td>Jeremias, P.</td>
<td>90, 102, 103, 362, 527, 528, 674</td>
</tr>
<tr>
<td>Jeribi, A.</td>
<td>800</td>
</tr>
<tr>
<td>Jerke, U.</td>
<td>806</td>
</tr>
<tr>
<td>Jesús, G.R.D.</td>
<td>811</td>
</tr>
<tr>
<td>Jesús, N.R.D.</td>
<td>811</td>
</tr>
<tr>
<td>Jiang, X.</td>
<td>804</td>
</tr>
<tr>
<td>Jiao, W.</td>
<td>619</td>
</tr>
<tr>
<td>Jimenez, C.A.</td>
<td>180</td>
</tr>
<tr>
<td>Jimenez, J.</td>
<td>375, 937</td>
</tr>
<tr>
<td>Jimenez, M.R.</td>
<td>36</td>
</tr>
<tr>
<td>Jiménez-Escrig, A.</td>
<td>720</td>
</tr>
<tr>
<td>Jin, H.M.</td>
<td>48</td>
</tr>
<tr>
<td>Jingyi, L.</td>
<td>414</td>
</tr>
<tr>
<td>Jinton, L.</td>
<td>802</td>
</tr>
<tr>
<td>Jirholt, J.</td>
<td>94, 413</td>
</tr>
<tr>
<td>Joaquín, O.</td>
<td>375</td>
</tr>
<tr>
<td>Joëlle Gregoire-Gauthier</td>
<td>790</td>
</tr>
<tr>
<td>Johanet, C.</td>
<td>426</td>
</tr>
<tr>
<td>Johansson, C.</td>
<td>94</td>
</tr>
<tr>
<td>Jokiranta, T.S.</td>
<td>882</td>
</tr>
<tr>
<td>Jones, C.</td>
<td>1 006</td>
</tr>
<tr>
<td>Jönsson, E.</td>
<td>319</td>
</tr>
<tr>
<td>Joos, A.</td>
<td>590</td>
</tr>
<tr>
<td>Joosten, L.</td>
<td>793</td>
</tr>
<tr>
<td>Jordan, M.</td>
<td>615</td>
</tr>
<tr>
<td>Jordan, N.</td>
<td>452</td>
</tr>
<tr>
<td>Jordens, M.</td>
<td>614</td>
</tr>
<tr>
<td>Jorgensen, C.</td>
<td>204, 1 007</td>
</tr>
<tr>
<td>Jose Carrillo, F.</td>
<td>1 048</td>
</tr>
<tr>
<td>Jose Seena Padayattil</td>
<td>660</td>
</tr>
<tr>
<td>Jourde-Chiche, N.</td>
<td>443</td>
</tr>
<tr>
<td>Jousse-Joulin, S.</td>
<td>182, 604, 930</td>
</tr>
<tr>
<td>Jozsi, M.</td>
<td>882</td>
</tr>
<tr>
<td>Juan Manuel, S.H.</td>
<td>394</td>
</tr>
<tr>
<td>Juarez, C.</td>
<td>586</td>
</tr>
<tr>
<td>Julia, A.</td>
<td>375</td>
</tr>
<tr>
<td>Julià, M.R.</td>
<td>36</td>
</tr>
<tr>
<td>Julien, H.</td>
<td>337</td>
</tr>
<tr>
<td>Jullien, D.</td>
<td>391</td>
</tr>
<tr>
<td>Jun, J.</td>
<td>385</td>
</tr>
<tr>
<td>Jung, J.Y.</td>
<td>583</td>
</tr>
<tr>
<td>Jung, K.H.</td>
<td>739</td>
</tr>
<tr>
<td>Jurado, F.</td>
<td>355</td>
</tr>
<tr>
<td>Just, D.</td>
<td>319</td>
</tr>
<tr>
<td>Käsermann, F.</td>
<td>787</td>
</tr>
<tr>
<td>Kahaly, G.</td>
<td>843, 847</td>
</tr>
<tr>
<td>Kahn, J.</td>
<td>279</td>
</tr>
<tr>
<td>Kahn, J.E.</td>
<td>281</td>
</tr>
<tr>
<td>Kalden, J.</td>
<td>1 011</td>
</tr>
<tr>
<td>Kalich-Philosoph, L.</td>
<td>286</td>
</tr>
<tr>
<td>Kalies, K.</td>
<td>935</td>
</tr>
<tr>
<td>Kalim, H.</td>
<td>46, 416, 733, 738, 1 010</td>
</tr>
<tr>
<td>Kalioudi-antanopoulou, C.</td>
<td>905</td>
</tr>
<tr>
<td>Kamel, M.</td>
<td>359</td>
</tr>
<tr>
<td>Kamerling, S.W.A.</td>
<td>91</td>
</tr>
<tr>
<td>Kampar, P.</td>
<td>711</td>
</tr>
<tr>
<td>Kanazawa, N.</td>
<td>136</td>
</tr>
<tr>
<td>Kanda, M.</td>
<td>801</td>
</tr>
<tr>
<td>Kanduc, D.</td>
<td>11, 284, 285</td>
</tr>
<tr>
<td>Kane, P.</td>
<td>972</td>
</tr>
<tr>
<td>Kaplaniski, G.</td>
<td>341, 443, 642</td>
</tr>
<tr>
<td>Kappel, R.</td>
<td>971</td>
</tr>
<tr>
<td>Kappler, M.</td>
<td>744</td>
</tr>
<tr>
<td>Karayev, D.</td>
<td>827</td>
</tr>
<tr>
<td>Karmakar, A.</td>
<td>49</td>
</tr>
<tr>
<td>Karussis, D.</td>
<td>509, 1 035</td>
</tr>
<tr>
<td>Karwan, M.</td>
<td>535</td>
</tr>
<tr>
<td>Käsermann, F.</td>
<td>108, 109</td>
</tr>
<tr>
<td>Kaski, J.C.</td>
<td>839</td>
</tr>
<tr>
<td>Kasler, M.</td>
<td>1 062</td>
</tr>
<tr>
<td>Kasprick, A.</td>
<td>465, 935</td>
</tr>
<tr>
<td>Kasuma, N.</td>
<td>267</td>
</tr>
<tr>
<td>Katchan, V.</td>
<td>342, 858</td>
</tr>
<tr>
<td>Kato, M.</td>
<td>356, 801</td>
</tr>
<tr>
<td>Katz-Agronov, N.</td>
<td>156</td>
</tr>
<tr>
<td>Katzav, A.</td>
<td>885</td>
</tr>
<tr>
<td>Kauderer, C.</td>
<td>465</td>
</tr>
<tr>
<td>Kaufmann, M.</td>
<td>611</td>
</tr>
<tr>
<td>Kaufmann, U.</td>
<td>479</td>
</tr>
<tr>
<td>Kaveri, S.</td>
<td>786, 976</td>
</tr>
<tr>
<td>Kayserova, J.</td>
<td>569</td>
</tr>
<tr>
<td>Kazic, K.</td>
<td>929</td>
</tr>
<tr>
<td>Keating, B.J.</td>
<td>651</td>
</tr>
<tr>
<td>Kechida, M.</td>
<td>74, 729</td>
</tr>
<tr>
<td>Kee, S.J.</td>
<td>48</td>
</tr>
<tr>
<td>Kelder, H.</td>
<td>603</td>
</tr>
<tr>
<td>Kelkka, T.</td>
<td>577</td>
</tr>
<tr>
<td>Kemna, M.</td>
<td>805</td>
</tr>
<tr>
<td>Kerekes, G.</td>
<td>977</td>
</tr>
<tr>
<td>Kern, J.</td>
<td>518</td>
</tr>
<tr>
<td>Kerstein, A.</td>
<td>38</td>
</tr>
<tr>
<td>Ketelslegers, I.A.</td>
<td>777</td>
</tr>
<tr>
<td>Kettritz, R.</td>
<td>806</td>
</tr>
<tr>
<td>Khademi, M.</td>
<td>302</td>
</tr>
<tr>
<td>khansa, R.</td>
<td>608</td>
</tr>
<tr>
<td>Kharitidis, A.</td>
<td>1 051</td>
</tr>
<tr>
<td>Khazaei, A.</td>
<td>54</td>
</tr>
<tr>
<td>Khazaei, B.</td>
<td>54</td>
</tr>
<tr>
<td>Khazaei, H.A.</td>
<td>54</td>
</tr>
<tr>
<td>Khochtali, I.</td>
<td>74</td>
</tr>
<tr>
<td>Khodadadi, L.</td>
<td>179</td>
</tr>
<tr>
<td>Khouatra, C.</td>
<td>391</td>
</tr>
<tr>
<td>Kim, A.</td>
<td>402</td>
</tr>
<tr>
<td>Kim, G.O.</td>
<td>402</td>
</tr>
<tr>
<td>Kim, H.A.</td>
<td>583</td>
</tr>
<tr>
<td>Kim, J.E.</td>
<td>47</td>
</tr>
</tbody>
</table>
Kim, S. 535
Kim, T.J. 381, 739
Kimberly, R.P. 441
Kivity, S. 348, 601, 677, 712, 716, 861, 862
Klassen, L.W. 441
Kleinert, H. 580
Kli, R. 74
Klöpper, J. 935
Klotz, W. 212, 715
Klumb, E.M. 811
Kneisch, K. 126
Knowland, D. 516
Knuschke, P. 884
Kockum, I. 302
Koenders, M. 161, 793, 1 007
Koenders, M.I. 412
Kohlschmidt, J. 1 050
Kolitz, T. 950
Koval, V. 354, 816
Komorowski, L. 303, 778
Kondza, K. 755
König, N. 138
Konikoff, F.M. 630
Kono, M. 801
Konsta, O.D. 649
Kooten, C. 91
Kopecky, O. 938
Kopic, A. 338
Kopylov, U. 630
Koren, O. 155, 163
Korf, H. 567
Korsholm, T. 717
Kortbeek, T. 269
Koslow, M. 601
Kosmehl, H. 907
Kostic, I. 612
Kotlan, B. 1 062
Kotra, L.P. 110
Koufomichali, X. 905
Koutsoumpas, A. 914
Kovacevic, A. 929
Kovacevic, J. 72
Kozmar, A. 240
Kraaij, T. 91, 584
Krämer, A. 1 051
Kramer, P.H. 78
K ramp, S.L. 827
Kraup, E. 717
Kratzsch, J. 96
Krautwald, S. 806
Kreye, J. 724
Kriibben, A. 838
Kromminga, A. 165, 168
Kronbichler, A. 280
Kronimus, Y. 613, 617
Krotkova, A. 39
Kruglov, A. 573
Kruotrön, K. 802
Kudryavstev, I. 234
Kuhn, A. 457, 466, 692, 876
Kuhn, I. 617
Kuijpers, J.H.S.A.M. 312
Kulshrestha, D. 565, 570
Kumar Khajuria, R. 577
Kumar, P. 639
Kümpfel, T. 303
Kungl, A. 479
Kunstner, A. 268
Kuo, C.C. 702
Kuret, T. 378
Kurniawan, A. 340
Kushak, R. 596
Kusworini, H. 738
Kütt, M. 718
Kuuliala, A. 577
Kuuliala, K. 577
Kuwana, M. 310
Kuzenko, A. 339, 958
Kuzmina, N. 894
Kwak-Kim, J. 321, 324
Kwekkeboom, J. 789
Kwiatkowska, B. 764
Kyle, W. 9
Kyurkchiev, D. 598
Labbene, I. 352
Labrador Horrillo, M. 586
Lackner, H.K. 354
Lacroix, R. 341
Laddha, N. 639
Lafreniere, R. 562
Lagier, R. 769
Lagstrom, S. 577
Lakota, K. 378
Lallemand, C. 493
Lamacchia, C. 896
Lambeau, G. 453
Lambert, J. 624, 626, 928
Lambert, M. 279
Lampecht, P. 38
Landmann, A. 466
Landolfo, S. 916
Landron, C. 281
Lang, U. 354, 815, 816
Langan, E. 268
Langevitz, P. 633
Lanio, N. 410
Lanza, A. 326
Lapin, S. 234, 730, 1 051
Lara Salazar, M.A. 836
Larosa, M. 233, 368, 438
Lascu-Dubos, G. 1 036
Laska, M.J. 768
Lavigne, C. 279, 281
Laviola, G. 576
Lavrovsky, Y. 39
Layouni, S. 917
Lazarus, A. 111
Lazurova, I. 541, 635
Lazzari, G. 597
Lazzaroni, M.G. 958
Le Besnerais, M. 338
Le Blaye, I. 265
Le Dantec, C. 649
Le Lann, L. 126
Le Panse, R. 478
Le Quellec, A. 204
Leal, B. 563, 703, 870
Leandro, M.J. 640
Leban, J. 258
LEBESNERAIS, M. 697
Lebl, J. 569, 546
Leboyer, M. 723
Lederer, S. 778
Lee, C. 51, 55
Lee, J.C. 402
Lee, J.W. 47
Lee, K.E. 47
Lee, S.K. 739
Lee, S.S. 47
Lee, W. 402
Lee, W.P. 721
<table>
<thead>
<tr>
<th>Name</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lee-Kirsch, M.</td>
<td>332, 1 000, 1 003</td>
</tr>
<tr>
<td>Lee-Kirsch, M.A.</td>
<td>138, 884</td>
</tr>
<tr>
<td>Lefaucheur, J.P.</td>
<td>384</td>
</tr>
<tr>
<td>Leftler, D.</td>
<td>100</td>
</tr>
<tr>
<td>Levkou, E.</td>
<td>339</td>
</tr>
<tr>
<td>Lehmann, J.</td>
<td>919, 1 050</td>
</tr>
<tr>
<td>Leierer, J.</td>
<td>280</td>
</tr>
<tr>
<td>Leila, F.</td>
<td>854, 1 045</td>
</tr>
<tr>
<td>Leirisalo-Repo, M.</td>
<td>577</td>
</tr>
<tr>
<td>Leite Dantas, R.</td>
<td>358, 363</td>
</tr>
<tr>
<td>Leite de Oliveira, F.</td>
<td>476</td>
</tr>
<tr>
<td>Lemoni, A.</td>
<td>377</td>
</tr>
<tr>
<td>Lenaerts, J.</td>
<td>373</td>
</tr>
<tr>
<td>Lens, A.</td>
<td>937</td>
</tr>
<tr>
<td>Leoncini, S.</td>
<td>513</td>
</tr>
<tr>
<td>Lerner, A.</td>
<td>26, 90, 102, 103, 527, 528, 592, 596, 630, 674</td>
</tr>
<tr>
<td>Leroy, J.</td>
<td>52</td>
</tr>
<tr>
<td>Leubner, J.</td>
<td>724</td>
</tr>
<tr>
<td>Leuci, S.</td>
<td>134</td>
</tr>
<tr>
<td>Leukel, P.</td>
<td>885</td>
</tr>
<tr>
<td>Leung, P.</td>
<td>535</td>
</tr>
<tr>
<td>Levo, Y.</td>
<td>988</td>
</tr>
<tr>
<td>Levy, P.</td>
<td>958</td>
</tr>
<tr>
<td>Levy, R.A.</td>
<td>483, 811</td>
</tr>
<tr>
<td>Levy, Y.</td>
<td>292, 434</td>
</tr>
<tr>
<td>Li, H.</td>
<td>651</td>
</tr>
<tr>
<td>Li, J.</td>
<td>51, 651</td>
</tr>
<tr>
<td>Li, M.T.</td>
<td>707</td>
</tr>
<tr>
<td>Li, Q.</td>
<td>51</td>
</tr>
<tr>
<td>Li, S.</td>
<td>441</td>
</tr>
<tr>
<td>Li, Y.R.</td>
<td>651</td>
</tr>
<tr>
<td>Li, Y.Y.</td>
<td>313</td>
</tr>
<tr>
<td>Li, Z.</td>
<td>404, 526</td>
</tr>
<tr>
<td>Lian, R.</td>
<td>323, 329</td>
</tr>
<tr>
<td>Lian, R.C.</td>
<td>313</td>
</tr>
<tr>
<td>Liang, P.</td>
<td>329</td>
</tr>
<tr>
<td>Liaskos, C.</td>
<td>914</td>
</tr>
<tr>
<td>Libert, C.</td>
<td>397</td>
</tr>
<tr>
<td>Lichtbroun, A.</td>
<td>1 025</td>
</tr>
<tr>
<td>Licini, L.</td>
<td>597</td>
</tr>
<tr>
<td>Lidar, M.</td>
<td>469</td>
</tr>
<tr>
<td>Lightstone, L.</td>
<td>448</td>
</tr>
<tr>
<td>Liljevald, M.</td>
<td>94</td>
</tr>
<tr>
<td>Lim, J.A.</td>
<td>739</td>
</tr>
<tr>
<td>Lin, J.</td>
<td>997</td>
</tr>
<tr>
<td>Lindblad, U.</td>
<td>158</td>
</tr>
<tr>
<td>Lindeberg, S.</td>
<td>158</td>
</tr>
<tr>
<td>Lindfors, K.</td>
<td>101</td>
</tr>
<tr>
<td>Lindhoff-Last, E.</td>
<td>357</td>
</tr>
<tr>
<td>Lindholm</td>
<td>319</td>
</tr>
<tr>
<td>Carlström, E.</td>
<td></td>
</tr>
<tr>
<td>Linkermann, A.</td>
<td>806</td>
</tr>
<tr>
<td>Lioger, B.</td>
<td>281</td>
</tr>
<tr>
<td>Lionel Benchimol</td>
<td>790</td>
</tr>
<tr>
<td>Lionel, C.</td>
<td>330</td>
</tr>
<tr>
<td>Lippi, G.</td>
<td>431, 904</td>
</tr>
<tr>
<td>Liszka, G.</td>
<td>1 062</td>
</tr>
<tr>
<td>Little, D.</td>
<td>288</td>
</tr>
<tr>
<td>Liu, A.</td>
<td>415</td>
</tr>
<tr>
<td>Liu, L.</td>
<td>51, 55</td>
</tr>
<tr>
<td>Liu, S.</td>
<td>899</td>
</tr>
<tr>
<td>Liu, X.</td>
<td>228</td>
</tr>
<tr>
<td>Liu, Y.</td>
<td>602</td>
</tr>
<tr>
<td>Liuchang, F.</td>
<td>994</td>
</tr>
<tr>
<td>Livneh, A.</td>
<td>992</td>
</tr>
<tr>
<td>Llano Hernandez, K.</td>
<td>223</td>
</tr>
<tr>
<td>Llop Vilailella, M.</td>
<td>1 047</td>
</tr>
<tr>
<td>Llurba, E.</td>
<td>339</td>
</tr>
<tr>
<td>Lo Schiavo, A.</td>
<td>139</td>
</tr>
<tr>
<td>Lo, Y.</td>
<td>185, 395</td>
</tr>
<tr>
<td>Lobo Antunes, M.</td>
<td>392, 732</td>
</tr>
<tr>
<td>Lochouarn Andreani, M.</td>
<td>800</td>
</tr>
<tr>
<td>Logullo, F.</td>
<td>116</td>
</tr>
<tr>
<td>Lohse, M.</td>
<td>853</td>
</tr>
<tr>
<td>Lojacono, A.</td>
<td>817</td>
</tr>
<tr>
<td>Londrino, F.</td>
<td>243</td>
</tr>
<tr>
<td>Lopergolo, L.</td>
<td>792</td>
</tr>
<tr>
<td>Lopez Herrera, G.</td>
<td>417</td>
</tr>
<tr>
<td>Lopez San Román, A.</td>
<td>1 047</td>
</tr>
<tr>
<td>Lopez Velez, M.D.S.</td>
<td>246</td>
</tr>
<tr>
<td>Lopez, L.</td>
<td>559</td>
</tr>
<tr>
<td>López-Díaz, P.E.</td>
<td>860</td>
</tr>
<tr>
<td>Lopez-Herrera, G.</td>
<td>475</td>
</tr>
<tr>
<td>López-Hoyos, M.</td>
<td>104, 215, 355</td>
</tr>
<tr>
<td>LopezRodriguez, W.</td>
<td>394</td>
</tr>
<tr>
<td>Lorenz, H.M.</td>
<td>138</td>
</tr>
<tr>
<td>Lorenzo Villalba, N.</td>
<td>74, 726, 729</td>
</tr>
<tr>
<td>Losen, M.</td>
<td>723</td>
</tr>
<tr>
<td>Lotufo, S.</td>
<td>226</td>
</tr>
<tr>
<td>Louail, A.</td>
<td>571</td>
</tr>
<tr>
<td>Lounici, Y.</td>
<td>222</td>
</tr>
<tr>
<td>Loza Santamaria, E.</td>
<td>1 047</td>
</tr>
<tr>
<td>Lu, Q.</td>
<td>643, 646</td>
</tr>
<tr>
<td>Lu, Y.</td>
<td>752</td>
</tr>
<tr>
<td>Lucas, A.C.</td>
<td>923</td>
</tr>
<tr>
<td>Ludeña-Cruz, M.D.</td>
<td>53</td>
</tr>
<tr>
<td>Ludwig, F.T.</td>
<td>39</td>
</tr>
<tr>
<td>Ludwig, R.</td>
<td>81, 464, 465, 935</td>
</tr>
<tr>
<td>Ludwig, R.J.</td>
<td>80</td>
</tr>
<tr>
<td>Ludwig, S.</td>
<td>363</td>
</tr>
<tr>
<td>Luecke, K.</td>
<td>907</td>
</tr>
<tr>
<td>Lueking, A.</td>
<td>147, 430</td>
</tr>
<tr>
<td>Luefjens, C.M.</td>
<td>39</td>
</tr>
<tr>
<td>Lugari, L.</td>
<td>713</td>
</tr>
<tr>
<td>Luger, T.</td>
<td>461, 466</td>
</tr>
<tr>
<td>Luis Eduardo C.</td>
<td>422</td>
</tr>
<tr>
<td>Andrade</td>
<td></td>
</tr>
<tr>
<td>Luisetto, R.</td>
<td>472, 476, 477, 751</td>
</tr>
<tr>
<td>Luján, L.</td>
<td>10, 152, 969</td>
</tr>
<tr>
<td>LukaBajalo, J.</td>
<td>594</td>
</tr>
<tr>
<td>Lunardi, C.</td>
<td>758, 762</td>
</tr>
<tr>
<td>Lund, M.</td>
<td>159</td>
</tr>
<tr>
<td>Lundelin, K.</td>
<td>339</td>
</tr>
<tr>
<td>Lundqvist, A.</td>
<td>802</td>
</tr>
<tr>
<td>Lung, T.</td>
<td>618</td>
</tr>
<tr>
<td>Luning Prak, E.T.</td>
<td>88</td>
</tr>
<tr>
<td>Lupetti, M.</td>
<td>909</td>
</tr>
<tr>
<td>Lupidi, F.</td>
<td>116</td>
</tr>
<tr>
<td>Luppa, P.</td>
<td>357</td>
</tr>
<tr>
<td>Lutalo, P.</td>
<td>727</td>
</tr>
<tr>
<td>Lüthke, K.</td>
<td>214</td>
</tr>
<tr>
<td>Lutovac, D.</td>
<td>929</td>
</tr>
<tr>
<td>Lutteri, L.</td>
<td>911</td>
</tr>
<tr>
<td>Lüttich, T.</td>
<td>56</td>
</tr>
<tr>
<td>Lux, A.</td>
<td>113</td>
</tr>
<tr>
<td>Lyne, P.</td>
<td>802</td>
</tr>
<tr>
<td>M. Benucci</td>
<td>216</td>
</tr>
<tr>
<td>M. D’Amico</td>
<td>451</td>
</tr>
<tr>
<td>M. Infantino</td>
<td>216</td>
</tr>
<tr>
<td>M. Mahler</td>
<td>216</td>
</tr>
<tr>
<td>M. Manfredi</td>
<td>216</td>
</tr>
<tr>
<td>M. Moumni</td>
<td>117</td>
</tr>
<tr>
<td>Ma, J.</td>
<td>997</td>
</tr>
<tr>
<td>Ma, Z.</td>
<td>55</td>
</tr>
<tr>
<td>Macaubas, C.</td>
<td>425</td>
</tr>
<tr>
<td>Maccallum, C.</td>
<td>489</td>
</tr>
<tr>
<td>Macchioni, P.</td>
<td>865</td>
</tr>
<tr>
<td>Macini, R.</td>
<td>901</td>
</tr>
<tr>
<td>Macor, P.</td>
<td>127</td>
</tr>
<tr>
<td>Macri, S.</td>
<td>576</td>
</tr>
<tr>
<td>Maddox, D.</td>
<td>248</td>
</tr>
<tr>
<td>Maestroni, C.</td>
<td>597</td>
</tr>
<tr>
<td>Name</td>
<td>Page Numbers</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>----------------</td>
</tr>
<tr>
<td>Menezes, M.F.</td>
<td>536, 1044</td>
</tr>
<tr>
<td>Meng, W.</td>
<td>88</td>
</tr>
<tr>
<td>Menon, B.</td>
<td>727</td>
</tr>
<tr>
<td>Mercuri, E.</td>
<td>382</td>
</tr>
<tr>
<td>Merheb, V.</td>
<td>515, 881</td>
</tr>
<tr>
<td>Merlach, P.</td>
<td>538</td>
</tr>
<tr>
<td>Meroni, P.</td>
<td>1064</td>
</tr>
<tr>
<td>Meroni, P.L.</td>
<td>27, 127, 203, 411, 487, 504, 553, 557, 653, 659, 664, 694, 809, 948, 955</td>
</tr>
<tr>
<td>Mesbah-Amroun, H.</td>
<td>701</td>
</tr>
<tr>
<td>Messaoudi, K.</td>
<td>897</td>
</tr>
<tr>
<td>Messiaen, A.S.</td>
<td>241</td>
</tr>
<tr>
<td>Mestkula, K.</td>
<td>550</td>
</tr>
<tr>
<td>Metwally, L.</td>
<td>235</td>
</tr>
<tr>
<td>Metzer, A.L.</td>
<td>827</td>
</tr>
<tr>
<td>Meuleman, L.</td>
<td>928</td>
</tr>
<tr>
<td>Meyer, W.</td>
<td>824</td>
</tr>
<tr>
<td>Michael, B.</td>
<td>424</td>
</tr>
<tr>
<td>Michallet, M.</td>
<td>616</td>
</tr>
<tr>
<td>Michaud, M.</td>
<td>277</td>
</tr>
<tr>
<td>Michaud, S.A.</td>
<td>52</td>
</tr>
<tr>
<td>Midiri, M.</td>
<td>367</td>
</tr>
<tr>
<td>Migliara, G.</td>
<td>328</td>
</tr>
<tr>
<td>Mignogna, M.D.</td>
<td>129, 135</td>
</tr>
<tr>
<td>Mihaljevic, O.</td>
<td>612</td>
</tr>
<tr>
<td>Miketic, N.</td>
<td>929</td>
</tr>
<tr>
<td>Mikita, N.</td>
<td>136</td>
</tr>
<tr>
<td>Milano, V.</td>
<td>382</td>
</tr>
<tr>
<td>Miller, A.</td>
<td>652</td>
</tr>
<tr>
<td>Miller, S.</td>
<td>1006</td>
</tr>
<tr>
<td>Milo, R.</td>
<td>295, 299</td>
</tr>
<tr>
<td>Milosevic, G.</td>
<td>72</td>
</tr>
<tr>
<td>Milosevic-Djordjevic, O.</td>
<td>612</td>
</tr>
<tr>
<td>Mimori, T.</td>
<td>123, 307, 310</td>
</tr>
<tr>
<td>Mimura, L.A.</td>
<td>403, 864</td>
</tr>
<tr>
<td>Mimura, L.A.N.</td>
<td>195</td>
</tr>
<tr>
<td>Mina, C.</td>
<td>887</td>
</tr>
<tr>
<td>Minadze, E.</td>
<td>568</td>
</tr>
<tr>
<td>Mineo, C.</td>
<td>33</td>
</tr>
<tr>
<td>Minota, S.</td>
<td>517</td>
</tr>
<tr>
<td>Miodovnik, M.</td>
<td>268</td>
</tr>
<tr>
<td>Miossec, P.</td>
<td>28, 1002</td>
</tr>
<tr>
<td>Miranda, F.</td>
<td>87, 160, 454</td>
</tr>
<tr>
<td>MIRANDA, S.</td>
<td>697</td>
</tr>
<tr>
<td>Miraull, T.</td>
<td>279</td>
</tr>
<tr>
<td>mirello, C.</td>
<td>698</td>
</tr>
<tr>
<td>Mirza Zaka, P.</td>
<td>416</td>
</tr>
<tr>
<td>Missio, A.</td>
<td>864</td>
</tr>
<tr>
<td>Miteva, P.</td>
<td>731</td>
</tr>
<tr>
<td>Mitrevski, M.</td>
<td>184, 767</td>
</tr>
<tr>
<td>Mitsios, N.</td>
<td>302</td>
</tr>
<tr>
<td>Mitsis, C.</td>
<td>893</td>
</tr>
<tr>
<td>Miyaoa, T.</td>
<td>1009</td>
</tr>
<tr>
<td>Miyara, M.</td>
<td>65</td>
</tr>
<tr>
<td>Mo, Y.</td>
<td>997</td>
</tr>
<tr>
<td>Modesto Caballero, C.</td>
<td></td>
</tr>
<tr>
<td>Moerli, M.</td>
<td>816</td>
</tr>
<tr>
<td>Moghaddam, A.</td>
<td>315</td>
</tr>
<tr>
<td>Mohr, A.</td>
<td>247</td>
</tr>
<tr>
<td>Moinuddin, H.</td>
<td>549</td>
</tr>
<tr>
<td>Mok, M.Y.</td>
<td>185, 395</td>
</tr>
<tr>
<td>Mold, M.</td>
<td>3</td>
</tr>
<tr>
<td>Molenaar, P.</td>
<td>723</td>
</tr>
<tr>
<td>Molina Fuentes, A.</td>
<td>36</td>
</tr>
<tr>
<td>Molli, C.</td>
<td>36</td>
</tr>
<tr>
<td>Möller, M.</td>
<td>614</td>
</tr>
<tr>
<td>Molnár, I.</td>
<td>890</td>
</tr>
<tr>
<td>Mona Hamed</td>
<td>552</td>
</tr>
<tr>
<td>Mondini, S.</td>
<td>368</td>
</tr>
<tr>
<td>Monika, J.</td>
<td>704</td>
</tr>
<tr>
<td>Monogioudi, E.</td>
<td>504</td>
</tr>
<tr>
<td>Monov, S.</td>
<td>731</td>
</tr>
<tr>
<td>Montagna, G.</td>
<td>892</td>
</tr>
<tr>
<td>Monteiro, A.</td>
<td>699</td>
</tr>
<tr>
<td>Montes, M.</td>
<td>36</td>
</tr>
<tr>
<td>Monti, C.</td>
<td>609</td>
</tr>
<tr>
<td>Montomoli, C.</td>
<td>609</td>
</tr>
<tr>
<td>Moore, R.</td>
<td>615</td>
</tr>
<tr>
<td>Morales, J.M.</td>
<td>455, 825</td>
</tr>
<tr>
<td>Morales, R.</td>
<td>403</td>
</tr>
<tr>
<td>Morariu, R.</td>
<td>115</td>
</tr>
<tr>
<td>Morell Hita, J.L.</td>
<td>1047</td>
</tr>
<tr>
<td>Morini, A.</td>
<td>1049</td>
</tr>
<tr>
<td>Morozzi, G.</td>
<td>824, 900, 909</td>
</tr>
<tr>
<td>Morris, R.I.</td>
<td>827</td>
</tr>
<tr>
<td>Morshed, S.</td>
<td>849</td>
</tr>
<tr>
<td>Mosca, M.</td>
<td>795, 798</td>
</tr>
<tr>
<td>Moshera, E.</td>
<td>912</td>
</tr>
<tr>
<td>Mota, A.</td>
<td>699</td>
</tr>
<tr>
<td>Mothes, T.</td>
<td>105</td>
</tr>
<tr>
<td>Motta, M.</td>
<td>817</td>
</tr>
<tr>
<td>Moudgil, K.</td>
<td>1008</td>
</tr>
<tr>
<td>Moulaei, N.A.</td>
<td>54</td>
</tr>
<tr>
<td>Moura, R.A.</td>
<td>259, 640</td>
</tr>
<tr>
<td>Mouthon, L.</td>
<td>198, 201, 506</td>
</tr>
<tr>
<td>Movafagh, A.</td>
<td>610</td>
</tr>
<tr>
<td>Mueller, A.</td>
<td>38</td>
</tr>
<tr>
<td>Mueller, J.</td>
<td>525</td>
</tr>
<tr>
<td>Muench, G.</td>
<td>853</td>
</tr>
<tr>
<td>Mulder, J.</td>
<td>302</td>
</tr>
<tr>
<td>Mulder, P.</td>
<td>338</td>
</tr>
<tr>
<td>Muller, G.</td>
<td>279</td>
</tr>
<tr>
<td>Münch, G.</td>
<td>526</td>
</tr>
<tr>
<td>Muramoto, F.J.</td>
<td>376</td>
</tr>
<tr>
<td>Muratore, F.</td>
<td>865</td>
</tr>
<tr>
<td>Muratori, L.</td>
<td>249, 531, 534</td>
</tr>
<tr>
<td>Muratori, P.</td>
<td>249</td>
</tr>
<tr>
<td>Murdaca, G.</td>
<td>225, 229</td>
</tr>
<tr>
<td>Musgro, A.</td>
<td>203</td>
</tr>
<tr>
<td>Murugan, R.</td>
<td>724</td>
</tr>
<tr>
<td>Murwani, S.</td>
<td>416</td>
</tr>
<tr>
<td>Müller, U.</td>
<td>352</td>
</tr>
<tr>
<td>Musial, J.</td>
<td>353</td>
</tr>
<tr>
<td>Musset, L.</td>
<td>65</td>
</tr>
<tr>
<td>Mustjoki, S.</td>
<td>577</td>
</tr>
<tr>
<td>Mustofa, E.</td>
<td>416</td>
</tr>
<tr>
<td>Muzalevkaya, M.</td>
<td>314</td>
</tr>
<tr>
<td>Mytilinaiou, M.</td>
<td>914</td>
</tr>
<tr>
<td>Naeun, L.</td>
<td>364, 998</td>
</tr>
<tr>
<td>Naftali, T.</td>
<td>561</td>
</tr>
<tr>
<td>Nagel, M.</td>
<td>564</td>
</tr>
<tr>
<td>Naguwa, S.</td>
<td>1018, 1022</td>
</tr>
<tr>
<td>Nagy, L.</td>
<td>977</td>
</tr>
<tr>
<td>Nahary, L.</td>
<td>304</td>
</tr>
<tr>
<td>Naides, S.</td>
<td>208, 217, 769</td>
</tr>
<tr>
<td>Najirmian, N.</td>
<td>711</td>
</tr>
<tr>
<td>Nakamura, H.</td>
<td>356, 801</td>
</tr>
<tr>
<td>Nallasivan, S.</td>
<td>173</td>
</tr>
<tr>
<td>Nall, C.</td>
<td>339</td>
</tr>
<tr>
<td>Nalotto, L.</td>
<td>438, 708, 863</td>
</tr>
<tr>
<td>Naor, D.</td>
<td>941, 945</td>
</tr>
<tr>
<td>Napalkova, O.</td>
<td>730</td>
</tr>
<tr>
<td>Naparstek, Y.</td>
<td>747, 990</td>
</tr>
<tr>
<td>Napodano, P.</td>
<td>243</td>
</tr>
<tr>
<td>Naranjo, J.C.</td>
<td>1027</td>
</tr>
<tr>
<td>Naretto, C.</td>
<td>73</td>
</tr>
<tr>
<td>Nasi, M.</td>
<td>607, 984</td>
</tr>
<tr>
<td>Nasser, M.</td>
<td>587</td>
</tr>
<tr>
<td>Navarra, S.</td>
<td>746, 749, 1012</td>
</tr>
<tr>
<td>Navarro, E.P.</td>
<td>70</td>
</tr>
<tr>
<td>Nawrot, I.</td>
<td>710</td>
</tr>
<tr>
<td>Nédospasov, S.</td>
<td>573</td>
</tr>
<tr>
<td>Néel, A.</td>
<td>279</td>
</tr>
<tr>
<td>Negrini, S.</td>
<td>229</td>
</tr>
<tr>
<td>Negru, M.M.</td>
<td>242, 684</td>
</tr>
<tr>
<td>Neidhofer, S.</td>
<td>90, 102, 362, 527, 528</td>
</tr>
<tr>
<td>Name</td>
<td>Page Numbers</td>
</tr>
<tr>
<td>-----------------------</td>
<td>--------------</td>
</tr>
<tr>
<td>Refaat, R.</td>
<td>683</td>
</tr>
<tr>
<td>Reggio, R.</td>
<td>233, 438, 817</td>
</tr>
<tr>
<td>Reggio, R.</td>
<td>863</td>
</tr>
<tr>
<td>Reich, G.</td>
<td>829</td>
</tr>
<tr>
<td>Reinhold, E. S.</td>
<td>239, 318, 424</td>
</tr>
<tr>
<td>Reinhold, D.</td>
<td>393, 396, 774</td>
</tr>
<tr>
<td>Reis, A. I.</td>
<td>392, 732</td>
</tr>
<tr>
<td>Rekvig, O.P.</td>
<td>42</td>
</tr>
<tr>
<td>Renaudineau, Y.</td>
<td>486, 604, 649, 883, 930</td>
</tr>
<tr>
<td>Rengers, P.</td>
<td>488</td>
</tr>
<tr>
<td>Rentouli, S.</td>
<td>914</td>
</tr>
<tr>
<td>Repo, H.</td>
<td>577</td>
</tr>
<tr>
<td>Resche Regon, M.</td>
<td>279</td>
</tr>
<tr>
<td>Reynolds, T.</td>
<td>485</td>
</tr>
<tr>
<td>Ria, F.</td>
<td>328</td>
</tr>
<tr>
<td>Ribeiro, N.</td>
<td>699</td>
</tr>
<tr>
<td>Ribeiro, R.</td>
<td>536, 1044</td>
</tr>
<tr>
<td>Ricard Cervera</td>
<td>657</td>
</tr>
<tr>
<td>Riccioli, V.</td>
<td>909</td>
</tr>
<tr>
<td>Richard, V.</td>
<td>338</td>
</tr>
<tr>
<td>Richter, J.</td>
<td>147, 430</td>
</tr>
<tr>
<td>Riekert, M.</td>
<td>735</td>
</tr>
<tr>
<td>Riemekasten, G.</td>
<td>38, 86, 197, 202</td>
</tr>
<tr>
<td>Riemschneider, S.</td>
<td>1050</td>
</tr>
<tr>
<td>Riesco, L.</td>
<td>104</td>
</tr>
<tr>
<td>Rieu, P.</td>
<td>443</td>
</tr>
<tr>
<td>Riganò, R.</td>
<td>886</td>
</tr>
<tr>
<td>Rigante, D.</td>
<td>678</td>
</tr>
<tr>
<td>Rijvers, L.</td>
<td>491, 492</td>
</tr>
<tr>
<td>Rinaldi, S.</td>
<td>368</td>
</tr>
<tr>
<td>Risch, L.</td>
<td>618</td>
</tr>
<tr>
<td>Roat, R.</td>
<td>545</td>
</tr>
<tr>
<td>Rober, N.</td>
<td>214, 428, 537</td>
</tr>
<tr>
<td>Robert, S.</td>
<td>341</td>
</tr>
<tr>
<td>Roberta, F.</td>
<td>73</td>
</tr>
<tr>
<td>Robier, C.</td>
<td>829</td>
</tr>
<tr>
<td>Robinet, M.</td>
<td>478</td>
</tr>
<tr>
<td>Robles-Marhuenda, Á.</td>
<td>339</td>
</tr>
<tr>
<td>Roccatello, D.</td>
<td>73, 878</td>
</tr>
<tr>
<td>Rodighiero, F.</td>
<td>744</td>
</tr>
<tr>
<td>Rodrigues, A.</td>
<td>923</td>
</tr>
<tr>
<td>Rodriguez Alba, J.C.</td>
<td>475</td>
</tr>
<tr>
<td>Rocheveld, D.</td>
<td>1007</td>
</tr>
<tr>
<td>Rocheveld, D.M.</td>
<td>412</td>
</tr>
<tr>
<td>Roers, A.</td>
<td>794</td>
</tr>
<tr>
<td>Roggenbuck, D.</td>
<td>127, 537, 554, 774, 916</td>
</tr>
<tr>
<td>Rogier, R.</td>
<td>161, 412</td>
</tr>
<tr>
<td>Roi, M.</td>
<td>300</td>
</tr>
<tr>
<td>Roic, G.</td>
<td>755</td>
</tr>
<tr>
<td>Roide, A.</td>
<td>426</td>
</tr>
<tr>
<td>Roll, G.</td>
<td>946</td>
</tr>
<tr>
<td>Rolla, D.</td>
<td>243</td>
</tr>
<tr>
<td>Romano, F.</td>
<td>139</td>
</tr>
<tr>
<td>Romao, V.</td>
<td>259</td>
</tr>
<tr>
<td>Romay-Penabad, Z.</td>
<td>957</td>
</tr>
<tr>
<td>Romeo, D.</td>
<td>382</td>
</tr>
<tr>
<td>Romeo, G.</td>
<td>835</td>
</tr>
<tr>
<td>Romero Ramirez, H.</td>
<td>417, 836</td>
</tr>
<tr>
<td>Romero, R.L.</td>
<td>65</td>
</tr>
<tr>
<td>Romero-Ramirez, H.</td>
<td>475</td>
</tr>
<tr>
<td>Romito, A.</td>
<td>538</td>
</tr>
<tr>
<td>Ronco, P.</td>
<td>445, 690</td>
</tr>
<tr>
<td>Roncucci, L.</td>
<td>249</td>
</tr>
<tr>
<td>Ronda, N.</td>
<td>557, 1064</td>
</tr>
<tr>
<td>Ronda, N.</td>
<td>636</td>
</tr>
<tr>
<td>Rondeau, E.</td>
<td>443</td>
</tr>
<tr>
<td>Ronnelid, J.</td>
<td>981</td>
</tr>
<tr>
<td>Rosado, M.M.</td>
<td>792</td>
</tr>
<tr>
<td>Rose, N.R.</td>
<td>24</td>
</tr>
<tr>
<td>Rose, T.</td>
<td>490</td>
</tr>
<tr>
<td>Rosenthal, E.</td>
<td>83, 960</td>
</tr>
<tr>
<td>Rossini, A.</td>
<td>59</td>
</tr>
<tr>
<td>Rossow, K.</td>
<td>248</td>
</tr>
<tr>
<td>Rottiers, P.</td>
<td>567</td>
</tr>
<tr>
<td>Roussinov, D.</td>
<td>731</td>
</tr>
<tr>
<td>Roux-Lombard, P.</td>
<td>896</td>
</tr>
<tr>
<td>Rouzaire, P.</td>
<td>897</td>
</tr>
<tr>
<td>Rovere-Querini, P.</td>
<td>339</td>
</tr>
<tr>
<td>Rovero, P.</td>
<td>513</td>
</tr>
<tr>
<td>Rowley, T.</td>
<td>745</td>
</tr>
<tr>
<td>Rower, D.</td>
<td>787</td>
</tr>
<tr>
<td>Roy, S.</td>
<td>1005</td>
</tr>
<tr>
<td>Rozen, L.P.</td>
<td>608</td>
</tr>
<tr>
<td>Rua, J.</td>
<td>923</td>
</tr>
<tr>
<td>Ruano, A.</td>
<td>339</td>
</tr>
<tr>
<td>Rudin, A.</td>
<td>413</td>
</tr>
<tr>
<td>Rudolph, S.</td>
<td>214</td>
</tr>
<tr>
<td>Rudrangi, R.</td>
<td>957</td>
</tr>
<tr>
<td>Ruffati, A.</td>
<td>339</td>
</tr>
<tr>
<td>Ruffatti, A.</td>
<td>662, 958</td>
</tr>
<tr>
<td>Ruffilli, I.</td>
<td>850, 851</td>
</tr>
<tr>
<td>Ruhrman-shahar, N.</td>
<td>292</td>
</tr>
<tr>
<td>Ruiperez, V.</td>
<td>595</td>
</tr>
<tr>
<td>Ruivo, J.</td>
<td>765</td>
</tr>
<tr>
<td>Ruiz Requena, R.</td>
<td>246</td>
</tr>
<tr>
<td>Ruiz-Olivera, M.D.R.</td>
<td>860</td>
</tr>
<tr>
<td>Ruland, V.</td>
<td>466</td>
</tr>
<tr>
<td>Ruso, A.</td>
<td>431, 828, 904</td>
</tr>
<tr>
<td>Rutten, B.P.</td>
<td>723</td>
</tr>
<tr>
<td>Sá, J.D.</td>
<td>376</td>
</tr>
<tr>
<td>Saad, F.</td>
<td>675</td>
</tr>
<tr>
<td>Saarela, J.</td>
<td>577</td>
</tr>
<tr>
<td>Saarimaki, J.</td>
<td>313, 329</td>
</tr>
<tr>
<td>Saavedra, M.A.</td>
<td>964</td>
</tr>
<tr>
<td>Saavedra-Diaz, C.</td>
<td>638</td>
</tr>
<tr>
<td>Sabatini, P.</td>
<td>698, 34, 909</td>
</tr>
<tr>
<td>Sablon, N.</td>
<td>729</td>
</tr>
<tr>
<td>Sabrina, R.</td>
<td>318</td>
</tr>
<tr>
<td>Sabrina, S.</td>
<td>946</td>
</tr>
<tr>
<td>Saccon, F.</td>
<td>233, 476, 477</td>
</tr>
<tr>
<td>Sacharidou, A.</td>
<td>33</td>
</tr>
<tr>
<td>Sachdeva, R.</td>
<td>442</td>
</tr>
<tr>
<td>Sack, U.</td>
<td>621, 775</td>
</tr>
<tr>
<td>Sadeghi, H.</td>
<td>1059</td>
</tr>
<tr>
<td>Sadoun, A.</td>
<td>744</td>
</tr>
<tr>
<td>Sáez-Salgado, R.</td>
<td>244</td>
</tr>
<tr>
<td>Sagcan, M.</td>
<td>230</td>
</tr>
<tr>
<td>Sahin, A.G.</td>
<td>230</td>
</tr>
<tr>
<td>Sainaghi, P.P.</td>
<td>59, 753</td>
</tr>
<tr>
<td>Sakuma, Y.</td>
<td>45</td>
</tr>
<tr>
<td>Sakuramoto-Tsuchida, S.</td>
<td>1009</td>
</tr>
<tr>
<td>Salama, A.</td>
<td>744</td>
</tr>
<tr>
<td>Salmi, L.</td>
<td>753</td>
</tr>
<tr>
<td>Salmon, J.</td>
<td>33</td>
</tr>
<tr>
<td>Saluc, C.</td>
<td>77</td>
</tr>
<tr>
<td>Salvado, M.</td>
<td>743</td>
</tr>
<tr>
<td>Salvarani, C.</td>
<td>865</td>
</tr>
<tr>
<td>Salvi, S.</td>
<td>326</td>
</tr>
<tr>
<td>Samavedam, U.</td>
<td>935</td>
</tr>
<tr>
<td>Samsonov, M.</td>
<td>39</td>
</tr>
<tr>
<td>Samuelsson, E.</td>
<td>802</td>
</tr>
<tr>
<td>Sánchez Ramón, S.</td>
<td>224</td>
</tr>
<tr>
<td>Sánchez, A.Y.</td>
<td>180</td>
</tr>
<tr>
<td>Sánchez, D.</td>
<td>60</td>
</tr>
<tr>
<td>Sánchez, V.</td>
<td>591</td>
</tr>
</tbody>
</table>
Sanchez-Martín, F. 595
Sánchez-Ramón, S. 223, 788, 32
Sanganee, H. 802
Sangle joint 1st author, S. 452
Sangle 1st joint author, S. 727
Sangle, S. 278
Santaguida, G. 850
Santaguida, M.G. 835
Santoro, D. 243
Santos, J. 316
Santos-Argumedo, L. 452
Santos, J. 316
Sarkhu, O´Callaghan, A. 586
Sena, P. 249
Sepp, N. 219
Seydel, A. 919, 1050
Seppanen, J. 266
Shal, R. 639
Shah, S. 548
Shaliv, T. 581
Shamkina, E. 894
Shankaran, H. 94
Shanesh, Z. 994
Shardlow, E. 2
Shaul, P. 33
Sheffield, W. 111
Sheldón, J. 119, 121, 501, 504
Shen, G. 827
Shen, L. 602
Shi, G. 602
Shamir, Y. 801
Shida, H. 801
Shima, Y. 801
Shapiaeva, E. 39
Shoenfeld, Y. 144, 157, 213, 286, 293, 342, 348, 361, 472, 495, 523, 581, 691, 742, 861, 862, 866, 901, 967, 970, 973, 979, 1062
Shovman, O. 213, 581, 979
Shukina, O. 1051
<table>
<thead>
<tr>
<th>Name</th>
<th>Page Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Takiishi, T.</td>
<td>567</td>
</tr>
<tr>
<td>Talotta, R.</td>
<td>487, 653</td>
</tr>
<tr>
<td>Tambuzzo, M.T.</td>
<td>538</td>
</tr>
<tr>
<td>Tampoia, M.</td>
<td>211, 725, 824, 1 073</td>
</tr>
<tr>
<td>Tan, I.</td>
<td>627</td>
</tr>
<tr>
<td>Tan, L.</td>
<td>251</td>
</tr>
<tr>
<td>Tan, W.</td>
<td>41</td>
</tr>
<tr>
<td>Tanaka, A.</td>
<td>287</td>
</tr>
<tr>
<td>Tanaka, Y.</td>
<td>1 009</td>
</tr>
<tr>
<td>Tanay, A.</td>
<td>141, 757, 824, 1 073</td>
</tr>
<tr>
<td>Tan, W.</td>
<td>41</td>
</tr>
<tr>
<td>Tanaka, Y.</td>
<td>1 009</td>
</tr>
<tr>
<td>Tanay, A.</td>
<td>141, 757, 824, 1 073</td>
</tr>
<tr>
<td>Tan, J.</td>
<td>527</td>
</tr>
<tr>
<td>Tansey, M.</td>
<td>947</td>
</tr>
<tr>
<td>Tao, W.</td>
<td>158</td>
</tr>
<tr>
<td>Taraborelli, M.</td>
<td>948, 967</td>
</tr>
<tr>
<td>Tarasov, A.</td>
<td>269</td>
</tr>
<tr>
<td>Tarasov, S.</td>
<td>269</td>
</tr>
<tr>
<td>Tatsina, E.</td>
<td>893, 912</td>
</tr>
<tr>
<td>Taylor, P.C.</td>
<td>1 071</td>
</tr>
<tr>
<td>Tea, F.</td>
<td>881</td>
</tr>
<tr>
<td>Tedesco, F.</td>
<td>814, 857</td>
</tr>
<tr>
<td>Teegen, B.</td>
<td>303, 778</td>
</tr>
<tr>
<td>Tejeda Velarde, A.</td>
<td>720</td>
</tr>
<tr>
<td>Tekcan, A.</td>
<td>654</td>
</tr>
<tr>
<td>Tekus, V.</td>
<td>474</td>
</tr>
<tr>
<td>Telier, Z.</td>
<td>877</td>
</tr>
<tr>
<td>Teng, Y.K.O.</td>
<td>91, 584</td>
</tr>
<tr>
<td>ter Borg, E.J.</td>
<td>603</td>
</tr>
<tr>
<td>Terrier, B.</td>
<td>443</td>
</tr>
<tr>
<td>Terrosio, G.</td>
<td>722</td>
</tr>
<tr>
<td>Tescari, S.</td>
<td>959</td>
</tr>
<tr>
<td>Tesija Kuna, A.</td>
<td>755</td>
</tr>
<tr>
<td>Thabah, M.</td>
<td>370</td>
</tr>
<tr>
<td>Thakur, I.</td>
<td>49</td>
</tr>
<tr>
<td>Thaler, M.</td>
<td>357</td>
</tr>
<tr>
<td>Theresia, R.</td>
<td>946</td>
</tr>
<tr>
<td>Thiyagarajan, D.</td>
<td>37, 42, 262</td>
</tr>
<tr>
<td>Thomas, K.</td>
<td>611</td>
</tr>
<tr>
<td>Thomas, M.</td>
<td>95, 98</td>
</tr>
<tr>
<td>Thomas, Q.</td>
<td>337</td>
</tr>
<tr>
<td>Thomas, R.</td>
<td>76</td>
</tr>
<tr>
<td>Thomé, R.</td>
<td>403</td>
</tr>
<tr>
<td>Thorén, A.</td>
<td>802</td>
</tr>
<tr>
<td>Thulin, P.</td>
<td>94</td>
</tr>
<tr>
<td>Thurau, S.</td>
<td>258</td>
</tr>
<tr>
<td>Tian, X.</td>
<td>671</td>
</tr>
<tr>
<td>Tibenska, E.</td>
<td>99</td>
</tr>
<tr>
<td>Tillmanns, S.</td>
<td>947</td>
</tr>
<tr>
<td>Tincani, A.</td>
<td>146, 233, 339, 350, 438, 650, 658, 808, 817, 863, 948, 958, 947</td>
</tr>
<tr>
<td>Titkov, A.</td>
<td>314</td>
</tr>
<tr>
<td>Titova, O.</td>
<td>730</td>
</tr>
<tr>
<td>Titulaer, M.J.</td>
<td>511, 723</td>
</tr>
<tr>
<td>Tlaskalová-Hogenová, H.</td>
<td>60</td>
</tr>
<tr>
<td>Tobón, G.</td>
<td>180, 638, 1 027</td>
</tr>
<tr>
<td>Tobón, G.J.</td>
<td>70</td>
</tr>
<tr>
<td>Toca, M.</td>
<td>104, 355</td>
</tr>
<tr>
<td>Toes, R.</td>
<td>145, 995</td>
</tr>
<tr>
<td>Toes, R.E.M.</td>
<td>91</td>
</tr>
<tr>
<td>Tofani, L.</td>
<td>389</td>
</tr>
<tr>
<td>Toh, B.H.</td>
<td>336</td>
</tr>
<tr>
<td>Tomáš, D.</td>
<td>635</td>
</tr>
<tr>
<td>Tormer, Y.</td>
<td>644, 848</td>
</tr>
<tr>
<td>Tomič Saremec, N.</td>
<td>240</td>
</tr>
<tr>
<td>Tomijenovic, L.</td>
<td>861</td>
</tr>
<tr>
<td>Tomijenovic, L.</td>
<td>6, 282</td>
</tr>
<tr>
<td>Tomšičů, M.</td>
<td>378</td>
</tr>
<tr>
<td>Tonello, M.</td>
<td>909</td>
</tr>
<tr>
<td>Tong, T.N.</td>
<td>110</td>
</tr>
<tr>
<td>Tonutti, E.</td>
<td>31, 211, 824</td>
</tr>
<tr>
<td>Tony, H.P.</td>
<td>735</td>
</tr>
<tr>
<td>Toricke, A.</td>
<td>287</td>
</tr>
<tr>
<td>Torres Rives, B.</td>
<td>585, 591</td>
</tr>
<tr>
<td>Torres-aguilar, H.</td>
<td>860</td>
</tr>
<tr>
<td>Torres-Ruiz, J.</td>
<td>970</td>
</tr>
<tr>
<td>Torres-Ruiz, J.J.</td>
<td>361</td>
</tr>
<tr>
<td>Torsten, M.</td>
<td>103</td>
</tr>
<tr>
<td>Torsten, W.</td>
<td>239, 318, 424</td>
</tr>
<tr>
<td>Toth, L.</td>
<td>1 062</td>
</tr>
<tr>
<td>Toubi, E.</td>
<td>345, 830, 834</td>
</tr>
<tr>
<td>Touli-Boukoffa, C.</td>
<td>701, 734</td>
</tr>
<tr>
<td>Touri, R.</td>
<td>734</td>
</tr>
<tr>
<td>Toupet, K.</td>
<td>204</td>
</tr>
<tr>
<td>Tovey, M.</td>
<td>493</td>
</tr>
<tr>
<td>Tozzoli, R.</td>
<td>892</td>
</tr>
<tr>
<td>Traggiai, E.</td>
<td>411</td>
</tr>
<tr>
<td>Traiš, A.</td>
<td>675</td>
</tr>
<tr>
<td>Trendelenburg, G.</td>
<td>303</td>
</tr>
<tr>
<td>Trenti, T.</td>
<td>431, 607, 828, 904, 984</td>
</tr>
<tr>
<td>Trezzi, B.</td>
<td>243, 909</td>
</tr>
<tr>
<td>Triggianese, P.</td>
<td>440</td>
</tr>
<tr>
<td>Trishina, I.</td>
<td>234</td>
</tr>
<tr>
<td>Trocmé, C.</td>
<td>150</td>
</tr>
<tr>
<td>Trojnar, E.</td>
<td>882</td>
</tr>
<tr>
<td>Trombetta, E.</td>
<td>126</td>
</tr>
<tr>
<td>Trouw, L.</td>
<td>145, 995</td>
</tr>
<tr>
<td>Truffault, F.</td>
<td>652</td>
</tr>
<tr>
<td>Truglia, S.</td>
<td>160, 454, 901</td>
</tr>
<tr>
<td>Trujilo-Murillo, K.</td>
<td>266</td>
</tr>
<tr>
<td>Trzonkowski, P.</td>
<td>371</td>
</tr>
<tr>
<td>Tsantikos, E.</td>
<td>629</td>
</tr>
<tr>
<td>Tsianakas, A.</td>
<td>446</td>
</tr>
<tr>
<td>Tsifetaki, N.</td>
<td>893, 912</td>
</tr>
<tr>
<td>Tsirogianni, A.</td>
<td>377</td>
</tr>
<tr>
<td>Tsokos, G.C.</td>
<td>346, 833</td>
</tr>
<tr>
<td>Tsujinaka, H.</td>
<td>1 009</td>
</tr>
<tr>
<td>Tsuneyama, K.</td>
<td>535</td>
</tr>
<tr>
<td>Tušiková, L.</td>
<td>60</td>
</tr>
<tr>
<td>Tumangelova-Yuzeir, K.</td>
<td>598</td>
</tr>
<tr>
<td>Tuna, K.</td>
<td>230</td>
</tr>
<tr>
<td>Tüngler, V.</td>
<td>138</td>
</tr>
<tr>
<td>Turiel, M.</td>
<td>58, 1 024</td>
</tr>
<tr>
<td>TURK, I.</td>
<td>388</td>
</tr>
<tr>
<td>Turner-Stokes, T.</td>
<td>450</td>
</tr>
<tr>
<td>Turpin, D.</td>
<td>92</td>
</tr>
<tr>
<td>Tzanova, T.</td>
<td>731</td>
</tr>
<tr>
<td>Tzioufas, A.</td>
<td>1 019, 1 023</td>
</tr>
<tr>
<td>U. Maggiore</td>
<td>451</td>
</tr>
<tr>
<td>Ubbila, G.</td>
<td>76</td>
</tr>
<tr>
<td>Ugur, E.</td>
<td>841</td>
</tr>
<tr>
<td>Ugurlu, S.</td>
<td>605</td>
</tr>
<tr>
<td>Uhlén, M.</td>
<td>302, 237</td>
</tr>
<tr>
<td>Uibo, O.</td>
<td>550</td>
</tr>
<tr>
<td>Uibo, R.</td>
<td>550</td>
</tr>
<tr>
<td>Ulrichts, P.</td>
<td>398</td>
</tr>
<tr>
<td>Um, J.H.</td>
<td>402</td>
</tr>
<tr>
<td>Unal, I.</td>
<td>388</td>
</tr>
<tr>
<td>Unger, L.</td>
<td>214</td>
</tr>
<tr>
<td>Ungerer, M.</td>
<td>526, 853</td>
</tr>
<tr>
<td>Uray, K.</td>
<td>882</td>
</tr>
<tr>
<td>Urazgildeva, S.</td>
<td>314</td>
</tr>
<tr>
<td>Urruticoechea, A.</td>
<td>36</td>
</tr>
<tr>
<td>Ütekhin, V.</td>
<td>891</td>
</tr>
<tr>
<td>Uyttenbroeck, W.</td>
<td>241</td>
</tr>
<tr>
<td>Uzonyi, B.</td>
<td>882</td>
</tr>
<tr>
<td>V. Grossi</td>
<td>216</td>
</tr>
<tr>
<td>Vadasz, Z.</td>
<td>175, 522</td>
</tr>
<tr>
<td>Vadim Jucaud</td>
<td>117</td>
</tr>
<tr>
<td>Vainer, S.</td>
<td>523</td>
</tr>
<tr>
<td>Vairo, D.</td>
<td>44</td>
</tr>
<tr>
<td>Valencia, J.</td>
<td>535</td>
</tr>
<tr>
<td>Valente, A.</td>
<td>906</td>
</tr>
<tr>
<td>Valentini, G.</td>
<td>694</td>
</tr>
<tr>
<td>Valentino, P.</td>
<td>725</td>
</tr>
</tbody>
</table>
Valenzise, M. 792
Valeri, C. 440
Valesini, G. 160, 317, 454, 641, 681, 887, 901, 975
van Beveren, N.J.M. 723
Van De Kerckhove, M. 928
van de Loo, F. 1 007
van den Berg, W. 161, 793
van den Berg, W.B. 412
van der Hulst, R. 968
van der Hulst, R.R. 194
van der Kraan, P. 161, 793
van der Maarel, S. 1 056
van der Meide, P. 269
van der Meide, W. 269
van der Pol, P. 312
van der Vuurst de Vries, R.M. 491, 492
van Es, H. 149
van Hauwermeiren, T. 777
van Hijum, S. 161
Van Hoovels, L. 125, 241, 255
van Houte, A.J. 603
van Langelaar, J. 491, 492
van Lith, H. 269
van Luijn, M.M. 491, 492
van Os, J. 723
van Paassen, P. 805
van Pettigravesteijn, E.D. 149
van Rosmalen, J. 995
van Vollenhoven, R. 29
Vandam, W. 67
Vande Keere, K. 125, 255
VandenBroucke, R. 397
Vandenbende, M. 279
Vandormael, P. 311, 427
Vanhoof, J. 373, 427
Vargas, A. 401
Varma, H. 727
Vasconcelos, C. 563, 688, 703, 750, 867
Vasina, L. 314
Vaslyev, V. 71
Vecchi, M. 916
Végh, E. 977
Végh, J. 560
Veglia, M. 328
Velikova, T. 598
velly, F. 791
Venkatesha, S. 1 008
Vento, S. 706, 709
Venturelli, B. 828
Vera-Lastra, O. 266
Vera-Lastra, O.L. 964
Verdugo, R. 76
Verfaillie, C. 241
Verheul, M.K. 145, 995
Verinaud, L. 403
Versari, A. 865
Verschuuren, P. 311
Verschuuren, J. 1 056
Versini, M. 960
Vettori, S. 694
Vezzosi, C. 828
Viallard, J.F. 791, 616
Viborg, K. 807
Vidarsson, G. 192
Vieira, A.R. 259
Vilches, D. 591
Villalobos Sánchez, L. 205
Villalta, D. 211, 826, 1 049
Villegas, E. 36
Villegas, J.A. 608
Villeret, B. 478
Villota-Eraso, C. 931
Vincent, T. 77
Vinci, C. 231
Virili, C. 835, 850
Visentini, M. 184, 767
Vishnevskaya-Dai, V. 601
Visona, A. 1 049
Vita, R. 852
Vitagliano, A. 698, 34
Vitetta, F. 607
Vittecoq, O. 182
Vittorio Penco 660
Vogeleere, P. 68
Vojdani, A. 620, 624, 626
Volkmuth, W. 89
Volkov, A. 157
Voll, R. 947
Vollbrandt, T. 88
vom Dahl, M. 303
Vormero, M. 641
von Darl, M. 147
von Herrath, M. 540, 543
von Mühlken, C. 123
von Pein, H.D. 885
von Toerne, C. 479
Vordenbaume, S. 147
Vordenbäumen, S. 430, 488, 756
Vorobjeva, N. 399
Vorobjova, T. 550
Vuiblet, V. 443
Vukasovic, I. 755
Wahl, D. 656, 665
Wahono, C.S. 46
Walker, R. 63, 67
Wallukat, G. 525
Wandinger, K.P. 303
Wang, A. 65
Wang, F.S. 619
Wang, H. 40
Wang, J. 55, 55
Wang, L. 619, 804
Wang, Q. 763
Wang, W. 40
Wang, Y. 41, 602
Wan-Uk, K. 364, 998
Ward, H. 289
Wardemann, H. 724
Wardowska, A. 371
Washburn, N. 113
Wasserfall, C. 567
Watad, A. 213, 637, 1 026
Waterboer, T. 302
Watts Soares, A. 392, 732
Webb, T. 896
Wei, M. 40
Wei, Q. 51
Weigold, F. 202
Weinmann-Menke, J. 580
Weinstein, E. 162
Weiss, R. 304, 885
Wen, L. 47
Wenke, N. 724
Wenzel, K. 525
Westman, K. 280
Weyd, H. 78
Wick, G. 1 028, 1 033
Wicks, I.P. 412
Wierenga-Wolf, A.F. 491, 492
Wiklund, F. 250
Wilkramanayake, T. 937
<table>
<thead>
<tr>
<th>Name</th>
<th>Page Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wilde, B.</td>
<td>838</td>
</tr>
<tr>
<td>Wildner, G.</td>
<td>228, 258, 479</td>
</tr>
<tr>
<td>Willekens, B.</td>
<td>721</td>
</tr>
<tr>
<td>Willis, R.</td>
<td>30, 35, 957</td>
</tr>
<tr>
<td>Wilmot, R.</td>
<td>64</td>
</tr>
<tr>
<td>Wingren, C.</td>
<td>802</td>
</tr>
<tr>
<td>Winter, H.</td>
<td>596</td>
</tr>
<tr>
<td>Wirlex, V.</td>
<td>363</td>
</tr>
<tr>
<td>Wirtz, D.</td>
<td>428, 780</td>
</tr>
<tr>
<td>Witte, T.</td>
<td>171, 335, 407</td>
</tr>
<tr>
<td>Witzke, O.</td>
<td>838</td>
</tr>
<tr>
<td>Wixler, V.</td>
<td>473</td>
</tr>
<tr>
<td>Wolf, J.</td>
<td>105</td>
</tr>
<tr>
<td>Wolfgang, G.</td>
<td>239</td>
</tr>
<tr>
<td>Wong, Y.Y.M.</td>
<td>777</td>
</tr>
<tr>
<td>Woo, S.B.</td>
<td>133</td>
</tr>
<tr>
<td>Wopereis, H.</td>
<td>161</td>
</tr>
<tr>
<td>Woszczyk, D.</td>
<td>744</td>
</tr>
<tr>
<td>Wozniewicz, B.</td>
<td>710</td>
</tr>
<tr>
<td>Wozniewicz, M.</td>
<td>710</td>
</tr>
<tr>
<td>Wu, G.</td>
<td>842</td>
</tr>
<tr>
<td>Wu, H.</td>
<td>185, 395</td>
</tr>
<tr>
<td>Xiaoh</td>
<td>40</td>
</tr>
<tr>
<td>Xiaofeng, Z.</td>
<td>994</td>
</tr>
<tr>
<td>Xiaojun, L.</td>
<td>994</td>
</tr>
<tr>
<td>Xiaoxue, Y.</td>
<td>404</td>
</tr>
<tr>
<td>Xie, Y.</td>
<td>55</td>
</tr>
<tr>
<td>Xu, J.</td>
<td>313, 323</td>
</tr>
<tr>
<td>Xu, X.</td>
<td>94</td>
</tr>
<tr>
<td>Yablecovitch, D.</td>
<td>630</td>
</tr>
<tr>
<td>Yada, T.</td>
<td>261</td>
</tr>
<tr>
<td>Yakovenko, A.</td>
<td>891</td>
</tr>
<tr>
<td>Yamamoto, K.</td>
<td>645, 944</td>
</tr>
<tr>
<td>Yamamoto, Y.</td>
<td>136</td>
</tr>
<tr>
<td>Yamauchi, A.</td>
<td>1 009</td>
</tr>
<tr>
<td>Yanagida, T.</td>
<td>45</td>
</tr>
<tr>
<td>Yanyan He, Y.H.</td>
<td>40</td>
</tr>
<tr>
<td>Yasuda, S.</td>
<td>356, 801</td>
</tr>
<tr>
<td>Yee, A.</td>
<td>995</td>
</tr>
<tr>
<td>Yenita, Y.</td>
<td>711</td>
</tr>
<tr>
<td>Yi, L.</td>
<td>899</td>
</tr>
<tr>
<td>Yilmaz, A.</td>
<td>230</td>
</tr>
<tr>
<td>Yirm, Y.R.</td>
<td>47</td>
</tr>
<tr>
<td>Ying, W.</td>
<td>414</td>
</tr>
<tr>
<td>Yoshimatsu, T.</td>
<td>136</td>
</tr>
<tr>
<td>Yoshimoto, K.</td>
<td>1 009</td>
</tr>
<tr>
<td>Yoshio, T.</td>
<td>45, 517</td>
</tr>
<tr>
<td>Youcef, Y.B.</td>
<td>387</td>
</tr>
<tr>
<td>Younou, P.</td>
<td>25, 181, 734</td>
</tr>
<tr>
<td>Younes, S.</td>
<td>235</td>
</tr>
<tr>
<td>Young, H.</td>
<td>535, 748</td>
</tr>
<tr>
<td>Yrlid, L.</td>
<td>413</td>
</tr>
<tr>
<td>Yu, X.</td>
<td>111, 418, 1 063</td>
</tr>
<tr>
<td>Yu, Y.</td>
<td>441</td>
</tr>
<tr>
<td>Yue, X.</td>
<td>1 063</td>
</tr>
<tr>
<td>Yuzhang, W.</td>
<td>414</td>
</tr>
<tr>
<td>Zabel, A.</td>
<td>551</td>
</tr>
<tr>
<td>Zahuczky, G.</td>
<td>977</td>
</tr>
<tr>
<td>Zaka Pratama, M.</td>
<td>1 010</td>
</tr>
<tr>
<td>Zaman, A.</td>
<td>539</td>
</tr>
<tr>
<td>Zampino, G.</td>
<td>382</td>
</tr>
<tr>
<td>Zandian, A.</td>
<td>237, 250, 302</td>
</tr>
<tr>
<td>Zandman-Goddard, G.</td>
<td>156, 432</td>
</tr>
<tr>
<td>Zanetti, V.C.</td>
<td>316</td>
</tr>
<tr>
<td>Zani, G.</td>
<td>44</td>
</tr>
<tr>
<td>Zanola, A.</td>
<td>233, 438, 863</td>
</tr>
<tr>
<td>Zbigniew, Z.</td>
<td>704</td>
</tr>
<tr>
<td>Zegers, I.</td>
<td>504</td>
</tr>
<tr>
<td>Zen, M.</td>
<td>233, 438, 708</td>
</tr>
<tr>
<td>Zeng, X.</td>
<td>667, 670</td>
</tr>
<tr>
<td>Zeng, X.F.</td>
<td>707</td>
</tr>
<tr>
<td>Zeng, Y.</td>
<td>313, 323, 329</td>
</tr>
<tr>
<td>Zeni, S.</td>
<td>203</td>
</tr>
<tr>
<td>Zenobia, C.</td>
<td>704</td>
</tr>
<tr>
<td>Zenone, T.</td>
<td>281</td>
</tr>
<tr>
<td>Zhang, H.H.</td>
<td>707</td>
</tr>
<tr>
<td>Zhang, K.</td>
<td>619</td>
</tr>
<tr>
<td>Zhang, M.</td>
<td>41, 752</td>
</tr>
<tr>
<td>Zhang, T.</td>
<td>313, 323</td>
</tr>
<tr>
<td>Zhang, X.</td>
<td>51</td>
</tr>
<tr>
<td>Zhang, Y.</td>
<td>415</td>
</tr>
<tr>
<td>Zhang, Z.</td>
<td>441</td>
</tr>
<tr>
<td>Zhao, D.</td>
<td>651</td>
</tr>
<tr>
<td>Zhao, W.</td>
<td>1 063</td>
</tr>
<tr>
<td>Zhao, Z.</td>
<td>55</td>
</tr>
<tr>
<td>Zhitan, C.</td>
<td>994</td>
</tr>
<tr>
<td>Zhou, S.</td>
<td>63</td>
</tr>
<tr>
<td>Zhu, J.</td>
<td>838</td>
</tr>
<tr>
<td>Zielinski, M.</td>
<td>371</td>
</tr>
<tr>
<td>Ziemssen, T.</td>
<td>611</td>
</tr>
<tr>
<td>Žigon, P.</td>
<td>378</td>
</tr>
<tr>
<td>Zillikens, D.</td>
<td>268</td>
</tr>
<tr>
<td>Zillikens, K.</td>
<td>80, 81, 480, 935, 1 005</td>
</tr>
<tr>
<td>Zimetti, F.</td>
<td>1 064</td>
</tr>
<tr>
<td>Zimmermann, N.</td>
<td>884</td>
</tr>
<tr>
<td>Zivančević, S.</td>
<td>612</td>
</tr>
<tr>
<td>Zong, S.</td>
<td>723</td>
</tr>
<tr>
<td>Zorzella-Pezavento, S.F.</td>
<td>403, 864</td>
</tr>
<tr>
<td>Zorzella-Pezavento, S.F.G.</td>
<td>195</td>
</tr>
<tr>
<td>Zota, A.</td>
<td>254</td>
</tr>
<tr>
<td>Zotos, N.</td>
<td>893, 912</td>
</tr>
<tr>
<td>Zuber, A.</td>
<td>126</td>
</tr>
<tr>
<td>Zubkov, A.</td>
<td>894</td>
</tr>
<tr>
<td>Zucht, H.D.</td>
<td>147, 428, 430, 488, 756, 780</td>
</tr>
<tr>
<td>Zuercher, A.</td>
<td>109, 784</td>
</tr>
<tr>
<td>Zvartsev, R.</td>
<td>573</td>
</tr>
</tbody>
</table>
ACKNOWLEDGEMENTS & INDUSTRY SUPPORT
The international forum for high-quality, innovative research in allergy and immunology

International Archives of Allergy and Immunology welcomes your contribution ...

International Archives of Allergy and Immunology provides a forum for basic and clinical research in modern molecular and cellular allergology and immunology. Appearing monthly, the journal publishes original work in the fields of allergy, immunopathology, immunogenetics, immunopharmacology, immunoendocrinology, tumor immunology, mucosal immunity, transplantation and immunology of infectious and connective tissue diseases. In addition to original papers it features short communications, reviews, minireviews, commentaries and opinions. Supported by online submission and peer-review systems, a team of internationally renowned and committed editors guarantees a fair review process, high scientific quality and fast dissemination of significant and novel work.

Benefits for Authors
- Cost-effective publishing (no submission fee and no page charges for papers of 5 or fewer printed pages)
- Free online color figures
- Rapid and fair peer-review process
- Full listing in all relevant bibliographic databases (PubMed/MEDLINE, Web of Science)
- Impact Factor: 2.673
- Author’s choice for open access publishing

Find out more: www.karger.com/iaa
ACKNOWLEDGEMENTS

AWARDS

AESKU AWARD FOR A LIFETIME CONTRIBUTION TO AUTOIMMUNITY 2016

MOSAIC OF AUTOIMMUNITY AWARD (MAI) 2016

DIAMOND SUPPORTERS

PLATINUM SUPPORTERS
INDUSTRY SYMPOSIA

WEDNESDAY, APRIL 6

HALL MP3&4

13:30-15:30

THE INTERPLAY OF T-CELLS AND B-CELLS IN AUTOIMMUNE DISEASE

Sponsored by Bristol Myers Squibb

Chairperson: Piercarlo Sarzi Puttini, Italy

13:30-13:35 Introduction
Piercarlo Sarzi Puttini, Italy

13:35-14:05 T-cells, B-cells and Autoantibodies in Autoimmune Disease
Jens Thiel, Germany

14:05-14:35 Autoantibodies and Joint Destruction in Autoimmune Disease
Georg Schett, Germany

14:35-15:05 Novel Therapy Strategies in the Treatment of Autoimmune Disease
Roberto Caporali, Italy

15:05-15:30 Question and Answer Session, Wrap up and Closing
Piercarlo Sarzi Puttini, Italy
Jens Thiel, Germany
Georg Schett, Germany
Roberto Caporali, Italy
HALL 4  
15:30-17:30

FOR THE ACHIEVEMENT OF OPTIMAL EFFECTIVENESS BY NOVEL TREATMENT STRATEGY WITH IL-6 SIGNALING TARGETED THERAPY IN RA

Sponsored by Chugai

Chairpersons: Takao Koike, Kazuhiko Yamamoto, Japan

15:30-15:35 Opening remarks: overview of Tocilizumab
Takao Koike, Japan

15:35-16:00 Cumulative safety data for Tocilizumab
Tatsuya Atsumi, Japan

16:00-16:25 Clinical, structural, and functional efficacy of Tocilizumab
Yoshiya Tanaka, Japan

16:25-16:55 The importance of IL-6 signaling inhibition from the translational research
Tsutomu Takeuchi, Japan

16:55-17:25 The relationship between bone loss and inflammatory cytokine in RA
Georg Schett, Germany

17:25-17:30 Closing remarks: future treatment of IL-6 signal inhibition
Kazuhiko Yamamoto, Japan
THURSDAY, APRIL 7

HALL MP3&4 12:30-14:00

A NEW AND INNOVATIVE PLATFORM IN IMMUNODIAGNOSTICS

Sponsored by Theradiag

Chairperson: M. Philippe Lestage, France

12:30-12:45  The trend for serological diagnosis of rheumatic diseases in China
Xiaofeng Zeng, China

12:45-12:50  Q & A

Jieruo Gu, China

13:15-13:20  Q & A

Charles Lee, China

13:45-13:50  Q & A

FRIDAY, APRIL 8

HALL MP3&4 12:30-14:00

LAB AND HEALTH ECONOMICS OF ANA SCREENING

Sponsored by Inova Diagnostics

Chairpersons: Michael Mahler, USA
Eckart Mummert, USA

12:30-13:10  An approach to prevention of SLE: economics and diagnostic testing
Marvin Fritzler, Canada

13:15-13:35  Anti-DFS70 Antibodies: A useful biomarker in a pediatric case with suspected autoimmune disease
Martina Fabris, Italy

13:40-14:00  Immunoadsorption of DFS70 antibodies during ANA screening reduces “false positive” results
Nicola Bizzaro, Italy
SATURDAY, APRIL 9

HALL MP3&4 12:30-14:00

IMMUNOGLOBULIN THERAPY IN AUTOIMMUNE DISEASES:
WHAT DO WE EXPECT?

Sponsored by LFB

Chairpersons: Abdulgabar Salama, Germany
Francesco Rodeghiero, Italy

12:30-12:55  Quality and Clinical Safety of Immunoglobulin Therapies: Regulatory viewpoint
Jacqueline Kerr*, Germany

13:00-13:25  Are all human intravenous immunoglobulin (IVIg) the same?
- How can the characteristics of IVIg improve tolerability in patients?
Srini Kaveri, INSERM (Paris) / CNRS (India)
- New insights in IVIg development process
Philippe Paolantonacci, LFB, France

13:30-13:55  Management of ITP: are we comfortable with our knowledge?
Francesco Rodeghiero, Italy

* Important: Dr Kerr is not sponsored by LFB and has no disclosures with the pharmaceutical company.
# LIST OF EXHIBITORS

<table>
<thead>
<tr>
<th>Name</th>
<th>Booth</th>
</tr>
</thead>
<tbody>
<tr>
<td>A. Menarini Diagnostics</td>
<td>5</td>
</tr>
<tr>
<td>AESKU. Diagnostics GmbH &amp; Co. KG</td>
<td>10</td>
</tr>
<tr>
<td>Association for the Advancement of Immunologic Diagnostics</td>
<td>Table top</td>
</tr>
<tr>
<td>Autoimmunity Network</td>
<td>38</td>
</tr>
<tr>
<td>Beckman Coulter</td>
<td>27</td>
</tr>
<tr>
<td>Bio-Rad Laboratories GmbH</td>
<td>4</td>
</tr>
<tr>
<td>Bio-Techne</td>
<td>24</td>
</tr>
<tr>
<td>Bristol-Myers Squibb GmbH</td>
<td>9</td>
</tr>
<tr>
<td>BÜHLMANN Laboratories AG</td>
<td>33</td>
</tr>
<tr>
<td>CTL Europe GmbH</td>
<td>23</td>
</tr>
<tr>
<td>DEVEXI</td>
<td>36</td>
</tr>
<tr>
<td>DiaSorin S.p.A.</td>
<td>7</td>
</tr>
<tr>
<td>Elsevier B.V.</td>
<td>34</td>
</tr>
<tr>
<td>Euro Diagnostica AB</td>
<td>32</td>
</tr>
<tr>
<td>EUROIMMUN AG</td>
<td>3</td>
</tr>
<tr>
<td>Eurospital S.p.A.</td>
<td>30</td>
</tr>
<tr>
<td>GRIFOLS</td>
<td>12</td>
</tr>
<tr>
<td>HUMAN Gesellschaft für Biochemica und Diagnostica mbH</td>
<td>21</td>
</tr>
<tr>
<td>IBA GmbH</td>
<td>25</td>
</tr>
<tr>
<td>Illumina</td>
<td>29</td>
</tr>
<tr>
<td>Immco Diagnostics, A Trinity Biotech Company</td>
<td>19</td>
</tr>
<tr>
<td>Immunodiagnostic Systems</td>
<td>22A</td>
</tr>
<tr>
<td>Inova Diagnostics</td>
<td>1</td>
</tr>
<tr>
<td>Invitalis GmbH</td>
<td>07A</td>
</tr>
<tr>
<td>LFB BIOMEDICAMENTSL</td>
<td>11</td>
</tr>
<tr>
<td>Lupus 2016</td>
<td>35</td>
</tr>
<tr>
<td>MEDIPAN GMBH</td>
<td>18</td>
</tr>
<tr>
<td>ORGENTEC Diagnostika GmbH</td>
<td>17</td>
</tr>
<tr>
<td>PEPperPRINT GmbH</td>
<td>22</td>
</tr>
<tr>
<td>Sensovation AG</td>
<td>31</td>
</tr>
<tr>
<td>Theradiag</td>
<td>14</td>
</tr>
<tr>
<td>Thermo Fisher Scientific</td>
<td>6</td>
</tr>
<tr>
<td>Unomedical a Convatec Company</td>
<td>28</td>
</tr>
<tr>
<td>Wisepress Medical Bookshop</td>
<td>37</td>
</tr>
</tbody>
</table>
Rooted in tradition, thriving by innovation

Trusted autoimmune products that evolve with your laboratory

Since pioneering autoimmune diagnostics with the introduction of the Kallestad® HEP-2 IFA slides, Bio-Rad Laboratories has been delivering high quality products to clinical laboratories worldwide. This commitment to quality has been at the root of all of our innovations over the years – from the reliable PhD™ lx System for EIA/IFA processing, to the BioPlex® 2200 System, the first and only fully automated, random access, multiplex platform for the detection of autoantibodies.

For more info, contact your local Bio-Rad office | 1-800-224-6723 | www.bio-rad.com/diagnostics
Rates for 2016 calendar year
USA/INTERNATIONAL

<table>
<thead>
<tr>
<th>INDIVIDUALS:</th>
<th>Print + Online</th>
<th>Online Only</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>$350 US</td>
<td>$285 US</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>INSTITUTIONAL:</th>
<th>On request</th>
<th>On request</th>
</tr>
</thead>
<tbody>
<tr>
<td>- Multisite *</td>
<td>$1025 US</td>
<td>$975 US</td>
</tr>
<tr>
<td>- Multisite (IP ranges)</td>
<td>$550 US</td>
<td>$500 US</td>
</tr>
<tr>
<td>- Basic (up to 4 users)</td>
<td>$215 US</td>
<td>$150 US+</td>
</tr>
<tr>
<td>TRAINEES*</td>
<td>$100 US</td>
<td></td>
</tr>
<tr>
<td>Airmail (ADD)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

For terms of access visit jrheum.org
*Supervisor certification required below.

NAME OF SUPERVISOR: ____________________________
SUPERVISOR SIGNATURE: __________________________
SUPERVISOR TELEPHONE: __________________________

Mail completed form to: The Journal of Rheumatology
365 Bloor Street East, Suite 901
Toronto, Ontario Canada M4W 3L4
Phone: (416) 967-5155
Fax: (416) 967-7556
E-mail: subscriptions@jrheum.com

Please enter my 2016 subscription to The Journal of Rheumatology

Name (please print) ____________________________

Address

City ____________________________ State/Province ____________________________
Country ____________________________ Zip/Postal Code ____________________________

Contact E-mail _______________

Amount Enclosed $ _______________
Bill Me

Telephone Number ____________________________ Fax Number ____________________________

VISA/MasterCard Number ____________________________ Expiration Date ____________________________

Signature ____________________________ CVV ____________________________

All subscriptions are for the calendar year. Renewals for print subscriptions received after May 31, 2016 will be charged an additional $5 per back issue. Back issues: 3 years including current year are available if in stock. Single copies are available at $30 each. Claims: US 2 months, elsewhere 4 months from issue date, e.g., March 1 and May 1, respectively, for the January issue. PRIVACY POLICY: For details of our privacy policy, visit our website at www.jrheum.org.
Baxalta Incorporated is a global biopharmaceutical leader developing therapies for orphan diseases and underserved conditions in hematology, oncology and immunology. Baxalta is driven by passion to make a meaningful impact for patients. At Baxalta, your life is our inspiration — that’s the promise of the Baxalta spark.

Baxalta.com
SUPPORTER & EXHIBITOR PROFILES

10TH EUROPEAN LUPUS MEETING
Via Ripamonti 129
Milan, 20141, Italy
Booth #: 35
www.lupus2016.org
The 10th European Lupus Meeting will be held in Venice on October 5-8, 2016. The Congress Chairpersons are Prof. Andrea Doria and Prof. Angela Tincani. The meeting is intended to present the latest clinical and experimental studies in the field of systemic lupus erythematosus. The scientific program will include lectures, symposia, abstract and poster sessions in order to give the chance to all the participants to present their personal contribution, pointing to knowledge growth and sharing.

A.MENARINI DIAGNOSTICS
Via Sette Santi 3
Firenze, 50131, Italy
Booth #: 05
www.menarinidiagnostics.com
For the European healthcare community we are a dynamic and reliable partner providing diagnostics solutions thanks to our close relation with the market, and therefore, knowledge of its needs. With experience, flexibility, technology and reliability, our aim is to make diagnostics management easier, more effective and result cost efficiency. With our network of European affiliates and world wide partners, we offer innovative diagnostics tools for clinical laboratories as well as patient glucose self testing. Our major business lines are autoimmunity, clinical chemistry, glycated haemoglobin, immunohistochemistry, self monitoring Blood Glucose and urine and sediment analysis.
ABBVIE DEUTSCHLAND GMBH & CO. KG

Mainzer Str. 81
Wiesbaden, 65189, Germany
abbvie.com

About AbbVie
AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world’s most complex and serious diseases. Together with its wholly-owned subsidiary, Pharmacyclics, AbbVie employs more than 28,000 people worldwide and markets medicines in more than 170 countries. AbbVie is represented in Germany with headquarters in Wiesbaden and a research and production site in Ludwigshafen. In total, AbbVie Deutschland has about 2600 employees. For further information on the company and its people, portfolio and commitments, please visit www.abbvie.com. Follow @abbvie on Twitter or view careers on our Facebook or LinkedIn page.

AESKU. DIAGNOSTICS GMBH & CO. KG

Mikroforum Ring 2
Wendelsheim, 55234, Germany
Booth #: 10
www.aesku.com

AESKU.DIAGNOSTICS is a research-focused manufacturer of innovative and efficient products and services for the early detection, diagnosis and prognosis of hemostasis, autoimmune & infectious diseases. Having launched over 150 different products together in more than 80 countries worldwide, AESKU® simplifies the lab routine with accurate, robust and reliable tests and lab automation systems. AESKU® offers unique diagnostic options: faster test systems, designed to improve clinical outcome, for the benefit of both patients and treating physicians, together with efficient systems for lab automation. AESKU® provides a solution for the three most used technologies in the diagnosis of autoimmune diseases.
AMERICAN AUTOIMMUNE RELATED DISEASES ASSOCIATION
22100 Gratiot Ave
Eastpointe, 48021, USA
www.aarda.org
The American Autoimmune Related Diseases Association is dedicated to the eradication of autoimmune diseases and the alleviation of suffering and the socioeconomic impact of autoimmunity through fostering and facilitating collaboration in the areas of education, public awareness, research, and patient services in an effective, ethical and efficient manner. AARDA is the only national nonprofit health agency dedicated to bringing a national focus to autoimmunity, the major cause of serious chronic diseases. Approximately 50 million Americans, 20 percent of the population or one in five people, suffer from autoimmune diseases.

AMORPHICAL LTD.
11 Haharash St.
Nes Ziona, 7403118, Israe
www.amorphical.com
Amorphical is a pioneering Israeli pharmaceutical company developing and manufacturing a proprietary synthetic form of calcium, Amorphous Calcium Carbonate (ACC). Our ACC-based therapeutics are in clinical development for the treatment of osteoporosis, hypoparathyroidism and a wide range of other calcium-related diseases. This novel technology is protected by several approved and pending patents. Inspired by the natural ability of the Australian Blue Crayfish to efficiently mobilize its calcium stores in order to shed and regrow its entire exoskeleton in only three days, Amorphical scientists have shown ACC’s safety and efficacy in preclinical studies. Moreover, the company has demonstrated ACC’s high bioavailability-twice that of conventional crystalline calcium.

AUTOIMMUNITY RESEARCH FOUNDATION
3423 Hill Canyon Ave
Thousand Oaks, 91360, USA
AutoimmunityResearch.org
The Autoimmunity Research Foundation is a 501(c)3 charity whose educational and research efforts are focused on helping Health Professionals, and the public, understand the cause of Th1 chronic inflammatory disease. Many chronic and autoimmune conditions, including Fibromyalgia (FM), Rheumatoid Arthritis (RA), Multiple Sclerosis (MS), Chronic Fatigue Syndrome (CFS/ME), Post Treatment Lyme Disease Syndrome (PTLDS), Sarcoidosis, Depression, and Bipolar Disorder, are now succumbing to therapy based on our molecular description of inflammatory disease biology.
BAXALTA ITALY SRL
Piazzale dell’Industria, 20
Roma, 00144, Italy
www.baxalta.it
Baxalta Incorporated (NYSE: BXLT) is a $6 billion global biopharmaceutical leader developing, manufacturing and commercializing therapies for orphan diseases and underserved conditions in hematology, oncology and immunology. Driven by passion to make a meaningful impact on patients’ lives, Baxalta’s broad and diverse pipeline includes biologics with novel mechanisms and advanced technology platforms such as gene therapy. The Baxalta Global Innovation and R&D Center is located in Cambridge, Massachusetts. Launched in 2015 following separation from Baxter International, Baxalta’s heritage in biopharmaceuticals spans decades. Baxalta’s therapies are available in more than 100 countries and it has advanced biological manufacturing operations across 12 facilities, including state-of-the-art recombinant production and plasma fractionation. Headquartered in Northern Illinois, Baxalta employs 16,000 employees worldwide.

BECKMAN COULTER
22 rue Juste-Oliver
Nyon, 1260, Switzerland
Booth #: 27
www.beckman.com
Beckman Coulter Life Sciences markets instrument systems, reagents and services that enable new discoveries in biology-based research and development. Our products are used in the forefront of genomics and proteomics. We are market leaders in centrifugation and flow cytometry. We have long been at the vanguard in capillary electrophoresis and laboratory automation and today our systems are some of the most advanced available. Beckman Coulter systems serve life science researchers in academic and commercial laboratories throughout the world and help advance the study of complex biological problems, including the causes of disease and the development of potential new drugs and therapies. For more information please visit www.beckmancoulter.com
BIOMED CENTRAL

236 Gray’s Inn Road
London, WC1X 8HB, UK
www.biomedcentral.com

BioMed Central publishes over 290 peer-reviewed, open access journals spanning all areas of biology, medicine and health, including not only broad interest titles such as BMC Genomics but also high impact journals such as Genome Biology and Genome Medicine.

BIO-RAD LABORATORIES GMBH

Heidemannstrasse 164
München, D-80939, Germany
Booth #: 04
www.bio-rad.com

Bio-Rad Laboratories is a world leader in providing a broad range of products for the life science research and diagnostic markets. In our Clinical Diagnostics Group, we build the industry leading solutions for diabetes, blood virus, autoimmune and microbiology testing alongside immunohematology instruments, QC systems and much more. With over 300 clinical diagnostic tests for the in vitro test market, we are renowned worldwide for our commitment to quality and customer service in hospital, reference and transfusion labs, universities, major research institutions, biotechnology and pharmaceutical companies. Visit us and experience first-hand how we are empowering labs to make informed decisions.

BIO-TECHNE

19 Barton Lane
Abingdon Science Park, Abingdon, OX14 3NB, UK
Booth #: 24
www.bio-techne.com

Bio-Techne brings together some of the most referenced brands in life science - R&D Systems, Novus Biologicals, Tocris Bioscience, and ProteinSimple providing innovative, high-quality research tools, including: Bioactive proteins – R&D Systems premiere bioactive proteins Application-qualified Antibodies – a diverse and extensive analyte selection from Novus and R&D Systems Immunoassays – Legendary R&D Systems Quantikine ELISAs, our huge selection of Luminex Assays and cost effective Proteome Profiler Arrays. High quality small molecules – a unique collection of over 3,500 Tocris reagents. Together we are Bio-Techne. Find out how we can be your partner and help you attain your research goals by visiting our stand.
BRISTOL-MYERS SQUIBB GMBH
Arnulfstr. 29
Munich, 80636, Germany
Booth #: 09
www.bms.com
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information, please visit www.bms.com or follow us on Twitter at twitter.com/bmsnews.

BÜHLMANN LABORATORIES AG
Baselstrasse 55
Schönenbuch, 4124, Switzerland
Booth #: 33
www.buhlmannlabs.ch
BÜHLMANN is offering the broadest calprotectin product range with the BÜHLMANN fCAL® ELISA, BÜHLMANN fCAL® turbo and the quantitative Quantum Blue® fCAL rapid test. Quantum Blue® Infliximab trough level rapid test is our first therapeutic drug monitoring test. BÜHLMANN has launched its newest innovation, the IBDoc® Calprotectin Home Testing Solution, allowing the patient to test calprotectin levels at home using a smart phone. Not only does BÜHLMANN stand for calprotectin, but also for a selection of unique, high-quality assays for clinical routine use such as the BÜHLMANN GanglioCombi™ products, the only screening ELISAs for anti-Ganglioside testing.

CHUGAI PHARMACEUTICAL CO., LTD.
1-1 Nihonbashi-Muromachi 2-Chome Chuo-ku
Tokyo, 103-8324, Japan
www.chugai-pharm.co.jp/english/
Chugai Pharmaceutical is one of Japan’s leading research-based pharmaceutical companies with strengths in biotechnology products. Chugai, based in Tokyo, specializes in prescription pharmaceuticals and is listed on the 1st section of the Tokyo Stock Exchange. As an important member of the Roche Group, Chugai is actively involved in R&D activities in Japan and abroad. Specifically, Chugai is working to develop innovative products which may satisfy the unmet medical needs. The consolidated revenue in 2014 of Chugai totaled 461.1 billion yen and the operating income was 77.3 billion yen (IFRS Core basis).
The Children’s Medical Safety Research Institute is a sponsor of the International Congress on Autoimmunity and a nonprofit organization dedicated to funding independent research into the causes of autoimmune diseases and to promoting awareness of scientifically validated and published findings.

CSL Behring is a leader in the plasma protein therapeutics industry. Committed to saving lives and improving the quality of life for people with rare and serious diseases, the company manufactures and markets a range of plasma-derived and recombinant therapies worldwide. CSL Behring therapies are used around the world to treat coagulation disorders including hemophilia and von Willebrand disease, primary immune deficiencies, hereditary angioedema and inherited respiratory disease, and neurological disorders in certain markets. The company’s products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic disease of the newborn. CSL Behring operates one of the world’s largest plasma collection networks, CSL Plasma. CSL Behring is a global biopharmaceutical company and a member of the CSL Group of companies. The parent company, CSL Limited (ASX:CSL), is headquartered in Melbourne, Australia. For more information, visit www.cslbehring.com.

CTL is the only company that specializes on GLP compliant high throughput ELISPOT analysis for monitoring T cell immunity in clinical trials (CRO). CTL is the leading manufacturer of ELISPOT analyzers, reagents required for ELISPOT standardization, including reference PBMCs, ImmunoSpot® ELISPOT T and B Cell Kits and Serum-Free-Media.
CYREX LABORATORIES, LLC
2602 S. 24th Street
Phoenix, AZ 85034, USA
www.joincyrex.com
Cyrex is a clinical immunology laboratory specializing in functional immunology and autoimmunity. Cyrex offers multi-tissue antibody testing for the early detection and monitoring of today’s complex autoimmune conditions. Cyrex develops innovative testing arrays through continuous collaboration with leading experts in medical research and clinical practice. Cyrex technology is built on four pillars of excellence, including the antigen purification system, optimized antigen concentration, antigen-specific validation and parallel testing technology. Cyrex is based in Phoenix, Arizona and is a CLIA Licensed laboratory.

DEVEXI
3201 Jermantown Road
Fairfax, 22030, USA
Booth #: 36
www.devexi.com
DEVEXI is a powerful, sophisticated yet intuitive health research data platform linking medical and dental data to enable researchers to connect the dots between diagnoses, treatments, prescribed drugs, exposures and short and long-term health outcomes – for groundbreaking, longitudinal studies never before possible. DEVEXI will help health and medical researchers, universities, teaching hospitals, insurance payers, government health agencies and pharmaceutical companies to improve quality of health care delivery, identify best practices and increase successful, cost-effective outcomes.

DIASORIN S.P.A.
Via Crescentino, snc
Saluggia (VC), 13040, Italy
Booth #: 07
www.diasorin.com
DiaSorin - The Diagnostic Specialist DiaSorin is a global leader in the field of biotechnologies, developing, producing and marketing reagent kits for in vitro diagnostics worldwide for over 40 years. DiaSorin has recently introduced new molecular offer entering the markets of nucleic acid isolation and cell separation. Its line of products used by diagnostic laboratories can meet the needs of the following clinical areas: infectious diseases, cardiac markers, bone metabolism, hepatitis and retrovirus, oncology and endocrinology. Today DiaSorin can offer an assay menu that is unique for its width and presence of specialty tests which identify DiaSorin as” the” in vitro diagnostics specialist.
ELSEVIER B.V.
Radarweg 29
Amsterdam, 1043NX, The Netherlands
Booth #: 34
www.elsevier.com
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals. We publish over 2,500 journals, including Autoimmunity Reviews, Journal of Autoimmunity and a prestigious collection of immunology journals, The Lancet and Cell, and more than 33,000 book titles. Visit elsevier.com for more information.

EURO DIAGNOSTICA
Lundavägen 151
Malmö, 202 11, Sweden
Booth #: 32
www.eurodiagnostica.com
Euro Diagnostica’s goal is to constantly develop solutions to aid clinicians in diagnosis, prognosis, monitoring and treatment of autoimmune and related diseases. Due to our flexibility as a complete, cross-functional organization, we are an optimal assay partner throughout the drug development process, beginning from the exploratory phase to the clinical trial stage and beyond. Our offerings include: of-the-shelf kits, custom assay development and custom manufacturing of ELISA and RIA kits, bioanalytical and laboratory services by our in-house laboratory Wieslab, and iLite™ cell lines for assessment of drug potency, i.e. drug activity, and neutralizing antibodies (NAbs).

EUROIMMUN AG
Seekamp 31
Luebeck, 23560, Germany
Booth #: 03
www.euroimmun.de
EUROIMMUN is an international provider of medical laboratory products with a strong focus on autoimmune diagnostics. The company’s portfolio includes indirect immunofluorescence, ELISA, immunoblot and radioimmunoassay test systems for the serological detection of hundreds of different autoantibody biomarkers. Specialised DNA microarrays allow determination of genetic risk factors, for example in coeliac disease or ankylosing spondylitis. State-of-the-art instruments and software provide efficient automation of analyses. The EUROPattern system, in particular, automates immunofluorescence microscopy including image interpretation, while the EUROBlotOne device allows complete walkaway processing of multiplex immunoblots. EUROIMMUN’s autoimmune diagnostics range complements its products for infection diagnostics, allergology and molecular diagnostics.
EUROSPITAL S.P.A.
Via Flavia 122
Trieste, 34147, Italy
Booth #: 30
www.eurospital.com
Eurospital aims at being No. 1 in the specific markets where it operates in order to give its customers with the highest quality systems. Eurospital focuses its activities in specific sectors such as in vitro diagnosis of Autoimmune Diseases, Coeliac Disease and IBD. To succeed Eurospital has to be able to renew itself and progress continuously in time and to set for itself increasingly ambitious goals. At the congress “Autoimmunity 2016” in Leipzig, Eurospital will launch the ”ERA Eurospital Random Access” chemiluminescence system which represents the most advanced and complete diagnostic system for autoimmune disorders.

FONDAZIONE AREA
Via Tavoleria 28
Pisa, 56100, Italy
www.fondazionearea.it
Foundation Area purposes are: -Supporting research, particularly about systemic and thyroid autoimmune diseases and thyroid cancer (Prof. Antonelli A, Prof. Miccoli P), in concert with public and private Italian and foreign institutions. -Establish links between industries and those of research, particularly to promote the activities of young scientists and the inclusions in operating domestic and international economic environments. -Cultivating relationships with the European Union to enhance the role of science and technology studies, and knowledge of funding opportunities for research and training. -Encourage initiatives to promote cultural awareness of the mutual benefits of better relations between science and society.

GFID E.V. (ASSOCIATION FOR THE ADVANCEMENT OF IMMUNOLOGIC DIAGNOSTICS)
Wasastraße 14
Dresden, 01219, Germany
www.gfid-ev.de
On behalf of the Organizing Committee we have the great pleasure to hereby announce the 13th Dresden Symposium on Autoantibodies taking place from September 27 to September 30, 2017. The aim of the Symposium is to bring together clinicians and scientists specializing in “autoimmunology” to exchange academic information and to present and discuss the results of basic and applied research on autoantigens, autoantibodies and autoimmunity. Main Subjects: Autoantibodies in systemic and organ specific autoimmune diseases (induction, pathology, clinical relevance), Novel Autoantibodies of pathogenic, diagnostic and predictive relevance, Autoimmune diagnostics: Methodical aspects and diagnostic strategies, Harmonization, Standardization Chairman: Karsten Conrad, Germany
Grifols is a global healthcare company whose mission is to improve the health and wellbeing of people around the world. We accomplish this mission by producing life-saving protein therapies for patients and by providing hospitals, pharmacies and healthcare professionals with the tools they need to deliver expert medical care. We have three primary divisions -- Bioscience, Diagnostic and Hospital -- which develop, produce and market our innovative products and services to medical professionals in more than 90 countries around the world. The Diagnostic division supplies clinical analysis and laboratory testing tools to labs, hospitals and blood banks worldwide. Our Diagnostic division produces analyzers, reagents and instrumentation to provide accurate and reliable test results for specialists in the fields of immunohematology, hemostasis and specialty tests including autoimmunity tests, Therapeutic Drug Monitoring tests and Infectious Diseases assay.

Human diagnostics worldwide  Discover HUMAN! Today one of the few global players in the in vitro diagnostics industry, maintaining what is perhaps the broadest distribution and service & support network in the world. Here in Leipzig discover one of the broadest selections of innovative and aligned LIA solutions for differential diagnosis in autoimmune diagnostics. To Discover HUMAN online, please visit: www.human.de

IBA GmbH offers you a new way of cell selection from whole blood for analytical and diagnostic purposes! The T-CATCH- technology is based on an affinity chromatography using fab fragments to isolate specific target cells without magnetic beads. The automatic device FABian® can select CD3, CD4, CD8 (T-cells), CD81 (PBMCs), CD19 (B-cells) and CD14 (Monocytes) cells. Moreover, we continuously develop different fab fragments for specific selections and customized solutions.
ILLUMINA
5200 Illumina Way,
San Diego, 92122, USA
Booth #: 29
www.illumina.com
Illumina is a leading developer, manufacturer, and marketer of life science tools and integrated systems for large-scale analysis of genetic variation and function. These systems are enabling studies that were not even imaginable just a few years ago, and moving us closer to the realization of personalized medicine. With rapid advances in technology taking place, it is mission-critical to offer solutions that are not only innovative, but flexible and scalable, with industry-leading support and service. We strive to meet this challenge by placing a high value on collaborative interactions, rapid delivery of solutions, and meeting the needs of our customers.

IMMCO DIAGNOSTICS,
A TRINITY BIOTECH COMPANY
60 Pineview Drive
Buffalo, NY, 14228, USA
Booth #: 19
www.trinitybiotech.com
Since 1971, Immco Diagnostics has provided high quality diagnostic products and services for the detection and diagnosis of autoimmune diseases. Our Product division supplies leading in vitro diagnostic assays and reagents to laboratories worldwide. Immco Reference Laboratory offers biopsy, serology and other test services for diagnosis of autoimmune disorders and related immunological conditions. The Contract Research group supports clinical research trials for organizations, pharmaceutical and biotechnology industries. Immco Diagnostics incorporates innovative medical devices, diagnostic laboratory testing expertise and pioneering research for a comprehensive solution to autoimmune disease diagnostics.

IMMUNODIAGNOSTIC SYSTEMS (IDS)
10 Didcot Way, Boldon Business Park
Boldon, NE35 9PD, UK
Booth #: 22A
www.idsplc.com
Immunodiagnostic Systems PLC (IDS) is a leading in-vitro diagnostic solution provider to the clinical laboratory market. We develop, manufacture and market innovative immunoassays and automated immunoanalyser technologies to provide improved diagnostic outcomes for patients. Our immunoassay portfolio is a combination of an endocrinology specialty testing menu and assay panels in complementary fields. We now offer 24 fully automated Autoimmune assays and 16 fully automated Infectious Disease assays for use on the IDS-iSYS Multi Discipline Automated system. If you would like to learn more about our product portfolio, please come and visit us at stand 22A.
INova Diagnostics is redefining the boundaries of autoimmune testing. Inova integrates the autoimmune laboratory with systems and instruments, including NOVA View®, a digital approach to reading and archiving IFA images, BIO-FLASH®, a rapid-response chemiluminescent analyzer, QUANTA-Lyser®, a family of EIA/IFA processors for increased flexibility and efficiency, and QUANTA Link®, a centralized network to make workflow management easy. Inova also offers a comprehensive menu of high quality NOVA Lite® IFA, QUANTA Lite® ELISA, and QUANTA Flash® CIA test kits for autoimmune diseases. Laboratories, clinicians and patients benefit from the excellent technical expertise, support and service offered by Inova Diagnostics.

Jackson ImmunoResearch Europe Ltd.
Unit 7 Acorn Business Centre
Newmarket, CB8 7SY, UK
www.jireurope.com
At Jackson ImmunoResearch, we manufacture secondary antibodies and related reagents, earning an outstanding reputation for quality over the past 30 years. Our products are used in Western Blotting, IHC/ICC/IF, Flow Cytometry, ELISA, Electron Microscopy and many other immunological techniques. Our range includes a wide choice of species and specificity options, enabling reliable and precise detection. All antibodies are available conjugated to a comprehensive selection of fluorophores (including Alexa Fluors®), Enzymes (HRP and Alkaline Phosphatase), Colloidal Gold or Biotin. We serve customers directly from our European distribution centre, providing outstanding technical service, fast delivery and euro pricing.

Janssen Pharmaceutical Research & Development, LLC
3210 Merryfield Row
San Diego, CA 92121, USA
www.janssen.com
At Janssen, we are dedicated to addressing and solving some of the most important unmet medical needs of our time in oncology, immunology, neuroscience, infectious diseases and vaccines, and cardiovascular and metabolic diseases. Driven by our commitment to patients, we develop innovative products, services and healthcare solutions to help people with serious diseases throughout the world. Beyond its innovative medicines, Janssen is at the forefront of developing education and public policy initiatives to ensure patients and their families, caregivers, advocates and healthcare professionals have access to the latest treatment information, support services and quality care.
LFB BIOMEDICAMENTS
31 avenue des Tropiques, BP 40305 - LES ULIS
91958, COURTABOEUF CEDEX, France
Booth #: 11
www.lfb.fr
The LFB group is a biopharmaceutical company that develops, manufactures, and markets medicinal products for the treatment of serious and often rare diseases in the fields of Immunology, Haemostasis, Perinatal, and Intensive Care. The LFB group is the leading manufacturer of plasma-derived medicinal products in France and 6th worldwide, and is also among the leading European companies for the development of new-generation medicinal products or treatments based on biotechnologies. The LFB group is pursuing a growth strategy that seeks to extend its international activities and develop innovative therapies. Today, the LFB group currently markets its products in more than 40 countries around the world.

LILLY DEUTSCHLAND GMBH
Werner-Reimers-Strasse 2-4
Bad Homburg, 61352, Germany
www.lilly-pharma.de
About Eli Lilly and Company Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com and newsroom.lilly.com/social-channels.

MEDICARE INTERNATIONAL TRADING LIMITED
Room 3, 3/F., Block B, Veristrong Industrial Centre,
34-36 Au Pui Wan Street
Fotan, N.T., 1000, Hong Kong S.A.R.
mcintl.en.alibaba.com
Medicare International Trading Limited was established in June 2012. The main business field is about Assisted Reproduction Technology. We are selling reagent, consumables, equipments and also hospital management software systems. In addition to the Hong Kong market, we also have long term customers from Macau and Mainland China. Our customers cover all over the provinces and municipalities in Mainland China which includes universities and education institutions, research laboratories, laboratory inspection and testing services, government laboratories, hospitals and clinics. Our mission is to become your partner. We provide competitive price, superior quality products and also efficient service to satisfy customer’s needs.
MEDIPAN GMBH
Ludwig-Erhard-Ring 3
Dahlewitz, 15827, Germany
Booth #: 18
www.medipan.de
MEDIPAN founded 1992, is a leading company in development, manufacturing and international distribution of in vitro diagnostic tests. The main fields are the diagnosis of thyroid disease, diabetes type 1, systemic rheumatic diseases and other autoimmune disorders. MEDIPAN invented the AKLIDES® system, a platform technology for digital immunofluorescence. This technology is used for automated evaluation of cell and bead based immunofluorescence tests. A new application here is the detection of DNA damage caused by radiation, oxidative stress or drugs. Our company is an accepted and innovative partner for laboratories and physicians worldwide.

NOVO NORDISK A/S
Novo Alle
Bagsvaerd, 2880, Denmark
www.novonordisk.com
Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 40,300 people in 75 countries and markets its products in more than 180 countries. Novo Nordisk’s B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com.

OCTAPHARMA
62 bis Avenue A. Morizet
Boulogne Billancourt, 92 100, France
www.octapharma.com
Headquartered in Lachen, Switzerland, Octapharma AG is one of the world’s largest human protein products manufacturers and has been committed to patient care and medical innovation for 30 years. With a broad and expanding pipeline, Octapharma’s core business is the development, production, and sale of high quality human protein therapies from both human plasma and human cell-lines, including intravenous immune globulin and von Willebrand Factor/Coagulation Factor VIII Complex. Octapharma employs over 6,000 people and has biopharmaceutical experience in 80 countries worldwide, including the United States, where Octapharma USA is located in Hoboken, New Jersey. Octapharma operates two state-of-the-art production sites licensed by the U.S. Food and Drug Administration (FDA), providing a high level of production flexibility. For more information, please visit www.octapharma.com.
**ORGENTEC DIAGNOSTIKA GMBH**

Carl-Zeiss-Str. 49-51
Mainz, 55129, Germany
Booth #: 17
www.orgentec.com

ORGENTEC Diagnostika, Mainz, Germany, is a global leader in research, development, and production of test systems for laboratory diagnostics. ORGENTEC offers numerous highly specific ELISA assays, immunoblots and kits for immunofluorescence. The innovative Alegria® instrument allows for rapid automated analysis of serum, stool and CSF biomarkers for autoimmune and infection diseases. The point of care test rheumachec® has been the first rapid test for diagnosing rheumatoid arthritis. With distribution channels and subsidiaries in Germany, Austria, Hungary, France, USA and China, and an established global network of distribution partners, ORGENTEC’s products are benefitting patients in over 100 countries around the world.

**PEPPERPRINT**

Rischerstr. 12
Heidelberg, 69123, Germany
Booth #: 22
www.pepperprint.com

PEPperPRINT provides high-content peptide microarrays with custom and off-the-shelf contents. PEPperCHIP®s are predominantly applied for antibody epitope mapping, antigen discovery and biomarker development. Our PEPperCHIP® Autoimmune Epitope Microarray covers 3,359 linear autoimmune epitopes including 192 citrullinated peptides to e.g. disclose differential antibody responses of autoimmune patient groups. Additionally, the PEPperCHIP® Cyclic Citrullinated Peptide Microarray covers 577 different cyclic peptides and the corresponding cyclic arginine controls for RA research. PEPperCHIP® Peptide Microarray analysis is straightforward and can be done in your own lab or by PEPperPRINT experts within a PEPperMAP® Service Offer.
About Roche

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry seven years in a row by the Dow Jones Sustainability Indices.

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2015 employed more than 91,700 people worldwide. In 2015, Roche invested CHF 9.3 billion in R&D and posted sales of CHF 48.1 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com. All trademarks used or mentioned in this release are protected by law.

About Sanofi Genzyme

Sanofi Genzyme, the specialty care business unit of Sanofi, focuses on rare diseases, multiple sclerosis, oncology, and immunology. We help people with debilitating and complex conditions that are often difficult to diagnose and treat. Our approach is shaped by our experience developing highly specialized treatments and forging close relationships with physician and patient communities. We are dedicated to discovering and advancing new therapies, providing hope to patients and their families around the world.
SENSOvation AG
Markthallenstraße 5
Radolfzell, 78315, Germany
Booth #: 31
www.sensovation.com
Sensovation is focused on the development and manufacturing of unique smart imaging solutions for the Life Science and Diagnostics market, certified for medical use (EN ISO 9001 and EN ISO 13485). We offer optical detection solutions ranging from scientific cameras up to highly integrated instrumentation for multiplexed diagnostics and microscopy. Sensovation is primarily active in the OEM business and designs customer specific imaging products. The SensoSpot® Microarray Analyzers are dedicated for routine analysis of planar, low-density microarrays for multiplexed diagnostics. This open and flexible platform allows for read-out of colorimetric and fluorescent microarrays in a very robust and affordable manner.

SHANGHAI CP GUOJIAN PHARMACEUTICAL CO., LTD.
No. 399, Libing Road, Zhangjiang Hi-Tech Park, Pudong New Area
Shanghai, 201203, China
www.cpgj-pharm.com/EN/
Shanghai CP Guojian Pharmaceutical Co., Ltd. (CPGJ) is a biopharmaceutical company invested and controlled by China International Trust and Investment Corporation (CITIC Limited). Since established in 2002, CPGJ has committed to the R&D, pilot scale development, industrialization and commercialization of antibody drugs. It has grown into a leading company in China’s antibody sector that provides targeted drugs for cancer, autoimmune diseases and organ transplantation immunosuppression treatment. As an R&D-based biopharmaceutical company, CPGJ has successfully developed its core technologies to continuously develop and commercialize new biologics therapies. CPGJ’s antibody manufacturing capacity is among the largest in the industry.
TEVA PHARMACEUTICAL INDUSTRIES LTD.
16 Basel St.
Petach Tikva, 4951008, Israel
www.tevapharm.com
Teva Pharmaceutical Industries Ltd. is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions used by millions of patients every day. Headquartered in Israel, Teva is the world’s largest generic medicines producer, leveraging its portfolio of more than 1,000 molecules to produce a wide range of generic products in nearly every therapeutic area. In specialty medicines, Teva has a world-leading position in innovative treatments for disorders of the central nervous system, including pain, as well as a strong portfolio of respiratory products. Teva integrates its generics and specialty capabilities in its global research and development division to create new ways of addressing unmet patient needs by combining drug development capabilities with devices, services and technologies. Teva’s net revenues in 2015 amounted to $19.7 billion. For more information, visit www.tevapharm.com

THERADIAG
14 rue Ambroise Croizat
Croissy Beaubourg, 77183, France
Booth #: 14
www.theradiag.com/en/
With 30 years’ experience in the development and commercialization of IVD tests, Theradiag keeps innovating with the development and commercialization of theranostics that measure the efficiency of biotherapies in the treatment of autoimmune diseases, cancer and AIDS. Theradiag notably markets the Lisa Tracker® range, which is a comprehensive multiparameter theranostic solution for patients with autoimmune diseases treated with biotherapies. Concerned of bringing new and up-to-date solutions for labs, Theradiag constantly develops its ranges of products and services. Today and thanks to its new solution, Theradiag positions more than ever as a key player of the specialized immunology diagnostic in Europe.

THERMO FISHER SCIENTIFIC
Phadia GmbH Munzingerstr. 7
Freiburg, 79111, Germany
Booth #: 06
www.thermoscientific.com/phadia
As the ImmunoDiagnostics experts within Thermo Fisher Scientific, we work to significantly improve the management of allergy, asthma and autoimmune diseases. We do this by providing healthcare professionals with superior diagnostics technologies and clinical expertise. This results in better healthcare and quality of life for millions of patients and their families.
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 8500 people in approximately 40 countries, the company generated revenue of € 3.3 billion in 2014. UCB is listed on Euronext Brussels (symbol: UCB).

UNOMEDICAL A/S
Aaholmvej 1-3. Osted
Lejre, 4320, Denmark
Booth #: 28
www.neria.com
Unomedical is a leading manufacturer of infusion sets. Since 1980s Unomedical has sold millions of infusion sets worldwide for use with continuous subcutaneous drug delivery. Our neria™ infusion sets have been drug compatibility tested with drugs for the following diseases; Primary Immune Deficiency, Parkinson Disease, Thalassemia, and Pain Management. Our success is based on a high degree of innovation supported by user-friendliness and superior quality. All over the world users benefit from the Unomedical infusion sets improving their quality of life and treatment options. Please visit www.neria.com for more information on the neria™ infusion set product line.

WISEPRESS LTD
25 High Path
London, SW19 2JL, UK
Booth #: 37
www.wisepress.com
Wisepress.com, Europe’s leading conference bookseller, has a range of books and journals relevant to the themes of the meeting. In addition to attending 200 conferences per year, Wisepress has a comprehensive medical and scientific bookshop online with great offers. Follow us on Twitter for the latest news @WisepressBooks.
The Autoimmunity Network is a dynamic social community of international medical professionals who share the common goal of exchanging knowledge about autoimmune diseases.

www.autoimmunity-network.com

Join Today!
JOIN US AT OUR
FUTURE CONGRESSES